WWOX, tumour suppressor and modifier gene, as a regulator of gene expression and apoptosis in ovarian cancer by Janczar, Szymon Lech & Janczar, Szymon Lech
  
WWOX, TUMOUR SUPPRESSOR AND MODIFIER 
GENE, AS A REGULATOR OF GENE EXPRESSION 
AND APOPTOSIS IN OVARIAN CANCER 
 
 
 
 
 
Szymon Lech Janczar 
Imperial College London, Department of Surgery and Cancer 
 
 
 
 
 
 
 
Thesis submitted for the degree of PhD 
2 
 
Acknowledgements 
 
First and foremost, I would like to express gratitude to my supervisors, Dr Adam Paige and 
Professor Hani Gabra, for their continual encouragement, support and mentoring. 
I would also like to thank Dr Mingjun Sun and Claudia Hayford for the demonstration of 
several laboratory techniques. This work would not be possible without the help and support 
of all the other Ovarian Cancer Action Research Centre laboratory members. Further, I 
appreciate the help of Christopher Datler with the planning of several experiments. 
The design, conduct and interpretation of Sequenom iPLEX genotyping assay would not be 
possible without the help of Dr Andrew Walley, Stephen Clark and Marlene Attard from the 
Section of Genomic Medicine, Imperial College London. 
This project was funded by Ovarian Cancer Action. 
3 
 
Statement of originality 
 
I hereby declare that all work presented in this thesis is my own, unless otherwise stated. 
 
Szymon Janczar 
4 
 
Abstract 
 
WWOX is a tumour suppressor gene, as demonstrated by increased neoplasia incidence in Wwox-
knock-out animals, and is frequently disrupted in human cancers. WWOX expression reconstitution 
abolishes xenograft growth of lung, pancreatic, breast, ovarian and prostate cancer cells. The tumour-
suppressive function of WWOX is suggested to be related to pro-apoptotic effects or interactions with 
potentially oncogenic transcription factors leading to their cytoplasmic sequestration and trans-activity 
inhibition. In physiology WWOX might be involved in metabolism. 
Our group demonstrated that WWOX reconstitution in ovarian cancer cells inhibits xenograft growth 
but this was not accompanied by altered in vitro growth or apoptosis rates. Rather, WWOX 
transfection reduced cancer cell adhesion to extracellular matrix due to reduction of integrin α3 
binding. Additionally, our group postulated that natural polymorphic variants of WWOX are linked to 
ovarian cancer clinicopathological features. 
The hypotheses behind this work were that WWOX regulates gene expression or promotes apoptosis 
in ovarian cancer. Further, this project aimed at confirming the associations of WWOX 
polymorphisms. 
I demonstrate no link between WWOX status and the subcellular localization of putative WWOX-
binding transcription factors or the expression of their target genes in ovarian cancer cells. The 
phenotypic consequences of WWOX expression manipulation do not appear to be explained by 
transcriptional changes. 
I show that WWOX increases apoptosis rates in ovarian cancer cells exposed to the chemotherapy 
agent paclitaxel, but not cisplatin. This is independent of the anti-mitotic function of taxanes and 
unrelated to integrin regulation. Rather, WWOX promotes cell death during taxane-induced 
endoplasmic reticulum stress. I propose WWOX-driven cell death during endoplasmic reticulum stress 
might be also linked to anti-tumorigenic effects in vivo. 
A validation study did not confirm the link between WWOX genetic variants and ovarian cancer 
pathology. There is also no link between WWOX polymorphisms and bone metabolism, a trait 
affected in WWOX-knock-out animals. 
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List of abbreviations 
AD –Alzheimer’s disease 
ADH –alcohol dehydrogenase 
APC – 1. anaphase promoting complex, 2. allophycocyanin 
AR –androgen receptor 
BMD –bone mineral density 
BSA –bovine serum albumin 
CFS –common fragile site 
CGP –a population of 554 UK ovarian cancer patients used by our group to link WWOX genotypes 
and clinicopathological features 
DAPI -4’-6-diamidino-2-phenylindole 
DMSO –dimethyl sulfoxide 
DTT –dithiothretiol 
dNTP –deoxyribonucleotide triphosphate 
ECM –extracellular matrix 
EDTA –ethylenediaminetetraacetic acid 
ELISA –enzyme-linked immunosorbent assay 
EMT –epithelial mesenchymal transition 
ENU –ethyl nitrosourea 
ER –endoplasmic reticulum 
ERSE –endoplasmic reticulum stress response element 
FACS –fluorescence activated cell sorter 
FCS –foetal calf serum 
FIGO –International Federation of Gynecology and Obstetrics 
FITC –fluorescein isothiocyanate  
FRA16D –common fragile site located to human chromose 16q23 
FSH –folicle stimulating hormone 
GEO –Gene Expression Omnibus 
GFP –green fluorescent protein 
GST –glutathione S-transferase 
GT –gene-trap 
HDL –high-density lipoprotein 
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HET –heterozygotic, heterozygote 
HGSC –high-grade serous carcinoma 
HNPCC –hereditary non-polyposis colorectal cancer 
HR –hazard ratio 
HRP –horse-radish peroxidise 
PMSF –phenylmethylsulphonyl fluoride 
IAP –inhibitor of apoptosis 
IgG –immunoglobulin 
IP -immunoprecipitation 
KD –kock-down 
KO –knock-out 
LB –Lauria-Bertani 
LD –linkage disequilibrium 
LDE –lethal dwarfism with epilepsy 
LGSC –low-grade serous carcinoma 
LH –luteinizing hormone 
LMP –low malignant potential 
LPD –locoperitoneal dissemination 
LOH –loss of heterozygosity 
MAF –minor allele frequency 
MALDI-TOF –Matrix Assisted Laser Desorption/Ionization Time-of-Flight 
MB –megabase 
MEF –mouse embryonic fibroblast 
MMP –matrix metalloproteinase 
MPM2 –mitosis-specific phosphoepitope, ‘’mitotic protein monoclonal 2’’ 
NFT –neurofibrillary tangle 
NLS –nuclear localization sequence 
OD –optical density 
ORF –open reading frame 
OS –overall survival 
OSE –ovarian surface epithelium 
PAGE –polyacrylamide gel electrophoresis 
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PBS –phosphate buffered saline 
PBS/T –phosphate buffered saline with Tween 
PCR –polymerase chain reaction 
PFA –paraformaldehyde 
PFS –progression free survival 
PPxY –peptide motif consisting of two proline, any amino acid, and tyrosine 
PR –progesterone receptor 
PTH –parathyroid hormone 
QTL –quantitative trait locus 
RIN –RNA integrity number 
RMA –Robust Multi Array 
RPM –revolutions per minute 
RT –reverse transcription 
RTK –receptor tyrosine kinase 
SCLC –small-cell lung cancer 
SDS –sodium dodecyl sulfate 
SDR –short-chain dehydrogenase/reductase 
siRNA –short inhibitory RNA 
SNP –single nucleotide polymorphism 
SRB –sulforhodamine B 
TAE –Tris-acetate-EDTA 
TBS –Tris buffered saline 
TBS/T –Tris buffered saline with Tween 
TEMED –Tetramethylethylenediamine 
TRIS –trishydroxymethylaminomethane 
TSG –tumour suppressor gene 
UPR –unfolded protein response 
UPRE –unfolded protein response element 
UTR –untranslated region 
UV –ultraviolet 
WB –Western blotting 
WT –wild-type 
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Chapter 1. Introduction 
1.1. WWOX: a tumour suppressor gene in multiple cancers 
1.1.1. Cloning of a gene at the 16q23.3-16q24.1 region frequently disrupted in multiple cancers 
It has been long recognized that cancer is a disease of the genome and arises as a result of somatic, 
and rarely germline, mutations of proto-oncogenes and tumour suppressor genes (now extended to 
include epigenetic and other events altering their expression or function). Proto-oncogenes promote 
cancer, when mutationally deregulated or abnormally over-expressed, in a genetically dominant 
manner. Conversely, experiments involving somatic cell fusion and chromosome segregation had 
pointed to genes that could suppress tumorigenicity and indeed a number of such genes have been 
identified. These, coined tumour suppressor genes, are usually recessive and require inactivation of 
both alleles. They are highly penetrant when affected in defined familial cancer syndromes. Tumour 
suppressor genes, such as TP53 believed to be implicated in around half of human cancers, are 
potentially ideal targets for therapeutic intervention through the restoration of their function, but this is 
challenging with current technologies [1]. 
FRA16D (16q23.2) is the second most commonly expressed common fragile site (CFS) in the human 
genome. Common fragile sites (of which there are at least 80) are chromosome regions displaying 
site-specific gaps and breaks on metaphase chromosomes of all individuals after partial inhibition of 
DNA synthesis such as by aphidicolin treatment. These sites are hot spots for chromosomal 
rearrangements, deletions, amplifications and exogenous DNA integration. Common fragile sites 
display evolutionary conservation and a number of them were found to span genes encoded by very 
large genomic regions. Because of their conservation, and despite the propensity towards genomic 
disruption, CFSs are believed to have functional significance such as involvement in stress response 
but this remains largely speculative. Interestingly, several CFS associated genes play a role in 
neurological development [2-5]. There is a scarcity of information on sequence elements causing 
fragility within CFSs, but a short AT-rich region contributing to chromosomal fragility of FRA16D was 
discovered in a genetic yeast assay, resulting in formation of a cruciform secondary structure stalling 
replication fork progression [6].  
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The 16q23-16q24 region encompassing the FRA16D common fragile site has been long noted to be 
affected by frequent structural and copy number genomic abnormalities in prostate [7-10], breast [11-
13], ovarian [14-15], colon [15], gastric [16] and hepatocellular cancer [17] as well as in hematologic 
malignancies [18-19]. This is due to homozygous deletions or loss of heterozygosity [7-17] and 
chromosomal translocations [18-19]. Those findings initiated a search of a putative tumour suppressor 
gene located at 16q23-16q24. 
A gene mapping to 16q23.3-24.1 was first identified by shotgun genomic sequencing and analysis of 
transcripts of a region frequently affected in breast cancer [20], and independently cloned shortly 
thereafter in two other labs [21-22]. The gene was named WWOX as it was predicted to contain two 
WW domains and a region with high homology to the short-chain dehydrogenase/reductase family of 
enzymes. The full length cDNA of the major WWOX isoform is 2264 bp long and contains predicted 
open reading frame (ORF) of 1245 bp encoding a 414-amino acid protein [20]. WWOX is composed 
of 9 exons (58-1060 bp long) spanning an extremely large genomic locus of around 1.1 MB [20], and 
this locus is the same as FRA16D common fragile site that was mapped to WWOX exon 8 [22]. None 
of the initial studies reported any cancer-specific somatic mutations within the WWOX ORF, and so 
far WWOX ORF mutations were only reported in single cases of oesophageal [23] and oral squamous 
cell carcinoma [24]. However, homozygous deletions and other genomic and epigenetic events 
disrupting WWOX expression have been indentified in many tumours [20-21] and this is presented 
below. 
The murine homologue of WWOX (Wox1/Wwox at chromosome 8) was cloned shortly after the 
human gene in a screen of hyaluronidase–induced cDNAs [25]. There is a high conservation not only 
between WWOX and its murine homologue (93% identity and 95% similarity at the protein level) but 
also between the FRA16D CFS and murine Fra8E1 fragile site that similarly colocalizes with 
Wox1/Wwox locus [26]. 
Other CFS-associated genes have also been implicated in human tumorigenesis. The most common 
fragile site in the human genome is FRA3B at 3p14.2. Fragile histidine traid (FHIT) gene was 
identified from within that region of instability. FHIT is frequently lost in cancer and was shown to be a 
tumour suppressor gene [2-3, 27]. Examples of other CFS genes implicated in cancer include Parkin, 
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GRID2 (glutamate receptor, ionotropic, delta 2), RORA (RAR-related orphan receptor A), DAB1 
(disabled homolog 1) and LRP1B (low density lipoprotein receptor-related protein 1B) [2-3, 28-29]. 
1.1.2. WWOX: structural predictions and subcellular localization  
Amino acid analysis of the putative WWOX protein showed two N-terminal regions with high 
homology to WW domain sequences (amino acids 18-47 and 59-88). WW domains are small, 35-40 
amino acid long, protein modules recognizing proline-rich peptides or phosphorylated 
serine/threonine-proline sites in partner binding proteins and are present in at least 50 human 
proteins. The name refers to two tryptophan residues (W) that are spaced 20-22 amino acids apart, 
with one of the residues in some instances substituted with another aromatic residue. Structural 
studies of several WW domains demonstrated a structure composed of a triple stranded parallel β-
sheet, and the binding pocket for peptide ligands was shown to be a shallow groove containing 
hydrophobic and aromatic residues between the three β-sheets. WW-domain mediated complexes 
are implicated in a variety of diseases such as hypertension, neurodegenerative disorders and cancer 
[30-32]. The first, N-terminal, WW-domain of WWOX (WWOX WW-1) displays typical features of WW 
domain i.e. it is 26 bp long and contains the two highly conserved tryptophan and one proline 
residues. In the second WW domain (WWOX WW-2) one tryptophan is replaced by tyrosine, which is 
also found in WW domains [20]. WW domains are classified into four groups based on ligand 
specificity. Group I domains (exemplified by YAP65) recognize PPxY motifs (P –proline, Y –tyrosine, x 
–any amino acid). Group II WW domains (present in for example amyloid β precursor protein-binding 
family B <APBB1> protein) recognize preferentially PPLP motifs (where L stands for leucine). Group 
III (such as in formin binding protein 4 –FNBP4) associate with proline –arginine rich motifs, whereas 
group IV (such as those in peptidyl prolylisomerase Pin1) recognize phosphorylated serine/threonine-
proline sites [30-32]. Both predicted WW domains of WWOX belong to the largest class 1. Example of 
other class 1 WW domain containing proteins include ubiquitin ligases such as SMURF1, NEDD4 or 
NEDD4-like ubiquitin ligase 1 and 3, Yes-associated protein 1, 65 kD (YAP65) and dystrophin  [32-
33]. Consistent with the structural predictions, initial study of WWOX binding partners utilizing protein 
arrays and using WWOX WW domains as a probe confirmed binding of PPxY–motif containing 
ligands to the first WW domain of WWOX, however no interactions were observed for the second 
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domain suggesting that this domain may recognize a novel motif or contribute to the structural 
integrity of the tandem of WW domains within the WWOX protein [34]. 
The C-terminal amino acid sequence reveals homology to members of the SDR (short chain 
dehydrogenase/reductase) proteins family. WWOX amino acid sequence analysis demonstrated both 
the potential coenzyme binding site (GANSGIG at positions 131-137, for NAD(H) or NADP(H) 
binding) and substrate biding site (YNRSK at positions 293-297) [20] as well as a catalytic tetrad 
NSYK that could bind steroid hormones (asparagines 232, serine 281, tyrosine 293 and lysine 297). 
SDR proteins constitute a large protein family of highly different enzymes with diverse ligands and 
examples of characterized human SDRs include 15-hydroxy prostaglandin dehydrogenase, 17β–
estradiol dehydrogenase and carbonyl reductase [35]. The murine homologue of WWOX was also 
predicted to contain an SDR domain [25]. Nevertheless there are no reports of documented WWOX 
enzymatic activity to date in any species. Figure 1.1 (adopted from the works by Bednarek et al. [20] 
as well as Chang et al. [36]) presents schematic representation of the location of various domains, 
motifs or other important residues within WWOX protein. 
There is some discrepancy with regard to the predicted localization signal peptides within WWOX with 
some studies predicting cytoplasmic localization [20] and others describing a nuclear localization 
signal (amino acids 50-55) or a mitochondrial targeting sequence mapping to the SDR domain region 
between amino acids 209 and 273 [25]. There is no consensus on WWOX and its murine 
homologue’s subcellular localization and its regulation. Different research groups using diverse 
experimental models reported WWOX/WOX1 localization as diffusely cytoplasmic [37-41], perinuclear 
Golgi–specific [34, 42], mitochondrial [25, 43-44], proximal to nuclear membrane and rough 
endoplasmic reticulum (ER) [45], shuttling between cytoplasm and nucleus (in cellular stress 
conditions such as confluent culture [43], TNF exposure [25] or hormonal stimulation [44]), or that 
WWOX can be recruited to the apical membrane (of gastric parietal cells) [46]. GFP-tagged protein 
products of WWOX aberrant transcripts (which lack part of the SDR domain) were demonstrated to 
localize in the nuclei [42]. The experimental details and reported outcomes are included in Table 1.1. 
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MAALRYAGLDDTDSEDELPPGWEERTTKDGWVYPYANHTEEKTQWEHPKT(GKRKRV)
AGDLPYGWEQETDENGQVFFVDHINKRTTYLDPRLAFTVDDNPTKPTTRQRYDGSTTA
MEILQGRDFTGKVVVVTGANSGIGFETAKSFALHGAHVILACRNMARASEAVSRILEEW
HKAKVEAMTLDLALLRSVQHFAEAFKAKNVPLHVLVCNAATFALPWSLTKDGLETTFQV
N*HLGHFYLVQLLQDVLCRSAPARVIVVSSESHRFTDINDSLGKLDFSRLS*PTKNDYPWA
ML→PAY*NRSK*LCNILFSNELHRRLSPRGVTSNAVHPGNMMYS→FNIHRSWWVYTLLF
TLARPFTKSMQQGAATTVYCAAVPELEGLGGMYFNNCCRCMPSPEAQSEETARTLWAL
SERLIQERLGSQSG 
 
 
WW domains are boxed 
W - signature tryptophan residue in the WW domain 
Y - signature tryptophan residue replaced by tyrosine (conservative change) in the second WW 
domain 
Short-chain dehydrogenase domain is underlined 
GANSGIG – GXXXGXG sequence typical of coenzyme NAD(H) or NADP(H) binding site 
S, YNRSK – putatative substrate binding site (S, YXXXK) 
(GKRKRV) – putative nuclear localization sequence 
N*, S*, Y*, K* motif – conserved catalytic NSYK motif for substrate binding 
Y
P
 – reported phosphorylation sites (tyrosine 33 and 287) 
L
→P
, S
→F
 – reported cancer–specific mutations (leucine → proline, serine → phenylalanine) 
 
 
Figure 1.1 
 
Human WWOX protein structural predictions and reported cancer-specific mutations 
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Experimental method Tissue /cell line Reported localization References 
Tissue 
immunohostochemistry* 
Various human tissues cytoplasmic [39] 
Tissue 
immunohostochemistry* 
Breast cancer samples cytoplasmic [40] 
Confocal microscopy†‡ Human cancer or 
normal immortalized 
cell lines 
cytoplasmic [37-38, 41] 
and others 
Confocal microscopy and 
colocalization with Golgi 
markers‡ 
Breast cancer cell line Perinuclear compartment, Golgi 
apparatus 
[34, 42] 
Confocal microscopy and 
colocalization with 
mitochondrial markers‡ 
Human and animal 
cancer or normal 
immortalized cell lines 
Mitochondrial, translocating to 
the nucleus in conditions of 
cellular stress 
[25] 
Subcellular 
fractionation, confocal 
microscopy, tissue 
immunohistochemistry 
and 
immunofluorescence* 
Monkey fibroblasts 
and human breast and 
prostate cancer 
samples 
Cytoplamsic (mitochondrial), 
translocating to the nucleus in 
cellular stress in or the 
progression of cancer 
[44] 
Confocal microscopy and 
tissue 
immunohistochemistry* 
Human fibroblasts and 
various normal and 
neoplastic epithelial 
tissue samples 
Cytoplasmic (mitochondria) or 
nuclear, translocating to the 
nucleus in cellular stress 
[43] 
Electron microscopic 
immunohistochemistry* 
Rat retinas Proximal to nuclear membrane 
and rough ER, translocating to 
mitochondria and nuclei in 
cellular stress 
[45] 
Confocal microscopy* Primary cultures of 
rabbit gastric cells 
Conditionally recruited to the 
apical membrane of gastric 
parietal cells 
[46] 
*-detected with WWOX antibody, ‡-fluorescently tagged protein, †-peptide tag 
Table 1.1. 
WWOX subcellular localization 
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1.1.3. WWOX expression is lost or down-regulated in multiple cancers of different origin and 
this frequently correlates with advanced disease and poor survival  
1.1.3.1. WWOX expression in normal tissues 
WWOX protein was demonstrated by immunohistochemistry of a tissue microarray of 30 organs to be 
expressed in multiple human tissues, with negative staining only seen in adipose, connective and 
lymphoid tissues, myelinized structures and blood vessels. The highest expression was reported in 
secretory epithelial cells of reproductive, exocrine and endocrine organs, as well as in some parts of 
the urinary and nervous systems [39]. 
1.1.3.2. FRA16D/WWOX locus is frequently disrupted in cancer 
Early reports of FRA16D locus disruption that preceded WWOX cloning are described above. 
Subsequently, tools to study WWOX expression became available (generation of antibodies 
recognizing WWOX or better understanding of its genomic locus and methylation patterns). WWOX 
expression is lost or down-regulated in cancers of the male and female reproductive and urinary 
systems, gastrointestinal tract, thyroid and lung cancer, osteosarcoma, and in haematopoietic and 
central nervous system malignancies. The summary of specific cancers, experimental approaches 
and observed patterns of WWOX expression are presented in Table 1.2. WWOX loss is due to 
genomic disruption (homozygous deletions, LOH and translocations), aberrant splicing, epigenetic 
silencing as a result of promoter methylation, or without easily identifiable cause.  
1.1.3.3. WWOX clinicopathological associations in cancer 
Reported correlations between WWOX expression loss and clinicopathological features in cancer 
include associations with: low estrogen and progesterone receptor status [40, 47-48], basal-like 
histology [49], high grade disease [49-50], poor survival, increased lymph node metastasis [51] and 
disease recurrence [48], and lack of response to tamoxifen in breast cancer [52]; mucinous and clear 
cell histology, low PR status and poor survival in ovarian cancer [53]; squamous cell and poorly 
differentiated histology, and high tumour grade in non–small cell lung cancer [54]; high grade, 
advanced stage and poor survival in bladder cancer [55]; and lymph node metastasis and poor 
survival in pancreatic cancer [56]. These findings are also presented in Table 1.2. The common topic 
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is the link between WWOX loss and advanced disease (breast, ovarian, bladder and pancreatic 
cancers), prognostically adverse histological features (breast, ovarian, lung and bladder cancers) and 
poor patient survival (breast, ovarian, bladder and pancreatic cancers). Interestingly, WWOX seems 
to be co-ordinately dysregulated with FHIT, the FRA3B common fragile site gene, and this might be 
related to common events disrupting multiple CFS-associated genes in tumorigenesis [47, 49-50, 57-
58]. 
1.1.3.4. Mechanisms of WWOX inactivation in cancer 
A wide range of genomic and molecular events leading to WWOX loss, down-regulation or 
inactivation in cancer have been identified. Somatic mutations are extremely rare and so far have only 
been observed in one case of esophageal and one case of oral squamous cell carcinoma. 
Interestingly they are both located in exon 8 (codons 291 and 329) in the C-terminus of the protein 
(whereas most of published reports on WWOX molecular biology focus on the N-terminal WW-
domains), and cause substitutions within the putative SDR domain that are possibly deleterious to its 
function [23-24]. In contrast, there is a high frequency of LOH or homozygous deletions within the 
WWOX locus in cancer and these findings are presented in Table 1.2. 
Another major mechanism contributing to WWOX expression loss appears to be promoter 
hypermethylation that was demonstrated in lung, breast, bladder and pancreatic cancers (reports 
summarized in Table 1.2). This hypermethylation appears to be related to WWOX gene silencing as 
treatment of several cancer cell lines with demethylating agent azacytidine [59-62], or microRNA 
mediated down-regulation of DNA methyltransferases 3A and 3B leading to demethylation [63], 
resulted in WWOX re-expression. Interestingly, a similar result of WWOX re-expression was obtained 
with histone acetylating agents, suggestive of a role for histone modifications in WWOX regulation 
[59, 61]. 
Multiple aberrant WWOX transcripts were identified, lacking several WWOX exons present in the only 
naturally observed protein isoform (isoform 1, NM_016373). The most frequently reported aberrant 
transcripts are those missing exons 5-8 or 6-8 but other variants, including a transcript consisting of 
WWOX exons 1-5 and an alternative exon 6a, exist [23-24, 42, 59-60, 64-67]. Some studies report 
cancer specificity or increased cancer prevalence of such aberrant transcripts, or a correlation with 
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decreased WWOX expression. It has also been suggested these transcripts could encode aberrant 
proteins with dominant negative function [24, 42, 64, 66-68]. However, protein isoforms corresponding 
to such truncated transcripts have not been observed so far, apart from in experiments with 
proteasome inhibitors, suggesting that they are normally targeted for proteolysis [43]. 
Finally, in vitro data from a prostate cancer cell line model suggest that another mechanism of WWOX 
loss could be enhanced proteasomal degradation following phosphorylation at tyrosine 287 by the 
non-receptor tyrosine kinase Ack1 and in a small panel of prostate carcinomas there was an inverse 
correlation of phospho-Ack1 and WWOX expression [69]. 
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Year 
 
 
Cancer 
 
Experimental method 
 
Findings 
 
Reference 
1998 
 
Multiple myeloma Genomic mapping, FISH t(16;22)(q23;q11) translocation in 25 % of cases [70] 
2000 
 
Multiple myeloma Genomic mapping Translocations within the locus [19] 
2001 Hepatocellular Genomic mapping, mutation 
screening 
LOH in 29% of tumours, correlation with aflatoxin exposure [71] 
2001 Ovarian and cell lines 
from other tumours 
Genomic mapping, mutation 
screening 
Presence of homozygous deletions inactivating WWOX [21] 
2001 Various tumours and cell 
lines 
qRT PCR, methylation analysis Low levels of WWOX expression in several tumours and cell lines, 
aberrant transcripts 
[42] 
2002 Breast qRT PCR WWOX expression loss in several tumour samples, aberrant 
transcripts 
[64] 
2002 Oesophageal Genomic mapping, mutation 
screening, RT PCR 
LOH in 39% of tumours, one case with missense mutation, 
aberrant transcripts 
[23] 
2003 Non –small cell lung 
cancer 
Genomic mapping, mutation 
screening, RT PCR 
LOH in 37% of tumours, aberrant transcripts [65] 
2003 Hematopoetic qRT PCR, WB, mutation screening 51% of cases show reduced expression, aberrant transcripts, rare 
insertions and substitutions in cell lines 
[59] 
2004 Prostate CGH, qRT PCR cases with copy number loss in the region, reduced WWOX  mRNA 
expression 
[72] 
2004 Pancreatic Genomic mapping, mutation 
screening, methylation analysis, 
RT PCR, qRT PCR, WB 
LOH in 27% of tumours, promoter hypermethylation in some cell 
lines, aberrant transcripts, reduced levels of mRNA and protein 
expression is several tumours 
[60] 
2004 Breast IHC reduced WWOX expression in 63.2% of tumours, correlation with 
ERα status 
[47] 
2004 Gastric Genomic mapping, mutation 
screening, RT PCR, WB, IHC 
LOH in 31% of tumours, reduced WWOX expression in 65% of 
cases, aberrant transcripts 
[66] 
2004 Hepatocellular CGH, mutation screening, RT PCR, 
WB on cell lines 
reduced mRNA and protein expression in a number of cell lines as 
compared to normal liver, aberrant transcripts 
[68] 
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2005 Lung, breast, bladder IHC, methylation analysis frequent methylation of WWOX promoter in cancer (correlating 
with lost protein expression) but not in normal tissues 
[73] 
2005 Breast IHC loss of WWOX expression in 34 -60% of cases, correlation with ER 
α status 
[40] 
2005 Ovarian qRT PCR loss of WWOX expression in cancer as compared to normal tissue, 
aberrant transcripts 
[67] 
2005 Ovarian IHC loss of WWOX expression in 30% of tumours, especially clear cell 
and mucinous, correlation with high stage, poor survival and PR 
status 
[53] 
2005 Breast IHC loss of WWOX expression in 61% of invasive tumours, correlation 
with high grade 
[50] 
2005 Cutaneous squamous cell IHC, semi qRT PCR WWOX protein but not mRNA downregulation in all cases as 
compared to normal skin 
[74] 
2006 Oral squamous cell Mutation screening, IHC, RT PCR, 
WB 
WWOX protein loss in 40% of cases, aberrant transcripts, somatic 
missense mutation 
[24] 
2006 Breast qRT PCR Aberrant transcripts, WWOX expression loss correlating with ERα 
and PR status, and disease recurrence 
[48] 
2006 
 
Prostate IHC WWOX expression loss in 84% of tumours [75] 
2007 Non-small cell lung 
cancer 
IHC WWOX expression loss in 85% of tumours, correlation with 
histology and grade 
[54] 
2007 Multiple myeloma Genomic mapping, microarray 
gene expression analysis 
cases with 16q LOH or t(14;16) have significantly lower WWOX 
expression 
[76] 
2007 Breast IHC WWOX expression loss in 36% of tumours, correlation with poor 
survival 
[51] 
2007 
 
Breast IHC WWOX loss predicts lack of response to tamoxifen [52] 
2007 
 
Thyroid IHC loss of WWOX expression in 64% of papillary thyroid carcinomas [77] 
2008 Oral leukoplakias * IHC, RT PCR reduced WWOX expression in 35% of the lesions as compared to 
normal mucosa 
[78] 
2008 Meningioma Microarray gene expression WWOX consistently down-regulated when compared to arachnoid [79] 
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analysis cysts 
2008 Bladder IHC low WWOX expression in 26% of tumours, correlating with high 
grade, advanced stage and poor survival 
[55] 
2008 Pancreatic IHC reduced WWOX expression in 79% of tumours, correlating with 
lymph node metastasis and poor survival  
[56] 
2008 Oesophageal SNP copy number arrays Homozygous deletion within the WWOX locus in 8 out of 23 
samples 
[80] 
2008 
 
Hepatocellular Genomic mapping, RT PCR LOH and reduced WWOX mRNA levels in 45% of the tumours  
2008 
 
Cholangiocarcinoma Genomic mapping, RT PCR, IHC LOH  and loss of expression in about 50% of tumours [81] 
2009 Breast IHC 64-78% of tumours displayed reduced WWOX expression, 
correlating with basal-like tumours and high grade 
[49] 
2009 Pancreatic IHC, methylation analysis loss of WWOX expression in 81% of intraductal papillary mucinous 
carcinomas, promoter hypermenthylation 
[82] 
2009 Multiple myeloma FISH, genemic mapping, 
microarray gene expression 
analysis 
cases with WWOX LOH have lower expression at the RNA level [83] 
2009 
 
Pancreatobillary IHC loss of WWOX expression in 72% of tumours [57] 
2009 Cervical 
 
IHC loss of WWOX expression in 69% of tumours [58] 
2009 Osteosarcoma CGH, IHC WWOX deletion in 30% and loss of WWOX protein expression in 
60% of samples 
[84] 
FISH – fluorescent in situ hybridization, LOH – loss of heterozygosity, (q)RT PCR – (quantitative) reverse transcription polymerase chain reaction, WB – 
western blotting, CGH – comparative genomic hybridization, IHC – immunohostochemistry, ERα – estrogen receptor α, PR – progesterone receptor, SNP – 
single nucleotide polymorphism, *- pre-cancerous lesion  
Table 1.2 
WWOX locus disruption or expression loss in various cancers 
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1.1.4. Murine models of Wwox inactivation reveal increased tumour susceptibility in Wwox-
deficient animals 
It is now widely recognized that mouse knock-out models provide definitive proof for anti-tumourigenic 
functions of putative tumour suppressor genes, and remain the animal model of choice because of the 
ease of manipulation and breeding, and the similar number of genes and high conservation of 
intracellular pathways between human and mouse [85]. 
Two studies using different murine models of Wwox inactivation demonstrating increased 
tumorigenicity in Wwox deficient animals were reported in 2007, and this led to the recognition of 
WWOX as a bona fide tumour suppressor gene [86-87]. The first model reported by Aqeilan et al. [86] 
used a targeting construct to replace Wwox exons 2, 3, and 4 with a β-Geo cassette with lacZ and 
Neo genes, which resulted in the abolishing of Wwox mRNA expression on a C57BL/6; 129/Svj mixed 
background. The group studied spontaneous tumour phenotype in Wwox knock-out (KO, Wwox
-/-
), 
heterozygous (HET, Wwox
+/-
) and wild-type (WT, Wwox
+/+
) animals. By four weeks of age all KO mice 
died, whereas HET animals were not distinguishable from WT animals. Several (6 out of 13) of the 
examined young homozygous mice (aged between 3 days and 2.5 weeks) developed lesions 
histologically consistent with osteosarcoma. Adult tumour analysis in homozygotes was precluded 
because of the postnatal mortality. Therefore authors monitored incidence of spontaneous tumours in 
WT and HET mice. The number of tumour-bearing animals was 5-fold higher in HET as compared to 
WT animals and this was due to increased occurrence of lung carcinomas and some rarer 
heamatologic neoplasia. Apart from studying spontaneous tumorigenicity, the authors studied 
carcinogen induced (ethyl nitrosourea, ENU) tumour phenotype in Wwox heterozygous (HET, Wwox
+/-
) and wild-type (WT, Wwox
+/+
) animals. The incidence of tumours, including lung carcinomas and 
lymphomas as well as some less prevalent solid cancers, was significantly higher in HET than in WT 
mice following ENU-induction. Interestingly, both spontaneous and ENU-induced tumours in HET 
animals were positive for WWOX expression, suggesting that loss of one allele of Wwox is sufficient 
to promote tumorigenesis (haploinsufficency) [86]. The same group reported another study using the 
same mouse model of WWOX inactivation in the setting of forestomach tumours. Again the incidence 
of carcinogen (intragastric N-nitrosomethylbenzylamine) driven tumours was significantly higher in 
HET than WT mice [88]. Histological examination of HET mice displayed moderately strong WWOX 
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protein
 
staining in the epithelium adjacent to the tumour, but weak and diffuse
 
staining in the 
cancerous lesion in the same tissue section, and the authors again suggest
 
that Wwox was thus 
haploinsufficient for the initiation of tumour
 
development [88]. 
Another murine model of WWOX inactivation reported by Ludes-Meyers was based on gene–trap 
technology [87] on a C57BL/6; 129/Ola mixed background. An ES (mouse embryonic stem cell) clone, 
obtained from a commercial source, harbouring a gene-trap inserted into Wwox intron 4 and resulting 
in a splice variant containing Wwox exons 1-4 in-frame with the β-geo gene was used. The 
homozygous knock-out mice (Wwox
gt/gt
) were viable and concluded to be hypomorphs as they 
retained low levels of Wwox expression in some tissues, notably testes, likely as a result of splicing 
around the gene-trap. They remained viable for up to 2 years of age, but Wwox
gt/gt 
mice had an 
increased death rate from 3-4 months of age as compared to WT animals (without a definable cause) 
and male mice displayed poorer reproductive abilities due to testicular defects (degeneration of 
seminiferous tumours). Despite marked difference when compared to Wwox KO animals from the 
study by Aqeilan (technology, Wwox expression, viability) Wwox
gt/gt 
mice also displayed increased 
tumorigenicity, but solely in females. This increased tumorigenicity in female Wwox
gt/gt
 as compared to 
WT mice was mainly due to high frequency of B-cell lymphomas that additionally appeared more 
invasive. Female Wwox
gt/gt
 mice also displayed adenopathies and splenomegaly and in some cases 
multiple neoplasias were noted [87]. 
Very recently the same group led by Marcelo Aldaz developed mice carrying a conditional allele of 
Wwox. Similar to the KO mice developed by Aqeilan et al., the conditional KO mice died early 
postnatally, but no tumours were noted. The authors are planning to use this model to investigate the 
role of Wwox loss in neoplastic transformation in specific target tissues in adult mice [89]. 
Consistent with the knock-out models, a genome-wide comparative oncogenomics study 
demonstrated enrichment in the number of spontaneous, retroviral, intragenic insertions promoting 
tumorigenicity in mice at the Wwox locus, overlapping with frequent deletions in human cell lines [90]. 
Collectively, the studies of Wwox knock-out mice demonstrate that WWOX is a potent bona fide 
tumour suppressor gene. However, the neoplasia spectrum and penetrance varies significantly 
dependent on the context, and the discrepancy between the two knock–out models might be, for 
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example, due to different natural predisposition for cancer development in the two backgrounds used 
[87]. Additionally, the studies on the animal models provided important insights into WWOX role in 
physiology, and this will be discussed below in detail. 
1.1.5. WWOX as a tumour suppressor: functional insights 
1.1.5.1. WWOX expression reconstitution abolishes in vitro tumorigenicity and promotes 
apoptosis 
As discussed above Wwox inactivation promotes spontaneous and carcinogen-induced tumorigenesis 
in knock-out mouse models demonstrating WWOX is a potent tumour suppressor gene [86-88]. 
Consistent with this, WWOX expression restoration abolishes in vivo tumorigenicity in xenograft 
models using WWOX-deficient breast, prostate, ovarian, lung and pancreatic cancer cell lines [42, 56, 
62, 75, 91-92]. 
Fabbri et al. [92] restored WWOX expression in WWOX-negative lung cancer cell lines. This caused 
dramatic suppression of tumorigenicity in xenograft models. This was accompanied by in vitro 
observations of WWOX-promoted apoptosis as demonstrated by the increase in sub-G1 cell cycle 
fraction (without otherwise modifying cell cycle profile), reduced growth rates, reduction in full-length 
PARP1 and pro-caspase 3 levels as well as an increase in cleaved caspase 3 signal. These effects 
were not observed in WWOX transfected lung cancer cell lines that expressed endogenous WWOX. 
This clearly demonstrated an apoptotic response, without, however, providing mechanistic insights. 
Qin et al. [75] reported a similar study in the setting of prostate cancer models. In their in vitro 
experiments the authors observed, following WWOX transfection in WWOX-deficient cell lines, 
reduction in clonogenic capacity, repression of cell growth, gain in the sub-G1 fraction, increase in 
caspase-3 and -9 activation and decrease in the levels of anti-apoptotic Bcl2. 
Very similar in vitro observations coupled with an in vivo study were reported by Iliopoulos et al. in 
breast cancer [62]. Growth inhibition of WWOX-negative but not WWOX-positive cell lines was 
observed after WWOX transfection and this was accompanied by increased caspase-3 and -9 
cleavage and Bax expression, as well as reduction in Bcl2 levels. 
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Similarly, Nakayama et al. reported caspase–dependent cell death following WWOX expression 
restoration in pancreatic carcinoma cells [56]. 
Aderca et al. [93] demonstrated that WWOX siRNA knock-down in hepatocellular cancer cell lines 
increased baseline proliferation, whereas WWOX over-expression in a WWOX-deficient cell line 
resulted in increased baseline and staurosporine-induced rates of apoptosis, as well as decreased 
baseline and FGF-stimulated proliferation. 
At the same time other groups also conducted studies that demonstrated that WWOX expression 
reconstitution abolished in vivo tumorigenicity, but did not observe any evidence of increased 
apoptosis in vitro. Notably, Bednarek et al. [42] reported the first xenograft model demonstrating 
WWOX tumour-suppressive function using breast cancer cell lines. In their in vitro experiments they 
did not observe any impact of WWOX transfection on cell growth in standard culture conditions, 
excluding a role for WWOX in proliferation and/or survival in such context, but they demonstrated 
strong inhibition of anchorage-independent growth in soft agar. This is in disagreement with the 
studies above but consistent with the findings from our group reported by Gourley et al. [91] and 
discussed below in detail. Briefly, our group demonstrated that WWOX expression restoration in a 
WWOX-null ovarian cancer cell line abolished in vivo tumorigenicity, but no difference in in vitro 
growth and apoptosis rates in standard conditions was seen. 
The reports of enhanced apoptosis in human cancer following WWOX transfection, as discussed 
above, did not provide extensive mechanistic data nor shed light on the signalling pathways involved. 
There are more data from the studies of the WWOX murine homologue, but they may need to be 
interpreted with caution as they are not always consistent with human observations. 
Chang at al. [25] demonstrated, using various mammalian and human cell lines, that WWOX/Wwox 
over-expression enhances TNF cytotoxicity and causes down-regulation of anti-apoptotic Bcl-2 and 
Bcl-xL and up-regulation of p53 (dependent on the SDR domain region referred there to as ADH – 
alcohol dehydrogenase domain), whereas expression of antisense Wwox mRNA causes resistance to 
TNF killing. This apoptotic phenotype was independent of caspases as demonstrated by the failure of 
caspase inhibitors to block cell death in those experiments. Surprisingly, transient expression of either 
the WW (amino acids 1-95) alone, or the SDR/ADH (amino acids 180-392) domain region promoted 
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cell death, even despite the fact that the product of the first construct was expressed in the nucleus, 
and the latter in cytoplasm. The authors also report an interaction between WWOX and p53 and 
suggest WWOX loss abolishes pro-apoptotic function of p53. They also demonstrated mitochondrial 
localization, with nuclear translocation of WWOX during cell stress, and show a loss of WWOX 
apoptotic function after mutating the putative nuclear localization signal (NLS, amino acids 50-55). 
Another study from the same lab demonstrated that JNK1 interacts with WWOX and this interaction, 
dependent on WWOX tyrosine (Tyr) 33 phosphorylation, blocks WWOX apoptotic function, otherwise 
resulting in a gain in the proportion of sub-G1 cells and a block in cell cycle progression. WWOX Tyr 
33 phosphorylation was stimulated by anisomycin (a bacterial antibiotic which activates stress-related 
pathways due to partial inhibition of protein synthesis) and UV light. The authors showed that 
mutation of tyrosine 33 into arginine, which removes the phosphorylation site, blocks WWOX pro-
apoptotic function [94]. Yet another report from the same group further demonstrates the significance 
of WWOX phosphorylation. The authors showed that estradiol promotes WWOX Tyr 33 
phosphorylation, nuclear translocation and interaction with p53 in estrogen receptor α (ERα) negative, 
but not ERα–positive, cell lines [44]. Other reports from Prof Chang’s laboratory demonstrate that 
WWOX siRNA knock-down abrogates UV-induced apoptosis in immortalized keratinocytes and 
cutaneous squamous cell carcinoma lines [74], UV-, TNF-, and staurosporine-induced cell death in 
fibroblasts, and p53 transfection–driven cell death in p53 negative lung cells [95]. They further 
demonstrate that WWOX forms a complex with MDM2 and stabilizes p53 protein [95]. Finally Chang’s 
group demonstrates WWOX promotes cytochrome c release from the mitochondria [96]. 
Collectively, these reports are suggestive of a pro-apoptotic role for WWOX as the basis of its tumour 
suppressive function, but there are also reports demonstrating that despite the fact that WWOX 
abolishes tumour growth in vivo in xenograft models, this is not reflected by any effects of WWOX-
transfection on baseline proliferation and survival rates in standard culture conditions. It is likely that 
these effects are highly context–dependent and may differ between different cancers and their diverse 
models. It is also worth taking note of the fact that while several studies demonstrated WWOX-driven 
caspase dependent apoptosis, other claim WWOX-induced cell death is independent of caspases. 
Furthermore, the in vitro studies that accompanied human xenograft model experiments did not report 
signalling pathways analogous to those described by Chang’s lab, and another study showing WWOX 
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interaction with p73 failed to demonstrate interaction with p53 [37], thereby leaving open the question 
of what proteins are WWOX binding partners in apoptosis. 
1.1.5.2. In search of the binding partners 
1.1.5.2.1 WWOX as a transcriptional regulator 
As discussed above WWOX contains two WW domains. WW domains mediate protein–protein 
interactions through recognition of proline-rich and phosphorylated serine/threonine–proline sites. 
Many proteins with WW domains also contain a number of other modules such as pleckstrin 
homology-, protein localization-, and phosphotyrosine-binding-domains, and a variety of catalytic 
modules including protein-ubiquitin ligase and Rho GTPase-activating domains. It has been proposed 
that WW domains provide a platform linking various proteins into physiological networks [31].  
WW domains are particularly suitable for high-throughput screening methodologies aiming at 
elucidation of protein-protein interactions, as they are small, relatively rare, well conserved, bind to 
short motifs with well–described consensus sequences, and it is believed that they function 
independently from the rest of their native protein with no requirement for cofactor recruitment [32]. 
This stimulated effort into elucidating proteins interacting with WWOX WW domains. 
Ludes-Meyers et al. [34] used WWOX WW domains as a bait. Initially they immobilized them on 
nitrocellulose membranes and probed with various proline-rich ligands. They demonstrated binding 
between the more N-terminal WWOX WW-1 domain and a peptide containing PPPY sequence, and 
failed to observe binding between proline rich peptides and WWOX WW-2. Subsequently they probed 
high-density protein arrays with WWOX WW domains peptides and found five candidate WWOX-
binding proteins, including SIMPLE (small membrane protein of the lysosome/late endosome )/LITAF, 
WW-domain binding protein-1 WBP-1, COTE1/FAM189B (FAM189B family with sequence similarity 
189, member B), SCOTIN/SHISA5 and one non-annotated protein, all of them containing PPxY motif. 
The interaction with endogenous SIMPLE was confirmed by GST pull-down assays from cellular 
extracts and partial co-localization was shown. The significance of these interactions remains largely 
unexplained and there is little literature on these proteins but SCOTIN may have a role in apoptosis 
[97] and SIMPLE is implicated in TNF signalling [98]. 
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Another global attempt at determining the WWOX WW domain interactome was conducted by AxCell 
Biosciences based on high-throughput, biochemical, ELISA-like methodology, using GST-tagged 
WWOX WW domain peptides combined with bioinformatics, and the preliminary results were 
validated by Carlo Croce’s group [32, 37, 99]. Strikingly, WWOX was reported to bind via its first WW 
domain to several transcription factors containing the PPxY motif such as p73 [37], AP2γ, AP2α [38], 
c-Jun [100] and ErbB4, a receptor tyrosine kinase whose C-terminal cleavage fragment functions in 
the nucleus [101]. 
The first of these studies reported on WWOX-p73 interaction [37]. The interaction was confirmed by 
GST pull-down assays as well as in vivo co-immunoprecipitation of tagged and endogenous proteins, 
and there was no interaction with p53 in the same conditions. By site-directed mutagenesis of either 
p73 (replacing tyrosine 487 with alanine) or WWOX (mutation of tyrosine 33 into arginine), the authors 
showed that WW-1 domain of WWOX and the PPPPY motif in p73 are indispensable for the 
interaction. It was also demonstrated that WWOX only pulled down the p73β isoform contaning the 
proline-rich motif but not p73γ which lacks this sequence. By confocal microscopy the authors 
demonstrated that WWOX causes cytoplasmic sequestration of p73 that is otherwise located in the 
nuclei. Subsequently the study reports that WWOX inhibits p73 trans-activity, as shown using a 
relevant luciferase reporter construct and also by the demonstration of reduced expression of p21, 
which is a p73 target gene. Further the authors demonstrate that p73 and WWOX may cooperate in 
the induction of apoptosis, but the results are difficult to interpret as this enhancement of apoptosis 
was not only seen when wild type WWOX and full length p73 were co-transfected but was similar, or 
even more pronounced, when tyrosine 33 mutated WWOX (which cannot bind p73) or the ΔNp73 
isoform (both having no pro-apoptotic effect in single transfection) were co-transfected with the WT 
form of the other protein. Finally the authors demonstrate that Src protein kinase phosphorylates 
WWOX at tyrosine 33 and this enhances the interaction with p73. 
Similarly designed studies from the same group demonstrated WWOX interaction with AP2γ, AP2α 
[38] and c-Jun [100]. The authors demonstrate the physical interaction between WWOX and the 
partner protein by GST pull-down assays and co-immunoprecipitation, and show with mutagenesis 
that this is based on the recognition of the PPxY motif by WWOX WW-1 domain. Subsequently they 
demonstrate WWOX mediated cytoplasmic sequestration of the transcription factor and inhibition of 
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its trans-activity [38, 100]. This allows the authors to propose a model of WWOX function whereby 
WWOX interacts with potentially oncogenic PPxY motif containing transcription factors, sequesters 
them in the cytoplasm and thus inhibits their activity to block the expression of target genes. Figure 
1.2 presents a schematic representation of this model of WWOX function. 
 
Figure 1.2 
WWOX as a transcriptional regulator – transcription factor sequestration model 
1. WWOX sequesters PPxY motif transcription factors (such as AP2γ, c-Jun, p73) in the cytoplasm 
due to direct physical binding via the WW domain. 2. When WWOX is lost the transcription factors 
translocate to the nucleus and their target genes are up-regulated. 
 
Subsequently the authors demonstrate that WWOX interacts with receptor tyrosine kinase ErbB4 
[101]. The C-terminal fragment of ErbB4 (CTF) can be released by γ-secretase, following kinase 
activation and cleavage of the ectodomain, and translocates to the nucleus where it can behave as a 
transcriptional regulator in the presence of the tandem WW domains containing co-activator protein 
YAP (Yes-associated protein). WWOX associates with ErbB4 as shown by co-immunoprecipitation 
and this is dependent on WW/PPxY recognition. Further, they demonstrate that WWOX and ErbB4 
colocalize in the cytoplasm, and WWOX co-expression prevents the CTF fragment from nuclear 
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translocation. Finally the authors show that WWOX abrogates YAP co-activator driven ErbB4 CTF 
trans-activity and this is dependent on WWOX WW-1 domain. WWOX competes with YAP for ErbB4 
binding as demonstrated by the gradually reduced levels of WWOX co-precipitation with ErbB4 when 
YAP expression is increased. Subsequently, the study also demonstrates that WWOX antagonizes 
YAP co-activation function towards p73 [101]. This report complements reports of WWOX interactions 
with PPxY motif containing transcription factors and further supports the model of WWOX as a 
transcriptional regulator. 
AP2 transcriptions factors, c-Jun, p73 and ErbB4 are involved in a plethora of cellular processes, 
including tumorigenesis, in multiple tissues. The oncogene JUN is the putative transforming gene of 
avian sarcoma virus. The literature on c-Jun dates back to 1980s and JUN was shown to promote a 
number of cancer-relevant cellular phenomena such as proliferation and survival and to be activated 
in cellular stress. c-Jun complexes with the Fos, Maf and ATF proteins to form the AP1 transcription 
factor. c-Jun is regarded as a growth promoting and anti-apoptotic protein and this is due to c-
Jun/AP1 mediated down-regulation of such tumour suppressive proteins as p53, p21 and p16, and 
up-regulation of cyclin D1, promoting cell cycle progression [102]. The significance of WWOX/c-Jun 
interaction in cancer has not been further investigated. 
p73 is a p53 tumour suppressor homologue and they have significant sequence and functional 
similarity. p73 binds to the same target gene promoter consensus sites as p53. TP73 mutations in 
cancer are rare but LOH is frequently observed. However, p73 has several isoforms, due to 
alternative splicing and the use of alternative promoters, some of which (N-terminally truncated 
ΔNp73) lack the transactivation domain and may be actually oncogenic due to a dominant negative 
impact on p73 or p53. p73 was reported to be pro-apoptotic and the mechanisms of its anti-survival 
role are believed to be largely identical to those of p53, and involve the transcriptional regulation of 
apoptosis regulators such as Bax or Puma [103]. It has been shown at the mRNA level that some of 
the N-terminally truncated p73 isoforms are over-expressed in ovarian cancer [104]. 
ErbB4 is structurally and functionally similar to other ErbB receptor tyrosine kinases, and has ecto-, 
transmembrane and cytoplasmic domains. However, ErbB4 is uniquely sensitive to ectodomain 
cleavage compared to other family members, is active without a co-receptor and has several 
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isoforms. ErbB4 ligands are neuregulins and some members of the EGF family. Ligand binding 
results in dimerization and autophosphorylation of the ErbB4 receptor. The downstream effects 
include increased cell proliferation or survival, differentiation and chemotaxis [105] as well as 
transcriptional regulation due to nuclear translocation of the C-terminal fragment of ErbB4 [51, 106]. 
ErbB4 is expressed in various human tumours but it is also ubiquitously expressed in most normal 
tissues [106]. ErbB4 is expressed in the majority of ovarian cancers and the co-expression of ErbB4 
and ErbB2 correlated with better survival in stage III patients [107]. 
Aqeilan et al. [51] attempted to assess the clinical significance of WWOX/ErbB4 interplay using 
immunohistochemical analysis of 556 breast cancer patients. Membranous location of ErbB4 was 
associated with improved survival versus women whose disease lacked such feature. WWOX 
expression was strongly correlated with membranous ErbB4 but not nuclear location, and presence of 
WWOX associated with favourable survival in patients with cell membrane ErbB4. Finally they show in 
vitro, by WWOX over-expression, siRNA knock-down and comparison of mouse embryonic fibroblasts 
(MEFs) from Wwox-null and WT mice, that WWOX is responsible for maintaining ErbB4 protein 
expression levels. Collectively [51, 101], the authors propose that WWOX suppresses ErbB4 nuclear 
activity but stabilizes membranous ErbB4, however another study failed to demonstrate a link 
between WWOX and ErbB4 levels [52]. 
AP2γ seems to be the best validated WWOX binding partner and contains two PPxY motifs, both of 
which were demonstrated to be capable of interaction with WWOX [38]. Several studies followed-up 
the possible clinical significance of that interaction and demonstrated a role for the interplay between 
WWOX and AP2γ in cancers of hormone-responsive organs [49, 52, 108]. This is consistent with 
previously reported WWOX clinical correlations and its postulated role in steroidogenesis or steroid 
response, based on WWOX expression pattern and protein structure [20, 39-40, 44, 53]. The AP2γ 
locus at 20q13.2 is amplified in breast cancer [109-110] and is regarded as a candidate oncogene in 
this neoplasia [111-113], a disease setting where WWOX is very well established as an important 
tumour suppressor. Therefore, AP2γ appears to be a particularly valid example for a ‘proof-of-
principle’ study in the setting of ovarian cancer model and will be further discussed in Chapter 5.  
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Recently the same group demonstrated the interaction between WWOX and another PPxY motif 
containing transcription factor Runx2. This was shown by co-immunoprecipitation, and the authors 
also demonstrate that the Runx2/WWOX complex associates with the osteocalcin promoter, which is 
neither consistent with their previous reports of WWOX being solely located to the cytoplasm nor with 
the model of WWOX causing cytoplasmic sequestration of transcription factors [114]. This study will 
be further discussed below in the context of WWOX role in normal physiology. 
Another group [41] demonstrated that WWOX interacts with Dishevelled-2 (DVL-2), a protein involved 
in the Wnt/β-catenin signalling pathway, by a yeast-two-hybrid screen and co-immunoprecipitation. 
They showed that the interaction requires presence of both WW and SDR domains of WWOX, 
whereas within DVL-2 the interaction was mapped to amino acids 231-409 containing the PDZ 
domain. DVL-2 possesses a PPxY motif but this motif is located at amino acids 565-568, outside of 
the interaction region proposed in the study. The authors utilized luciferase reporter plasmids with 
TCF (T-cell factor family of proteins whose transactivity is stimulated by activated Wnt/β-catenin 
pathway) binding elements, as well as the cyclin D1 (CCND1) promoter that is an established target 
of the Wnt/β-catenin pathway, and demonstrated that WWOX over-expression inhibits transcriptional 
activity of Wnt/β-catenin pathway. As expected WWOX siRNA knock-down stimulated TCF element 
reporter transcriptional activity and also increased the basal levels of β-catenin in the cells (but there 
was no effect of WWOX expression manipulation on DVL-2 protein levels). It is worth noting that the 
authors observed the effect of WWOX ectopic expression in both MCF-7 and BT-474 breast cancer 
cell lines – previously shown to have high-WWOX and low-WWOX expression respectively [62]. 
Finally, consistent with the model proposed by Aqeilan, WWOX sequestered DVL-2 in the cytoplasm 
as demonstrated by immunofluorescence [41]. However, to demonstrate this, the authors transfected 
WWOX expression plasmid in MCF-7 cells that already express high levels of endogenous WWOX, 
whereas Aqeilan and his co-workers described nuclear translocation of p73 in the same cell line 
following WWOX siRNA knock-down [37], which questions the pathophysiological validity of this over-
expression experiment. Even given some difficulties with interpretation of the results, this is another 
study that is suggestive of the role for WWOX of a potent transcriptional regulator. It is also worth 
taking note that several other transcription factors posses the PPxY motif including RUNX1, SMAD3, 
PPARγ, OCT4, BMP4, BMP7 and p63. 
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1.1.5.2.2. WWOX binding partners that are not directly linked to gene expression regulation 
Several other proteins were reported as WWOX binding partners, both containing and lacking the 
PPxY motif. Mahajan et al. [69] demonstrated that over-expression of the non-receptor tyrosine 
kinase Ack1 (acitivated cdc42 associated kinase 1) in prostate cancer cells accelerated tumorigenesis 
in a xenograft model and enhanced anchorage-independent cell growth in vivo. They utilized an 
immunoaffinity assay with myc antibody resin and lysates from myc-tagged Ack1- (or empty vector-) 
transfected prostate cancer cells coupled with electrophoresis, gel band excision and mass 
spectrometry analysis of the peptide, and indentified the 36 kDa interacting protein as WWOX protein 
isoform lacking the region corresponding to exons 5-8 (Δ5-8 WWOX). They further confirm this finding 
by co-immunoprecipitation and demonstrate that full length WWOX protein is absent in complexes 
with constitutively active Ack1, but co-precipitates with mutant Ack1 with disrupted kinase activity, 
which suggests that Ack1-dependent phosphorylation of WWOX affects the stability of this interaction. 
They demonstrate that Ack1 phosphorylates WWOX (but not Δ5-8 WWOX), and map the 
phosphorylation site to tyrosine 287 (but not WWOX tyrosine 33, previously shown to be a 
phosphorylation site). This leads to WWOX ubiquitination and subsequent proteasomal degradation 
[69]. Ack1 contains a PPxY motif. This kinase can phosphorylate WWOX protein in which WW-1 
domain was mutated (change of the tyrosine 33 into phenylalanine) [69], which most likely suggests 
that a change into phenylalanine is conservative enough to preserve the interaction or that the 
interaction is not mediated by the WW-1 domain unlike the case with PPxY transcription factors. As 
mentioned above this study proposes an interesting mechanism of WWOX expression loss in cancer 
complementary to genetic and epigenetic events. 
Another group identified WWOX in a screen for ezrin binding partners [46]. Ezrin is an actin–binding 
protein belonging to the ezrin-radixin-moesin family of cytoskeleton-membrane linker proteins. They 
identified WWOX by gel electrophoresis/MS analysis of proteins eluted from ezrin affinity columns and 
confirmed this finding with co-immunoprecipitation. Further, deletion mutagenesis of GST–fused 
proteins was used to demonstrate binding is mediated by the WWOX WW-1 domain and the PPPVY 
motif of ezrin. They also demonstrate by confocal microscopy WWOX/ezrin partial colocalization and 
that the interaction with ezrin recruits WWOX to the apical membrane of the gastric parietal cells, 
whereas disruption of this interaction (mutant ezrin) results in WWOX cytoplasmic localization [46]. 
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The significance of WWOX/ezrin interaction was not investigated in the setting of neoplastic diseases. 
Ezrin was postulated to be important in metastatic phenomena in sarcomas [115-116] and its retained 
expression correlated with poor survival in ovarian cancer in one study [117]. 
As described above, WWOX was also demonstrated to interact with p53, Mdm2 [25, 95] and Jnk1 
[94] and these proteins do not have the PPxY motifs. Another WWOX binding partner described by 
Chang’s group is Zfra (zinc-finger-like peptide that regulates apoptosis), a protein with dual context-
dependent pro-and anti-apoptotic roles, and the interaction with WWOX was suggested to block the 
apoptotic function of WWOX [96, 118-119]. 
The same group also demonstrated that WWOX is down-regulated in autopsy brain samples of 
patients with Alzheimer’s Disease (AD). Subsequently they demonstrated by in vitro experiments that 
WWOX siRNA knock-down induces phosphorylation of the Tau protein in a neuroblastoma cell line. 
Tau phosphorylation is considered to be important for the formation of the neurofibrillary tangles 
(NFTs), which are strongly implicated in AD pathogenesis. The authors demonstrate that WWOX 
knock-down in the same cell line causes increased neurofibrillary tangle formation as determined with 
an NFT–specific antibody. Further they show that WWOX co-localizes with Tau, JNK and GSK3β 
(glycogen synthase kinase 3β), and that WWOX-dependent changes in phosphorylation of kinases 
such as GSK3β or ERK/MAPK1 (mitogen-activated protein kinase 1) may alter Tau phosphorylation. 
Finally they demonstrate that WWOX physically interacts with Tau and that this interaction is likely 
mediated by the C-terminal SDR domain of WWOX [120]. 
Finally, the fact that WWOX is phosphorylated by SRC would also imply that WWOX and SRC are 
interaction partners [37]. 
In conclusion, a number or proteins have been demonstrated to be WWOX binding partners and in 
most cases this was attributed to the WW/PPxY recognition (however most of the approaches were 
only trying to elucidate WW domain-dependent interactions). The common topic is WWOX interaction 
with transcription factors or co-factors leading to inhibition of their trans-activity, but much less is 
known about WWOX interacting proteins directly relevant to its pro-apoptotic function. 
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1.2. WWOX in ovarian cancer 
1.2.1. Epithelial ovarian cancer 
1.2.1.1. Clinical presentation –symptoms and signs 
Ovarian cancer is frequently referred to as a ‘silent killer’ but this leaves the incorrect notion that the 
disease is generally asymptomatic. Ovarian tumours produce several symptoms, though unspecific 
and common to several more prevalent pelvic, and especially abdominal, conditions. Patients report 
the feeling of abdominal fullness and discomfort, constipation, early satiety, dyspepsia and bloating. 
These are due to increased abdominal pressure and are more pronounced in advanced disease, 
whereas early disease may truly be asymptomatic. Pain or presentation as a surgical emergency are 
not common. The findings on physical examination vary and may include a palpable pelvic mass, 
distension of the abdomen, ascites, pleural effusions, and enlarged lymph nodes. Paraneoplastic 
syndromes are not common [121-122].  
1.2.1.2. Ovarian cancer epidemiology 
There is some variation in the epidemiological data across various populations and periods when the 
data were collected. The incidence is highest in Europe and Northern America and lowest in Asia and 
Africa. The lifetime risk of ovarian cancer is estimated at 1 in 70 (1.4%) and the lifetime risk of dying 
from ovarian cancer at 1 in 95 [123-124]. In the European Union ovarian cancer is the sixth 
commonest cancer in women (5% of all female cancers) with about 60 000 new cases and 40 000 
deaths annually [122]. Epithelial ovarian cancer is uncommon below the age of 40 years and the 
majority of cases occur in peri- and postmenopausal women. The median age at diagnosis is 63 
years and the incidence peaks between 80 and 84 years of age [122, 125]. 
Survival is generally low, however the 5-year survival rates improved moderately over the last two 
decades (from 37-41% to 44-46% in the United States and Europe), but there is no corresponding 
improvement in the cure rates (as determined by survival 10 years after diagnosis, estimated at 
around one-third) [125-126]. Five-year survival is markedly decreased in the group of patients older 
than 75 years (20%) as compared to the youngest patients below 45 years (70%). 
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Epithelial ovarian tumours account for 90% of ovarian neoplasms but the other non-epithelial and 
biologically distinct pathologic entities are also very important clinically and frequently affect younger 
women (especially germ cell tumours). These include sex–cord stromal tumours, germ cell tumours, 
sarcomas and lymphomas [123, 127]. Ovary might be also a metastatic site for other epithelial 
tumours (sometimes referred to as Krukenberg tumours [128]). 
1.2.1.3. Ovarian cancer staging and patterns of spread 
One of the main factors causative to poor survival in ovarian cancer is that two-thirds
 
of all cases are 
diagnosed when the cancer is disseminated in the peritoneal cavity or spread to other organs (FIGO –
International Federation of Gynaecology and Obstetrics – stages III and IV) [126]. Ovarian cancer 
staging is presented in Table 1.3 adopted from the report by Benedett et al. [123]. Recent studies 
reported that 28-37% of tumours were diagnosed as stage I, 8% stage II, 44-47% stage III and 11-
18% stage IV [126, 129]. Survival is to a huge extent predetermined by the stage at diagnosis so it is 
believed that improving the diagnosis at early stages would reduce the mortality. 5-year overall 
survival rates are reported at 84-93% for stage I (highest in stage IA), 65-71% in stage II, 33-47% in 
stage III and 19% in stage IV [122, 124]. 
The unique clinicopathological feature of ovarian cancer is the fact that the transcoelomic route of 
metastasis is most common, and this locoregional peritoneal spread is what most patients die of 
rather than haematogenous metastasis as in most other cancers [130]. Interestingly, it was reported 
that patients classified as stage IIIC on the basis of lymph node involvement have better prognosis 
than stage IIIC patients with peritoneal spread [131-132]. The dissemination usually includes pelvic 
and abdominal visceral peritoneum as well as diaphragmatic and liver surfaces. Such spread is 
suggested to consist of several steps including detachment from the primary site, the transcoelomic 
journey promoted by the very frequent presence of ascitic fluid (and requiring evasion of anoikis, cell 
death whilst in suspension, facilitated by multicellular spheroid formation), attachment to the 
secondary site at the peritoneal wall and subsequent signalling mediating survival, invasion and 
angiogenesis. Several molecules are implicated in ovarian cancer peritoneal dissemination including 
VEGF (vascular endothelial growth factor) and VEGF receptors (implicated in ascites formation and 
angiogenesis), integrins, CD44 (hyaluronan receptor) and other adhesion molecules playing a role in 
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spheroid formation, attachment to the peritoneal wall and pro-survival signalling pathways [123, 130, 
133]. I discussed the mechanisms of locoregional peritoneal dissemination in ovarian cancer in more 
detail elsewhere [134]. 
FIGO stage  
I Tumour limited to the ovaries 
IA Tumour limited to one ovary, capsule intact, no tumour on ovarian surface, no 
malignant cell in ascites or peritoneal washings 
IB Tumour limited to both ovaries, capsule intact, no tumour on ovarian surface, no 
malignant cell in ascites or peritoneal washings 
IC Tumour limited to one or both ovaries, with any of the following: capsule ruptured, 
tumour on ovarian surface, malignant cell in ascites or peritoneal washings 
 
II Tumour involving one or both ovaries with pelvic extension 
IIA Extension and/or implants on uterus and/or tubes, no malignant cell in ascites or 
peritoneal washings 
IIB Extension to other pelvic tissues, no malignant cell in ascites or peritoneal washings 
IIC Pelvic extension (as IIA or IIB) and malignant cell in ascites or peritoneal washings 
 
III Tumour involving one or both ovaries with microscopically confirmed peritoneal 
metastasis* outside the pelvis and/or regional lymph node metastasis 
IIIA Microscopic peritoneal metastasis beyond pelvis  
IIIB Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension  
IIIC Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or 
regional lymph node metastasis 
 
IV Distant metastasis* (excludes peritoneal metastasis) including pleural effusion with 
positive cytology 
*-liver capsule metastasis is stage III, liver parenchymal metastasis is stage IV 
Table 1.3 
Ovarian cancer staging 
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1.2.1.4. Serum markers and screening for ovarian cancer 
Cancer antigen 125 (CA125, a cell adhesion molecule mucin 16) was originally found to be elevated 
in 80% of women with ovarian cancer and only 1-2% of the normal population. The value of serum 
CA125 as a screening tool is limited however as only 50% of stage I ovarian cancers express CA125, 
and CA125 might be elevated in a number of other conditions including other cancers, endometriosis, 
pelvic inflammatory disease, hepatitis or pregnancy [124]. On the other hand, CA125 measurement is 
an extremely important tool in monitoring ovarian cancer therapy and has very widespread clinical 
use. Novel experimental markers include mesothelin, telomerase, and YKL-40/CHI3L1 (chitinase-3-
like 1) [135]. It is hoped that combining CA125 measurement and ovarian imaging with transvaginal 
ultrasonography may provide efficient, cost-effective and widely acceptable screening strategies for 
ovarian cancer and several screening trials are ongoing [124].  
1.2.1.5. Epithelial ovarian cancer aetiology 
Ovarian carcinoma is thought to arise from ovarian surface epithelium (OSE) although there is 
growing evidence for its origin from cells of the fallopian tube epithelium, peritoneal lining or 
endometriosis [136-140]. OSE is a cuboidal, monolayered epithelium that forms part of the lining of 
the intraembryonic coelom early in development and shares origin with extra-ovarian peritoneal 
mesothelium. Interestingly, unlike other epithelia, OSE do not express the important epithelial marker 
E-cadherin [136]. It has long been noted that the cumulative number of ovulations is linked to ovarian 
cancer risk, while pregnancies, prolonged breast feeding and oral contraception – that reduce the 
number of ovulations – diminish the risk. Two major theories, ‘incessant ovulation’ and ‘gonadotropin 
release’, have been proposed as an explanation for the epidemiological data. The ‘incessant 
ovulation’ theory proposes that the repetitive cycles of OSE wounding and proliferative repair promote 
accumulating mutations and consequently carcinogenesis. It is also suggested that the ovulation-
related inclusion cysts are the environment for ovarian carcinoma origins. The gonadotropin theory 
proposes that the surges of gonadotropin release also induce cellular transformation and this might 
be due to promoting inflammation or affecting tissue organization, including transient loss of 
basement membrane. The ‘inflammation theory’ is also proposed independently of the ‘gonadotropin 
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release’ hypothesis. The mechanisms suggested by the theories are likely complementary and are all 
related to ovulation [141-143]. 
The data on environmental factors in ovarian carcinogenesis are sparse and frequently contradictory 
and point to dietary factors and talc exposure. Ovarian cancer is most common in developed 
countries with the exception of Japan [122].  
1.2.1.5.1. Hereditary forms of ovarian cancer 
Up to 10% of all ovarian cancers result from a hereditary predisposition and three distinctive patterns 
have been described. In breast-ovarian cancer syndrome two or more cases of ovarian and breast 
cancer in successive generations are seen, and this is accompanied by early age at diagnosis. The 
syndrome is transmitted in an autosomal dominant mode with variable penetrance and has been 
mapped to BRCA1 (breast cancer 1, early onset gene at chromosome 17q) and BRCA2 (13q) genes. 
The lifetime risk of ovarian cancer in these families is lower than that of breast cancer and highly 
dependent on the mutation seen and other genes or factors modifying the risk (16-63%). 
Ovarian cancer incidence is also increased (12% lifetime risk) in patients with hereditary non-
polyposis colorectal cancer (HNPCC, Lynch syndrome II) that is otherwise characterized by an excess 
of colorectal and endometrial cancers. This syndrome is due to inherited defects in DNA mismatch 
repair genes (hPMS1, hPMS2, hMLH1, hMSH2). 
Site-specific ovarian cancer syndrome is associated with 4-7% lifetime risk of ovarian cancer and was 
also linked to a spectrum of BRCA1 mutations that are not specific for breast cancer. 
Prophylactic oophorectomy might be offered to patients with genetic predisposition to ovarian cancer 
whose childbearing is complete but this is not completely protective against already present occult 
ovarian cancer or primary peritoneal cancer and not universally recommended given the 
psychological burden.  
BRCA1 and -2 proteins have multiple functions apart from the most important role in DNA repair by 
homologous recombination. BRCA1 is also a transcription factor regulating estrogen receptors, plays 
a role in chromatin remodelling and interacts with p53 and Rb tumour suppressor genes products to 
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control cell cycle progression. BRCA2 also plays a role in cell cycle checkpoint control and in 
chromatin remodelling [122, 144]. 
The reports on the role of BRCA1 and BRCA2 genes in sporadic ovarian cancer are conflicting. Some 
authors reported that more than 80% of sporadic ovarian cancers contained genetic or epigenetic 
alterations in BRCA1, BRCA2 or both [145] and that BRCA1 or -2 related molecular pathways are 
also altered in sporadic tumours [146], whereas others suggest BRCA2 is actually over-expressed in 
ovarian cancer [147]. Importantly patients with BRCA1 or -2 related ovarian cancer have better 
outcomes then other groups of patients due to higher response rates to platinum based treatment 
[148]. The emerging role of poly (ADP-ribose) polymerase (PARP) inhibitors in the management of 
patients with BRCA–deficient tumours is discussed below. 
1.2.1.6. Histological subtypes of ovarian cancer and grading 
Epithelial ovarian cancer is subclassified into the following histotypes: serous, mucinous, 
endometrioid, and clear cell as well as Brenner cell (very rare), undifferentiated and mixed tumours 
[123, 149]. 
Serous histology is the most common subtype (80-85%) with a wide spectrum of morphological 
changes, that usually presents with high-stage disease and is associated with elevated CA125 levels. 
Only 3-4% of ovarian carcinomas are of mucinous type and they resemble cells of endocervix, gastric 
pylorus or intestine. Mucinous tumours are relatively less responsive to chemotherapy than other 
subtypes. Endometrioid tumours closely resemble those seen in endometrium and account for 10% of 
ovarian carcinomas. These are usually diagnosed as an early stage disease and are frequently 
associated with endometriosis. Clear cell carcinoma (approximately 10% of ovarian carcinomas) also 
typically presents with early-stage disease, but this subtype is associated with worse prognosis than 
other low-stage ovarian cancers and is less likely to respond to chemotherapy [121, 149-150]. The 
characteristic genetic alterations and specific biological characteristics will be described below as they 
frequently traverse the traditional subtypes and are best discussed in view of the dualistic model of 
low-grade and high-grade ovarian cancer pathogenesis. 
Surprisingly, and unlike in other neoplasia, epithelial ovarian cancer appears more differentiated than 
its cells of origin (OSE cells), exhibits complex patterns of histologic differentiation, and, in contrast to 
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OSE, expresses the important epithelial marker E-cadherin. Serous tumours resemble epithelium of 
the fallopian tube, endometrioid tumours resemble endometrial tissues, whereas mucinous tumours 
mimic endocervix. Clear cell carcinomas express features similar to mesonephros [136, 151]. 
Epithelia of the reproductive tract (such as fallopian, endometrial, or cervical) derive embryologically 
from müllerian ducts, whereas OSE derive from other regions of coelomic epithelium. Apparently, 
ovarian carcinoma involves cellular ‘’differentiation-up’’ towards more committed phenotypes 
resembling tissues related to OSE but evolved through different pathways. A series of elegant studies 
demonstrated that this is due to aberrant expression of homeodomain HOXA genes. HOXA genes are 
not expressed in OSE but are expressed in the reproductive tract (HOXA9 in fallopian tubes, HOXA10 
in uterus and HOXA11 in cervix). The expression of HOXA9, -10, and -11 is recapitulated respectively 
in serous, endometriod and mucinous tumours. The significance of HOXA genes in the differentiation 
of clear cell tumours is less well established but these tumours express HOXA9 and HOXA10. OSE 
cells can undergo differentiation along müllerian lineages after experimental ectopic expression of 
HOXA genes. It is not well established whether apart from the differentiation patterns HOXA genes 
also contribute to neoplastic transformation in ovarian cancer [151-153]. 
1.2.1.6.1. Benign and borderline tumours 
Borderline tumours (LMP, low malignant potential) form a separate type of epithelial ovarian 
neoplasms. They are characterized by a degree of cellular atypia but no infiltrative growth or stromal 
invasion. They occur in younger patients than carcinomas and are usually diagnosed in early stage, 
which results in excellent survival rates. Surgical removal is fundamental to the cure but its extent is a 
matter of controversy in view of possible fertility preservation. There is no evidence for improved 
survival due to postoperative chemotherapy [154]. The significance of serous borderline tumours as a 
precursor lesion for low-grade serous carcinomas will be discussed below. There are genetic 
abnormalities specific for borderline tumours e.g. BRAF (v-raf murine sarcoma viral oncogene 
homolog B1) mutation in serous; KRAS (Kirsten rat sarcoma viral oncogene homolog) in serous, 
mucinous and clear cell; PTEN (phosphatase and tensin homolog) and β-catenin in endometrioid 
subtypes [155]. 
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Apart from malignant and borderline tumours each histotype of ovarian epithelial tumours may also 
appear as a benign tumour [122]. 
1.2.1.6.2. Grading in ovarian cancer 
There is still no universally accepted ovarian cancer grading system but in view of the ovarian 
carcinoma heterogeneity a histotype–specific system is advisable. FIGO system is based on 
architectural features (grade 1, 2 and 3 containing respectively less than 5%, 5-50% and more than 
50% of solid component). WHO system also has 3 grades but these are not defined in a quantitative 
manner and are based on pathologist impression. Clear-cell carcinoma is treated as high-grade by 
definition. Even with some discrepancies there are significant correlations between high grade and 
advanced stage and importantly in patients with stage I disease, grading is the most important 
prognostic factor [122, 156]. 
1.2.1.7. Novel molecular subclasses, key genetic abnormalities and hallmarks of ovarian 
cancer biology 
1.2.1.7.1. Two-pathway model of ovarian carcinoma 
At the histological and molecular level ovarian cancers are remarkably heterogenous and there is 
growing genetic, molecular and clinical evidence for two broad pathways in ovarian carcinogenesis. 
This is most pronounced in serous tumours. High-grade tumours have no defined precursor lesion, 
are rapidly growing and relatively chemosensitive. Low-grade tumours grow slowly and have better 
overall survival than high-grade tumours but are less responsive to chemotherapy. Low-grade 
tumours share molecular characteristics with borderline/LMP tumours and frequently contain areas of 
LMP. In particular, KRAS and BRAF mutations are rarely detected in high-grade serous carcinoma 
(HGSC) but are frequent in low-grade serous carcinoma (LGSC) and LMP tumours. On the other 
hand TP53 is frequently mutated whereas HER2, AKT and HLA-G (human leukocyte antigen-G) are 
frequently over-expressed in high-grade but not low-grade tumours. Tumours in patients with BRCA 
inactivation have HGSC histology. It is believed that LGSC account for less than 5% of ovarian 
carcinomas and arise from borderline/LMP tumours, whereas LMP tumours do not progress into 
HGSC. LGSC progression into HGSC is rare [143, 149]. KRAS and BRAF mutations were also found 
in serous cystadenomas, the putative precursor lesions for serous borderline tumours [157], which 
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suggests that KRAS or BRAF mutations are early events in tumorigenesis and the pathogenesis of 
LGSC has defined stages: benign cystadenoma –LMP –LGSC, distinct from HGSC of no obvious 
precursor lesion, but resembling the pattern in colorectal cancer and melanoma (where RAS or BRAF 
mutations occur in preinvasive stages – that is adenomatous polyp and nevus respectively) [155].  
Some authors propose dividing all epithelial ovarian tumours into type I (prototypic tumour LGSC) and 
type II (exemplified by HGSC). Type I are slow growing and develop from well-defined precursor 
lesions (LMP). They are genetically stable and mutational spectrum includes KRAS, BRAF, PTEN 
and CTNNB1 (β-catenin gene). Type I tumours include LGSC, mucinous, clear cell and endometrioid 
subtypes. Type II are aggressive tumours with no defined precursors including HGSC and 
undifferentiated carcinomas. Genetic instability and TP53 mutations are typical [139]. 
Finally, it has been recently postulated that the true cell of origin of HGSC/type II ovarian carcinoma is 
fallopian tube secretory epithelium rather than ovarian surface epithelium that LGSC/type I tumours 
originate from [140]. 
1.2.1.7.2. Other histotype–specific genetic abnormalities in ovarian 
Apart from the genetic abnormalities typical in serous tumours described above there are common 
genetic events in the other histotypes as well. Typical alterations in mucinous tumours are KRAS 
mutations and relatively frequent ERBB2 amplification. Endometrioid carcinoma is characterized by 
somatic mutations in CTNNB1 and PTEN. Clear cell carcinoma is not well characterized molecularly 
but a gene expression pattern separating from other subtypes can be indentified [149, 158]. 
1.2.1.7.3. Tumour suppressors and oncogenes in ovarian cancer 
There are myriads of genetic and epigenetic abnormalities in ovarian cancer, but most attention is 
given to a set of well defined tumour suppressor genes and oncogenes. Their deregulated expression 
and function results in the appearance of cancer traits as defined by Robert Weinberg that includes 
self-sufficiency in growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless 
replicative potential, sustained angiogenesis, invasiveness and metastasis, that are postulated to be 
shared between all cancers [159]. Different phenotypic expression of these cancer traits in each 
unique neoplasia such as ovarian carcinoma is likely due to the specific features of the cells and 
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target tissue as well as their interaction with the compartment where the cancer is progressing. 
Ovarian cancer cells display all these ‘cancer traits’ during the natural course of this disease. 
1.2.1.7.3.1. Tumour suppressor genes in ovarian cancer 
The significance and prevalence of BRCA1 and BRCA2 tumour suppressors inactivation in familial 
and sporadic ovarian cancer was described above. 
TP53 (tumour protein p53 gene) genetic abnormalities are observed in 60-80% of ovarian cancers. 
TP53 is considered the single most important tumour suppressor gene in humans, whose inactivation 
promotes tumorigenesis:  ‘the guardian of the genome’. TP53 has been already implicated in virtually 
every process in tumorigenesis and the ample literature will not be further discussed here [160-161]. 
In the setting of ovarian cancer, adenoviral restoration of p53 was attempted clinically but so far this 
has not provided improvements in response to standard therapy [162]. 
PTEN is a protein/lipid phosphatase and its main substrate is PIP3 (phosphatidyl inositol 3,4,5-
triphosphate), the product of PI3K (phosphatidyl inositol-3 kinase). PIP3 accumulation as a result of 
PTEN loss results in activation of several signalling pathways and especially the AKT/PKB oncogenic 
kinase. AKT has pleiotropic effects on cell behaviour including pro-survival signalling, proliferation, 
metabolism and migration, contributing to malignant transformation and chemoresistance [163]. PTEN 
LOH was reported to be common in endometrioid (43%) and serous (28%) tumours. Twenty-one 
percent of endometrioid tumours had somatic PTEN mutations whereas no somatic mutations were 
seen in serous tumours. 
A GTPase ARHI (DIRAS3, DIRAS family, GTP-binding RAS-like 3) is subject to frequent LOH, 
promoter hypermethylation or transcriptional deregulation in ovarian cancer leading to down-
regulation in more than 70% of cases [164]. ARHI was shown to be a suppressor of ovarian 
tumorigenesis due to inhibition of proliferation and induction of autophagic cell death [165-168]. 
RASSF1 (Ras association domain family member 1) was linked to modulation of cell cycle, apoptosis, 
genomic stability and invasion [169]. RASSF1 is lost due to promoter hypermethylation in 10-40% of 
ovarian carcinomas [170-171]. 
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DOC2/DAB2 (disabled homolog 2) was cloned from a library of cDNAs expressed in normal ovarian 
epithelium but lost in ovarian tumours. DAB2 loss is particularly frequent in serous tumours (80%) and 
was shown to inhibit tumour growth [172]. In breast cancer DAB2 was shown to promote anoikis and 
this was likely due to ILK inhibition [173]. 
OPCML (opioid binding protein/cell adhesion molecule-like) is lost due to LOH, somatic mutations and 
promoter hypermethylation in 83% of ovarian cancers and is a potent inhibitor of ovarian cancer cell 
growth [174]. 
The evidence for a tumour suppressive role of WWOX in ovarian carcinoma is described in detail 
below. 
Restoration of the function of tumour suppressor genes or their associated pathways is an area for a 
development of new therapeutic modalities in cancer. 
1.2.1.7.3.2. Key oncogenes in ovarian cancer 
KRAS, BRAF and CTNNB1 mutations were already discussed as frequent events in ‘Type I’ tumours 
(prototypic tumour LGSC). A recent review lists 15 major oncogenes implicated in ovarian cancer, 11 
of which show genomic amplification (including RAB25, PRKCI, PIK3CA, MYC, EGFR, NOTCH3, 
KRAS, ERBB2, CCNE1, AKT2, AURKA) [162]. 
RAB25 is a member of RAS superfamily implicated in vesicle trafficking. RAB25 mRNA levels were 
shown to be increased in more than 80% of ovarian tumours as compared to normal ovarian 
epithelium, especially in advanced disease, and its loci at 1q22 was amplified in 54% of cases. 
RAB25 was further shown to be the likely driving force of the amplicon, and high RAB25 expression 
was associated with poor survival of ovarian cancer patients. RAB25 over-expression due to 
transfection in ovarian cancer cell lines resulted in increased rates of proliferation, enhanced survival 
under stress conditions such as serum starvation, suspension, and paclitaxel exposure, and promoted 
xenograft tumour growth in vivo [175]. 
PIK3CA (catalytic subunit of phosphoinositide-3-kinase, PI3K) is a potential target of 3q26 amplicon in 
ovarian cancer. The PIK3CA region is amplified in about 40% of ovarian cancer cases. PIK3CA 
amplification correlated with increased expression at mRNA and protein levels as well as increased 
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PI3K catalytic activity. The abrogation of this catalytic activity in ovarian cancer cell lines with a PI3K 
inhibitor resulted in a decrease in cell proliferation and increased rates of apoptosis. Several cancer-
related traits have been linked with PI3K signalling in various neoplasia, including proliferation, 
survival, metabolism, oncogenic transformation, and cell adhesion [176]. 
The 3q26 amplicon may be also driven by EVI1 (ectopic viral integration site 1), an oncogene 
associated with myelogenous leukemia, that is amplified in 43% of ovarian cancers. EVI1 gene 
product was shown to inhibit anti-growth TGFβ signalling in ovarian cancer [177]. 
AURKA (aurora kinase A) at 20q13 is amplified in 21% and over-expressed in 57% of ovarian cancers 
[178-179]. AURKA is a centrosome associated kinase and its over-expression in non-transformed 
cells leads to centrosome amplification and transformation in vivo [180]. 
The definition of well characterized oncogenes, such as those whose amplification and over-
expression in clinical samples seem to be correlated with gain of pro-tumorigenic functions in vivo, 
helps to identify key features of the dysregulated molecular circuit of ovarian cancer cells. Oncogenes 
are potential therapeutic targets in cancer, e.g. targeting ERBB2 epithelial growth factor family 
receptor is already an important clinical modality in breast cancer (ERBB2 is relatively rarely amplified 
and over-expressed in ovarian cancer) [162].  
MicroRNAs, a gene-regulatory subclass of non-coding RNAs, are also dysregulated in cancer and 
may have oncogenic or tumour–suppressive functions and emerge as novel biomarkers and 
therapeutic targets [181]. 
1.2.1.8. Ovarian cancer treatment 
Appropriate surgical staging in all patients fit for surgery is prerequisite to systematic treatment of 
ovarian cancer. This staging laparotomy consists of total abdominal hysterectomy, bilateral salpingo-
oophorectomy and omentectomy. Inspection of serosal surfaces and biopsies of suspected areas as 
well as blind peritoneal and lymph node sampling, peritoneal lavage and cytological examination of 
ascites should be conducted. The surgical approach for patients with disease dissemination at 
laparotomy should aim at optimal surgical debulking (primary cytoreduction), usually defined by 
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largest remaining disease nodule smaller than 1 cm in diameter, which is strongly associated with 
improved survival (as opposed to suboptimal debulking) [121-122, 182]. 
Few carefully selected and staged patients with stage IA, grade 1 disease who wish to preserve 
fertility might be considered for unilateral salpingo-oophorectomy [121]. 
Neoadjuvant chemotherapy refers to chemotherapy (following diagnostic biopsy) before cytoreductive 
surgery and is currently reserved for patients at high surgical risk and poor performance status [125]. 
The majority of ovarian cancer patients require postoperative adjuvant chemotherapy as an attempt to 
eradicate the residual macro- and microscopic disease. Nevertheless, it is possible to identify a 
subset of early-stage disease patients with excellent survival prognosis that is not further improved by 
chemotherapy. This subgroup is usually considered to be stage IA, grade 1 disease, however some 
authors include in this subgroups patients with stage IA /grade 2 or stage IB, grade 1 and 2 disease 
as well. Patients with more advanced disease or at higher risk of relapse based additionally on grade 
and histology information should receive postoperative chemotherapy. 
The standard first-line chemotherapy in ovarian cancer is a platinum and taxane combination but 
occasionally platinum single agent can be used and some studies failed to show the superiority of 
taxane /platinum regimens over platinum monotherapy. Ovarian cancer is a chemosensitive disease 
and response rates for platinum-taxane combination are as high as 80% with 40-60% complete 
responses. The potential role for maintenance therapy is not well established. Most patients relapse 
with a median progression-free survival of 18 months. The follow-up is based on bimanual pelvic 
examination and CA125 measurement, and the imaging study of choice is computed tomography 
(CT). A CA125 rise with no clinical symptoms is referred to as marker-only relapse (there is no 
evidence for improved survival following second-line chemotherapy initiated on the basis of marker-
only relapse). Dependent on the duration of relapse-free time, patients are categorized as ‘platinum 
refractory’ (progression while on primary therapy), ‘platinum resistant’ (recurrence within 6 months of 
completion of primary chemotherapy) and ‘platinum sensitive’ (recurrence more than 6 months post 
chemotherapy). 
Recurrent ovarian cancer, whose primary goal of management is palliation, can be treated with 
platinums, taxanes, topotecan, liposomal doxorubicine, etoposide, gemcitabine, vinorelbine. All these 
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agents have similar response rates of 10-20% in platinum resistant disease and 20-30% in platinum 
sensitive patients. The choice is dependent on the expected toxicities and quality of life 
considerations. In patients with ‘platinum sensitive’ disease platinum monotherapy is a reasonable 
option with 30% or greater response rates, whereas patients with a relapse less than 6 months after 
completion of chemotherapy are usually treated with non-platinum regimens. Some patients might be 
offered secondary surgical cytoreduction [121-122, 125, 141, 182-185]. It has been suggested that 
dose-dense chemotherapy (that is administration of carboplatin and paclitaxel weekly rather than in 
the usual 3-week intervals) might yield high response rates and good tolerability in patients with 
heavily pre-treated platinum resistant/refractory disease [186]. Anti-angiogenic therapy and other 
novel approaches are discussed below. 
Intraperitoneal chemotherapy has been long attempted in ovarian cancer. Although some authors 
propose intraperitoneal therapy should become standard treatment in ovarian cancer others interpret 
the results of trials with caution and suggest intraperitoneal therapy remains experimental [187-188]. I 
discussed several aspect of intraperitoneal therapy elsewhere [134]. 
1.2.1.8.1. Platinum chemotherapy and chemoresistance 
By 1985 randomised trials of cisplatin in ovarian cancer had demonstrated that response rates and 
progression-free survival were significantly improved as compared to other regimens at that time. 
Carboplatin is significantly less toxic than cisplatin and has very little oto-, neuro- and nephrotoxicty at 
standard doses, as well as reduced frequency of nausea and vomiting [182]. Meta-analysis of 12 trials 
comparing cisplatin and carboplatin found no difference in efficacy, and as carboplatin was 
significantly better tolerated it became standard platinum agent for first-line treatment of ovarian 
cancer [189]. 
Cisplatin is intracellularly activated by aquation of one of the chloride groups, and subsequently forms 
DNA adducts (primarily intra-strand crosslink adducts) which cause distortions in DNA recognized by 
several cellular proteins, especially those involved in DNA–repair pathways. The downstream 
pathways are not fully understood but the DNA adducts impede basic cellular processes such as 
transcription, and this combined with activation of multiple signal–transduction pathways, such as 
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ATR (ATM- and Rad3-related protein), MAPK (mitogen-activated protein kinase family including e.g. 
ERK and p38) or p53, usually leads to apoptosis.  
The development of platinum resistance is a common clinical observation and many studies provide 
mechanistic basis for this phenomenon. Major proposed mechanisms include: reduced intracellular 
concentrations due to decreased drug uptake or increased activity of efflux pumps, increased 
inactivation by thiol-containing molecules (such as metallothioneins), increase in DNA damage repair 
(e.g. of the NER proteins such as ERCC1–excision repair cross-complementing-1), over-activation of 
pro-survival pathways (such as PI3K/AKT), p53 dysfunction, and up-regulation of apoptosis inhibitors 
of the Bcl2 family. It is hoped that targeted agents can modulate platinum resistance in the clinical 
setting, and several approaches developed preclinically have entered clinical trials [190-191]. 
The mechanism of action of taxanes and molecular basis for taxane resistance are presented in 
Chapter 6. 
1.2.1.8.2. Inhibition of PARP in BRCA-deficient ovarian cancer  
Poly (ADP-ribose) polymerase (PARP) is an enzyme involved in the repair of single-strand DNA 
breaks. The inhibition of PARP results in accumulation of DNA single-strand breaks, which eventually 
leads to the appearance of DNA double-strand breaks. These are repaired in normal cells by 
homologous recombination DNA repair mechanisms, which is ineffective in the absence of functional 
BRCA1 or BRCA2 proteins whereupon the resulting chromosomal instability leads to cell death. 
Olaparib, an oral PARP inhibitor, displays a low to moderate toxicity profile and encouraging efficacy 
(recently reported 33% response rate or up to 60% disease stabilization with CA125 drop in BRCA-
deficient patients with recurrent ovarian cancer) [184-185, 192].  
1.2.1.8.3. Hormonal therapy for ovarian cancer 
Anti-oestrogen therapy has a prominent role in the treatment and prevention of breast cancer [193]. 
Anti-hormonal therapy has been long attempted in ovarian cancer where endocrine factors are 
strongly implicated in tumorigenesis. Estrogen receptor α is expressed in about 40-55% ovarian 
carcinomas, and as frequently as in 70-80% in endometrioid and serous subtypes, but rarely in 
mucinous and clear cell tumours [194-195]. 
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Surprisingly, the results of anti-oestrogen therapy are disappointing so far with the exception of some 
phase II studies evaluating letrozole (aromatase inhibitor). The largest study demonstrated 17% 
response rate and 26% disease stabilization. The response was correlated with ERα levels and a 
number of other protein markers were identified as possible predictors of response to letrozole. Given 
the low toxicity, letrozole or other anti-oestrogenic agent could be used in ovarian cancer patients 
selected on the basis of a pattern of predictive markers [196]. Anti-hormonal therapy might be also 
used in patients with marker only (CA125 rise with no clinical symptoms) relapse [121]. 
1.2.1.8.4. Novel therapeutic modalities and potential therapeutic targets 
The accumulating knowledge about cancer biology should ultimately lead to the development of novel 
therapeutic strategies that will inhibit, restore or modulate key molecules and pathways, whose 
deregulation results in the appearance of the malignant phenotype and adverse clinical outcomes. 
Several such ‘targeted’ (as opposed to the huge majority of currently used cytotoxics identified in 
various screens) approaches proved successful in clinical trials in various neoplasia settings and are 
gaining importance in the clinic. These might be used as single agents or in combination with 
cytotoxic drugs, in first- or second-line and maintenance therapy. 
1.2.1.8.4.1. Targeting angiogenesis in ovarian cancer 
Angiogenesis is a process by which tumours develop new vasculature, a process that is essential for 
growth of tumours beyond the volume of 2 mm
3
. It is important to realize that angiogenesis is an 
important component of normal ovulatory cycles (maturation of the follicle, growth and regression of 
corpus luteum). The signalling axis consisting of members of the family of VEGF (vascular endothelial 
growth factor) ligands and receptors appears to be a promising target to inhibit tumour angiogenesis. 
Interestingly, VEGF, also known as vascular permeability factor, is strongly implicated in ascites 
formation in ovarian cancer. Additionally, signalling elicited by PDGF (platelet-derived growth factor), 
FGF (fibroblast growth factor), integrins and numerous cytokines is implicated in angiogenesis. 
Bevacizumab, an antibody against VEGF (VEGFA), has been evaluated in phase II and III studies in 
patients with advanced colorectal, breast and non-small cell lung cancer. These demonstrated 
significantly improved patient survival, and bevacizumab was subsequently approved by the FDA as 
an anti-angiogenic therapy. In ovarian cancer, single agent bevacizumab demonstrated 16-20% 
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response rates and disease stabilization for several months in 50% of patients with recurrent ovarian 
cancer. The anti-angiogenic therapy was well tolerated with the exception of relatively high (5%) 
frequency of bowel perforation. Bevacizumab is now being assessed in clinical trials in the adjuvant 
setting added to standard platinum/taxane combination therapy, and followed by placebo or 
bevacizumab maintenance therapy. Several other anti-angiogenic strategies are in clinical 
development for ovarian cancer [162, 184, 197-199]. 
1.2.1.8.4.2. Adhesion and invasion 
As already mentioned ovarian cancer disseminates via the transcoelomic route and this is what most 
patients die from. Adhesion to the peritoneum is one of the critical steps in such spread. Targeting 
various integrin subunits or CD44 (hyaluronan receptor) might be a strategy to limit locoregional 
peritoneal dissemination in ovarian cancer, but has not been so far tested in a clinical setting [130, 
162]. However, anti-integrin agents entered clinical trials on the basis of their anti-angiogenic acitivity 
[200] and may display additional benefit in the setting of ovarian cancer. In pre-clinical experiments, 
targeting integrins or pro-survival protein kinases stimulated by integrin engagement (FAK and SRC) 
produced in vivo anti-growth properties and synergized with chemotherapeutic drugs, in particular 
taxanes [201-204]. 
Several in vitro models provide evidence for the role of invasiveness and matrix metalloproteinases 
(MMPs) in ovarian cancer progression [205-208]. Targeting MMPs has long been proposed as a 
therapeutic strategy in multiple cancers but the results of clinical trials of MMP inhibitors (such as 
Marimastat, Prinomastat or Tanomastat) conducted so far were disappointing [209-210]. The 
significance of such approaches is thus limited in ovarian cancer especially given that the role of 
tissue invasion is limited in ovarian cancer as compared to cancers that typically spread via the 
haematogenous route. 
1.2.1.8.4.3. Targeting pro-survival receptors and signalling pathways 
Various strategies have been adopted to target dysregulated pathways leading to enhanced 
proliferation or survival of ovarian cancer cells, and the knowledge of what approaches might be 
feasible in ovarian cancer accumulates. Several examples including growth factor receptors, folate 
transporter and AKT-PI3K pathway are presented below. 
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PDGF and EGFR are growth factor receptors, whose alterations were linked with growth stimulatory 
and pro-survival signalling in multiple cancers. PDGF is dysregulated relatively infrequently in ovarian 
cancer but EGFR is over-expressed in 70% of cases. Imatinib that targets PDGF (platelet-derived 
growth factor) and KIT has produced minimal clinical responses. Targeting EGFR (epithelial growth 
factor receptor) with kinase activity inhibitors (erlotinib, gefitinib) or monoclonal antibodies (e.g. 
cetuximab) as well as treatment with trastuzumab that blocks the ERBB2 receptor of the EGFR family 
have only shown low or modest efficacy. It is proposed that careful selection of patients (such as 
those with unique EGFR mutation) may yield higher response rates.  
Alpha-folate receptor is expressed in several malignancies and might confer a growth advantage by 
increasing folate availability. Monoclonal antibody against α-folate receptor demonstrated 
encouraging effects in a phase II trial. 
AKT-PI3K pathway has pleiotropic cellular functions including growth, metabolism and survival, and is 
one of the most frequently activated pathways in a range of tumours. Several of the components of 
this pathway display mutations or copy number abnormalities in ovarian cancer including PIK3CA 
(catalytic subunit of phosphoinositide-3-kinase, PI3K), PIK3R1 (regulatory subunit of 
phosphoinositide-3-kinase, PI3K), PTEN, AKT kinase, receptors activating AKT (VEGFR, EGFR) and 
oncogenes feeding into the AKT-PI3K pathway (such as RAS and SRC). Clinically this has been 
linked with adverse prognosis and resistance to chemotherapy. It is hoped that targeting PI3K-AKT 
pathway will be a successful strategy in ovarian cancer (including chemoresistance reversal) but this 
is still very early in clinical development. 
Numerous other pathways and molecules appear as potential therapeutic targets in ovarian cancer 
but this remains to be tested in the setting of clinical trials. These include Jak-Stat, Ras-Raf-Mek-Erk 
and NF-κB pathways, proteins regulating epigenetic DNA methylation and histone modifications, 
SRC, FAK, GTPases, lysophosphatidic acid axis, CXCR4-CXCL12 axis, TGFβ signalling, and anti-
apoptotic proteins including Bcl2, Bcl-xL and survivin [141, 162, 184-185, 211]. 
1.2.1.8.4.4. Immunological strategies 
A study comparing the outcomes of ovarian cancer patients whose tumours were or were not 
infiltrated by CD3+ T cells demonstrated dramatic survival benefit for patients with intratumoural T 
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cells (five-year survival rates of 38 versus 4.5%) [212]. This study demonstrates that immune 
surveillance might play a role in prevention of ovarian cancer spread and that immunotherapeutic 
strategies and targeting immune evasion should be attempted in ovarian cancer. Currently, 
immunotherapy remains experimental in ovarian cancer. Encouraging results of some phase II trials 
of various immunotherapeutic strategies have not yet been confirmed in phase III trials [213]. 
1.2.2.1. WWOX abolishes ovarian tumorigenicity in vivo and might be a locoregional 
dissemination suppressor 
WWOX protein is strongly expressed in human ovaries as determined by immunohistochemistry, 
especially in ovarian surface epithelial cells believed to be cells of origin of epithelial ovarian cancer, 
but not in stromal cells [39, 53]. WWOX is also highly expressed in the ovaries of mice [86, 214]. 
Our group investigated WWOX expression profile in ovarian cancers and normal ovarian surface 
epithelium and demonstrated that WWOX full-length isoform1 mRNA levels are significantly reduced 
in ovarian carcinoma as compared to normal ovarian tissue, and were not detectable in two tumours. 
WWOX levels did not correlate with any specific clinical subgroup. On the other hand, high levels of 
an aberrant transcript lacking exons 6-8 that can potentially exert dominant–negative effects 
significantly correlated with high grade (p=0.006), high stage (p=0.012) and worse survival (a trend 
with p=0.057, and p=0.048 in the subgroup of patients who expressed high levels of full-length 
transcript), but this aberrant transcript is also detected in normal ovaries and its role remains 
speculative [67]. 
Nunez at al. [53] utilized western blotting and immunohistochemistry of ovarian carcinoma tissue 
microarrays (444 samples) to explore the clinicopathological correlations of WWOX expression loss in 
ovarian cancer. They screened 375 serous, 40 endometrioid, 10 mucinous and 19 clear–cell 
carcinomas. In total 30% of ovarian carcinomas displayed the loss of WWOX protein expression (29% 
of serous, 23% of endometroid, 42% of clear–cell and 70% of mucinous tumours were negative for 
WWOX). There was no correlation between WWOX expression and disease grade. WWOX loss was 
significantly correlated with high tumour stage (p=0.007) and shorter overall survival (p=0.03). There 
was no correlation between WWOX and ERα levels but a strong correlation with PR levels (p=0.008). 
Our group conducted a study examining the impact of WWOX on ovarian cancer cells tumorigenic 
64 
 
potential and on their in vitro behaviour following WWOX expression manipulation [91]. Parts of this 
study were conducted during the course of my project and will be thus presented in the results 
section. The PEO1 ovarian cancer cell line was initially established in Edinburgh from poorly 
differentiated serous carcinoma ascites from a patient treated with cisplatin, fluorouracil and 
chlorambucil [215]. The genomic region corresponding to WWOX exons 4-8 is homozygously deleted 
and WWOX protein is not expressed in the PEO1 cell line [21, 67] , and therefore the PEO1 line is an 
ideal model for studying WWOX reconstitution effects in ovarian cancer. Our group generated several 
stable clones of the PEO1 cell line by transfecting its hygromycin–tagged derivative with an 
expression vector containing WWOX isoform1 coding region (and also produced several empty vector 
clones) [21, 67, 91]. 
When grown subcutaneously in nude mice PEO1 parental cell line and vector-transfected controls 
formed large tumours, but there was no growth of four independent WWOX-transfected lines. At the 
same time there was no difference in in vitro growth of WWOX- or vector-transfected lines when 
plated on plastic or in soft agar. These findings show that WWOX re-expression in a WWOX-null 
ovarian cancer cell line dramatically reduces its tumorigenicity but does not alter baseline proliferation 
in vitro. 
WWOX transfection did not increase apoptosis in the PEO1 transfectants in standard culture 
conditions or after exposure to 10 µM cisplatin as measured with Annexin V staining, DNA 
condensation and subG1 cell fraction. There was also no difference in colony-forming ability in the 
absence or presence of cisplatin. 
The group further explored how WWOX could reduce tumorigenicity in xenograft models without 
reducing in vitro proliferation and apoptosis rates by examining the interactions of tumour cells with 
the surrounding extracellular matrix (ECM). WWOX-transfected PEO1 cells adhered more slowly to 
fibronectin and this phenotype of altered adhesion was reproduced by transient WWOX over-
expression in SKOV3 cells, and siRNA knock-down of WWOX expression in the A2780 ovarian 
cancer cell line. WWOX-transfected PEO1 cells also displayed decreased capacity to migrate towards 
fibronectin in transwell migration assays as compared to control lines, however there was no 
difference in matrigel invasion rate. 
65 
 
It was further postulated that engrafting the cells for xenograft experiments with matrigel, an artificial 
ECM component, may create a privileged environment increasing the in vivo survival of WWOX-
transfected cells, and consistent with this all cells survived with similar growth rates until about day 
56, after which point the tumours formed by WWOX-transfected cells started to regress. This finding 
was suggestive of the view that the excess of matrix proteins in matrigel could compensate for 
reduced adhesion of WWOX-transfected cells and support their growth until matrigel resorption. 
The altered interaction with fibronectin was suggestive of a defect in integrin function. To investigate 
this, integrin binding assays were conducted using a commercial kit. This showed that integrins α2 
and α3 are the main functioning integrins in PEO1 cells and their membranous levels are significantly 
reduced in WWOX-transfected PEO1 cells. It was further demonstrated using function-blocking 
antibodies that α3 was the main α integrin responsible for fibronectin binding and WWOX transient 
transfection reduced the levels of membranous integrin α3 in PEO1 cells as measured by FACS. 
Finally, it was shown during the course of my project that WWOX-transfected cells display increased 
rates of apoptosis in non-adherent culture but not when they are allowed to adhere [91].  
This study demonstrated that WWOX abolishes ovarian tumorigenicity, but this dramatically 
decreased growth in vivo was not reflected by alterations in growth or apoptosis in vitro. It was 
postulated that the decreased tumorigenicity was due to WWOX-mediated inhibition of cancer cell 
adhesion to ECM as a result of reduced integrin α3 expression and/or binding capacity. Ovarian 
cancer spreads by locoregional peritoneal dissemination (LPD). One of the critical early events in LPD 
is the evasion of anoikis (death of cells that lost attachment to the ECM, in this case in suspension in 
the ascetic fluid) and many of the steps in LPD are mediated by integrins. The data demonstrating 
that WWOX inhibits integrin function and promotes anoikis are strongly suggestive of the potential 
role for WWOX as a suppressor of LPD in ovarian cancer. This study also suggests a novel tumour 
suppressive role for WWOX in ovarian cancer due to the regulation of the interplay with ECM, distinct 
from direct induction of apoptosis observed in some other cancers. 
1.2.2.2. WWOX as ovarian cancer modifier gene 
While somatic mutations within the WWOX gene are very rare, there is accumulating evidence that 
natural polymorphic variants of WWOX may regulate its expression or function. Several SNPs within 
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the WWOX gene were associated with WWOX expression in a genome wide study [216]. Further, a 
SNP in WWOX intron 8 was associated with serum HDL-cholesterol levels and linked to a cis-
regulatory function; this study is discussed below [217]. WWOX variants were also linked with 
prostate cancer incidence [218]. Concurrently, the animal knock-out model is suggestive of WWOX 
haploinsufficiency in tumorigenesis [86]. The fact that complete loss of expression was not necessary 
for tumour development suggests that factors that constitutively modulate WWOX levels, such as 
polymorphisms, may contribute to tumorigenesis.  
Our group have previously identified natural polymorphic variants within WWOX, some of which have 
potential to affect WWOX expression [21]. Subsequently, a potential ovarian cancer modifier role for 
those SNPs was examined. Eight polymorphisms were genotyped in 554 ovarian cancer patients and 
associations with clinicopathological and survival data was examined. These SNPs were chosen 
based upon location, allele frequency and potential to affect WWOX expression. They include SNPs 
within the Kozak translation-start site (C121T), splice consensus sequences (Isnp8, Isnp13), within 
(T1497G) or close to (C1442T) predicted microRNA target regions, and a non-synonymous SNP 
(A660G).  
Two SNPs (Isnp1 and Isnp8) showed associations with tumour grade (p=0.0041 and p=0.0040 
respectively), which remained significant after correcting for multiple testing. In both cases, presence 
of at least one copy of the rarer allele correlated with higher grade. Isnp1 also showed association 
with clear cell histology (p=0.0057), as did the A660G SNP (p=0.0275), and the association with Isnp1 
remained significant after Bonferroni correction. The presence of at least one copy of the rarer Isnp1 
T allele positively correlated with clear cell histology, while the C/C genotype positively correlated with 
mucinous tumours.  
Survival data was available for 235 patients who were treated at the Western General Hospital, 
Edinburgh, UK (median follow-up 8.2 years). Any missing data for these patients was imputed, and 
the effect of the WWOX SNPs on progression-free survival (PFS) and overall survival (OS) was 
determined in univariate tests. T1497G (p=0.0045) and C1442T (p=0.0443) showed association with 
PFS, and T1497G showed association with OS (p=0.0284). However, only the association of T1497G 
with PFS remained significant after multiple testing correction. T1497G was combined with the clinical 
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covariates to assess whether it is an independent prognostic factor for PFS in a multivariate Cox 
regression model. T1497G was found to be an independent prognostic indicator of PFS (HR = 2.1, 
95% CI = 1.28-3.40, p=0.0030 for the rare G/G genotype). Patients carrying the T/T genotype (n=82, 
median PFS=34.8 months) exhibited better prognosis than those with either the T/G or G/G genotype 
(n=151, median PFS=20.7 months). 
These data are consistent with the published data for WWOX in ovarian cancer, where loss of WWOX 
expression was associated with clear cell and mucinous histologies and poor survival [53]. There was 
no correlation with grade reported in that study [53], however WWOX loss associates with high 
disease grade in breast [49-50], bladder [55],and lung [54] cancers. These findings allowed our group 
to propose that WWOX is a modifier gene in ovarian cancer in addition to the functional role of 
locoregional dissemination supressor. 
1.3. Animal models and association studies point to the role for WWOX in metabolism 
Apart from proving WWOX to be a bone fide tumour suppressor gene, animal knock-out models 
provided important insights into the role of WWOX in normal and pathological physiology. 
Aqeilan at al. [114] studied the phenotypic abnormalities in Wwox
-/-
 mice (KO). They demonstrate that 
Wwox is essential for early postnatal survival. While Wwox HET pups were indistinguishable from WT 
animals at all stages of postnatal life, Wwox KO mice were easily recognizable from 3 days post 
partum. They had smaller size and 100% mortality by 3 weeks of age. The internal organs of KO 
animals were smaller with the exception of brain, adrenal and pituitary glands and there were no 
obvious microscopic lesions. Serum chemistry showed a severe metabolic defect in KO pups 
(hypoproteinemia, hypoalbuminemia, hypoglycaemia, hypocalcemia, hypotriglyceridemia and 
hypocholesterolemia). Radiography revealed decreased density of the bones in the limbs of KO mice. 
The authors conducted a series of experiments to determine whether this was solely due to the 
severe metabolic disorder (as expected in hypocalcemia due to osteoclast stimulation and increased 
bone resorption) or whether this was also due to factors intrinsic to osteogenesis. Using an 
osteoprogenitor cell line in vitro model they demonstrate that Wwox expression exhibits changes 
during osteoblast differentiation. Subsequently Wwox KO and WT calvaria cells were compared in an 
ex vivo osteoblast differentiation assay and the cells derived from Wwox KO mice displayed 
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decreased expression of osteoblast differentiation markers (day 12) and reduced mineralization of the 
cell layer (day 20), pointing to a role of Wwox in osteoblast lineage commitment.  The authors further 
demonstrate that Wwox reduces RUNX2 transcription factor (regarded as a master regulator of 
osteoblast differentiation) expression and activity, and eventually show the physical interaction 
between WWOX and RUNX2 in several cell types including breast cancer, as well as the association 
of RUNX2/WWOX complex with osteocalcin promoter as already discussed above [114]. 
Further, a range of endocrine abnormalities in Wwox
-/-
 mice is demonstrated [214]. In males, they 
demonstrate histological testicular abnormalities, low testosterone levels, altered expression of Leydig 
cells markers and Leydig cell atrophy. In females, they observe anatomical and histological 
abnormalities in the reproductive organs and reduced expression of genes related to steroidogenesis 
in ovaries. The authors report reduced expression of Fsh (follicle–stimulating hormone) and Lh 
(luteinizing hormone) in pituitary glands of both sexes. Finally, they demonstrate that Wwox 
expression manipulation alters the levels of some genes implicated in steroidogenesis in MLTC-1 
mouse Leydig cells. The authors conclude that Wwox is indispensable for efficient steroidogenesis, 
which is consistent with previous suggestions based on the fact that WWOX is particularly highly 
expressed in hormonally active or responsive organs and contains an SDR domain that might be 
involved in steroidogenesis [214]. The question remains, in light of the severe metabolic disorder and 
macroscopic abnormalities of internal organs, as to whether impaired steroidogenesis is not 
secondary to the metabolic syndrome and generalized wasting. 
It is also important to stress, with relation to both phenotypic studies of Wwox KO mice by Aqeilan et 
al. [114, 214], that there are no abnormalities in HET mice as compared to WT mice. So the loss of 
one allele of the Wwox gene does not seem to affect metabolism, bone parameters or 
steroidogenesis, whereas it was already demonstrated to promote tumorigenesis, which is suggestive 
of a separate mechanism of Wwox impact on tumorigenesis and metabolism. 
Ludes-Meyers et al. [87] used the ‘hypomorph’ mice (described above in the context of accelerated 
tumorigenesis) and reported reduced lifespan without an identifiable cause in both sexes, as well as 
reduced fertility and testicular abnormalities (degeneration of seminiferous tubules devoid of mature 
spermatocytes and Leydig cells hyperplasia) in male animals. Very recently the same group led by 
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Marcelo Aldaz reported generation of mice carrying a conditional allele of Wwox intended to be used 
for the functional analysis of Wwox role in neoplastic transformation in target tissues of adult mice. 
Importantly, these conditional Wwox knockout (KO) mice displayed a severe metabolic disorder, 
growth retardation and atrophy of multiple organs remarkably similar to KO mice reported by Aqeilan 
et al. (and the two studies consistently demonstrated no such abnormalities in Wwox heterozygous 
animals). Ludes-Meyers et al. report the following abnormalities in KO mice: severe growth 
retardation, early postnatal lethality by 3 weeks of age, impaired haematopoiesis, splenic atrophy, 
abnormal sizes of internal organs, metabolic acidosis and signs of kidney failure, hypoglycaemia, 
hypocalcemia and abnormal bone mineralization [89].  
Another group (Suzuki et al.) established several spontaneously mutated inbred rat strains, described 
their phenotypes and sought to identify responsible genes [219-221]. They studied the Lde/Lde rat 
strain (lethal dwarfism with epilepsy) and hereditary analysis showed that the defects were inherited 
as a single recessive trait. They map the trait to a 13-bp deletion in exon 9 of the Wwox gene, 
resulting in aberrant amino acid sequence at the C-terminus, and also loss of full-length WWOX 
expression likely as a result of altered protein degradation. They did not observe increased 
tumorigenicity in the animals, but the proper analysis might have been precluded by the fact that all 
Lde/Lde rats died by the age of 77 days. The mutant phenotype consists of short lifespan, severe 
dwarfism, male hypogonadism, mild osteopenia, high incidence of epileptic seizures and many 
vacuoles in hippocampus and amygdala. In general the phenotype is very consistent with the 
abnormalities in mice models including lowered levels of Fsh and Lh in male rats, however no 
significant biochemical abnormalities in Lde/Lde rats were observed, with the exception of increased 
plasma urea nitrogen, creatinine and phosphates. 
The link between WWOX and metabolic phenotypes is also suggested by studies in humans. Lee at 
al. [217] conducted a genome wide single nucleotide polymorphism (SNP) association study for 
genotypes linked with low serum HDL-cholesterol (HDL-C), a major risk factor for coronary artery 
disease. The multi-stage analysis of several diverse populations, consisting of nearly 10 000 subjects 
pointed to a significant association between the rs2548861 SNP in WWOX exon 8 and HDL-C levels. 
This not only supports the observation that WWOX might be implicated in metabolism but also shows 
that natural variation with the WWOX gene might have a regulatory function. Although the SNP maps 
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to a non-coding, intronic sequence, it seems to be localized to an element conserved between several 
vertebrate species and was computationally predicted to function as a cis-regulatory element. 
Consistent with this, cloning of the rs2548861 region into a luciferase reporter construct results in 
significantly different luciferase activities as compared to empty vector, which is consistent with the 
hypothesis that it contains a cis-regulatory element. The authors further use an electrophoretic 
mobility shift assay and demonstrate the presence of a DNA-nuclear complex with the 25 bp genomic 
region surrounding the SNP (of both alleles but preferentially with the non-risk allele sequence). This 
study stresses the potential role of WWOX in metabolism but the mechanisms remain to be 
elucidated [217]. Interestingly, WWOX was ranked the 12
th
 most stable expressed gene in liver during 
primate evolution providing yet another link to metabolism [222]. WWOX was also suggested to be 
involved in a network of genes implicated in ostheoarthritis pathogenesis [223]. 
Collectively, there are several lines of evidence pointing to a role for WWOX in metabolism and in 
particular in bone metabolism, growth or disorders with an endocrine component related to steroid 
signalling. In general, and to a varied extent, animal models display growth retardation, bone defects, 
metabolic syndrome, impaired steroidogenesis, and reduced fertility and viability, and a human 
genome-wide association study linked WWOX to HDL-C levels. This evidence is also consistent with 
the possible role for WWOX in endocrine regulation based on its expression pattern and structural 
predictions. It is also of interest that in breast cancer WWOX expression correlates with the outcomes 
of anti-hormonal therapy. It is likely that, apart from its tumour suppressive function, WWOX plays a 
role in normal physiology and pathobiology of non-neoplastic disorders. 
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1.4. Aims of the project 
Hypothesis 1: WWOX is an ovarian cancer modifier gene 
- validate previous associations of WWOX SNP variants with ovarian cancer clinicopathological 
features in an independent patient population 
- identify the causative polymorphisms underlying these associations 
- determine the functional effects of the causative polymorphisms on WWOX expression 
Hypothesis 2: WWOX variants are linked to bone metabolism phenotypes 
- examine the correlation between WWOX variation and bone mineral density as well as serum 
parameters of bone turn-over in an extensively phenotyped population of postemenopausal women 
Hypothesis 3: WWOX is a regulator of ovarian cancer cells gene expression 
- confirm the interaction between WWOX and its putative transcription factor binding partners and the 
proposed cytoplasmic sequestration resulting from this 
- identify genes differentially expressed following WWOX transfection or siRNA knock-down in ovarian 
cancer cells 
- prioritize candidates from the list of WWOX-regulated genes or binding partners regulating gene 
expression) and test their impact on ovarian cancer cells behaviour 
Hypothesis 4: WWOX is pro-apoptotic in ovarian cancer cells  
- test the impact of WWOX transfection on apoptosis in baseline conditions as well as in cellular 
stress 
- determine the mechanism of WWOX effects on apoptosis if anti-survival role demonstrated 
- examine the clinical relevance of pro-apoptotic role for WWOX. 
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Chapter 2. Materials and methods 
2.1. Nucleic acid analysis 
2.1.1. Nucleic acid concentration measurement 
DNA and RNA concentration was quantified and the purity initially assessed with NanoDrop® ND-
1000 Spectrophotometer. 
2.1.2. DNA sequencing 
The PCR products were cleaned with 1.25 U/µl exonuclease I (Fermentas Life Sciences #EN0581) 
and 0.125 U/µl shrimp alkaline phosphatase (Fermentas Life Sciences #EF0511) for 15 minutes at 
37°C, followed by 15 minutes at 80°C. The samples for sequencing were prepared as follows: 3.2 
pmol of an appropriate primer, a nucleic acid template (30-90 ng /1kb for PCR products and 200-500 
ng /1 kb for dsDNA) and water were combined to the final volume of 10 µl in one tube and sequenced 
at the Genomics Core Laboratory (Hammersmith Campus) by capillary electrophoresis using 3730xl 
DNA Analyzer (Applied Biosystems). 
2.1.3. Microarray analysis 
RNA integrity was assessed by loading 1 µl aliquot of total RNA onto an
 
RNA Labchip (Agilent 
Technologies, Stockport, UK) and analyzed
 
on an Agilent 2100 Bioanalyzer (Agilent Technologies) at 
the Genomics Core Laboratory (Hammersmith Campus). RNA integrity number (RIN) is a 
standardized numerical representation of RNA integrity developed by Agilent Technologies, where 10 
represents the most intact RNA in the scale from 1 to 10, and RIN values above 8 are typically 
accepted for microarray applications. RINs were obtained for all the RNA samples and varied 
between 9.6 and 10.0. The traces were assessed visually and accepted when two sharp ribosomal 
peaks with the signal returning to the baseline were present. The OD 260 nm /OD 280 nm ratios of 
the pooled RNA samples (as described in methods) varied between 2.05 and 2.10 (typical values 
recommended for microarray experiments are 1.9-2.1). 
Appropriate RNA dilutions at 400 ng /µl concentration were combined in equal proportions to obtain 5 
samples used for microarray analysis: 1) WWOX Smartpool, 2) Non-Targeting 1, 3) MOCK from 
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siRNA experiment in A2780 cell line (3 independent experiments combined), and 4) pooled PEO1 
WWOX-6, WWOX-7, WWOX-8 (stably WWOX transfected) and 5) pooled PEO1 Vector-9, Vector-p1, 
Vector-p2 (vector transfected), 2 replicates each transfectant. 7 µl of each the final RNA dilution was 
loaded into the wells of a bar-coded Hard-Shell 96-well PCR Plate (Bio-Rad #HSP99-01) and shipped 
to the Affymetrix HTArray Genomics Core at the Lawrence Berkeley National Laboratory, where RNA 
was reverse transcribed, labelled and hybridised against the Affymetrix HT_HG-U133A GeneChip 
expression microarray. The resulting expression data was normalised by RMA (Robust Multi Array) 
algorithm using Affymetrix Expression Console and then imported into the GeneSpring software 
(Agilent Technologies). The data for microarray re-analysis against PEO1 parent cell line was 
provided by Dr Euan Stronach (RNA hybridized and processed simultaneously on the same 
Affymetrix HT_HG-U133A GeneChip), normalized and imported into GeneSpring as above. 
2.1.4. RNA reverse transcription and cDNA quality control 
1.5 µg of total DNase-treated RNA was mixed with the appropriate volume of RNase-free water and 
incubated for 5 minutes at 65°C followed by 2 minutes at 37°C to remove the RNA secondary 
structure. The RNA solution was mixed with M-MLV Reverse Transcription reaction cocktail to the 
final volume of 20 µl -final concentrations: 1x M-MLV RT Buffer (Promega #M531A), 0.4 mM dNTPs, 
0.5 µg /µl oligo dt15 (Promega #C110A) and 3 U/µl M-MLV Reverse Transcriptase (Promega 
#M1701). The samples were incubated for 1 hour at 37°C, followed by 2 minutes at 95°C to inactivate 
M-MLV Reverse Transcriptase. For each RNA sample a control reaction was run in identical 
conditions but without adding the M-MLV Reverse Transcriptase. The presence of cDNA in the 
reverse transcription reaction product and the absence of residual genomic DNA in the control 
reactions were confirmed by performing a PCR amplification of a fragment of β-actin cDNA using the 
following primers: bACTF: CTACGTCGCCCTGGACTTCGAGC and bACTR: 
GATGGAGCCGCCGATCCACACGG. The final concentration of reagents in the PCR mix were as 
follows: dNTP mix: 200 µM, PCR buffer 1x, MgCl2: 2 mM, primers: 0.5 µM each, Taq polymerase: 
0.04 U/µl. The PCR programme (elsewhere referred to as TD55) used was as follows: 94ºC for 3 
minutes, 9 cycles: 94ºC for 30 seconds, 65ºC for 30 seconds (-1ºC per cycle), 72ºC for 30 seconds 
and 29 cycles: 94ºC for 30 seconds, 55ºC for 30 seconds, 72ºC for 30 seconds; followed by the final 
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elongation step: 72ºC for 5 minutes. The PCR products were separated on 1% agarose/TAE gel with 
0.5 µg/ml ethidium bromide and visualized in UV light. 
2.1.5. Quantitative real-time polymerase chain reaction (PCR) 
The reactions were run in 96-well plate format using a 7900HT Fast Real-Time PCR System (Applied 
Biosystems). The final volume of a 1x reaction was 10 µl -containing 1 x Platinum SYBR Green qPCR 
SuperMix-UDG (Invitrogen #11733-046), 0.2 µl ROX Reference Dye (Invitrogen #12223-012), primers 
at 0.625 µM concentration and 2 µl of an appropriate cDNA dilution as a template. The samples were 
thermocycled using the following programme: 95ºC for 10 seconds and 40 cycles: 95ºC for 3 seconds 
and 56ºC for 20 seconds, which was followed by an acquisition step after each cycle. A dissociation 
step (95ºC for 15 seconds, 56ºC for 15 seconds, 95ºC for 15 seconds) was added to generate the 
melt curve. A set of dilutions of a reference cDNA (usually 1:5, 1:25, 1:125, 1:625, 1:3125 and 
1:15625) was used to generate a standard curve for each run. The results were analyzed using the 
7900 HT Sequence Detection Systems Version 2.3 software (Applied Biosystems). The expression of 
the genes of interest was normalized with the geometric mean of the expression of two housekeeping 
genes (peptidylprolyl isomerase A and tubulin alpha 1b) and multiple runs were averaged. 
The sequences of primers used for quantitative RT PCR are provided in Appendix 1. 
2.2. Protein analysis 
2.2.1. Western blotting 
Cells were washed with cold PBS and lysed in the Protein Lysis Buffer (68 mM Tris HCl pH=6.8, 2.2% 
SDS, 13.5% glycerol) supplemented with Complete Protease Inhibitor Cocktail (Roche #11 697 498 
001), unless specified otherwise. Total protein concentration in the lysates was quantified with BCA 
Protein Assay Kit (Pierce #23225) according to manufacturer’s protocol. The samples were 
supplemented with DTT (dithiothreitol) to the final concentration of 100 mM and with 1x PAGE loading 
buffer (Fermentas #R0611), and boiled at 95ºC for 5 minutes. The proteins were separated on a 1D 
denaturing acrylamide gel (resolving gel: 8, 10, 12 or 15% acrylamide, 8% sucrose, 375 mM Tris HCl 
pH=8.8, 0.1% SDS, 0.1% APS, 0.06% TEMED; stacking gel: 5% acrylamide, 126 mM Tris HCl 
pH=6.8, 0.1% SDS, 0.1% APS, 0.05% TEMED) using 1 x Running Buffer (25 mM Tris HCl pH=8.3, 
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192 mM glycine, 0.1% SDS). The proteins were transferred onto a nitrocellulose memebrane (Bio-
Rad #162-0112) with 1x Transfer Buffer (20% methanol, 0.37% SDS, 20 mM Tris, 154 mM glycine) 
and the efficiency of the transfer was verified by Ponceau S solution staining (Sigma #P7170). The 
membranes were blocked in 5% fat-free milk or 2% BSA in PBS/T (or TBS/T) and incubated with 
appropriate dilution of the primary antibody overnight at 4ºC on a shaker. After several washes with 
PBS/T (or TBS/T) the membranes were incubated for 1 hr at room temperature with appropriate 
dilution of the secondary antibody on a shaker. Following washes with PBS/T (or TBS/T), horseradish 
peroxidase chemiluminescent detection system -Immobilon Western Chemiluminescent HRP 
Substrate (Millipore #WBKLS01000) and Amersham Hyperfilm ECM (Amersham #28906837) or other 
X-ray films were used to visualize protein bands. For re-probing with another antibody, the 
membranes were stripped with Restore Western Blot Stripping Buffer (Pierce #21059) according to 
manufacturer’s protocol. 
The primary antibodies used for western blotting are characterized in Appendix 2. 
2.2.2. Co-immunoprecipitation 
The cells were cultured on 15-cm Petri dishes and collected when they reached 70-80% confluence 
(when using PEO1 stable transfectants the medium with blasticidin was replaced with media without 
the drug 24 hrs before plating for the experiment). The cells were washed with ice-cold PBS, and 
detached with a cell scraper into 5 ml volume of fresh PBS, centrifuged and lysed immediately or 
stored as a pellet in -80ºC. Cells collected from each dish were lysed in 400 µl of the following buffer 
for 30 minutes on ice (0.5-1% Triton X or 0.5%-1% NP40, 10% glycerol, 150 mM NaCl, 50 mM Tris 
HCl pH=7.2, 0.2 mM Na3VO4, 50 mM NaF, 2 mM EDTA, 1 mM PMSF, supplemented with 100 U/ml 
aprotinin, 10 µg/ml leupeptin and 1 µg/ml pepstatin). The lysates were centrifuged at 13 000 rpm at 
4ºC for 20 minutes and the supernatant was transferred to a new tube. The supernatant in each tube 
was pre-cleared by incubation for 1 hr with 10 µl of Protein A/G UltraLink Resin (Pierce # 53132). 2 µg 
of a relevant or control antibody as appropriate was added to each pre-cleared sample and incubated 
at 4ºC on a circular shaker for 3-6 hrs. Subsequently, 10 µl of the resin was added to each sample 
and incubated at 4ºC on a circular shaker for 3 hrs to overnight. The beads pellets were washed four 
times with the lysis buffer and re-suspended in 30 µl of 1x PAGE loading buffer (Fermentas #R0611), 
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supplemented with DTT to the final concentration of 100 mM and boiled at 95ºC for 5 minutes. The 
immunoprecipitates were analysed by immunoblotting as described above. 
The antibodies used for immunoprecipitation are characterized in Appendix 2. 
2.2.3. Nuclear-cytoplasmic fractionation 
Cells were grown in 15 cm diameter Petri dishes till they reached 70-80% confluence, washed with 
ice-cold PBS and collected with a cell scraper into 5 ml of ice-cold PBS. Cells were collected by 
centrifugation, single cell suspension ensured by syringing through a 21G needle and washed twice 
with ice-cold PBS. Cell pellet was was re-suspended in ‘hypotonic buffer’ (10 mM HEPES pH=7.9, 1.5 
mM MgCl2, 10 mM KCl) and centrifuged. The pellet was resuspended with ‘hypotonic buffer’ 
supplemented with 0.5% NP-40 and lysed on ice for 10 minutes. The nuclei were pelleted by 
centrifugation and the supernatant collected as cytoplasmic fraction. The pellet was washed 3 times 
with the ‘hypotonic buffer’ and the pellet lysed for 40 minutes (vortexing every 10 minutes) in nuclear 
extraction buffer (20 mM HEPES pH=7.9, 1.5 mM MgCl2, 0.5 M NaCl, 0.2 mM EDTA, 20% glycerol 
and 1% Triton X100). ‘Hypotonic buffer’ and nuclear extraction buffer were supplemented with 
protease inhibitor cocktail and kept on ice at all times. The lysates were analyzed by western blotting 
as described above. Lamin A/C was used as a nuclear marker and β-actin and β-tubulin were used as 
cytoplasmic markers. 
2.2.4. Immunohistochemistry 
Deparaffinized and rehydrated tissue sections were microwave pre-treated for 20 minutes in 1 mM 
EDTA (pH=8.0) as an antigen retrieval procedure. Following washes with PBS, the slides were 
incubated for 30 minutes at room temperature with 0.3% hydrogen peroxide to quench endogenous 
peroxidise activity. Subsequently, to block non-specific protein binding samples were incubated for 30 
minutes at room temperature in 10% normal horse serum. Goat anti-WWOX (N-19, Santa Cruz #sc-
20528) at 1:100 dilution was applied to the sections overnight at 4°C. Following washes with PBS the 
samples were incubated with 1:200 anti-goat biotinylated secondary antibody (Vector #BA-9500) for 
one hour at room temperature. This was followed by incubation with avidin-biotin complex (Vectastain 
Elite ABC kit, Vector Laboratories #PK-6100) for 30 minutes at room temperature. The staining was 
visualized with 25 mg/ml 3,3′-diaminobenzidine in 0.015% hydrogen peroxide (Sigma Aldrich 
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#D4418), the immunostained sections were counterstained with hematoxylin, dehydrated and 
mounted with Pertex Mounting Medium (CellPath #SEA-0100-00). Immunoreactions with omission of 
the primary antibody were performed as negative controls. The results of the staining are expressed 
as an immunohistoscore, which is the product of percentage of cells and staining index (0 –negative, 
1 –weak, 2 –moderate, 3 –strong as well as 0.5, 1.5, 2.5 values) and varies between 0 and 300. 
Immunohistochemistry was conducted and scored in Dr Mona El-Bahrawy’s laboratory (Imperial 
College London). 
2.2.4.1. Statistical analysis of the correlation between WWOX levels, therapy response and 
gene expression in the population of ovarian cancer patients treated with Letrozole 
The correlation between WWOX immunoscore and CA125 levels (percentage relative to the value at 
the beginning of the therapy) following 3 months of Letrozole therapy as well as the expression of 
marker genes was assessed with Spearman’s test. All analyses were performed with PASW Statistics 
18.0 (formerly SPSS). 
2.3. Cell culture and cell line–based assays 
2.3.1. Basic maintenance of the cell lines 
Established ovarian cancer cell lines were maintained in RPMI-1640 medium (HEPES modification) 
(Sigma #R5886) supplemented with 10% FCS (foetal calf serum) (First Link UK #02-00-850), 0.4mM 
L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin (Sigma #G1146) in an atmosphere of 5% 
CO2 at 37⁰C. The following cell lines were used: A2780, SKOV3, PEO1, CAOV3 and a series of 
PEO1 stable WWOX- (WWOX-6, WWOX-7, WWOX-8) and vector- (Vector-9, Vector-p1, Vector-p2) 
transfectants. Stable PEO1 transfectants were cultured in media supplemented with 3 µg/ml 
Blasticidin (Calbiochem #203351). PEO1 WWOX clones were previously transfected with the WWOX 
coding region inserted into pEF6/V5-His TOPO-cloning vector (Invitrogen #K9610-20) and PEO1 
Vector clones were transfected with empty vector. The cells were cryopreserved with a mix of 90% 
FCS and 10% DMSO. 
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2.3.1.1. PEO1 transfectants authentication 
The presence of a specific homozygous WWOX deletion described previously in PEO1 cells was 
demonstrated with RT PCR on cDNA from WWOX-6, -7, -8 and Vector-9, -p1, -p2 cells (TD55 PCR 
programme as described above, primers located in WWOX exons 1 and 9 -forward: 
AGGTGCCTCCACAGTCAGCC, reverse: TGTGTGCCCATCCGCTCT). 
2.3.2. Cell line DNA isolation 
Cells were grown on 10 cm diameter Petri dishes, trypsinized, washed twice with PBS and pelleted. 
The DNA from the cell pellets was isolated with the DNeasy Tissue Kit (Qiagen #69504) according to 
manufacturer’s protocol. 
2.3.3. Cell line RNA isolation 
RNA was isolated with RNeasy Mini Kit (Qiagen #74104) for microarray experiment and Absolutely 
RNA Miniprep Kit (Stratagene #0470039) for generating cDNA. Cells were grown on 10 cm diameter 
Petri dishes till they reached 70-80% confluence, washed with cold PBS and lysed with 600 -1000 µl 
lysis buffer supplemented with 0.1 M β-mercaptoethanol. The DNA digestion step was performed 
following the manufacturer’s protocol for all the samples used to generate cDNA. 
2.3.4. RNA intereference experiements 
2.3.4.1. siRNA knock-down of WWOX expression in A2780 cell line 
A2780 cells were counted in a haemocytometer and 2.5 x 10
4
 cells per well of a 6-well plate were 
plated in 3 ml of RPMI-1640 MEDIUM supplemented with 10% FCS, L-glutamine, penicillin, 
streptomycin. The cells were transfected with appropriate siRNA oligos (WWOX Smartpool siRNA, 
Dharmacon #M-003961-02; WWOX Duplex 1 and 4, #D-003961-01 and D-003961-04; Non-Targeting 
siRNA pool 1 or 2, #D-001210-01 and -02) after 48 and 72 hrs (at approximately 40 and 70% 
confluence respectively). For each experiment 100 µl of the working dilution of appropriate siRNA 
oligos at the concentration of 2 µM in 1x siRNA buffer (Dharmacon #B-0020000-UB-100) was mixed 
with 100 ul OPTIMEM I medium (Gibco /Invitrogen #51985) and incubated for 5 minutes at room 
temperature. For MOCK control 100 µl of 1x siRNA buffer without siRNA oligos was used. At the 
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same time 5 µl of DharmaFECT 1 transfection reagent (Dharmacon #T-2001-02) was combined with 
195 µl OPTIMEM I medium and also incubated for 5 minutes at room temperature. The dilutions were 
subsequently combined to the final volume of 400 ul and incubated for 20 minutes at room 
temperature. The cells in 6-well plates were washed with PBS and 1 ml of RPMI-1640 MEDIUM 
supplemented with 10% FCS, L-glutamine, but without antibiotics was added per well. After 20 
minutes of incubation the dilution of transfection reagents was mixed with 600 µl of RPMI medium and 
added in a dropwise manner to the appropriate well. Cells were trypsinized and replated 24 hrs post 
second transfection into 6 well plates for protein extraction to verify the level of knock-down (by 
immunoblotting as described above) and into 10 cm diameter Petri dishes for RNA extraction (96 hrs 
post transfection). 
2.3.4.2. siRNA knock-down of WWOX expression in PEO1 WWOX-6 and WWOX-8 cell lines 
WWOX-6 or WWOX-8 cells were counted in a haemocytometer and 2.5 x 10
4
 cells per well of a 6-well 
plate were plated in 3 ml of RPMI-1640 MEDIUM supplemented with 10% FCS, L-glutamine, 
penicillin, streptomycin. The cells were transfected with appropriate siRNA oligos (as for A2780 cells 
and WWOX Duplex 15, Dharmacon, #D-003961-15, as stated in results) after 24 hrs (at 
approximately 50% confluence). The transfection protocol and following steps were identical to those 
for A2780 cells with the exception of the use of 3 µl of DharmaFECT 1 transfection reagent. 
2.3.4.3. siRNA knock-down of ITGA3 expression in PEO1 cell line 
PEO1 cells were counted in a haemocytometer and 2.5 x 10
4
 cells per well of a 6-well plate were 
plated in 3 ml of RPMI-1640 MEDIUM supplemented with 10% FCS, L-glutamine, penicillin, 
streptomycin (as described above). The cells were transfected with appropriate siRNA oligos (ITGA3 
SMARTpool, Dharmacon #M-004571-01; Non-Targeting siRNA pool 2, #D-001210-02) after 24 hrs (at 
approximately 50% confluence). The transfection protocol was identical as for PEO1 WWOX-6 and 
WWOX-8 cells. Cells were trypsinized and replated 24 hrs post transfection into 6 well plates for 
FACS analysis to verify the level of knockdown at 72 hrs post transfection. For FACS analysis, the 
cells were incubated for 5 minutes in 300 µl of 0.02% EDTA (Sigma #E8008), detached after adding 
500 µl of cold PBS and transferred to glass FACS tubes. The cells were centrifuged for 5 minutes at 
1500 rpm and washed twice with PBS (re-suspension and a 5-minute spin at 1500 rpm) and fixed with 
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2% paraformaldehyde (PolySciences #18814) at room temperature for 20 minutes. Following the 
fixation the cells were washed twice in 500 µl PBS, re-suspended with 500 ul 1% BSA (Sigma 
#A9418) solution in PBS and incubated at 4°C from 1 hour to overnight. After the blocking of 
unspecific reactivity with 1% BSA in PBS the cells were centrifuged at 1500 rpm for 5 minutes and re-
suspended with 100 µl of a 1:100 dilution of the mouse anti-integrin α3 antibody (Chemicon 
#MAB1952Z) in 1% BSA/PBS, and incubated at RT for 60 minutes. Subsequently, the cells were 
washed twice with 500 µl 1% BSA in PBS and re-suspended in 100 µl of 1:500 dilution of the 
secondary goat anti-mouse FITC-conjugated antibody (Sigma #F0257) in 1% BSA in PBS. The cells 
were incubated for 45 minutes at 4°C (wrapped in foil from this point whenever possible to reduce 
exposure to light) and washed twice with 500 µl 1% BSA in PBS, re-suspended and counted on BD 
FACSCanto flow cytometer (Beckton Dickinson). 
2.3.5. Transient transfection of WWOX in SKOV3 cell line for RNA and protein extraction 
400 000 cells were plated into a 25 cm
2
 flasks and transfected after 24 hrs with 2 µg of WWOX-,  
WWOX-V5 or empty vector plasmid, in a 1:3 ratio with Lipofectamine 2000 (Invitrogen, #11688-027), 
in 2 ml of RPMI-1640 serum- and antibiotic-free medium. Medium was replaced after 4 hours with 10 
ml fresh medium supplemented with 10% FCS without antibiotics. 24 hrs after transfection cells were 
replated into 10 cm diameter Petri dishes for RNA extraction and 6-well plates for transfection 
efficiency monitoring by FACS and collection of protein lysates. Transfection efficiency was monitored 
(throughout all experiments using transient transfection) by simultaneous transfection with a plasmid 
expressing GFP and/or transfection with WWOX-V5. The percentage of positive cells was measured 
by FACS. The staining for V5 was performed as described below (2.3.6) for WWOX but the primary 
antibody was rabbit anti-V5 (Abcam #15828). 
2.3.6. FACS analysis of the impact of WWOX transfection on the membranous expression of 
integrins α5β1 and α3 
150 000 SKOV3 cells were grown in 6-well plates for 24 hrs and transfected with 3 µl Lipofectamine 
2000 (Invitrogen, #11668-027) and 1 µg of an appropriate plasmid (WWOX or empty vector) in 500 µl 
of RPMI-1640 MEDIUM without FCS and antibiotics. The medium with transfection reagents was 
replaced after 6 hours with 3 ml of RPMI-1640 MEDIUM supplemented with 10% FCS without 
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antibiotics. The cells were re-plated on the following day and grown further in 6-well plates. 48 hrs 
after the transfection, the cells were incubated for 5 minutes in 300 µl of 0.02% EDTA (Sigma 
#E8008), detached after adding 500 µl of cold PBS and transferred to FACS tubes. The cells were 
washed twice with PBS and fixed with 2% paraformaldehyde (PolySciences #18814) at room 
temperature for 20 minutes. Following the fixation the cells were washed twice in PBS, re-suspended 
with 500 µl 1% BSA (Sigma #A9418) solution in PBS and incubated at 4ºC from 1 hour to overnight. 
After the blocking of unspecific reactivity with 1% BSA in PBS the cells were centrifuged at 1500 rpm 
for 5 minutes and re-suspended with 100 µl of a 1:100 dilution of the mouse anti-integrin α5β1 
antibody (Chemicon #MAB1969) or mouse anti-integrin α3 antibody (Chemicon #MAB1952Z) in 1% 
BSA/PBS, and incubated at RT for 60 minutes. Subsequently, the cells were washed twice with 1% 
BSA in PBS and re-suspended in 100 µl of 1:200 dilution of the secondary donkey anti-mouse APC-
conjugated antibody (eBioscence #17-4012) in 1% BSA in PBS. The cells were incubated for 45 
minutes at 4ºC (wrapped in foil from this point whenever possible to reduce exposure to light) and 
washed twice with 1% BSA in PBS. To permeabilize, the cells were re-suspended with 500 µl of 1x 
BD Perm/Wash (Beckton Dickinson #554723) and incubated at room temperature for 20 minutes. 
Subsequently, the cells were re-suspended with 100 µl of an appropriate primary antibody dilution in 
1x BD Perm/Wash (1:200 rabbit anti-WWOX, gift of Professor Marcelo Aldaz) and incubated at room 
temperature for 60 minutes. After two washes with 1x BD Perm/Wash the cells were re-suspended 
with 100 µl of 1:500 dilution of the secondary goat anti-rabbit FITC-conjugated antibody (Sigma 
#F9887) and incubated for 45 minutes at 4ºC. Following two washes with 1x BD Perm/Wash the cells 
were re-suspended with 500 µl of 1x BD Perm/Wash and counted on BD FACSCanto flow cytometer 
(Beckton Dickinson). The data were analyzed with BD FACSDiva Version 6.0 software. 
2.3.7. Immunofluorescence of cultured cells 
20-50 000 cells were cultured on coverslips in the wells of a 24-well plate for approximately 48 hours. 
The cells were washed with warm RPMI-1640 MEDIUM and fixed by incubation in 4% 
paraformaldehyde for 20 minutes. After three 5-minute washes with PBS the cells were permeabilized 
in 0.25% Triton X 100 for 5 minutes at room temperature. Following three 5-minute washes with PBS 
the cells were incubated for 1 hr at room temperature in 1%BSA/2%FCS PBS to minimize non-
specific reactivity. The coverslips were dried with fibre-free paper, transferred to the slides, covered 
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with an appropriate dilution of a primary antibody in 1%BSA/2%FCS PBS (1:20 mouse anti-AP2γ, 
Upstate #05-909; 1:20 goat anti-WWOX, Santa Cruz #sc-20528) and incubated for 1 hr at room 
temperature in a humid chamber. Subsequently the coverslips were washed and dried as above and 
incubated in an appropriate dilution of the secondary antibody in 1%BSA/2%FCS PBS for 45 minutes 
at room temperature (1:200 APC–conjugated donkey anti-mouse, eBioscence #17-4012; 1:500 FITC-
conjugated rabbit anti-goat, Sigma #F9887). From this point the coverslips were protected from direct 
light exposure whenever possible. After the incubation, the coverslips were washed with PBS five 
times for 10 minutes, dried and each coverslip was inverted onto a slide containing 10 µl of the 
ProLong Gold antifade reagent mounting media (Invitrogen #P36934) supplemented with 1 µl of 
VECTASHIELD mounting medium with DAPI (Vector Laboratories #H1200). The edges of the 
coverslips were sealed with a transparent nail polish and the cells were visualised with a confocal 
microscope. I appreciate the help of Dr Mingjun Sun with the microscopy. 
2.3.8. Apoptosis, survival and cell cycle assays 
2.3.8.1. Determination of apoptosis following WWOX transient transfection in SKOV3 cell line 
by Annexin V /PI assay 
The assay was performed using TACS
TM
 Annexin V-FITC Apoptosis Detection kit (R&D Systems 
#TA4638) as per manufacturer's protocol. Briefly, 400 000 cells were plated into a 25 cm
2
 flasks and 
transfected after 24 hrs with 2 µg of WWOX-expression plasmid or empty vector plasmid, in a 1:3 
ratio with Lipofectamine 2000 (Invitrogen, #11668-027), in 2 ml of RPMI-1640 serum- and antibiotic-
free medium. Medium was replaced after 4 hours with 10 ml fresh medium supplemented with 10% 
FCS without antibiotics. 24 hrs after transfection cells from one flask per WWOX- or empty vector 
plasmid were collected for the first timepoint and cells from another flask per plasmid were 
trypsynized and replated for later timepoints. 
At each of the timepoints (24, 48, 72 hrs post transfection), following the collection of the media with 
floating cells, adherent cells were briefly trypsynized and trypsin was immediately neutralized with 
10% FCS RPMI. The combined floating and adherent cells were collected by centrifugation at 
approximately 500 g  for 5 -10 minutes at room temperature, washed with 500 µl cold 2% BSA PBS 
and collected by centrifugation again. The cells were resuspended with 100 µl Annexin V Incubation 
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Reagent and incubated in the dark for 15 minutes at room temperature. Following the incubation, 400 
µl 1 x Binding Buffer was added to each sample and the samples were analyzed within one hour by 
flow cytometry using BD FACSCanto flow cytometer (BD Biosciences, Oxford, UK) and BD FACSDiva 
Version 6.0 software. The apoptotic population was visualized as Annexin V-positive, PI-negative 
cells. 
2.3.8.2. Paclitaxel exposure assays 
2.3.8.2.1. Paclitaxel cytotoxicity assay in PEO1 cells stably transfected with WWOX or vector 
and following WWOX siRNA knock-down in WWOX-8 cell line or ITGA3 siRNA knock-down in 
PEO1 parent cell line 
6 000 log-phase cells per well (in triplicate for each treatment) were plated into 96-well plates. After 24 
hrs the medium was removed and replaced with medium containing 0, 8 or 16 nM paclitaxel. The cells 
were fixed with 10% trichloroacetic acid (1 hour at 4°C) at the time of treatment and after 24, 48 and 
72 hrs. The plates were washed with water, left to air-dry and stained with 0.4% sulforhodamine B 
solution in 1% acetic acid, washed with 1% acetic acid and air-dried. Cell-bound dye was resolubilized 
with 10 mM Tris, pH=10.5 and the absorbance was read at 570 nM. The background was subtracted. 
2.3.8.2.2. Caspase 3/7 activation assay following paclitaxel exposure of PEO1 cells stably 
transfected with WWOX or vector 
15 000 log-phase cells per well (in triplicate for each treatment) were plated into 96-well plates. After 
24 hrs the medium was removed and replaced with medium containing 0, 8, 16 nM paclitaxel. 
Caspase 3/7 activity was measured with a luminometer after 24 hrs of drug exposure according to 
manufacturer’s protocol with Caspase Glo 3/7 Assay kit (Promega #TB323). Background reading 
(media and caspase substrate only) was subtracted and the values were normalized to the values of 
untreated for each of the cell lines. Cells were also fixed with 10% trichloroacetic acid and processed 
as for growth curves (as described above) at the same timepoint (24 hrs). 
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2.3.8.2.3. Determination of apoptosis following paclitaxel exposure in PEO1 cells stably 
transfected with WWOX or vector by Annexin V5 /PI assay 
The assay was performed using TACS
TM
 Annexin V-FITC Apoptosis Detection kit (R&D Systems 
#TA4638) as per manufacturer's protocol. Log-phase cells (2.5 x 10
5
 per well) were seeded into 6-well 
plates. Following 24 hr incubation medium was replaced with medium containing 8 nM paclitaxel. 
After 24 hrs of drug exposure floating cells were collected, whereas adherent cells were briefly 
trypsynized and trypsin was immediately neutralized with 10% FCS RPMI. The assay was performed 
using TACS
TM
 Annexin V-FITC Apoptosis Detection kit (R&D Systems #TA4638) following the 
manufacturer's protocol as described above in 2.3.8.1. 
2.3.8.2.4. Parellel determination of the relative levels of apoptosis related proteins 
Log-phase cells (2.5 x 10
5
 per well) were seeded into 6-well plates. Following 24 hr incubation 
medium was replaced with medium containing 8 nM paclitaxel. After 24 hrs of drug exposure floating 
and adherent cells were collected and lysed. Cell lysates from three independent experiments (100 ug 
protein each) were combined and incubated overnight with nitrocellulose arrays spotted with 35 
apoptosis-related protein capture antibodies (R&D, ARY009) and further processed and developed as 
per manufacturer’s protocol. The X-ray films were scanned with transmission-mode scanner and pixel 
densities analyzed with ImageQuant (GE Healthcare). 
2.3.8.2.5. Determination of mitotic index following paclitaxel exposure in PEO1 cells stably 
transfected with WWOX or vector 
Log-phase cells (2.5 x 10
5
 per well) were seeded into 6-well plates. Following 24 hr incubation 
medium was replaced with medium containing 8 nM paclitaxel. After 8 or 24 hrs of drug exposure 
floating and adherent cells were collected, fixed with 2% paraformaldehyde, blocked with 1% BSA 
and permeablized with 1 x BDPerm/Wash solution (BD Biosciences). Cells (2 x 10
5
) were stained with 
1:100 dilution of anti-MPM2 antibody (Millipore #05-368), followed by incubation with 1:500 dilution of 
goat anti-mouse FITC-conjugated antibody (Sigma #F0257)). Cells were analyzed by FACS and the 
percentage of cells stained by the MPM2 antibody was designated as mitotic index as described 
before [224]. 
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2.3.8.2.6. A2780 paclitaxel exposure for the analysis of the impact on WWOX protein 
expression 
Paclitaxel IC50 at 48 hrs exposure in A2780 cells was determined with SRB assay. To this end, 175 
000 cells per well were plated into 6-well plates, treated with a range of paclitaxel concentrations after 
48 hrs, fixed with 10% TCA following 24, 48 and 72 hrs of drug exposure, and processed as 
described above. For the analysis of WWOX protein expression, 175 000 cells per well were plated 
into 6-well plates. After 48 hrs the medium was replaced with medium containing 0, 16 and 32 nM 
paclitaxel, the latter two concentrations corresponding to IC50 and IC75. Protein was collected after 
24, 48, and 72 hrs. 
2.3.8.3. Cisplatin, monastrol and tunicamycin exposure experiments 
2.3.8.3.1. Monastrol cytotoxicity assay following WWOX siRNA knock-down in WWOX-8 cell 
line 
Monastrol (Tocris Bioscience #1305) was dissolved in 96% ethanol and stored at -20°C as a 50 mM 
stock solution. 6 000 log-phase cells per well (in triplicate for each treatment) were plated into 96-well 
plates. After 24 hrs the medium was removed and replaced with medium containing vehicle or 100 µM 
monastrol. The cells were fixed with 10% trichloroacetic acid and processed as for paclitaxel 
experiments. 
2.3.8.3.2. Cisplatin cytotoxicity assay following WWOX siRNA knock-down in WWOX-8 cell line 
6 000 log-phase cells per well (in triplicate for each treatment) were plated into 96-well plates. After 24 
hrs the medium was removed and replaced with medium containing 0 or 6 µM cisplatin. The cells 
were fixed with 10% trichloroacetic acid and processed as for paclitaxel experiments. 
2.3.8.3.3. Tunicamycin cytotoxicity assay in PEO1 cells stably transfected with WWOX or 
vector and following WWOX siRNA knock-down in WWOX-8 cell line 
Tunicamycin (Sigma #T7765) was dissolved in DMSO and stored at -20°C as a 1 mg/ml stock 
solution. 6 000 log-phase cells per well (in triplicate for each treatment) were plated into 96-well 
plates. After 24 hrs the medium was removed and replaced with medium containing vehicle or 200 
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ng/µl tunicamycin. The cells were fixed with 10% trichloroacetic acid and processed as for paclitaxel 
experiments. 
2.3.8.4. JNK inhibition experiments in WWOX-8 cell line 
SP600125 (Tocris Bioscience #1496), a selective competitive JNK inhibitor [225], was dissolved in 
DMSO and stored at -20°C as a 20 mM stock solution. 6 000 log-phase cells per well (in triplicate for 
each treatment) were plated into 96-well plates. After 24 hrs the medium was removed and replaced 
with medium containing vehicle or 200 ng/µl tunicamycin, 8 nM paclitaxel, 10 µM SP600125 or 
SP600125 combined with paclitaxel or tunicamycin. The cells were fixed with 10% trichloroacetic acid 
and processed as for paclitaxel experiments. The protocol for the mitotic index experiment (MPM2 
positivity) was identical as for paclitaxel exposure (2.3.8.2.5) and 8 nM paclitaxel with or without 10 
µM SP600125 was used. 
2.4. Re-analysis of a publically available microarray dataset for the associations between 
WWOX and GRP78 expression and patient outcomes 
GSE9899 [226] microarray dataset and available clinicopathological data was down-loaded from 
Gene Expression Omnibus (GEO) depository. Patients’ characteristics are presented in Chapter 6. 
260 individuals were retained in the analysis after removal of low-malignant potential tumours and 
patients without survival data. The microarray platform was Affymetrix Human Genome U133 Plus 2.0 
Array and there were multiple microarray probes for several analyzed genes. For univariate log rank 
survival analysis of each of the genes of interest, the samples were stratified as low or high 
expression for a given gene (for genes with a single U133 Plus 2.0 probe high expression 
samples were defined as above median, for genes with multiple probes on the chip high 
expression samples were defined as those with more than half of the probes above median). 
Association between expression of the genes of interest was assessed with Fisher’s exact test. 
2.5. Cloning of a vector for expression of V5 –tagged WWOX protein 
A 3063 bp plasmid generated by modifying the 5446 bp pcDNA3 plasmid by removing the part 
located between bases 1249 and 3632 (f1 ori, SV40 promoter, SV40 origin of replication, neomycin 
ORF, SV40 poly A) was a kind gift of Dr Vera Chan, Imperial College London. V5-tagged WWOX was 
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amplified by PCR from pcDNA3.1/V5-his plasmid with WWOX inserted at HindIII and XbaI with the 
following primers –forward: GCAAGCTTTCAGCCATGGCAGCGCTGCGCT and reverse: 
CGCGAATTCTCAACCGGTACGCGTAGAAT. The dNTP and primer concentration were as described 
for genomic DNA PCR elsewhere. PfuUltra High-Fidelity DNA Polymerase at the concentration of 
0.05 U/µl and 1x PfuUltra HF Reaction Buffer (Stratagene #600380) were used. The PCR programme 
was as follows: 94ºC for 5 minutes, 29 cycles: 94ºC for 45 seconds, 58ºC for 45 seconds, 72ºC for 20 
seconds and a final elongation step: 72ºC for 5 minutes. The PCR product was separated on 1% 
agarose/TAE gel with ethidium bromide and extracted from the gel with QIAquick Gel Extraction Kit 
(Qiagen #28704) according to manufacturer’s protocol. The PCR product and the modified pcDNA3 
plasmid described above were subjected to restriction digestion with HindIII (Biolabs #R0101S) and 
EcoRI (Biolabs #R0104S) in 1x NEbuffer EcoRI (Biolabs #B0101S) for 90 minutes at 37ºC. The 
restriction digestion products were separated on a gel, extracted as described above and ligated 
overnight at 14°C with T4 DNA ligase (Bioline #BIO-27026) at the insert : vector 3 : 1 ratio. The 
plasmid was transferred into JM109 competent E.coli cells (Promega #L1001), bacteria plated on 
Petri dishes coated with agar containing 50 µg/ml ampicilline and grown overnight at 37ºC. Several 
clones were selected and grown in LB medium with 50 µg/ml ampicilline. The plasmid DNA was 
purified from the bacterial culture with Qiaprep Spin MiniPrep Kit (Qiagen #27104). The clone 
containing and insert (determined by enzymatic EcoRI /HindIII digestion and agarose gel 
electrophoresis) was further propagated in JM109 cells and purified with QIAfilter Maxi Kit (Qiagen 
#12263) according to manufacturer’s protocol.  The plasmid was sequenced bidirectionally with the 
following primers: BGH (TAGAAGGCACAGTCGAGG), T7 (TAATACGACTCACTATAGGG) and a pair 
of primers complementary to WWOX transcript –F: TGAAGCAGTGTCACGCATTT and R: 
TGGACCTGTTATAAGCCAGCATCG. 
2.6. Sequenom Massarray iPLEX single nucleotide polymorphism genotyping 
2.6.1. Study population 
The study was performed on 871 DNA samples isolated from blood of women who entered the 
SCOTROC I clinical trial (provided by the Scottish Gynaecological Clinical Trials Group), 1473 
samples from postmenopausal Danish women aged 60-84 without cancer (provided by Professor 
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Philippe Froguel, Imperial College London) and  DNA samples isolated from ovarian cancer cell lines. 
All participating women signed an approved consent form, and the study was carried out in 
accordance with the Helsinki Declaration II and the European Standards for Good Clinical Practice. 
The demographic characteristic of the populations are presented in Chapters 3 and 4. 
2.6.2. SNP selection and assay design 
HapMap Phase II database and HaploView 3.32 software were used to generate a list of 77 tagging 
SNPs selected across the region covering predicted promoter and all WWOX exons (including their 
flanking intronic sequences) corresponding to the only observed protein isoform with minor allele 
frequency (MAF) of >0.02 (or MAF of >0.01 in the regions, where previous associations with ovarian 
cancer clinicopathological features were observed) and linkage disequilibrium (LD) of r
2
>0.8 with 
other SNPs in the LD bin. The list was further supplemented with a list of 6 non-tagging candidate 
SNPs including coding non-synonymous polymorphisms or SNPs previously associated with ovarian 
cancer clinicopathological features (described in Chapter 3). Full rationale for SNP selection is 
presented in Chapter 3. For each of the SNPs 200 bp genomic sequence centred on the 
polymorphism was downloaded from the Ensembl Genome Browser website 
(www.ensembl.org/biomart) and MassArray Assay Design Software was used to design multiplex 
Sequenom MassArray assays (reported additional variation within the 200bp sequences adjacent to 
the assay SNPs was marked and excluded from the primer design). Four SNPs failed in the assay 
design because there was too high primer potential for dimer or hairpin formation or interference with 
other primers. Low multiplicity assay (4 SNPs) were not run to minimise the costs. Because of assay 
design issues, 69 tagging SNPs and 6 extra candidate SNPs were eventually run. I appreciate the 
help of Stephen Clark from Section of Genomic Medicine, Imperial College London, with running the 
primer design software. 
2.6.3. Genotyping 
SNP analysis was carried out using Sequenom MALDI-TOF mass spectrometer. 28-, 25-, and 22- 
plex PCR reactions were carried out in 384-well plates according to Sequenom protocols. The PCR 
and extension reaction primers (Appendix 3) were obtained from Sigma-Genosys and Invitrogen, 
based on output from Sequenom assay design software. PCR was carried out using 1.25 x Qiagen 
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HotStar buffer, 3.5 mM Mg2+, 0.5 mM dNTPs, 100 nM primer, and 0.5 U Qiagen HotStar Taq 
polymerase (Qiagen #203205) (1 U for 28-plex PCR reaction) with 5 ng DNA in a 5-µl reaction. The 
concentration of the extension primers added to the extension reaction cocktail were adjusted 
according to Sequenom High iPlex Gold protocol.  The plate was further processed (single nucleotide 
extension reaction and MALDI–TOF <matrix-assisted laser desorption/ionization time-of-flight> mass 
spectroscopy) at the Section of Genomic Medicine laboratory, Imperial College London, by Marlene 
Attard. The spectra were analyzed using MassArray Typer 3.4 Analyzer software. Assays with call 
rates lower than 90% were not carried forward to further analysis. Three SNPs (rs442608, rs383362 
and rs441004) were genotyped in duplicate in around 300 samples each as a technical replicate and 
the average reproducibility was 99.8%. 
2.6.4. Scotroc1 and Danish women population genotyping studies: statistical analysis 
All analyses were performed with PASW Statistics 18.0 (formerly SPSS) and Microsoft Excel. 
Presented p values are 2-sided where applicable. 
2.6.4.1. Statistical analysis for the validation of the SNPs from the original study in the 
Scotroc1 population 
SNPs were tested for Hardy-Weinberg equilibrium by Fisher’s Exact tests. Univariate test for 
independence from genotype were performed for rs4887937 versus histology (chi-squared test), 
rs4887937 and rs2303191 versus grade (Fisher’s exact test) and rs11545028 versus age (1-way 
Anova). Assessment of rs383362 as prognostic factor independent of the clinical factors for 
progression-free survival was performed using a multivariate Cox proportional hazards regression 
model. The progression free survival analysis was conducted by Manuela Zucknick (Imperial College) 
and Jim Paul (University of Glasgow). 
2.6.4.2. Statistical analysis of the associations between WWOX variation and ovarian cancer 
phenotypes in Scotroc1 clinical trial patient population 
SNPs were tested for Hardy-Weinberg equilibrium by Fisher’s Exact tests. Univariate tests for 
independence from genotype (Fisher’s exact) were performed for histology, grade (1 and 2 versus 3), 
stage (1 and 2 versus 3 and 4), CA125 response and clinical/radiological response (complete and 
90 
 
partial reponse versus stable and progressive disease) and chemotoxicity: neurotoxicity (grade 1 
versus 2-4), serious hematologic toxicity (docetaxel patients) and gastrointestinal toxicity. Markers 
with strongest evidence of association for each trait where re-assessed with chi-square linear-by-
linear association test, an approximation of Cochrane-Armitage test for trend in PASW/SPSS 
software. Univariate overall and progression-free survival analysis was performed with log-rank test. 
2.6.4.3. Statistical analysis of the associations between WWOX variation and bone metabolism 
parameters in the population of Danish postmenopausal women 
SNPs were tested for Hardy-Weinberg equilibrium by Fisher’s Exact tests. Assessment of the 
contribution of covariates (BMI, number of years from menopause) and factors (current and ever 
smoking status, hormone replacement therapy and osteoporosis treatment), to the phenotypes of 
interest was carried out using multivariate ANCOVA. Subsequently, for univariate ANCOVA analysis 
of each phenotype in turn, only those covariates and factors with p-values of less than 0.1 were 
included with the genotypes for analysis. The analysis strategy was proposed and the analysis 
subsequently supervised by Dr Andrew Walley (Section of Genomic Medicine, Imperial College 
London). 
2.6.4.4. Statistical analysis of the associations between WWOX variation and BMI as well as 
height in the population of Danish postmenopausal women 
Assessment of the contribution of a covariates (number of years from menopause) and factors 
(current and ever smoking status, hormone replacement therapy and osteoporosis treatment), to BMI 
(body mass index) and height was carried out using multivariate ANCOVA. Subsequently, for 
univariate ANCOVA analysis of BMI and height, only those covariates and factors with p-values of 
less than 0.1 were included with the genotypes for analysis. 
2.7. Evaluation of putative splice site variation in an in vitro assay with pSpL3 exon trapping 
vector 
Isnp8/rs2303191 polymorphism is located in the +6 splice donor consensus site and may have effects 
on splicing. A T+6/C+6 substitution in COL3A1 gene causes exon skipping [227] and Isnp8 may have 
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a similar effect on WWOX splicing. The effect of splice-site substitutions might be evaluated with an in 
vitro assay utilizing pSpL3 exon trapping vector as described by Schneider et al [228]. 
I cloned the genomic region of WWOX exon 5 and flanking intronic sequences including the 
Isnp8/rs2303191 variation as well as splice acceptor-, donor-, and putative branch sites into the 
multiple cloning site of pSpL3 (Figure 2.1). The site is located between two artificial exons that are 
expressed from pSpL3. Any sequence cloned between them that has properties of an exon will be 
present in the expressed mRNA and this can be shown as a difference in the length of the PCR 
product amplified with a pair of SA2/SD6 primers complementary to pSpL3 artificial exons (SA2: 
ATCCAGTGGTATTTGTGAG, SD6: TCTGAGTCACCTGGACAAC). A schematic representation of the 
possible assay outcomes is presented in Figure 3.1 (Chapter 3) 
The sequence covering WWOX exon 5 and flanking intronic sequences  was PCR amplified from two 
ovarian cancer cell lines –IGROV1 (rs2303191 rare homozygote) and CAOV3 (rs2303191 common 
homozygote). Overhangs containing BamHI and XhoI restriction sites were added to primers 
complementary to the genomic sequence), forward XhoI: 
GCCTCGAGTCACCCCTGGTTGAGAACTT, reverse BamHI: 
GCGGATCCGTTAGCCCGGCATGTGTATT. The PCR products were subcloned into pGEM-T Easy 
vector (Promega #TM042) according to the manufacturer’s protocol. The PCR products subcloned 
into pGEM-T Easy as well as pSpL3 empty vector were subjected to restriction digestion with BamHI 
(Biolabs #R0136) and XhoI (Biolabs #R0146) in 1x NEbuffer3 (Biolabs #B7003) for 90 minutes at 
37°C. The restriction digestion products were separated on an agarose gel, extracted from the gel 
with QIAquick Gel Extraction Kit (Qiagen #28704) according to manufacturer’s protocol and 
subsequently ligated overnight at 14°C with T4 DNA ligase  (Bioline #BIO-27026) at the insert : vector 
3 : 1 ratio. The plasmids containing the inserts were propagated as described above for WWOX-V5 
plasmid and finally isolated with QIAfilter Plasmid MidiKit (Qiagen #12243). The correct orientation of 
the inserts and sequence verifications was performed by sequencing using pSpL3-1 
(GAGAAATATCAGCACTTGTG) and pSpL3-2 (GTACACCGGCATGTGTGGCC) primers. 
SKOV3 ovarian cancer cells were transfected with pSpL3 empty vector or pSpL3 containing WWOX 
exon 5 region with opposite rs2303191 genotypes. The transfection protocol was as described above 
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for RNA extraction.  RNA lysis 48 hrs post transfection and cDNA synthesis were as described above. 
cDNA was PCR amplified with SA2 and SD6 primers using the TD55 programme and analyzed by gel 
electrophoresis. 
(GCCTCGAG)TCACCCCTGGTTGAGAACTTGGGGTAATTTAAGTGGTGCTCCGGTAAAGGCCATTC 
 
 
AACATGACTCACTGTGTTGATGTTATGTTTTCTAACATTGACTTTCCTTTAAACCATAGGGTTCGAA 
 
 
ACCGCCAAGTCTTTTGCCCTCCATGGTGCACATGTGATCTTGGCCTGCAGGAACATGGCAAGGG 
 
 
CGAGTGAAGCAGTGTCACGCATTTTAGAAGAATGGGTAAG
T
/CGCTTGACTGTTGTTGTTTTTTTTAA 
 
 
TTGTCAAATACACATGCCGGGCTAAC(GGATCCGC) 
 
 
 
 
PCR primers (introduced BamHI and XhoI restriction sites with GC overhangs) 
 
Exon 6 -boxed 
 
splice donor 
 
splice acceptor 
 
putative lariat branch sites 
 
T
/C -rs2303191 (Isnp8) 
 
 
Figure 2.1 
 
Isnp8 genomic region illustration  
 
2.8. Buffers, media and reagents 
Phosphate buffered saline pH=7.4 (PBS) 
Per 1 litre: 
Na2HPO4 1.15 g 
KaH2PO4 0.2 g 
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NaCl 8.0 g 
KCl 0.2 g 
 
PBS-Tween (PBS/T) 
0.1% Tween 20 PBS 
Tris Buffered Saline pH=7.6 (TBS) 
Per 1 litre: 
Tris Base 2.42 g 
NaCl 8.0 g 
 
TBS-Tween (TBS/T) 
0.1% Tween 20 TBS 
LB (Lauria-Bertani) media (pH=7.5) 
Per 1 litre: 
Bacto-tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
 TAE (Tris-acetate-EDTA) buffer (pH=8.0) 
Per 1 litre: 
Tris Base 4.84 g 
Acetic acid 1.09 g 
EDTA 0.292 g 
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Chapter 3. WWOX as a modifier gene in ovarian cancer 
3.1. Genetic association studies in cancer 
Although in principle a disease of the genome, cancer is a result of a complex interplay between 
inherited and environmental factors and, apart from the rare highly penetrant cancer predisposition 
syndromes, the role of genetic predisposition in an individual’s cancer risk is less than the risk 
attributed to environmental factors. Still, there is a degree of familial clustering in cancer (2-4 fold 
increased risk in first–degree relatives of individuals with cancer). It is believed that known genes and 
syndromes account for only a small proportion of the observed heritability of cancer and most of the 
increased risk in relatives of cancer sufferers appears to be due to complex polygenic mode of 
inheritance where the effects of single genes are modest and additive. For example, it is estimated 
that highly penetrant germline variants of breast cancer susceptibility genes BRCA1, BRCA2, TP53, 
ATM and PTEN account for no more than 1/4
th
 of the genetic risk of breast cancer. The genetic study 
of polygenic disease is much more challenging than mapping susceptibility loci in disorders inherited 
according to Mendelian rules [229]. Much insight into cancer pathobiology, both familial and sporadic, 
was gained by linkage familial studies indentifying genes responsible for cancer syndromes such as 
RB1 at 13q14.3 in familial retinoblastoma –the first tumour suppressor gene to be characterized [230] 
- but investigating predisposition to polygenic disease is much more challenging due to genetic 
heterogeneity, incomplete penetrance and strong environmental impact [229]. The main alternative for 
linkage studies are association studies in which the frequencies of variants are compared in cases 
(individuals affected by the disease) and controls (without the disease), and are more suited for 
mapping loci with moderate effects. Association studies utilize a candidate gene or genome–wide 
approaches. It remains unclear however, if the effects of the genetic variants predisposing to cancer 
are strong enough to be easily demonstrated by association studies and few convincing cancer–
susceptibility genes have been identified this way so far [229]. 
The completion of the human genome sequencing and rapid acquisition of data on the occurrence 
and frequency of single nucleotide polymorphisms (SNP, an existence of variants of the same 
nucleotide sequence at significant frequency in the population) facilitated the introduction of high–
throughput technologies that determine SNP variants within known genes or other loci. The fact that 
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several SNPs (or other polymorphisms such as copy number variation) can co-occur more often than 
expected by chance, i.e. show linkage disequilibrium (LD), enables the genetic diversity across a 
particular region to be captured with a limited number of SNPs, called tagging SNPs, as opposed to 
the need to genotype every single variation. The information thus obtained can be used to 
demonstrate if variation within the region is associated with some phenotype, but it does not normally 
map causative variation. The LD between SNPs, in the context of gene association studies, is most 
conveniently expressed by r
2
 correlation coefficient where 1 means complete disequilibrium and 0 no 
linkage, and takes into account both recombination frequency between the variants and the frequency 
of each SNP variant in the population (as SNPs with very different frequencies will not tag one 
another efficiently). Several algorithms have been developed to facilitate selection of the most efficient 
sets of tagging SNPs for association studies, and they use frequency and LD data deposited on the 
HapMap database, a catalogue of genetic similarities and differences in humans [229, 231]. 
Despite the conceptual and technological progress, the major pitfall of many of the reported cancer 
genetic association studies is the frequent lack of reproducibility of the findings in independent 
populations. Gaudet et al. for example, genotyped ERCC4 (excision repair cross-complementing 
rodent repair deficiency, complementation group 4), TNF, CASP10 (caspase 10), PGR (progesterone 
receptor) and BID (BH3 interacting domain death agonist) SNPs previously linked with breast cancer 
risk in around 30 000 cases and 30 000 controls from 30 studies in the Breast Cancer Association 
consortium, and did not find evidence of an association between any of these variants and cancer risk 
[232]. It is believed that increasing the size and homogeneity of the populations to enhance statistical 
power, improved selection of candidate genes and more stringent significance criteria should improve 
the reproducibility of association studies. It is postulated that the usual levels of significance (p value 
of 0.05) should be replaced with p values of 10
-4
 for candidate-gene and 10
-7
 for whole-genome 
studies [229]. 
3.1.1 Genetic association studies in ovarian cancer 
About 10% of epithelial ovarian cancers are attributed to rare, high penetrance germline variants in 
susceptibility genes, including BRCA1, BRCA2 and mismatch repair genes [231, 233], and these 
hereditary syndromes are discussed in detail in Introduction (Chapter 1). For the remaining 90% of 
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cases, where there is no obvious high penetrance heredity manner, most of the reported genetic 
associations for ovarian cancer incidence fall into three functional classes, but this is biased by 
candidate gene choice as many authors selected candidates based on the assumption that variants of 
genes involved in phenomena commonly linked to ovarian cancer initiation or progression (that is sex 
steroid signalling, cell cycle control and DNA repair genes) should modify ovarian carcinogenesis 
[231]. The examples of genes, whose variants displayed significant associations with ovarian cancer 
incidence in the recently published studies, involved in sex steroid pathway or metabolism include 
PGR (progesterone receptor) [234], and cytochromes CYP19A1 [235] and CYP3A4 [236]; cyclins 
CDKN2A, CDKN1B [237] and RB1 (retinoblastoma 1) [238] represent cell cycle control genes, and 
XRCC2 or XRCC3 [239] (X-ray repair complementing protein 2 or 3) exemplify DNA repair genes. 
RB1 [238, 240] and CYP3A4 [236] associations were demonstrated in more than one population.  
A recent, genome-wide, multi-stage study of more than 13 000 cases and controls identified 12 SNPs 
at chromosome 9p22 strongly associated with ovarian cancer risk (p<10
-8
) with best evidence at 
rs3814113, and interestingly no other variation reached this level of significance. This is so far the 
best documented common genetic variant associated with ovarian cancer incidence, but neither 
rs3814113 nor highly correlated (r
2
=0.99) rs4445329 are located within an open reading frame or 
intron of any gene. The nearest gene is BNC2 (basonuclin 2) 44 kbp down-stream of rs3814113. 
Further studies are needed to describe the significance of rs3814113 variation in ovarian cancer. 
Additionally, the authors present, as supplementary material, the association results, within this 
genome-wide association study, of 15 variants in 11 loci previously reported to be linked with ovarian 
cancer incidence in nine previous reports. Variants in three of those loci are significantly associated 
with ovarian cancer in this study with the p values of 0.01 to 0.027 (that are above threshold for 
genome-wide significance). It is of note that the authors do not report the association results for these 
15 SNPs following the removal of the populations, in which the associations were initially shown (all of 
them were conducted by the same Ovarian Cancer Association Consortium) [241]. 
Our group have previously genotyped 8 WWOX SNP variants in 554 ovarian cancer patients (CGP 
samples) and this demonstrated significant associations after correction for multiple testing between 
several WWOX SNPs and clinicopathological features in ovarian cancer [242]. These finding are 
discussed in detail in Introduction (Chapter 1). 
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Two SNPs (Isnp1 and Isnp8) showed associations with tumour grade (p=0.0041 and 0.0040). Isnp1 
also showed association with histology, the presence of at least one copy of the rarer Isnp1 T allele 
positively correlated with clear cell histology, while the C/C genotype positively correlated with 
mucinous tumours (p=0.0057). The C121T SNP associated with age at diagnosis (p=0.0073) and the 
corrected p value (p=0.0584) was just above the cut-off for significance. 
T1497G showed association with progression free survival (p=0.0045), and with overall survival 
(p=0.0284), survival data was available for 295 patients. However, only the association of T1497G 
with PFS remained significant after multiple testing correction. T1497G was found to be an 
independent prognostic indicator of PFS (HR = 2.1, 95% CI = 1.28-3.40, p=0.0030 for G/G). Patients 
carrying the T/T genotype (median PFS=34.8 months) exhibited better prognosis than those with 
either the T/G or G/G genotype (median PFS=20.7 months). 
3.2. Results 
3.2.1. The study into the associations between WWOX variation and clinicopathological 
features in ovarian cancer: strategy 
Major aim of this study was to validate WWOX SNPs’ associations previously demonstrated by our 
group in an independent population of ovarian cancer patients so as to prove their clinical significance 
or reject them as likely false positive findings. Additionally, the study attempted finding association 
hotspots (SNPs with best evidence of association) within the linkage disequlibrium (LD) bins of the 
original four SNPs so as to determine whether they are likely causative SNPs themselves or just 
markers of other causative variation within the region. The minor allele frequency of SNPs used for 
assay design was set at a relatively low threshold of 1% to allow for inclusion of rare, potentially 
functional SNPs (5% is the usual threshold for studies aiming at finding tagging but not causative 
SNPs associated with a particular trait, such as genome-wide studies). 
Further, provided positive validation, the project aimed at elucidation of the mechanistic link between 
WWOX genotypes and the observed clinicopathological features. This was expected to be attempted 
primarily by examining their potential impact on WWOX expression. The SNPs of interest, located in 
non-coding sequences (C121T within Kozak translation start site, Isnp1 upstream of exon 2, Isnp8 
within splice donor consensus sequence of intron 5 and T1497G in the 3’ untranslated region of exon 
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9) are potentially involved in the WWOX gene transcription, translation, RNA splicing or stability 
ultimately leading to altered WWOX expression. 
The genomic regions encompassing the four original SNPs were assessed for the presence of linkage 
disequilibrium (LD) blocks using the HapMap phase II database. Haploview software was used to 
generate a list of 15-20 tagging SNPs representing the genetic information of each such LD region as 
described in Materials and Methods (a common region for Isnp1 and C121T encompassing exons 1 
to 4, Isnp8 block covering exon 5 and T1497G region spanning exon 9).  
The three LD blocks represented by the tagging SNPs covered the WWOX promoter region as well as 
exons 1-5 and 9 with flanking intronic sequences. We decided to extend the genotyping assays so as 
to additionally cover closely positioned exons 6-8 and thus collectively tag the genetic information of 
the whole WWOX open reading frame (i.e. all the exons corresponding to the only observed 46 kDa 
protein isoform) as well as the putative promoter and untranslated exonic regions and thus 
comprehensively analyze the whole exon-related genomic region of WWOX for associations with 
ovarian cancer. A minor allele frequency of 2% was chosen for this exon 6-8 region because a 1% 
MAF (as used for the other LD blocks) yielded an excessive number of markers necessitating several 
multiplex assays, which would be cost-prohibitive, in a region with no prior evidence of association 
with clinicopathological features in ovarian cancer. Two extra coding non-synonymous SNPs were 
added to the list of 26 HapMap tagging SNPs for this LD block.  
Collectively, 77 tagging and 6 extra putative functional SNPs (C121T, Isnp1, Isnp8, C1442T as well 
as coding non-synonymous rs7201683 and rs12918952) were used for assay design (Table 3.1). 
(Potentially functional T1497G/rs38362 and a non-synonymous rs3764340 were also HapMap 
tagging SNPs). We decided to use the Sequenom iPLEX genotyping platform based on highly 
multiplex PCR reactions. The most optimal output suggested by the Sequenom assays design 
software involved 3 highly multiplex PCR reactions: 28-, 25- and 22-plex, and one low multiplicity 
assay (4 SNPs) that was not run to minimize the costs. A further 4 SNPs failed in design due to too 
high primer potential for dimer or hairpin formation. The genotyping was thus attempted for 69 tagging 
and 6 extra putative functional SNPs (C121T, Isnp1, Isnp8, C1442T, rs7201683, rs12918952).  
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SNP identifier Alternative 
name/comments 
Chromosomal 
coordinate 
WWOX location Multiplex assay 
rs8059851  76.675.833 5' of the gene failed in design 
rs8061268  76.680.194 5' of the gene 1 
rs11642734  76.682.672 5' of the gene 2 
rs16947106  76.685.038 5' of the gene 1 
rs11545028 C121T 76.691.172 exon 1, 5'UTR 2 
rs4887935  76.691.956 intron 1 2 
rs7192129  76.693.915 intron 1 1 
rs8049744  76.698.706 intron 1 2 
rs4887937 Isnp1 76.699.710 intron 1 1 
rs2287972  76.701.108 intron 2 1 
rs11645081  76.704.648 intron 3 1 
rs2072587  76.706.245 intron 3 2 
rs1469117  76.706.295 intron 3 1 
rs16947129  76.709.247 intron 4 1 
rs10492874  76.710.132 intron 4 1 
rs11645006  76.710.658 intron 4 2 
rs17649341  76.713.962 intron 4 2 
rs8056446  76.745.997 intron 4 1 
rs8059793  76.746.799 intron 4 2 
rs7190335  76.747.719 intron 4 2 
rs10871347  76.748.607 intron 4 1 
rs12932880  76.753.394 intron 4 1 
rs2303191 Isnp8 76.755.693 intron 5 2 
rs2303190  76.755.737 intron 5 1 
rs12325408  76.756.003 intron 5 1 
rs4887940  76.757.590 intron 5 3 
rs12926108  76.757.600 intron 5 failed in design 
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rs11150044  76.758.793 intron 5 1 
rs11150046  76.759.162 intron 5 1 
rs11150047  76.759.254 intron 5 1 
rs17572124  76.760.321 intron 5 1 
rs7206823  76.762.452 intron 5 2 
rs11644126  76.762.676 intron 5 1 
rs2161636  76.763.071 intron 5 2 
rs16947220  76.764.443 intron 5 2 
rs4243156  76.971.397 intron 5 not run 
rs7198580  76.974.431 intron 5 3 
rs9928827  76.974.845 intron 5 3 
rs8055871  76.975.211 intron 5 3 
rs11643643  76.977.006 intron 5 3 
rs12918952 non-synonymous 76.978.276 exon 6 3 
rs12446823  76.978.383 intron 6 3 
rs4083383  76.988.134 intron 6 3 
rs4609864  76.988.341 intron 6 not run 
rs7192844  76.988.721 intron 6 not run 
rs7199086  76.989.639 intron 6 not run 
rs7192626  76.983.363 intron 6 3 
rs9938424  76.988.376 intron 6 3 
rs6564537  76.984.187 intron 6 3 
rs3897139  76.986.890 intron 6 3 
rs11150075  76.989.993 intron 6 3 
rs13331309  76.991.062 intron 6 3 
rs9923888  76.996.600 intron 6 3 
rs8046289  77.012.206 intron 6 3 
rs4130513  77.016.251 intron 6 3 
rs7201683 non-synonymous 77.016.308 exon 7 3 
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rs4129722  77.016.656 intron 7 3 
rs9921967  77.017.035 intron 7 3 
rs6564559  77.021.013 intron 7 3 
rs3764340 non-synonymous 77.023.938 exon 8 3 
rs11646795  77.027.206 intron 8 3 
rs7200731  77.030.931 intron 8 3 
rs9927016  77.031.591 intron 8 failed in design 
rs424074  77.792.088 intron 8 1 
rs12445829  77.792.167 intron 8 1 
rs398255  77.792.535 intron 8 1 
rs400497  77.794.068 intron 8 1 
rs1129030  77.794.095 intron 8 2 
rs441004  77.794.331 intron 8 2 
rs1813526  77.795.011 intron 8 1 
rs1553723  77.795.109 intron 8 2 
rs12927043  77.796.355 intron 8 2 
rs442608  77.796.467 intron 8 2 
rs421405  77.799.640 intron 8 3 
rs368920  77.800.003 intron 8 2 
rs12446313  77.801.523 intron 8 2 
rs11150144  77.801.597 intron 8 1 
rs16949956  77.802.161 intron 8 failed in design 
C1442T  77.803.266 exon 9, 3'UTR 1 
rs383362 T1497G 77.803.321 exon 9, 3'UTR 2 
rs2288035  77.803.431 exon 9, 3'UTR 1 
rs12828  77.803.824 exon 9, 3'UTR 2 
rs270422  77.810.152 3' of the gene 1 
Table 3.1 
A list of WWOX SNPs entered into Sequenom iPLEX genotyping assays design 
102 
 
3.2.2. The study into the link between WWOX variation and clinicopathological features of 
ovarian cancer in the Scotroc 1 population: assays performance 
I performed the genotyping assays using DNA extracted from blood of 871 out of 1077 patients who 
entered the Scotroc1 clinical trial, utilising the Sequenom platform as described in Materials and 
methods. Scotroc1 was a phase III randomized trial of docetaxel-carboplatin versus paclitaxel-
carboplatin as first line treatment in ovarian cancer [243]. Table 3.2 summarizes the clinical data of 
patients in the CGP and Scotroc1 populations. 
57 of 75 attempted SNP genotyping assays yielded informative spectra. The reasons for assay failure 
were no amplification in PCR reaction or presence of false-positive spectra in control wells, failure of 
the extension step or poor separation between genotype clusters. The performance of the assays was 
within the expected rate of informative results and did not differ from the rates obtained by other users 
of the same Sequenom facility (personal communication, Dr Andrew Walley, Section of Genomic 
Medicine, Imperial College London). The assay success rate can be occasionally increased by re-
running the multiplex reactions after exclusion of the SNPs that performed successfully in the first 
round of reactions but this was not done as the costs were prohibitive. Three SNPs (rs442608, 
rs383362 and rs441004) were genotyped in duplicate in around 300 samples as a technical replicate 
and the average reproducibility was 99.8%. 
54 SNPs were carried forward to the final analysis after exclusion of three SNPs, whose genotyping 
call rates were below 90%. None of the SNP genotyping results was significantly deviated from 
Hardy-Weinberg equilibrium at the p of <0.01 apart from rare C1442T (p=0.003). This SNP was 
previously similarly deviated from Hardy-Weinberg equilibrium in the CGP population genotyped with 
different technology i.e. SNAPshot assays (and similarly in Danish women genotyped with Sequenom 
platform as presented below in Chapter 4). Consequently, this may represent a true deviation rather 
than a sampling error, and C1442T was retained in the analysis. The HapMap database defines 
SNPs with Hardy-Weinberg statistic p>0.001 as suitable for mapping and association studies [244]. 
The genotype frequencies, call rates and Hardy-Weinberg statistic p values are presented in Table 
3.3. 
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 CGP CGP survival Scotroc1 
Total number of 
subjects 
554 235 871 
Median age at 
diagnosis, years 
(range) 
59 (22 – 88) 60 (28 – 88) 59 (18 – 84) 
Median OS, months 
(range) 
 70 (10 - 226) 34 (0 – 41) 
Median PFS, months 
(range) 
 25 (10 - 190) 15 (0 -41) 
 
FIGO stage 
   
I 138 (25%) 59 (25%) 61 (7%) 
II 64 (12%) 30 (13%) 103 (13%) 
III 282 (51%) 119 (51%) 586 (67%) 
IV 63 (11%) 26 (11%) 121 (14%) 
unknown 7 (0%) 1 (0%) 0 
 
Tumour grade 
   
1 70 (13%) 15 (6%) 61 (7%) 
2 131 (24%) 51 (22%) 212 (24%) 
3 263 (47%) 144 (61%) 470 (54%) 
Clear cell cases* 40 (7%) 19 (8%) 42 (5%) 
Unknown 50 (9%) 6 (3%) 86 (10%) 
 
 
Histology 
   
Clear cell 40 (7%) 20 (8%) 42 (5%) 
Endometrioid 125 (22%) 63 (27%) 97 (11%) 
Mucinous 38 (7%) 13 (5%) 28 (3%) 
Serous 298 (54%) 133 (57%) 389 (45%) 
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Anaplastic 0 0 3 (0%) 
Adenocarcinoma 0 0 136 (16%) 
Other 0 0 170 (20%) 
Unknown 53 (10%) 6 (3%) 6 (1%) 
*-clear cell cases were assigned as high grade 
 
Table 3.2 
Summary of patient clinicopathological data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 
Scotroc1 population  genotyping results 
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SNP 
identifier 
Chromosomal 
coordinate 
Genotype frequencies Call rate [%] Hardy-
Weinberg 
equilibrium AA Aa aa 
rs8061268 76.680.194 247 408 181 95.98 0.61 
rs11642734 76.682.672 420 362 76 98.51 0.83 
rs16947106 76.685.038    uninformative  
rs11545028 76.691.172 370 366 97 95.64 0.30 
rs4887935 76.691.956 329 391 142 98.97 0.16 
rs7192129 76.693.915 421 352 77 97.59 0.78 
rs8049744 76.698.706 798 62 0 98.74 0.27 
rs4887937 76.699.710 575 191 24 90.70 0.10 
rs2287972 76.701.108 233 393 210 95.98 0.09 
rs11645081 76.704.648 831 4 0 95.87 0.94 
rs2072587 76.706.245    uninformative  
rs1469117 76.706.295 593 184 24 91.96 0.04 
rs16947129 76.709.247 555 225 24 92.31 0.84 
rs10492874 76.710.132 224 403 182 92.88 0.98 
rs11645006 76.710.658 374 388 95 98.39 0.14 
rs17649341 76.713.962 395 91 7 56.60 0.50 
rs8056446 76.745.997 253 399 189 96.56 0.19 
rs8059793 76.746.799    uninformative  
rs7190335 76.747.719 754 103 1 98.51 0.19 
rs10871347 76.748.607    uninformative  
rs12932880 76.753.394 431 334 64 95.18 0.95 
rs2303191 76.755.693 448 349 65 98.97 0.79 
rs2303190 76.755.737    uninformative  
rs12325408 76.756.003 708 117 6 95.41 0.63 
rs4887940 76.757.590    uninformative  
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rs11150044 76.758.793 313 392 124 95.18 0.94 
rs11150046 76.759.162 585 225 22 95.52 0.95 
rs11150047 76.759.254 433 290 52 88.98 0.72 
rs17572124 76.760.321 587 231 18 95.98 0.39 
rs7206823 76.762.452 562 266 32 98.74 0.07 
rs11644126 76.762.676    uninformative  
rs2161636 76.763.071 771 45 0 93.69 0.42 
rs16947220 76.764.443 810 49 0 98.62 0.39 
rs7198580 76.974.431 724 119 8 97.70 0.21 
rs9928827 76.974.845 715 138 8 98.85 0.64 
rs8055871 76.975.211    uninformative  
rs11643643 76.977.006 311 407 143 98.85 0.61 
rs12918952 76.978.276 307 400 150 98.39 0.32 
rs12446823 76.978.383 728 120 9 98.39 0.11 
rs4083383 76.988.134    uninformative  
rs7192626 76.983.363    uninformative  
rs9938424 76.988.376 668 174 19 98.85 0.06 
rs6564537 76.984.187 749 110 8 99.54 0.08 
rs3897139 76.986.890    uninformative  
rs11150075 76.989.993 541 263 51 98.16 0.01 
rs13331309 76.991.062 784 83 1 99.66 0.43 
rs9923888 76.996.600 742 113 4 98.62 0.89 
rs8046289 77.012.206    uninformative  
rs4130513 77.016.251 746 114 8 99.66 0.12 
rs7201683 77.016.308 831 21 0 97.82 0.72 
rs4129722 77.016.656 701 152 12 99.31 0.26 
rs9921967 77.017.035    uninformative  
rs6564559 77.021.013 713 144 7 99.20 0.93 
rs3764340 77.023.938    uninformative  
107 
 
rs11646795 77.027.206 639 211 16 99.43 0.77 
rs7200731 77.030.931    uninformative  
rs424074 77.792.088 373 352 95 94.14 0.39 
rs12445829 77.792.167 744 86 5 95.87 0.15 
rs398255 77.792.535    uninformative  
rs400497 77.794.068 301 355 124 89.55 0.26 
rs1129030 77.794.095 768 88 4 98.74 0.39 
rs441004 77.794.331 313 373 122 92.77 0.53 
rs1813526 77.795.011 491 303 58 97.82 0.23 
rs1553723 77.795.109 577 252 33 98.97 0.41 
rs12927043 77.796.355 649 192 20 98.85 0.20 
rs442608 77.796.467 610 222 24 98.28 0.49 
rs421405 77.799.640 473 328 59 98.74 0.83 
rs368920 77.800.003    uninformative  
rs12446313 77.801.523 620 212 26 98.51 0.13 
rs11150144 77.801.597 645 191 21 98.39 0.13 
C1442T 77.803.266 770 61 5 95.98 0.00 
rs383362 77.803.321 276 421 158 98.16 0.91 
rs2288035 77.803.431 739 106 5 97.59 0.57 
rs12828 77.803.824    uninformative  
rs270422 77.810.152 427 331 79 96.10 0.21 
A-common allele, a-rare allele; Fisher’s exact test p value is given for Hardy-Weinberg equilibrium 
 
3.2.3. The associations between WWOX variation and clinicopathological features in ovarian 
cancer are not validated in an independent patient population 
Isnp1, Isnp8, C121T and T1497G were genotyped in the Scotroc1 population as a validation study to 
confirm the initial findings of their associations with clinicopathological features in ovarian cancer. All 
four SNPs were in Hardy-Weinberg equilibrium in the Scotroc1 samples and there were no significant 
differences in genotype frequencies between CGP and Scotroc1 sets (Table 3.4). 
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We first examined in the Scotroc1 dataset the previous associations with clinicopathological features 
of ovarian cancer (chi-square or Fisher’s exact test, Isnp1 and Isnp8 versus tumour grade, Isnp1 
versus histology; 1-way ANOVA, C121T versus age at diagnosis). Disappointingly, none of the 
original associations was recapitulated in the Scotroc1 population (Table 3.5) with all p values >0.1. 
Subsequently, the previous T1497G association with PFS was examined in a multivariate Cox 
regression model. Again, this did not demonstrate a significant association in the Scotroc1 samples 
(p=0.223), Table 3.6. These results suggest that the initial findings were either false positives or 
specific to characteristics of the initial study population (CGP) that are not recapitulated in Scotroc1 
population. 
There are several differences between the two datasets. These are mainly due to the fact that the 
CGP samples were collected from unselected patients with definitive diagnosis of ovarian cancer and 
therefore represent a general ovarian cancer population, whereas patients with stage Ia and Ib 
disease were not recruited into Scotroc1 clinical trial [243]. As a result of this, CGP samples have a 
higher proportion of stage I and grade 1 tumours and hence exhibit longer median overall and 
progression free survival (Table 3.2). Another difference between the populations is the country of 
origin of the patients (unlike the CGP population confined to patients from across the UK, Scotroc1 
population had a proportion of patients from several centres abroad, Table 3.7). The apparent 
difference in the prevalence of histological subtypes is mainly due to discrepancies in histological 
classifications used in the two populations (Table 3.2) and may not represent real clinicobiological 
differences. When stage I cases are removed from the CGP samples significant associations with 
tumour grade (Isnp1, p=0.0156, Isnp8 p=0.0098) and progression free survival (T1497G, p=0.0088) 
are still detected. However, these are no longer resistant to Bonferroni correction, and this could be 
thus argued that the paucity of early stage disease samples in Scotroc1 population may account for 
the lack of validation, but this change in p values is also likely due to loss of statistical power because 
of the lower number of samples in analysis. 
This work was published in the European Journal of Cancer [242]. 
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SNP 
identifier 
 Genotype frequencies of CGP samples  Genotype frequencies of Scotroc1 samples 
 A/A A/a a/a unknown  A/A A/a a/a unknown 
C121T  211 (47%) 183 (41%) 52 (12%) 108  370 (44%) 366 (44%) 97 (12%) 38 
Isnp1  381 (71%) 146 (27%) 10 (2%) 17  573 (73%) 191 (24%) 24 (3%) 83 
Isnp8  284 (42%) 233 (42%) 32 (6%) 5  448 (52%) 349 (40%) 65 (8%) 9 
T1497G  184 (33%) 273 (50%) 94 (17%) 3  276 (32%) 421 (49%) 158 (19%) 16 
 
Table 3.4 
Validation study: C121T, Isnp1, Isnp8, T1497G genotype frequencies in CGP and Scotroc1 populations 
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 p values 
 C121T Isnp1 Isnp8 T1497G 
CGP 
Grade NS 0.0041 0.0040 NS 
Stage NS NS 0.0143 NS 
Histology NS 0.0057 NS NS 
Age at diagnosis 0.0073 NS NS NS 
 
Scotroc1 
Grade ND 0.877 (NS) 0.120 (NS) ND 
Stage ND ND ND ND 
Histology ND 0.839 (NS) ND ND 
Age at diagnosis 0.575 (NS) ND ND ND 
NS –non-significant, ND –not determined, p values in bold remain significant following Bonferroni 
correction 
Table 3.5 
C121T, Isnp1, Isnp8, T1497G SNPs associations: validation study 
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 CGP Scotroc1 
HR 95% CI p value HR 95% CI p value 
T1497G T/G 1.6 1.13-2.32 0.0092 0.9 0.71-1.04 0.123 
 G/G 2.1 1.28-3.40 0.0030 0.9 0.68-1.10 0.223 
Age at diagnosis  1.0 1.01-1.04 0.0003 1.0 0.99-1.01 0.938 
Stage III-IV 3.4 2.21-5.23 0.0000 3.4 2.55-4.65 0.000 
grade 2 3.7 1.19-11.65 0.0239 1.7 1.10-2.56 0.016 
 3 5.4 1.76-16.60 0.0033 1.5 0.97-2.20 0.071 
histology Clear cell 3.0 0.84-10.43 0.0929 1.8 1.19-2.74 0.006 
 Endometrioid 0.6 0.41-0.91 0.0166 0.7 0.49-0.94 0.019 
 Mucinous 0.4 0.09-1.75 0.2167 1.0 0.58-1.76 0.960 
 Anaplastic N/A N/A N/A 1.0 0.24-3.94 0.972 
 Adenocarcinoma N/A N/A N/A 1.1 0.86-1.40 0.441 
 Other N/A N/A N/A 1.0 0.81-1.27 0.895 
HR-hazard ratio, CI- confidence interval, N/A –not applicable  
Table 3.6 
Prognostic model (T1497G and clinical covariates) for progression-free survival in multivariate Cox regression 
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Country Proportion of patients (%) 
UK 69.4 
Australia 7.3 
USA 6.6 
Austria 5.6 
Switzerland 4.2 
Finland 3.0 
New Zealand 2.9 
Greece 0.6 
Poland 0.5 
 
Table 3.7 
Country of origin of Scotroc1 patients 
 113 
 
3.2.4. Isnp8 /rs2303191 variation does not effect splicing in an in vitro assay 
Isnp8/rs2303191 showed association with tumour grade (p=0.004, pcorr=0.032) in the CGP population. 
The presence of at least one copy of the rarer allele correlated with higher grade. Also, as presented 
separately in Chapter 4 rs2303191 demonstrated associations with bone mineral density, although 
these are not resistant to multiple testing correction. In parallel to validating the Scotroc1 samples I 
examined the potential of this SNP to affect WWOX expression. 
The Isnp8/rs2303191 polymorphism is located in the +6 position of the splice donor consensus site of 
WWOX intron 6, and thus may have effects on splicing. A T+6/C+6 substitution in COL3A1 gene 
causes exon skipping, and this mutation manifests clinically as Ehlers-Danlos syndrome [227]. The +6 
position donor consensus site can be redundant for spliceosome recognition but it has been shown 
that when the -1/-2 (exonic) positions are not the highly conserved AG dinucleotide (GG in the case of 
WWOX exon 6 adjacent to rs2303191) positions +4/+5/+6 tend to conform to consensus and are 
important for U1RNA binding [245]. I hypothesised that Isnp8 may have a similar effect on splicing 
and thus affect WWOX expression. The associations between Isnp8 and ovarian cancer grade as well 
as bone mineral density, and the definable potential mechanistic link to WWOX expression, are 
suggestive of a modulatory role for this variation. 
The effects of this variation, based on the hypothetical mechanism, would be then relatively easy to 
study with an in vitro assay utilizing pSpL3 exon trapping vector as described by Schneider et al [228]. 
The experimental strategy, including a schematic representation of the Isnp8 genomic region with 
relation to sequences important for splicing (Figure 2.1), is described in detail in Materials and 
Methods (Chapter 2.7). Figure 3.1 presents a schematic representation of the location of artificial 
exons within the pSpL3 vector together with the possible effects of an insertion of a putative exon into 
a multiple cloning site in the intervening intron. 
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Figure 3.1 
Schematic representation of the location of artificial exons with pSpL3 exon trapping vector 
and the possible outcomes of WWOX exon 5 genomic region insertion into the intervening 
multiple cloning site 
 
I transiently transfected SKOV3 ovarian cancer cells with exon trapping pSpL3 vector or pSpL3 vector 
containing WWOX exon 5 region with either the T/T or C/C rs2303191 genotypes. RNA was isolated 
and reverse transcribed into cDNA. cDNA was used as a template for PCR reactions with primers 
complementary to pSpL3 sequences. A 261 bp product is predicted when two artificial exons of 
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pSpL3 are spliced into mRNA product without intervening exon. A product of 378 bp (261 +107 bp) is 
expected when WWOX exon 5 of 107 bp length is included in mRNA. Figure 3.2 demonstrates, in the 
empty vector lane, a PCR product of an expected 261 bp size. Analogous PCR products from cDNA 
obtained from the cells transfected with pSpL3 containing WWOX exon 5 region with both T/T and 
C/C Isnp8 genotypes yields single products of identical sizes corresponding to 378 bp. This 
demonstrates that rs2303191 substitution has no impact on the splicing of WWOX exon 5 in an in 
vitro assay and argues against a functional role for this variation. This is consistent with the view that 
the initial finding of an association with neoplasia grade in ovarian cancer might be false positive. 
 
Figure 3.2 
Isnp8/rs2303191 in vitro splicing assay 
The genomic region of WWOX exon 5 and flanking intronic sequences including the Isnp8/rs2303191 
variation as well as splice acceptor-, donor-, and putative branch sites (PCR amplified from two 
ovarian cancer cell lines –IGROV1, Isnp8 rare homozygote T/T, and CAOV3 Isnp8 common 
homozygote C/C) were inserted into the multiple cloning site of pSpL3 exon trapping verison. 
SKOV3 cells were transiently transfected with empty pSpL3 vector of vector containing the inserts 
(WWOX exon 5 region with opposite rs2303191 genotypes), RNA extracted following 48 hrs of 
culture, reverse transcribed into cDNA and analyzed by PCR with primers complementary to pSpL3 
artificial exons (SA2, SD6). 
 116 
 
3.2.5. The study into the link between WWOX variation and clinicopathological features of 
ovarian cancer in the Scotroc 1 population: association results 
The initial findings of the associations between Isnp1, Isnp8, C121T as well as T1497G and 
clinicopathological features in ovarian cancer were not recapitulated in the Scotroc1 population. 
Therefore, I next analyzed all 54 genotyped SNPs with >90% genotyping success rates for links with 
ovarian cancer pathology and clinical characteristics, independently of the initial findings in the CGP 
population. Fisher’s exact test was used for stage, grade, histology, chemotoxicity and response (and 
most significant associations re-assessed with chi-square linear-by-linear test, an approximation of 
Cochrane-Armitage test for trend in SPSS package) and log rank test was used for overall and 
progression-free survival. All presented p values are 2-sided and unadjusted. 
3.2.5.1. Stage 
Univariate tests for independence from genotype (Fisher’s exact test) were performed for disease 
stage (stage I and II cases were categorized as early stage and stage III and IV as late stage 
disease). SNPs associated with high stage may indicate modifier variants that promote ovarian 
cancer spread.  
3 SNPs display association with disease stage: rs4887935 (p=0.023), rs442608 (p=0.00292) and the 
strongest evidence of association at rs7192129 in intron 1 (p=0.00097), Table 3.8. However, 
rs7192129 association with stage is not significant (p=0.417) when assessed with chi-square linear-
by-linear association test. This reflects the fact that there is no corresponding gain in the number of 
heterozygotes reflecting the relatively increased number of rare homozygotes in the early disease (the 
genotype frequencies do not show the same trend as referred to in the ‘trend test’ name). Although 
this may depend on the particular model of the genotype effects, the discrepancy between the results 
of heterogeneity and trend tests may highlight the SNPs where significantly different distribution 
between strata is due to sampling or genotyping errors. Similar comment can be made about 
rs442608 SNP association with stage with Fisher’s exact test p value of 0.00292 and linear-by-linear 
association test of p=0.402. The association between stage and rs4887935 is not resistant to multiple 
testing correction. 
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In conclusion, there is no strong evidence for a link between WWOX variation and ovarian cancer 
stage in the Scotroc1 population. 
3.2.5.2. Grade 
Univariate tests for independence from genotype (Fisher’s exact test) were performed for disease 
grade (grade 1 and 2 cases were categorized as low grade and grade 3 cases as well as all cases 
with clear cell histology as high grade). SNPs associated with high grade could indicate modifier 
variants that affect growth and differentiation properties. None of the SNPs show association with 
disease grade at the significance level of 0.05, Table 3.8. 
3.2.5.3. Histology 
It must be noted that a large proportion of Scotroc1 samples was annotated as ‘not known’ or ‘other’ 
and these were excluded from the analysis. Additionally some samples were assigned as ‘anaplastic’, 
or ‘adenocarcinoma’. These entities were infrequent and thus the association tests were not run for 
them. The proportion of different histological samples in the dataset is presented in Table 3.2. 
Univariate tests for independence from genotype (Fisher’s exact test) were performed for serous, 
endometrioid, mucinous and clear cell cases, each as compared to all other histologies, Table 3.8. 
Serous 
Three SNPs display formal association with serous histology: rs4887935 (p=0.015), rs2287972 
(p=0.031) and the strongest evidence of association at rs441004 (Fisher’s exact, p=0.006, linear-by-
linear association, p=0.152). 
Endometriod 
Two WWOX SNPs demonstrate association with endometrioid histology: rs4887935 (p=0.047) and 
rs441004 (Fisher’s exact, p=0.019, linear-by-linear association, p=0.069). 
Mucinous 
Three WWOX SNPs demonstrate association with mucinous histology: rs7201683 (p=0.030), 
rs720683 (p=0.044) and rs17572124 (Fisher’s exact, p=0.006, linear-by-linear association, p=0.004). 
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Clear cell 
Four WWOX SNPs demonstrate weak association with clear-cell histology: rs9928827 (p=0.036), 
rs7190335 (p=0.032), rs12932880 (p=0.023), and the strongest evidence at rs11643643 (Fisher’s 
exact, p=0.014, linear-by-linear association, p=0.906). There is no compelling evidence for an 
association between WWOX variants and clear cell histology. 
In conclusion, the associations between WWOX genetic variants and various histologies in ovarian 
cancer are of weak/moderate strength and likely false positive findings. None of them reaches the 
significance level suggested for candidate gene studies (p<0.0001) or would yield an adjusted p value 
of <0.05 (when corrected for multiple testing using the Bonferroni procedure, given the number 
markers attempted to be genotyped, n=75, or the numbers of markers entered into final analysis, 
n=54). 
 
 
 
 
 
 
 
 
 
 
Table 3.8 (next page) 
The associations between WWOX SNPs and stage, grade, and histology in Scotroc1 patients 
(Fisher’s exact test, p values) 
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SNP 
identifier 
stage grade histology 
serous endometrioid mucinous clear cell 
rs8061268 NS NS NS NS NS NS 
rs11642734 NS NS NS NS NS NS 
rs11545028 NS NS 0.054 NS NS NS 
rs4887935 0.023 NS 0.015 0.047 NS NS 
rs7192129 0.00097 NS NS NS NS 0.085 
rs8049744 NS NS NS NS NS NS 
rs4887937 NS NS NS NS NS NS 
rs2287972 NS NS 0.031 NS NS NS 
rs11645081 NS NS NS NS NS NS 
rs1469117 NS NS NS NS NS NS 
rs16947129 NS NS NS NS NS NS 
rs10492874 NS NS NS NS NS NS 
rs11645006 NS NS NS NS NS NS 
rs8056446 NS NS NS NS NS NS 
rs7190335 NS NS NS NS NS 0.032 
rs12932880 NS NS 0.056 NS NS 0.023 
rs2303191 NS NS NS NS 0.094 NS 
rs12325408 NS NS NS NS NS NS 
rs11150044 0.078 NS NS NS NS NS 
rs11150046 NS NS NS NS NS NS 
rs17572124 NS NS 0.062 NS 0.006 NS 
rs7206823 NS NS NS NS 0.044 NS 
rs2161636 NS NS NS NS NS NS 
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rs16947220 NS NS NS NS NS NS 
rs7198580 NS NS NS NS NS NS 
rs9928827 NS NS NS NS NS 0.036 
rs11643643 NS NS NS NS NS 0.014 
rs12918952 NS NS NS NS NS 0.088 
rs12446823 NS NS NS NS NS NS 
rs9938424 NS NS NS NS NS NS 
rs6564537 NS 0.085 NS NS NS 0.074 
rs11150075 NS NS NS NS NS NS 
rs13331309 NS NS NS 0.090 NS NS 
rs9923888 NS NS NS NS NS NS 
rs4130513 NS NS NS NS NS NS 
rs7201683 NS NS NS NS 0.030 NS 
rs4129722 NS NS NS 0.087 NS NS 
rs6564559 0.073 NS NS NS NS NS 
rs11646795 NS 0.099 NS NS NS NS 
rs424074 NS NS NS 0.069 NS NS 
rs12445829 NS NS NS NS NS NS 
rs1129030 NS NS NS NS NS NS 
rs441004 NS NS 0.006 0.019 NS NS 
rs1813526 NS NS NS NS NS NS 
rs1553723 NS NS NS NS NS NS 
rs12927043 NS NS NS NS NS NS 
rs442608 0.00292 NS NS NS NS NS 
rs421405 NS NS NS NS NS NS 
rs12446313 NS NS NS NS 0.087 NS 
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rs11150144 NS NS NS NS NS NS 
C1442T NS NS NS 0.090 NS NS 
rs383362 NS NS NS NS NS NS 
rs2288035 NS NS NS NS NS NS 
rs270422 NS NS NS NS NS NS 
NS- not significant, significant values (p<0.05) are in bold, trend for significance (0.05<p<0.1) in 
italics 
3.2.5.4. Chemotoxicity 
Univariate tests for independence from genotype (Fisher’s exact test) were performed for the clinical 
measures of chemotoxicity (the association with neutropenia was assessed in the docetaxel arm only, 
for gastrointestinal toxicity the cases were stratified as grade 0-2 versus grade 3-4, and for 
neurotoxicity as grade 0-1 versus 2-4). SNPs associated with chemotherapy toxicity may indicate 
variants that modulate cellular response to taxanes and platinums, Table 3.9. 
Neutropenia (docetaxel patients) 
Two SNPs show weak association with neutropenia: rs2161636 (p=0.025), rs11643643 (Fisher’s 
exact, p=0.024, linear-by-linear association, p=0.743). 
Gastrointestinal toxicity 
Two SNPs show association with gastrointestinal toxicity: rs16947129 (p=0.038) and rs7190335 
(Fisher’s exact, p=0.017, linear-by-linear association, p=0.139). 
Neurotoxicity 
7 WWOX SNPs show association with neurotoxicity: rs7190335 (p=0.048), rs441004 (p=0.047), 
rs11150046 (p=0.036), rs2161636 (p=0.026), rs7206823 (p=0.019), rs424074 (p=0.019) and best 
evidence at rs442608 (Fisher’s exact, p=0.004, linear-by-linear association, p=0.12). 
In summary, given the strength of the associations, there is no compelling link between WWOX 
variation and chemotoxicity in ovarian cancer patients treated with taxanes and platinums, however of 
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note is the large number of markers formally associated with peripheral neuropathy and this might be 
regarded as contentious evidence of a link between WWOX variants and taxane–specific toxicity. 
SNP identifier neurotoxicity gastrointenstinal 
toxicity 
neutropenia (docetaxel 
patients) 
rs8061268 NS NS NS 
rs11642734 NS NS NS 
rs11545028 0.097 NS NS 
rs4887935 NS NS NS 
rs7192129 NS NS NS 
rs8049744 NS NS NS 
rs4887937 NS NS NS 
rs2287972 NS NS NS 
rs11645081 NS NS NS 
rs1469117 NS NS NS 
rs16947129 NS 0.038 NS 
rs10492874 NS NS NS 
rs11645006 NS NS NS 
rs8056446 0.095 NS NS 
rs7190335 0.048 0.017 NS 
rs12932880 NS NS NS 
rs2303191 NS NS NS 
rs12325408 NS NS NS 
rs11150044 NS NS NS 
rs11150046 0.036 NS NS 
rs17572124 NS NS NS 
rs7206823 0.019 NS NS 
rs2161636 0.026 NS 0.025 
 123 
 
rs16947220 NS 0.082 NS 
rs7198580 NS NS NS 
rs9928827 NS NS NS 
rs11643643 NS NS 0.024 
rs12918952 NS NS 0.094 
rs12446823 NS NS NS 
rs9938424 0.054 NS NS 
rs6564537 NS NS NS 
rs11150075 NS NS 0.067 
rs13331309 NS NS NS 
rs9923888 NS NS NS 
rs4130513 NS NS NS 
rs7201683 NS NS NS 
rs4129722 NS NS NS 
rs6564559 NS NS NS 
rs11646795 NS NS NS 
rs424074 0.019 NS NS 
rs12445829 NS NS NS 
rs1129030 NS NS NS 
rs441004 0.047 NS NS 
rs1813526 NS NS NS 
rs1553723 NS NS NS 
rs12927043 NS NS NS 
rs442608 0.004 NS NS 
rs421405 NS NS NS 
rs12446313 NS 0.1 NS 
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rs11150144 NS 0.083 NS 
C1442T NS NS NS 
rs383362 NS NS NS 
rs2288035 NS 0.081 NS 
rs270422 0.063 NS NS 
 NS –not significant, significant values (p<0.05) are in bold, trend for significance (0.05<p<0.1) in 
italics 
Table 3.9 
The associations between WWOX SNPs and chemotoxicity in Scotroc1 patients (Fisher’s exact test, 
p values) 
 
3.2.5.5. Clinical/radiological and CA125 response 
Univariate tests for independence from genotype (Fisher’s exact test) were performed for 
clinical/radiological (complete and partial response versus stable and progressive disease) and 
CA125 response. 5 SNPs are formally associated with CA125 response with best evidence at 
C1442T (Fisher’s exact, p=0.020, linear-by-linear association, p=0.043), and 6 SNPs with 
clinical/radiological response with strongest evidence at rs11150075 (Fisher’s exact, p=0.0078, linear-
by-linear association, p=0.023). The results for remaining significantly associated markers are 
presented in Table 3.10. None of the SNPs is associated with both measures of response. In 
conclusion, there is no strong evidence of association between WWOX genetic variants and therapy 
response measures in the Scotroc1 population. 
3.2.5.6. Overall and progression free survival 
Seven WWOX SNPs show association with overall or progression free survival in univariate analysis 
but these are of borderline strength (log rank, p values of 0.016 to 0.044) and only one of them is 
associated with both OS and PFS. These are presented in Table 3.10. None of the markers remains 
significant after correction for multiple testing and they were thus not carried forward to multivariate 
analysis. 
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SNP identifier CA125 response Clinical response OS PFS 
rs8061268 NS NS NS 0.085 
rs11642734 NS NS 0.093 0.037 
rs11545028 NS NS NS 0.043 
rs4887935 NS NS NS NS 
rs7192129 0.044 NS NS NS 
rs8049744 0.030 NS NS NS 
rs4887937 NS NS NS NS 
rs2287972 NS NS 0.016 NS 
rs11645081 NS NS NS NS 
rs1469117 NS NS NS NS 
rs16947129 NS NS NS NS 
rs10492874 NS NS NS NS 
rs11645006 NS NS NS NS 
rs8056446 NS NS NS NS 
rs7190335 NS NS NS NS 
rs12932880 NS 0.062 NS NS 
rs2303191 NS 0.090 NS NS 
rs12325408 NS 0.049 NS NS 
rs11150044 NS NS NS NS 
rs11150046 NS NS NS NS 
rs17572124 NS NS NS NS 
rs7206823 NS NS NS NS 
rs2161636 NS NS NS NS 
rs16947220 NS NS NS NS 
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rs7198580 NS NS NS NS 
rs9928827 NS NS 0.098 0.086 
rs11643643 NS 0.070 NS 0.023 
rs12918952 NS NS NS 0.041 
rs12446823 NS NS NS NS 
rs9938424 0.046 NS NS NS 
rs6564537 NS NS NS 0.052 
rs11150075 NS 0.0078 NS NS 
rs13331309 NS NS NS NS 
rs9923888 NS 0.049 0.023 0.072 
rs4130513 NS NS NS NS 
rs7201683 NS NS 0.044 0.044 
rs4129722 NS NS NS NS 
rs6564559 NS 0.050 NS NS 
rs11646795 NS NS NS NS 
rs424074 NS 0.058 NS NS 
rs12445829 NS NS NS NS 
rs1129030 NS NS NS NS 
rs441004 NS 0.032 NS NS 
rs1813526 0.032 0.056 NS NS 
rs1553723 NS NS NS NS 
rs12927043 NS 0.025 NS NS 
rs442608 NS 0.082 NS NS 
rs421405 NS NS NS NS 
rs12446313 NS NS NS NS 
rs11150144 NS NS NS NS 
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C1442T 0.020 NS NS NS 
rs383362 NS NS NS NS 
rs2288035 0.070 NS NS NS 
rs270422 0.067 NS NS NS 
OS –overall survival, PFS –progression free survival, NS –not significant, significant values (p<0.05) 
are in bold, trend for significance (0.05<p<0.1) in italics 
Table 3.10 
The association between WWOX SNPs and measures of therapy response and survival in Scotroc1 
patients (Fisher’s exact test, p values) 
 
3.2.5.6.1. The association between non-synonymous coding rs7201683 WWOX SNPs and 
survival 
Interestingly, the only SNP that associates with both OS (p=0.044) and PFS (p=0.044) is rs7201683, 
a rare, non-synonymous coding SNP in exon 6. There are no rare rs7210683 homozygotes in 852 
successfully genotyped patient DNAs and only 21 heterozygotes, which corresponds to a MAF of 
1.2%. The log rank test p values are of weak/moderate significance but this appears to be due to the 
low number of patients with minor alleles as the analysis of Kaplan-Meier survival curves reveals a 
very clear separation of survival curves (Figure 3.3) with a very pronounced difference in median 
survival between the genotypes, 21.3 versus 34.3 months for OS and 10.5 versus 14.7 months for 
PFS (Table 3.11 presents mean and medians with 95% confidence intervals).  
rs7201683 is also associated with mucinous histology (Fisher’s exact, p=0.030, linear-by-linear 
association, p=0.030) with 30% of heterozygotes falling into this category as opposed to 6.4% in 
homozygotes and WWOX loss was previously shown to occur most frequently in this histotype [53]. 
The impact of rs7201683 SNP on survival cannot be explained by association with mucinous 
histology as there is no association between mucinous histology and survival in Scotroc1 pateints 
[246]. Interestingly, when assessed with CA125 there are 30.8% non-responders in rs7201683 
heterozygotes versus 24.0% in homozygotes and using clinical/radiological criteria there are 52.9% 
non-responders in heterozygotes versus 37.9% in homozygotes. Also 90.5% patients heterozygotic 
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for rs7201683 presented with late stage disease versus 81.5% in homozygotes. Although these are 
not statistically significant, this is consistent with poor patient outcomes and it must be noted that 
these analyses are effectively precluded by low number of heterozygotes. 
It is striking that the only WWOX SNP showing convincing association with survival in ovarian cancer 
is a protein sequence-altering exonic SNP with a potential functional role, thus likely a causative 
variation (rs7201683 was added as an extra candidate functional SNP to the assay covering exons 6-
8). rs7201683 variation in exon 6 results in a leucine → valine substitution at amino acid position 216 
in WWOX. Although this is a relatively conservative substitution, any substitution may be deleterious 
to protein function and this depends on the context in the particular polypeptide, and there are 
examples of leucine → valine substitutions leading to inherited syndromes [247-248] or altering 
enzymatic activity [249]. This position does not overlap with any clearly defined domain or motif within 
WWOX protein. 
Overall survival (log rank, p=0.044) 
genotype mean 95% CI median 95% CI 
AA 29.6 28.4-30.7 34.3 ND 
Aa 21.2 15.8-26.6 21.3 8.9-33.6 
Progression free survival (log rank, p=0.044) 
genotype mean 95% CI median 95% CI 
AA 20.0 19.0-21.1 14.7 13.7-15.8 
Aa 13.9 8.8-18.9 10.5 7.3-13.7 
CI –confidence interval, ND –not determined, A-common allele, a-rare allele  
Table 3.11 
rs7201683 SNP association with overall and progression-free survival  in Scotroc1 population 
(log rank test) 
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Figure 3.3 
The impact of rs7201683 variation on overall and progression free survival in Scotroc1 population, 
Kaplan-Meier survival curves 
A.Overall survival (OS); B. Progression free survival (PFS). 
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3.3. WWOX as an ovarian cancer modifier gene: discussion 
Loss of WWOX expression was previously linked in ovarian cancer with poor patient survival, high 
stage disease as well as with clear cell and mucinous histology [53]. Cancer specific mutations within 
the WWOX gene are rare but our group has identified a number of single nucleotide polymorphisms 
that could potentially impact on WWOX expression or function [21]. It has been proposed that WWOX 
might be a haploinsufficient tumour suppressor gene [86, 88], therefore a subtle loss of its expression 
or function, potentially due to modulatory effects of germline variation, could contribute to 
tumorigenesis. 
Polymorphic variants within the WWOX gene were associated with WWOX expression in a genome 
wide study [216] and have been postulated to be linked to a cis-regulatory function [217] suggesting a 
functional potential likely impacting on WWOX expression levels. Further, WWOX variants were linked 
with prostate cancer incidence [218] and serum HDL-cholesterol levels, and altered WWOX 
expression is the most likely commonly shared theme between these traits [217]. This is consistent 
with the role in WWOX expression regulation predicted for WWOX SNPs originally associated by our 
group with clinicopathological features in ovarian cancer. 
Our previous data demonstrated significant associations of four WWOX SNPs with higher grade, clear 
cell and mucinous histology, earlier age at diagnosis and shorter PFS. Importantly potential functional 
effects could be easily ascribed to three out of four of those SNPs. T1497G/rs383362 variation, 
associated with progression-free survival, is located within the sequence complementary to the seed 
region of microRNA hsa-mir134, with the common G allele, which is associated with better patient 
survival, disrupting the site. The shorter survival associated with T allele could be thus due to reduced 
WWOX levels due to 3’UTR microRNA targeting. Isnp8/rs2301391 SNP, associated with disease 
grade affects splice donor site of WWOX intron 6, and aberrant splicing is strongly implicated in 
WWOX expression loss [42, 64, 67]. C121T variation, associated with age at diagnosis, is located 
within Kozak translation start site. 
Disappointingly, I was unable to confirm the original exciting findings in a large independent 
population of patients who entered Scotroc1 clinical trial, suggesting that the initial findings were 
either false positives or specific to the initial study population. It may be argued that the paucity of 
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early stage disease samples in Scotroc1 population may potentially account for the lack of validation. 
On the other hand, I did not observe Isnp8 effects on splicing in an in vitro assay, arguing against a 
functional role for this SNP. 
With the increasing number of genetic association studies being conducted the absence of 
confirmation in independent populations has been noted to be a very frequent outcome. This appears 
to be due to spurious findings being reported because of observer or selection bias, relaxed 
significance criteria, poor selection of candidate markers, between-study heterogeneity, the bias for 
the publication of positive findings only in the discovery phase and the replication studies being 
underpowered. Increasingly more rigorous approaches are proposed to improve this such as 
increasing the size and homogeneity of the populations to enhance statistical power, improved 
selection of candidate genes, multi-stage studies aiming at reproducing the associations in 
independent populations, meta-analysis and stringent significance criteria [229, 250]. At the same 
time there is an increasing demand of high-profile journals for the genetic data to be accompanied by 
functional evidence.   
A particularly valid example is the study by Marsh et al. using the same Scotroc1 population. The 
authors assessed 27 SNPs in 16 genes previously genetically or functionally linked with 
platinum/taxane chemotherapy response and/or toxicity and failed to reproduce any of the previously 
reported associations. Among the possible basis for this discrepancy the authors propose small size 
of previous studies and population differences in allele frequencies [251]. 
A consortium analysis, pooling several independent studies to analyse 7 SNPs previously linked with 
ovarian cancer in a large number of samples, has only reproduced the association for one of them 
(p=0.041) but even this was no longer significant when samples from the original study were excluded 
(p=0.233). The authors note that most moderately significant findings in association studies will be 
false positives because of the very high number of polymorphic variants in human genome but very 
low prior chance that a given marker is linked to a disease state [240]. 
While the differences between the CGP and Scotroc1 populations may partly account for the lack of 
validation, the likeliest explanation is that the initial findings were false positives. Similarly, the 
analysis of 54 WWOX SNPs in the Scotroc1 population provides little evidence of a link between 
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WWOX variants and clinicopathological features in ovarian cancer and do not warrant for further 
studies. The likely explanation is that none of the SNPs included in the assay or effectively tagged by 
them has noticeable functional effects as is the case for rs2303191/Isnp8 that was predicted to affect 
mRNA splicing but showed no evidence of splicing regulation in my in vitro assay. 
The potential exception is the rs7201683 marker, a non-synonymous coding SNP that may alter 
protein properties, rather than modulate expression as was predicted for a huge majority of the SNPs 
I screened. The rare variant of this polymorphism appears to be associated with poor patient survival 
but this needs to be replicated in an independent population of ovarian cancer patients (of at least a 
similar size to the Scotroc1 population as indicated by the p values just below the significance levels). 
Additionally, the effects of this variant as compared to wild-type could be studied in vitro by 
comparison of the effects on WWOX-regulated phenotypes in parallel transfections as well as 
assessing the impact of rs7201683 on the reported WWOX protein-protein interactions (or enzymatic 
activity if such function is ascribed to WWOX in the future). At the same time, the example of 
rs7201683 demonstrates that deep sequencing for rare substitutions rather than tagging SNP 
approaches might be necessary to find cancer relevant variants. Although the clinical utility of very 
rare variants can be questioned they may still highlight important genes and pathways and feed into 
multi-marker prognostic models.  
The studies into the link between WWOX natural variation and clinicopathological features in ovarian 
cancer conducted by our group demonstrate that multi-stage approaches such as validation study in 
Scotroc1 population we conducted, and rigorous statistical approach demonstrated here by carrying 
forward to further stage solely associations resistant to multiple testing correction are needed to avoid 
reporting spurious findings. Huge conceptual and technological progress have been made in the 
genetic epidemiology of cancer but many lessons are still to be learnt before the efforts lead to robust 
discoveries that can translate into clinical applications. 
My study provides evidence against a tumour modifier role for the common natural variants of the 
WWOX gene in the setting of ovarian cancer. Further studies are warranted to elucidate the potential 
significance of rare variants of WWOX.  
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Chapter 4. Natural variation within the WWOX gene is not associated with bone metabolic 
phenotypes 
4.1. The biology and genetics of bone mass 
The skeleton is a metabolically active organ and around 10% of bone is replaced each year. This 
metabolic activity is necessary for continuous bone remodelling (resorption mediated by osteoclasts 
and new bone formation dependent on osteoblasts) and necessary for general organism homeostasis 
due to regulation of serum calcium, phosphates and buffering capacity. Bone mass is dependent on 
the net effects of normal or pathological bone remodelling and peak bone mass reached following the 
growth phase in young adults.  
Bone remodelling is under strong influence of calcium–regulating hormones, steroids and hormones 
regulating growth. Parathyroid hormone (PTH) concentration is tightly regulated in response to 
ionized serum calcium levels. When serum calcium concentration is low PTH secretion increases and 
PTH stimulates osteoclastic bone resorption to release calcium from the skeleton and thus restore 
homeostasis. At the same time PTH (as well as low serum phosphates) stimulates renal production of 
1,25-dihyroxy vitamin D. Vitamin D promotes intestinal calcium and phosphate absorption and may 
directly modulate bone remodelling increasing both bone resorption and bone formation. Calcitonin, 
whose secretion is stimulated by high serum calcium, inhibits bone resorption. Bone resorption is also 
inhibited by estrogens but stimulated by glucocorticoids. Growth hormone, insulin–like growth factors 
and androgens promote new bone formation [252-255]. 
Bone remodelling can be monitored in baseline conditions or during treatment affecting bone turn-
over with several serum and urine markers. Resorption markers include collagen break-down 
products (hydroxyproline, pyridinium cross-links and cross-linked telopeptides) whereas formation 
markers are exemplified by alkaline phosphatase and osteocalcin [253].  
Bone mass exhibits a wide range in the general population and varies according to age, sex and 
ethnic background. The peak in BMD (bone mineral density) is achieved in the third decade of life and 
then it is lost steadily until the end of life. BMD is usually measured with dual X-ray absorptiometry 
(DXA) or quantitative computed tomography (QCT). Bone mineral density has a very strong genetic 
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contribution and it is assessed, based on twin and family studies, that up to 90% of the peak BMD 
variance is genetically determined [256-257]. 
Osteoporosis is a multifactorial disease of reduced bone mass that manifests clinically as fragility 
fractures. The essential feature of osteoporosis is a reduced amount, or altered architecture, of bone 
tissue in bone treated as an organ. It affects both sexes and all racial groups. A number of 
environmental and lifestyle risk factors have been identified including malnutrition, low physical 
activity levels and smoking. The diagnosis of osteoporosis relies on imaging techniques measuring 
BMD [256]. 
The common form of osteoporosis is considered to be a polygenic disorder with very high heredity 
estimated at 0.5-0.9 (when heredity of the following osteoporosis surrogates or associated traits is 
assessed: BMD, bone size, structure, loss and turn-over as well as osteoporotic fractures incidence) 
[256-257].  
Several linkage studies, as well as candidate gene and genome wide association studies, have been 
conducted to find the loci associated with BMD. 
The candidate genes associated with BMD include VDR (vitamin D receptor), ESR1 (estrogen 
receptor α), ESR2 (estrogen receptor β), genes for collagens (COL1A1, COL1A2), genes for a 
number of cytokines/paracrine factors or their receptors believed to regulate osteoclasts and 
osteoblasts, and several others. However, many of these associations were not reproduced in 
independent populations or only shown in some replication studies (and it might be assumed more 
negative results were not published), taking the example of most extensively studied VDR and genes 
for estrogen receptors, and collagens. This might be because of the fact that the associations are 
false positive findings or because the validation studies were underpowered. Alternatively, this may 
represent true differences between the populations or reflect the fact that different genes may impact 
on BMD in different age and sex groups or diversely modulate BMD at various sites, as these 
parameters were rarely homogenous between various studies. Further, a number of BMD quantitative 
trait loci (QTLs) were identified in linkage studies of various design and some were reproduced in 
multiple studies [254, 256-258]. The analysis of two large independent cohorts suggested a linkage of 
BMD to 3p21 and 1p36 chromosomal loci in both populations (each loci predicted to contain 
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approximately 350-400 genes) [259] and the evidence for their linkage with BMD was later confirmed  
in meta-analysis of several studies [260]. 
Several recent, rigorously controlled genome-wide association studies of large populations pointed to 
genes previously linked to BMD such as ESR1; osteoprotegerin (OPG), receptor activator of nuclear 
factor-κB gene (RANK) and RANK ligand gene (RANKL) that form a cytokine signalling axis [261] and 
highlighted several new loci including ARHGEF3, which encodes rho guanine-nucleotide exchange 
factor 3 [262]; ADAM metallopeptidase with thrombospondin type 1 motif, 18 (ADAMTS18); and TGFβ 
receptor III (TGFBR3) [263] or major histocompability complex region [261]. The fact that even large, 
statistically robust studies report different loci might be partly due to the fact that different mechanisms 
likely impact on bone density dependent on sex, age, examined population and exact measurement 
site. 
Twenty loci reached genome-wide significance (p<10
-8
) in a recent large-scale meta-analysis of 
genome-wide association studies of BMD at total hip and lumbar spine, seven of which, including 
ESR1, map to regions previously associated with these traits [264]. 
Finally, a number of knock-out or transgenic mice models, including a strain with constitutive over-
expression of vitamin D receptor, display bone density alterations as compared to wild-type animals 
[256]. 
4.2. The study into the associations between WWOX variation and bone mineral density and 
serum markers of bone metabolism: rationale 
As discussed in detail in introduction (Chapter 1) Wwox is essential for early postnatal survival. 
Aqeilan at al. [114] studied the phenotypic abnormalities in Wwox
-/-
 mice (KO). KO pups had smaller 
size than wild-type animals and 100% mortality by 3 weeks of age. The internal organs of KO animals 
were smaller with the exception of brain, adrenal and pituitary glands. Further, serum chemistry 
showed severe metabolic defect in KO pups including hypoproteinemia and hypocalcemia. 
Radiography revealed decreased density of the bones in the limbs of KO mice. This was likely not 
only due to the metabolic disorder but a consequence of osteoblast differentiation defect as shown in 
vitro. The authors demonstrate that Wwox regulates expression of Runx2, a critical transcription factor 
in osteoblast differentiation. Further, WWOX physically interacts with RUNX2 and RUNX2/WWOX 
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complex associates with the promoter of osteocalcin, which is an osteoblast differentiation marker 
[114].  
Very recently, the group led by Marcelo Aldaz described mice carrying conditional allele of Wwox. 
Wwox knockout (KO) mice displayed severe growth retardation, early postnatal lethality by 3 weeks of 
age, impaired hematopoiesis, abnormal sizes of internal organs, metabolic acidosis, hypoglycaemia, 
hypocalcemia and abnormal bone mineralization [89] and this is strikingly similar to the phenotype of 
mice developed by Aqeilan et al. 
Another group (Suzuki et al.) established spontaneously mutated inbred Lde/Lde rat strain. The 
mutant phenotype consists of short lifespan, severe dwarfism, male hypogonadism, mild osteopenia 
and several neurological defects, without significant biochemical abnormalities and this trait was 
mapped to Wwox [220]. 
Further, Wwox KO mice described by Aqeilan et al. and spontaneously mutated Lde/Lde rat strain 
display impaired steroidogenesis [214, 220]. This endocrine defect is consistent with the proposed 
role for WWOX in endocrine regulation based on the expression pattern and structural predictions [20, 
36]. It is also of interest that in breast cancer WWOX expression correlates with the outcomes of anti-
hormonal therapy [52]. 
In conclusion, several independent animal models point to a role for Wwox in bone metabolism as 
demonstrated by reduced bone mineral density and/or microarchitectural defects. Analysis of the 
models suggests that this might be caused by increased bone resorption and impaired bone 
formation, due to metabolic and endocrine disturbances, as well as osteoblast differentiation defects 
[89, 114, 214, 220]. 
WWOX SNPs were linked with WWOX expression in a genome wide study [216] and postulated to 
have a cis-regulatory effect [217], indicative of a functional potential. Consistently, WWOX variants 
were linked with serum HDL-cholesterol [217] and prostate cancer incidence [218]. 
Based on this evidence, we proposed a study into a link between the natural variation within the 
WWOX gene and bone formation and metabolism parameters. 
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4.3. Results 
4.3.1. The study into the associations between WWOX variation and bone mineral density and 
serum markers of bone metabolism: strategy 
We gained access to an extensively phenotyped population-based sample of 1473 Danish 
postmenopausal women provided by Professor Philippe Froguel (Imperial College London) and Dr 
Inger Byrjalsen (Denmark).  
The clinical data associated with these patient samples included BMD measured at femoral neck, 
total hip, lumbar spine and Ward’s triangle, and the presence of vertebral fractures determined by the 
analysis of lateral X-rays of the thoracic and lumbar spine (defined as a difference of >20% between 
the anterior and posterior edges of each vertebral body). We also received the values of osteocalcin 
(a marker of bone formation) and CrossLaps (a collagen I degradation product, which is a marker of 
bone resorption) measured in the patients’ serum. The basic phenotypic, lifestyle and treatment 
characteristics of the Danish women population are presented in Table 4.1. 
In addition to the skeletal phenotypic data, we received information on age, height, weight, smoking 
status, use of hormonal replacement therapy and pharmacological treatment for osteoporosis (Table 
4.1). These all have potential impact on bone metabolism and BMD, and were used as covariates and 
cofactors in the analysis of the impact of WWOX variation on bone metabolism related phenotypes. 
The selection of polymorphic markers encompassing all WWOX exons and promoter region was the 
same as was used in the screening of the Scotroc1 ovarian cancer population (Chapter 3). In total 75 
SNPs across the WWOX gene were genotyped in this Danish postmenopausal women population 
using the Sequenom platform, Table 3.1. 
 
 
Table 4.1 (next page) 
Basic characteristics of Danish study population (n=1473).
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 N Mean ± SD 
Age (years) 1473 71.0 ± 5.3 
Height (cm) 1461 160.5 ± 5.8 
Weight (kg) 1461 67.4 ± 10.5 
BMI (kg/m
2
) 1461 26.2 ± 3.8 
Years since menopause (years) 1444 21.9 ± 7.4 
Serum osteocalcin (ng/ml) 1457 31.7 ± 13.6 
Serum CrossLaps (ng/ml) 1448 0.42 ± 0.22 
Femoral neck BMD (g/cm
2
) 1462 0.67 ± 0.11 
Total hip BMD (g/cm
2
) 1462 0.79 ± 0.12 
Spine BMD (g/cm
2
) 1473 0.88 ± 0.15 
Ward’s BMD (g/cm
2
) 1462 0.47 ± 0.12 
   
Vertebral fractures 1437  
     Present 18.7 %  
     None 81.3 %  
   
Smoking status 1473  
     Current 20.6 %  
     Past 30.9 %  
     Never 48.5 %  
   
HRT status 1472  
     Current 2.1 %  
     Never 97.9 %  
   
Osteoporosis treatment 1447  
     Current 12.4 %  
     Never 87.6 %  
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4.3.2. The study into the associations between WWOX variation and bone mineral density and 
serum markers of bone metabolism: assay performance 
 
61 out of 75 SNP assays yielded informative spectra. The reasons for Sequenom assay failure were; 
no amplification in PCR reaction or presence of false-positive spectra in control wells, failure of the 
extension step or poor separation between genotype clusters. 
50 SNPs were carried forward to the final analysis, after exclusion of SNPs whose genotyping call 
rates were below 90%. None of the SNP genotyping results was significantly deviated from Hardy-
Weinberg equilibrium at the p of <0.01 level. The genotype frequencies, call rates and Hardy-
Weinberg statistic p values are presented in Table 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2 (next page) 
Danish women population genotyping results 
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SNP 
identifier 
Chromosomal 
coordinate 
Genotype frequencies Call rate [%] Hardy-
Weinberg 
equilibrium AA Aa aa 
rs8061268 76.680.194 409 629 291 90.22 0.09 
rs11642734 76.682.672 665 506 108 86.83 0.40 
rs16947106 76.685.038    uninformative  
rs11545028 76.691.172 449 417 109 66.19 0.41 
rs4887935 76.691.956 516 608 225 91.58 0.04 
rs7192129 76.693.915 661 571 125 92.12 0.92 
rs8049744 76.698.706 1271 73 2 91.38 0.38 
rs4887937 76.699.710 947 325 40 89.07 0.06 
rs2287972 76.701.108 353 644 343 90.97 0.16 
rs11645081 76.704.648 1312 9 0 89.68 0.90 
rs2072587 76.706.245    uninformative  
rs1469117 76.706.295 985 305 35 89.95 0.06 
rs16947129 76.709.247 928 362 37 90.09 0.81 
rs10492874 76.710.132 315 473 211 67.82 0.18 
rs11645006 76.710.658 536 611 188 90.63 0.51 
rs17649341 76.713.962 1047 248 15 88.93 0.94 
rs8056446 76.745.997 434 652 258 91.24 0.64 
rs8059793 76.746.799 394 475 148 69.04 0.80 
rs7190335 76.747.719 1164 176 6 91.38 0.81 
rs10871347 76.748.607    uninformative  
rs12932880 76.753.394 638 566 130 90.56 0.78 
rs2303191 76.755.693 769 509 76 91.92 0.49 
rs2303190 76.755.737    uninformative  
rs12325408 76.756.003 1123 183 9 89.27 0.61 
rs4887940 76.757.590    uninformative  
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rs11150044 76.758.793 464 664 232 92.33 0.83 
rs11150046 76.759.162 925 369 40 90.56 0.66 
rs11150047 76.759.254 698 495 103 87.98 0.25 
rs17572124 76.760.321 910 401 39 91.65 0.52 
rs7206823 76.762.452 917 388 35 90.97 0.43 
rs11644126 76.762.676    uninformative  
rs2161636 76.763.071 1248 91 1 90.97 0.62 
rs16947220 76.764.443 1248 91 1 90.97 0.62 
rs7198580 76.974.431 1197 191 9 94.84 0.65 
rs9928827 76.974.845 1183 224 12 96.33 0.70 
rs8055871 76.975.211    uninformative  
rs11643643 76.977.006 502 666 221 94.30 1.00 
rs12918952 76.978.276 514 687 214 96.06 0.53 
rs12446823 76.978.383 1218 192 13 96.61 0.08 
rs4083383 76.988.134    uninformative  
rs7192626 76.983.363 626 43 2 45.55 0.18 
rs9938424 76.988.376 1101 299 21 96.47 0.89 
rs6564537 76.984.187 1221 199 11 97.15 0.36 
rs3897139 76.986.890 994 387 46 96.88 0.27 
rs11150075 76.989.993 831 504 78 95.93 0.89 
rs13331309 76.991.062 1318 113 5 97.49 0.13 
rs9923888 76.996.600 1236 180 9 96.74 0.38 
rs8046289 77.012.206    uninformative  
rs4130513 77.016.251 1243 189 5 97.56 0.44 
rs7201683 77.016.308 1375 30 1 95.45 0.05 
rs4129722 77.016.656 1181 240 12 97.28 0.96 
rs9921967 77.017.035    uninformative  
rs6564559 77.021.013 1190 230 9 97.01 0.56 
rs3764340 77.023.938    uninformative  
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rs11646795 77.027.206 1053 327 22 95.18 0.55 
rs7200731 77.030.931 463 204 28 47.18 0.36 
rs424074 77.792.088 632 572 144 91.51 0.39 
rs12445829 77.792.167 1166 184 9 92.26 0.56 
rs398255 77.792.535    uninformative  
rs400497 77.794.068 550 591 191 90.43 0.12 
rs1129030 77.794.095 1167 181 6 91.92 0.72 
rs441004 77.794.331 540 641 187 92.87 0.88 
rs1813526 77.795.011 718 535 112 92.67 0.38 
rs1553723 77.795.109 846 440 66 91.79 0.37 
rs12927043 77.796.355 1009 311 28 91.51 0.48 
rs442608 77.796.467 1044 291 21 92.06 0.89 
rs421405 77.799.640 836 515 74 96.74 0.64 
rs368920 77.800.003    uninformative  
rs12446313 77.801.523 913 373 53 90.90 0.06 
rs11150144 77.801.597 1042 326 27 94.70 0.80 
C1442T 77.803.266 1233 112 7 91.79 0.01 
rs383362 77.803.321 498 636 244 93.55 0.10 
rs2288035 77.803.431 1182 153 6 91.04 0.66 
rs12828 77.803.824    uninformative  
rs270422 77.810.152 709 548 108 92.67 0.88 
A-common allele, a-rare allele; Fisher’s exact test p value is given for Hardy-Weinberg equilibrium 
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4.3.3. Assessment of the contribution of WWOX variation to individual’s height and BMI 
One of the striking commonalities between the three independent rodent models of Wwox inactivation 
is severe growth retardation [89, 114, 220]. This raises the possibility that WWOX SNPs could be 
associated with height or BMI (body mass index), the phenotypic features measured in the Danish 
women population that correspond to growth characteristics. If such association was observed, the 
utility of BMI as a covariate for controlling the analysis of WWOX genotypes versus bone metabolism 
phenotypes would be questionable. To address this issue, first, assessment of the contribution of a 
covariate (number of years since menopause) and factors (current and ever smoking status, hormone 
replacement therapy and osteoporosis treatment ststus) to BMI and height was carried out using a 
multivariate ANCOVA. BMI was only associated with osteoporosis treatment status (p=0.024), 
whereas height was associated with number of years since menopause (p<0.001) and there was a 
trend for a link between height and hormone replacement therapy status (p=0.084), Table 4.3. 
Subsequently, for univariate ANCOVA analysis of WWOX genotypes versus BMI and height, only 
those covariates and factors with p-values less than 0.1 as given above were included with the 
genotypes for analysis. 
As presented in Table 4.4 a few of the WWOX SNPs demonstrated formal association (p<0.05) with 
BMI and height but none of these associations was resistant to multiple testing correction and thus 
there is no evidence for a link between WWOX variants and these traits. Consequently BMI can be 
used as a covariate for bone metabolism phenotypes analysis. 
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 BMI Height 
Years since menopause 0.350 <0.001 
Current smoking status 0.436 0.483 
Smoking history status 0.748 0.717 
HRT treatment status 0.786 0.084 
Osteoporosis treatment status 0.024 0.115 
significant results (p<0.05) are in bold, trend for significance 
(0.05<p<0.1) in normal script, and non-significant p values 
(p>0.1) in italics. 
Table 4.3.  
Correlation between years since menopause, smoking status, HRT status and osteoporosis 
treatment with BMI and height 
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SNP name BMI Height 
rs1813526 0.039 0.927 
rs8056446 0.020 0.023 
rs11150075 0.032 0.719 
rs7206823 0.158 0.003 
rs7201683 0.467 0.005 
rs9923888 0.876 0.028 
rs11643643 0.002 0.100 
rs12918952 0.082 0.042 
rs442608 0.744 0.003 
rs383362 0.028 0.115 
SNPs not significantly linked to any of the traits are not 
presented; significant results (p<0.05) are in bold, trend for 
significance (0.05<p<0.1) in normal script, and non-significant p 
values (p>0.1) in italics. 
Table 4.4  
Associations of WWOX SNPs with BMI and height 
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4.3.4. Assessment of the contribution of covariates and factors to phenotypes related to bone 
metabolism 
Assessment of the contribution of covariates and factors to the phenotypes of interest was carried out 
using a multivariate ANCOVA. As expected BMD at all sites and serum markers of bone metabolism 
were strongly linked (p<0.001) with BMI, however there was no association between BMI and the 
number of vertebral fractures. The number of years since menopause was significantly associated 
(p<0.001) with BMD at the femoral neck, hip and Ward’s triangle. Smoking status had no impact on 
any of the phenotypes. Hormonal replacement therapy was associated with BMD at all sites (p<0.005) 
and with serum markers (p<0.05), and was marginally associated with the number of vertebral 
fractures (p=0.094). Treatment for osteoporosis was marginally associated with vertebral fractures 
(p=0.069) and serum osteocalcin (p=0.053), and strongly associated with all other phenotypic 
measures (p<0.05). These data are gathered in Table 4.5. Subsequently, for univariate ANCOVA 
analysis of WWOX genotypes association with each phenotype in turn, only those covariates and 
factors with p-values less than 0.1 were included with the genotypes for analysis (presented below).
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 Serum 
osteocalcin 
Serum 
CrossLaps 
Femoral 
neck BMD 
Ward’s 
BMD 
Total hip 
BMD 
 Spine 
BMD 
Vertebral 
Fractures 
Body mass index (BMI) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.153 
Years since menopause 0.853 0.981 <0.001 <0.001 <0.001 0.231 0.312 
Current smoking status 0.352 0.316 0.303 0.319 0.670 0.268 0.299 
Smoking history status 0.355 0.530 0.757 0.657 0.742 0.724 0.769 
HRT treatment status 0.018 0.015 0.001 0.003 0.002 0.002 0.094 
Osteoporosis treatment status 0.053 0.011 0.027 0.002 <0.001 <0.001 0.069 
significant results (p<0.05) are in bold, trend for significance (0.05<p<0.1) in normal script, and non-significant p values (p>0.1) in italics. 
 
Table 4.5 
Correlation of BMI, years since menopause, smoking status, HRT status and osteoporosis treatment with clinical data 
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4.3.5. Association between WWOX variation and serum markers of bone metabolism 
The association between WWOX variation and serum markers of bone metabolism was assessed 
with univariate ANCOVA. BMI was included in the model as a covariate, and HRT and osteoporosis 
treatment status as random factors. 
Two SNPs were formally associated with the levels of serum osteocalcin: rs1813526 (p=0.036) and 
rs442608 (p=0.046). Three SNPs displayed association with serum CrossLaps: rs12446313 
(p=0.015), rs442608 (p=0.026), rs383362 (p=0.047). The results are presented in Table 4.6. Given 
the number of polymorphic markers tested these associations are likely false positive findings and are 
not resistant to Bonferroni correction. 
SNP name Serum osteocalcin Serum CrossLaps 
rs1813526 0.036 0.080 
rs12446313 0.150 0.015 
rs383362 0.057 0.047 
rs442608 0.046 0.026 
SNPs not significantly linked to any of the traits are not 
presented; significant results (p<0.05) are in bold, trend for 
significance (0.05<p<0.1) in normal script, and non-significant p 
values (p>0.1) in italics. 
Table 4.6. 
Associations of WWOX SNPs with serum markers of bone metabolism 
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4.3.6. Association between WWOX variation and BMD 
The association between WWOX variation and bone mineral density was assessed with univariate 
ANCOVA. BMI and the number of years since menopause (with the exception of spine BMD) were 
included in the model as covariates, and HRT and osteoporosis treatment status as random factors.  
Two WWOX SNPs displayed formal association with BMD measured at femoral neck: rs2303191 
(p=0.042), rs9928827 (p=0.043). Similarly two SNPs associate with BMD measured at Ward’s 
triangle: rs9928827 (p=0.037), rs7198580 (p=0.039). None of the WWOX SNPs was significantly 
linked to hip BMD. Three SNPs displayed association with spine BMD: rs6564559 (p=0.018), 
rs2303191 (p=0.019) and rs17572124 (p=0.027). The results are presented in Table 4.7. Similar to 
the associations with serum markers, none of these associations is resistant to multiple testing 
correction. 
4.3.7. Association between WWOX variation and the number of vertebral fractures 
The association between WWOX variation and vertebral fractures was assessed with univariate 
ANCOVA. HRT and osteoporosis treatment status were included in the model as random factors in 
the analysis. 
Only one WWOX SNP displayed association with the number of vertebral fractures –rs9938424 
(p=0.049) –Table 4.7. Again this association is not resistant to multiple testing correction. 
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SNP name 
Femoral 
neck BMD 
  Ward’s   
BMD 
Total hip 
BMD 
 Spine  
BMD 
Vertebral 
fractures 
rs17572124 0.610 0.506 0.136 0.027 0.946 
rs2303191 0.042 0.063 0.093 0.019 0.190 
rs6564559 0.799 0.892 0.448 0.018 0.099 
rs7198580 0.105 0.039 0.063 0.114 0.248 
rs9928827 0.043 0.037 0.062 0.112 0.373 
rs9938424 0.770 0.539 0.639 0.881 0.049 
SNPs not significantly linked to any of the traits are not presented; significant results (p<0.05) 
are in bold, trend for significance (0.05<p<0.1) in normal script, and non-significant p values 
(p>0.1) in italics. 
Table 4.7.  
Association of WWOX SNPs with bone mineral density and fractures 
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4.4. The study into the associations between WWOX variation and bone mineral density and 
serum markers of bone metabolism: discussion 
 
The common form of osteoporosis is considered to be a polygenic disorder with very high heredity 
estimates of 0.5-0.9 [256-257]. Several linkage studies as well as candidate gene and genome-wide 
association studies have been conducted to find the loci that could explain the variability in BMD or in 
the incidence of osteoporotic fractures.  
SNPs within the WWOX gene were linked with WWOX expression [216] and postulated to have a cis-
regulatory role [217] demonstrating a functional potential. Consistently, WWOX variants were linked 
with prostate cancer incidence [218] and serum HDL-cholesterol [217]. Further, it has been proposed 
that WWOX might be a happloinsufficient tumour suppressor gene [86, 88] and therefore it might be 
predicted that a subtle loss of WWOX expression, such as that due to modulatory effects of germline 
variation, may affect its function. These observations provide the rationale for studying the correlates 
of WWOX genetic variation. 
Wwox-deficient animals display reduced bone mineral density in three independent models and 
Wwox loss was associated with several phenomena in the bone as demonstrated by defects in 
osteoblast differentiation or development of osteosarcomas in Wwox
-/- 
mice [89, 114, 220], strongly 
suggestive of a likely impact of WWOX on bone biology, including BMD regulation. Further potential 
link between WWOX and BMD and/or osteoporosis, traits with a strong endocrine component, is the 
fact that WWOX/Wwox was shown to be indispensable for effective steroidogenesis in mice [214], 
and proposed to play a role in hormonal regulation in humans based on structural predictions and 
expression profile [20, 39].  
The Danish women population analysed in this study was previously used to demonstrate association 
between SNP variants in the leptin receptor gene and BMD as well as frequency of vertebral fractures 
[265]. The WWOX gene represents another good candidate modifier gene regulating bone mass. 
However, given the borderline strength of the associations in our study, the lack of any SNP 
associated with vertebral fractures and BMD at multiple sites, and the fact that none of the 
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associations remain significant after multiple testing correction, I conclude that there is no evidence 
for a genetic link between WWOX variants and BMD. 
There are several explanations that may account for the apparent discrepancy between strong in vivo 
evidence for the role of Wwox/WWOX in bone metabolism and other metabolic traits, and the lack of 
genetic proof for a link between WWOX SNPs and bone metabolism traits in an extensively 
phenotyped population of postmenopausal Danish women. Firstly, the function of WWOX in humans 
may differ from that in rodents, such that WWOX exhibits tumour suppressive potential in both 
species but modulates metabolism only in rodents. This could be due to the presence of a gene that 
regulates WWOX expression or modulates WWOX function in humans but not in rodents (or vice 
versa). Similarly, there may be a protein expressed in humans but not rodents that can compensate 
for the loss of WWOX on metabolic function. 
Another likely explanation is gene dosage. WWOX has been suggested to be haploinsufficient for its 
role in tumour suppression, with tumours arising in Wwox
+/-
 mice still expressing Wwox protein [86]. 
Unlike its role in tumorigenesis however, the metabolic defects due to Wwox loss were only reported 
following total abrogation of Wwox expression in the knock-out, and not detected in heterozygous and 
hypomorph animals [87, 89, 114]. The effects of natural SNP variation on WWOX expression or 
function may therefore be too subtle to produce a detectable difference in bone mineral density or 
serum markers of bone metabolism, despite an impact of WWOX variation on serum HDL-C levels 
[217].  
In conclusion, Wwox expression is essential for normal bone metabolism in rodents, but its effect on 
bone metabolism in humans remains undetermined. My data demonstrate that natural SNP variants 
within the WWOX gene do not contribute to the inter-individual variability in bone mineral density or 
serum markers of bone turn-over in humans. Further studies are needed to find the mechanistic 
explanation for WWOX function in metabolism and to explore its function in the skeleton in health and 
disease. 
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Chapter 5. WWOX as a global transcriptional regulator 
5.1. Introduction: the potential role of WWOX/AP2γ interaction in tumorigenesis 
As already discussed in the introduction, WWOX was reported to interact with a number of PPxY 
motif containing transcription factors including AP2γ and α, p73, c-Jun and RUNX2 via its N-terminal 
WW-1 domain [37-38, 100, 114]. AP2γ appears to be one of the best validated WWOX binding 
partners and contains two PPxY motifs, both of which were demonstrated to be capable of interaction 
with WWOX, leading to AP2γ cytoplasmic sequestration and inhibition of its trans-activity [38]. 
The clinical significance of WWOX/AP2γ interaction was examined in the setting of breast and 
prostate cancers. Qin et al. [108] show that WWOX interacts with AP2γ in prostate cancer cells, 
sequesters AP2γ in the cytoplasm and prevents its recruitment to the ERBB2 promoter (as 
demonstrated by chromatin immunoprecipitation). WWOX was shown to inhibit AP2γ driven ERBB2 
expression and there was an inverse correlation between WWOX and ERBB2 expression in prostate 
cancer samples as demonstrated by western blotting. AP2γ transfection enhanced prostate cancer 
cell line model growth in conditions simulating low androgen environment, whereas AP2γ/WWOX (but 
not mutant WWOX with altered WW-1 domain) co-transfection reduced the growth to below the levels 
of vector controls. The authors suggest this is due to WWOX–mediated regulation of the 
AP2γ/ERBB2/AR (androgen receptor) axis [108]. It should be noted however that the same group 
previously showed that WWOX transfection causes massive caspase–dependent cell death in 
prostate cancer cell lines [75], so it is difficult to convincingly attribute WWOX growth–inhibitory 
effects to the abrogation of AR signalling rather than direct pro-apoptotic effects observed in multiple 
cancers, including those in which sex hormone signalling is not implicated. 
Several reports demonstrate a link between WWOX and estrogen receptor α (ERα) expression levels 
in breast cancer [40, 47-48]. Intriguingly, AP2γ was demonstrated via several independent 
approaches to be one of the main transcription factors regulating ERα expression [266-270], being 
also itself regulated by ERα signalling [271] and linked to anti-hormonal therapy resistance [113]. 
Consistent with this Guler et al. [52], in their immunohostochemical study of 58 tamoxifen–sensitive 
and 38 tamoxifen–resistant ERα-positive breast cancer tumours, demonstrated that loss of WWOX 
and high AP2γ were stronger independent predictors of tamoxifen resistance in multivariate analysis 
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than progesterone receptor (PR) and ERBB2 levels. There was no correlation between WWOX levels 
and the subcellular localization of AP2 factors, but the authors point out that a more developed 
approach for quantifying cytoplasmic AP2 proteins might be required. This is strongly suggestive of a 
role for WWOX in tamoxifen response in ERα positive breast cancer patients and supports the view 
that the interplay between WWOX and AP2γ might be important. 
The same group studied the correlations between the expression of WWOX, AP2γ, AP2α, ERα, PR, 
ERBB2 and other proteins, and breast cancer phenotypes in an extensive panel of 837 tumours by 
immunohistochemistry [49]. WWOX loss correlated with triple negativity for ERα, PR and ERBB2, and 
positivity for EGFR and/or cytokeratins 5 and 6 (a profile suggested to delineate ‘’basal-like 
phenotype’’ in breast cancer [272]). ‘’Basal-like’’ tumours also displayed elevated expression of AP2γ. 
The authors also mention in the discussion that nuclear AP2γ is more frequent in basal–like tumours 
but there was no correlation between WWOX levels and nuclear AP2γ, perhaps because there were 
only three WWOX–positive ‘’basal-like’’ tumours, which might be too few for statistical analysis. The 
expression pattern in other molecular subtypes is not presented [49]. 
In summary, the model emerging from the studies of the interaction between WWOX and AP2γ, as 
well as their clinicopathological correlates, is that following AP2γ binding, via its PPxY motifs to the 
first WW domain of WWOX, this transcription factor is sequestered in the cytoplasm. This blocks its 
transcriptional activity and expression of target genes such as ERBB2, Figure 1.2. AP2γ is strongly 
implicated in ERα signalling and the same was demonstrated for WWOX. These reports are highly 
suggestive of AP2γ inhibition as one of the mechanism in which WWOX exerts its tumour suppressive 
function. This is best documented in breast and prostate cancers, where sex hormone signalling is 
strongly implicated in the pathobiology, and points to ovarian cancer (where high AP2γ expression 
was shown to correlate with high stage [273]) as another neoplasia where WWOX/AP2γ interplay 
might be particularly relevant. 
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5.2. Results 
5.2.1. AP2γ, the prototypic WWOX-binding transcription factor, is highly expressed in PEO1 
cells but there is no evidence of its interaction with WWOX 
Stably transfected PEO1 cells (WWOX-transfected: WWOX-6, -7, -8; and vector-transfected: Vector-
9, -p1, -p2) were previously used to demonstrate that WWOX abolishes in vivo tumorigenicity in 
ovarian cancer and regulates cancer cell interactions with extracellular matrix due to reduction of 
integrin α3 binding capacity [91]. AP2γ is so far the most extensively validated WWOX binding 
partner. Therefore my hypothesis was that WWOX/AP2γ interaction, leading to AP2γ cytoplasmic 
sequestration, may regulate the expression of genes implicated in cell adhesion, including integrins, 
and thus be causative to the altered ECM adhesion properties of WWOX transfected cells or, 
ultimately, regulate their tumorigenic potential. AP2γ is highly expressed in the clonal derivatives of 
PEO1 cells, as well as in SKOV3 ovarian cancer cells, and there is no obvious relationship with 
WWOX status, Figure 5.1. 
 
Figure 5.1 
AP2γ protein expression in PEO1 and SKOV3 cell lines 
AP2γ protein levels were analyzed in the series of stably WWOX- (WWOX-6, -7, -8) or vector- 
(Vector-9, -p1, -p2) transfected PEO1 cells, and in SKOV3 cells 48 hrs after transient transfection with 
WWOX or empty vector, by western blotting. Protein was isolated from cells at less than 80% 
confluence. Two isoforms are observed in PEO1 cells and one in SKOV3 cells (lower molecular 
weight band in SKOV3 cells is due to previous probing for another protein). 
 
I optimized WWOX immunoprecipitation with two polyclonal antibodies (N-19 against amino acids 50-
100 and P-20 against amino acids 100-150). A polyclonal antibody against Ap2γ (V-18) was 
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successfully used to pull-down this protein. I used buffers identical to those reported in the original 
papers describing WWOX/AP2γ interaction [38, 108], and also tried altering the detergents (NP-40 or 
Triton X100) and their concentrations, and there was no evidence of interaction, Figure 5.2. The blots 
of WWOX precipitates were also probed with p53, ezrin and Ack1 (other reported WWOX binding 
partners [25, 46, 69, 100]), as well as ERα that was not previously shown to interact with WWOX, and 
again there was no evidence of interaction, Figure 5.3. 
 
Figure 5.2 
No evidence of WWOX/AP2γ interaction in PEO1 WWOX-7 cells 
WWOX/AP2γ co-immunoprecipitation experiments with goat anti-WWOX (N-19, P-20), anti-AP2γ (V-
18) and control goat antibodies in PEO1 WWOX-7 cell line. A. WWOX and AP2γ were 
immunoprecipitated in 0.5% NP40 buffer (as described in Materials and Methods) and analyzed by 
western blotting –probed for WWOX (46 kDa) and subsequently for AP2γ (48-50 kDa); B. WWOX and 
AP2γ were immunoprecipitated in 0.5% Triton X100 buffer, probed for AP2γ and subsequently for 
WWOX. AB. The blots were not stripped between exposure to WWOX and AP2γ antibodies so as not 
to reduce signal thus the signal for the putative binding partner of a distinct molecular weight is still 
visible. 
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Figure 5.3 
WWOX precipitates are negative for p53, ERα, Ack1 and Ezrin 
Immunoprecipitation with goat anti-WWOX (N-19, P-20) and control goat antibodies in PEO1 WWOX-
7 cell line in 0.5% NP40 buffer. Immunoprecipitates analyzed with western blotting and probed for A. 
ERα, p53, WWOX; B.Ack1, Ezrin, WWOX. 
 
I used co-immunoprecipitation to demonstrate the well validated interaction between integrins α3 and 
β1 that form a heterodimer relevant to the cell adhesion phenotype described by our group. This was 
performed as a control co-immunoprecipitation assay and confirmed the expected interaction. This 
demonstrates that the protocol I used is suited for studying protein–protein interactions (although 
does not exclude false negative results for other protein interactions that require different, even less 
disruptive conditions than the study of integrin heterodimers), Figure 5.4. 
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Figure 5.4 
Integrin β1, α2 and α3 co-immunoprecipitation experiment in PEO1 cells 
Integrin β1, α2 and α3 co-immunoprecipitation experiment in PEO1 cells with mouse anti-integrin α2 
and –α3 antibodies and control mouse antibody (0.5% NP40 buffer). Immunuprecipitates analyzed by 
western blotting and probed for integrin β1. 
 
5.2.2. The subcellular localization of candidate WWOX binding partners is not altered by 
WWOX transfection 
The series of works demonstrating WWOX interactions with PPxY motif containing transcription 
factors postulate that the interaction with WWOX leads to a transcription factor localization shift from 
the nucleus to cytoplasm, and subsequently cytoplasmic sequestration inhibiting the trans-activity of 
such a factor. 
I performed nuclear-cytoplasmic fractionation using Lamin A/C as a nuclear marker and β-actin as 
well as β-tubulin as cytoplasmic markers. I determined subcellular localization of candidate WWOX 
binding transcription factors in the WWOX–transfected WWOX-7 line as compared to the vector 
transfected Vector-p2 or parent line. WWOX transfection did not lead to a cytoplasmic shift in the 
localization of AP2γ, c-Jun or p53 (nor ERα, whose expression is related to WWOX in breast cancer, 
but is not reported to bind WWOX), Figure 5.5. As TP53 is mutated in the PEO1 cell line this 
approach was also applied following WWOX knock-down in the WWOX-expressing, TP53-wild-type 
A2780 ovarian cancer cell line and similarly there was no evidence for a role of WWOX in 
transcription factor cytoplasmic sequestration in the case of p53 (AP2γ, c-Jun and ERα are not 
expressed in A2780 cells), Figure 5.6. 
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Figure 5.5 
WWOX transfection does not lead to a nuclear–cytoplasmic translocation of candidate WWOX-
binding transcription factors in PEO1 cells 
Nuclear–cytoplasmic fractionation experiment in PEO1 WWOX-7, Vector-p2 and parent lines. N and 
C denote the nuclear and cytoplasmic fractions, respectively. Analysed by western blotting and 
probed for Lamin A/C (nuclear marker), β-actin (cytoplasmic marker), WWOX, AP2γ, ERα, c-Jun and 
p53. 
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Figure 5.6 
WWOX siRNA knock-down does not affect the subcellular localization of p53 protein in A2780 
cells 
Nuclear–cytoplasmic fractionation experiment in A2780 cells following siRNA knock-down of WWOX 
expression (NT2 –non-targeting 2 siRNA oligo). N and C denote the nuclear and cytoplasmic 
fractions, respectively. Analysed by western blotting and probed for Lamin A/C (nuclear marker), β-
actin (cytoplasmic marker), WWOX, and p53. 
 
Interestingly, although the majority of WWOX is cytoplasmic, the nuclear fraction is positive for 
WWOX in both WWOX-transfected PEO1 or endogenously expressing WWOX A2780 cells which is 
consistent with some reports that suggested WWOX nuclear localization (Table 1.1). However, it 
cannot be excluded that WWOX signal is related to its presence in the nuclear membrane or 
structures linked to nuclear membrane such as endoplasmic reticulum that could not be completely 
sheared off the nuclei during the fractionation, Figure 5.7. 
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Figure 5.7 
WWOX protein is present in the nuclear fraction 
Endogenenous (A2780 cells) and stably transfected WWOX protein (WWOX-7 line) is present in the 
nuclear fraction. N and C denote the nuclear and cytoplasmic fractions, respectively. Analysed by 
western blotting and probed for Lamin A/C (nuclear marker), β-actin or β-tubulin (cytoplasmic marker) 
and WWOX. A. experiment from Figure 5.5, probed for WWOX; B. independent fractionation 
experiment in WWOX-7 cells; C. experiment from Figure 5.6, long exposure for WWOX; D. 
independent fractionation experiment in A2780 cells. 
Subsequently I examined the possible impact of transient over-expression of WWOX in PEO1 cells on 
the subcellular localization of AP2γ by confocal microscopy (transient transfection was not used for 
nuclear–cytoplasmic fractionation because of low transfection efficiency in PEO1 cells but single 
WWOX-transfected cells can be visualized with microscopy). Again there was no consistent 
relationship between WWOX status and AP2γ localization. Cells with predominant nuclear or 
cytoplasmic AP2γ pattern are present in the population of both WWOX-transfected and -untransfected 
cells, Figure 5.8. 
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Figure 5.8 
WWOX transient transfection does not lead to a nuclear-cytoplasmic translocation of the AP2γ 
transcription factor 
PEO1 cells were transiently transfected with WWOX-expression vector, cultured on coverslips for 48 
hrs, fixed with paraformaldehyde, further processed for immunofluorescent microscopy as described 
in Materials and Methods and visualized with a confocal microscope: DAPI, WWOX (green), AP2γ 
(red). There is no consistent relationship between AP2γ subcellular localization and WWOX 
expression and predominant AP2γ nuclear (*) or cytoplasmic (±) localization is observed in both 
WWOX-transfected and negative cells. 
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5.2.3. WWOX–mediated regulation of integrin expression and function is not at the 
transcriptional level 
Our group showed that integrins α2 and α3 are the main functioning α integrins in PEO1 cells and 
their membranous levels are significantly reduced in WWOX–transfected PEO1 cells. It was further 
demonstrated using function–blocking antibodies that α3 was the main α integrin responsible for 
fibronectin binding and WWOX transient transfection reduced the levels of membranous integrin α3 in 
PEO1 cells as measured by FACS. This explained the reduced fibronectin attachment of WWOX-
transfected cells. The adhesion phenotype was also reproduced in A2780 cells [91]. As WWOX was 
postulated to be a transcriptional regulator the reduction in integrin α3 levels could be due to changes 
at mRNA level.  
I examined the mRNA expression levels of integrin α3 and its functional partner integrin β1 in 
WWOX–transfected PEO1 cells and in A2780 cells following WWOX siRNA knock-down. This 
demonstrated that the alteration of integrin α3 membranous levels is not due to transcriptional 
regulation by WWOX, Figure 5.9. 
 
Figure 5.9 
WWOX status does not impact ITGA3 or ITGB1 mRNA levels 
48 hrs after seeding (before cells exceeded 80% confluence) RNA was extracted from PEO1 cells 
stably transfected with WWOX or Vector and A2780 cells following siRNA knock-down of WWOX 
expression (NT2 –non-targeting 2 siRNA oligo, WWOX 1 and 4 –WWOX siRNA oligos 1 and 4). 
Expression levels were measured by qRT PCR and normalized with the geometric mean of two 
housekeeping genes (TUBA1B, PPIA). Quantitation performed in triplicate in each of 2 biological 
replicates (1 replicate for ITGA3 in PEO1 cells), +/-SEM. 
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5.2.4. Microarray analysis of transcripts regulated by WWOX 
5.2.4.1. Microarray analysis of transcripts regulated by WWOX: experimental strategy 
As described in detail in methods, I utilised a microarray gene expression approach to study the role 
of WWOX as a transcriptional regulator. I used Affymetrix HT_HG-U133A GeneChip of nearly 23 000 
probes. I combined RNA from three WWOX–transfected cell lines (WWOX-6, -7, -8) and compared 
against RNA combined from three Vector–transfected PEO1 sublines (Vector-9, -p1, -p2) that were 
previously characterized phenotypically by our group (as discussed in detail in Chapter 1). 
WWOX expression restoration in the WWOX-null PEO1 cell line is a robust on/off system that should 
be among the most sensitive approaches to detect WWOX-related effects. Additionally it is the model, 
in which WWOX re-expression abolished ovarian tumorigenicity in vivo and demonstrated in vitro 
phenotypic effects. The approach was to identify candidate downstream genes mediating WWOX 
function and subsequently study their phenotypic effects. 
The RNAs were pooled to minimize the costs as described in Material and Methods (as opposed to a 
separate chip for every clone) and every target gene carried forward to further analysis planned to be 
validated by quantitative RT PCR in each of the sublines separately. 
The second comparison was between mock, non-targeting siRNA and WWOX siRNA pool 
transfection experiments in WWOX expressing A2780 ovarian cancer cell line (RNA preparations 
were combined from three independent A2780 siRNA transfections, Figure 5.10A presents western 
blotting confirming WWOX down-regulation in the three experiments used). This system of WWOX 
expression manipulation is likely less sensitive than transfection in the WWOX–null PEO1 cell line as 
a result of incompleteness of the knock-down, but is less prone to potential false positive changes 
than the PEO1 system due to clonal heterogeneity following stable transfection. The strategy was to 
superimpose any changes observed in the microarray in the stable transfection model with changes 
following WWOX knock-down in A2780 cell line. The changes identified following stable transfection 
in PEO1 cell line that show consistent alteration with regard to WWOX status in A2780 siRNA 
experiment would be then validated by quantitative RT PCR and tested for their relationship with the 
phenotypes identified by our group (especially fibronectin adhesion) and other features of cancer cell 
behaviour. 
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Figure 5.10 
WWOX siRNA knock-down in A2780 for gene expression experiments 
WWOX siRNA knock-down in A2780 cells (NT1 and -2 –non-targeting siRNA oligo 1 and 2). A. 3 
experiments combined for microarray experiment; B. 2 experiments used for quantitative RT PCR 
validation and integrin expression profiling. 
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5.2.4.2. Microarray analysis of transcripts regulated by WWOX: results 
The microarray data was normalized with RMA (Robust Multi Array) algorithm and a 2-fold expression 
change cut-off was initially used to generate a list of differentially regulated genes. This rendered 133 
gene probe sets up-regulated and 181 gene probe sets down-regulated in PEO1 cells after WWOX 
transfection (presented in Appendices 4 and 5).  
The same cut-off yielded 3 gene probe sets down-regulated in A2780 after WWOX siRNA knock-
down (with WWOX being the top differentially regulated gene, fold change 2.86) and 2 probe sets up-
regulated as compared to ‘mock’ treated cells (presented in Appendices 6 and 7). 51 gene probe sets 
were down-regulated and 20 up-regulated in A2780 cells after siRNA knock-down of WWOX 
expression as compared to cells transfected with non-targeting oligo NT1 (Appendices 8 and 9). None 
of the probe sets was consistently down-regulated following WWOX siRNA as compared to both 
Mock and non-targeting or consistently up-regulated following WWOX siRNA as compared to both 
controls. The higher number of gene expression changes between WWOX siRNA and NT1 siRNA 
than between WWOX and mock transfection might be due to off-target effects of NT1 oligo 
subsequently reported by the manufacturer (http://www.dharmacon.com). In conclusion, there was no 
evidence of consistent gene expression changes following WWOX knock-down in A2780 line at 2-fold 
change cut-off. 
When a more relaxed 1.5-fold expression change cut-off is used for the likely less sensitive A2780 
system there are 12 gene probe sets consistently down-regulated following WWOX siRNA as 
compared to Mock and non-targeting siRNA (and two of these are WWOX probes) and 14 probe sets 
are up-regulated following WWOX siRNA as compared to Mock and non-targeting. None of these 
probe sets displayed a corresponding change with regard to WWOX status at 2-fold cut-off in PEO1 
stable transfection experiment (Figure 5.11). Appendices 6-9 list probe sets altered at ≥ 1.5-fold in any 
direction following WWOX siRNA versus either of the controls (mock, non-targeting) in A2780 cells. 
This result is suggestive of no common gene expression regulation following WWOX status alteration 
in PEO1 and A2780 cell lines. It is thus unlikely that common transcriptional targets may be down-
stream effectors of WWOX function in both cell lines. Furthermore, there are very few gene 
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expression changes in A2780 cell line following WWOX knock-down and none of them can be easily 
associated with WWOX status. 
 
 
Figure 5.11 
The number of genes altered consistently with WWOX status in PEO1 and A2780 cells in the 
HGU-133A microarray experiment 
Venn diagrams demonstrate the number of genes altered consistently with WWOX status in PEO1 (2-
fold) and A2780 (1.5-fold) cells in the HGU-133A microarray experiment. A. genes down-regulated 
following WWOX stable transfection and up-regulated following WWOX knock-down; B. genes up-
regulated following WWOX stable transfection and down-regulated following WWOX knock-down. 
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5.2.4.3. Microarray analysis of transcripts regulated by WWOX: quantitative RT PCR validation 
I selected 15 genes differentially regulated between WWOX- and Vector-transfected PEO1 cells 
based on their possible role in tumorigenesis and regulation of cancer cell behaviour, including 
adhesion and motility, so as to validate the microarray experiment technically and document gene 
expression patterns of potential candidate downstream mediators of WWOX function before 
attempting the study of their functional effects. Several of these genes were also in parallel quantified 
by qRT PCR following WWOX siRNA knock-down in A2780 cell line. This was to ensure that the lack 
of common gene expression changes between the two cell line models in the microarray experiment 
was not due to technical difficulty in the A2780 arm. Additionally, to exclude the possibility of off-target 
effects that might have obscured gene expression regulation, separate WWOX siRNA oligos, rather 
than siRNA pool, and a new control non-targeting oligo were used (WWOX knock-down was 
confirmed by western blotting -Figure 5.10B). The results for all 15 genes attempted reproduced the 
direction of changes observed in the microarray experiment in the PEO1 cell line (Figure 5.12) and 
thus validated the microarray experiment technically. Six of them were also tested by qRT PCR in the 
A2780 system (IGFBP3, TFPI2, NEDD9, VAV3, Rac2, PLCε1), Figure 5.12A, and there was no 
evidence of their association with WWOX status, consistent with the microarray results. The full 
names of genes validated by qRT PCR are provided in the table with primer sequences (Appendix 1). 
The emerging pattern was that these genes were differentially expressed between WWOX-
transfected clones and Vector-p1 and –p2 controls, however the expression in the Vector–transfected 
Vector-9 clone was more similar to the expression levels in WWOX–transfected cells (WWOX-6, -7, -
8) than to the remaining control clones (Vector-p1, -p2), especially for ESR1, IGFBP3, VAV3, CD90, 
TGFBI, FN1, NEDD9, PLCε1, Figure 5.12. 
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Figure 5.12 
Quantitative RT PCR validation of the microarray experiment  
48 hrs after seeding (before cells exceeded 80% confluence) RNA was extracted from PEO1 cells 
stably transfected with WWOX or Vector and/or A2780 cells following siRNA knock-down of WWOX 
expression (NT2 –non-targeting 2 siRNA oligo). Expression levels were measured by qRT PCR and 
normalized with the geometric mean of two housekeeping genes (TUBA1B, PPIA). Quantitation was 
performed in triplicate for each of 2 biological replicates (1 replicate for CD90 in PEO1 cells), +/-SEM. 
A. PEO1 and A2780 cells; B. PEO1 cells (following page).  
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This raised the possibility that Vector-9 is an outlier that should be excluded from the study due to, for 
example, cross-contamination with WWOX-expressing cells. I authenticated the cell lines to address 
this possibility. To this end I measured WWOX expression by qRT PCR and demonstrated that 
WWOX-6, -7 and -8 clones express WWOX whereas Vector-9, -p1, -p2 are negative for full length 
WWOX mRNA (Figure 5.13A). The fact that all six clonal lines grow under blasticidin selection 
confirms presence of the expression vector. I further demonstrated by RT PCR the presence of a 
specific homozygous WWOX deletion that is present in the parental cell line in all 6 PEO1 derivatives 
tested, Figure 5.13B. All 6 clones were also negative for Mycoplasma as determined during regular 
Mycoplasma testing run in our laboratory. Consequently, I demonstrated that the Vector-9 clone is 
derived from the parental PEO1 cell lines, is transfected with the empty vector, and is null for WWOX 
so cannot be treated as an outlier. 
 
Figure 5.13 
Cell lines authentication 
A. 48 hrs after seeding (before cells exceeded 80% confluence) RNA was extracted from PEO1 
WWOX-6, -7, -8 and Vector-9, -p1, -p2 lines. WWOX expression levels were measured by qRT PCR 
and normalized with the geometric mean of two housekeeping genes (TUBA1B, PPIA). Quantitation 
was performed in triplicate for each of 2 biological replicates, +/-SEM; B. RT PCR product of expected 
455 bp size in all 6 stably transfected PEO1 derivatives corresponding to the unique homozygous 
deletion within the WWOX gene in the PEO1 cell line. 
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This was suggestive of the possibility that Vector-p1 and Vector-p2 clones diverged from the parental 
cell line, for example due to genomic instability, and their gene expression levels are no longer an 
appropriate control for comparison with WWOX–transfected cells. To address this possibility I 
compared the expression of PEO1 Vector sublines against PEO1 parent cell line. The gene 
expression data of the PEO1 parent line was provided by Dr Euan Stronach, Imperial College 
London. Using a 1.5-fold cut-off I compared the list of probe sets altered in either direction between 
WWOX–transfected clones (WWOX-6, -7, -8) versus Vector–transfected clones (Vector-9, -p1, -p2) 
and between WWOX–transfected clones and the parent cell line. The first comparison yielded 1396 
probes differentially regulated and the comparison with parent cell line yielded 2688 probes. The two 
lists were extremely similar with 630 common changes (Fisher’s exact test, p=2 x 10
-228
). Although at 
this fold change cut-off there are 2661 probe sets altered between Vector-transfected cells and the 
parent line, 1503 of those are also altered between WWOX–transfected cells and the parent line. In 
particular, 11 of the 15 genes that were used for qRT PCR validation of the microarray experiment 
that are altered between pooled WWOX–transfected clones (WWOX-6, -7, -8) versus Vector–
transfected clones (Vector-9, -p1, -p2) are also similarly altered between WWOX–transfected clones 
and the parent cell line (at 2-fold change level: TGFBI, IGFBP3, Rac2, CD90, ARHGAP26, ESR1, 
NEDD9, TFPI2, CDH1; and additionally at 1.5-fold change level: PLCε1, VEGFA). Therefore there is 
no evidence that Vector-p1 or –p2 divergence from the parent line could explain the gene expression 
pattern observed in the qRT PCR validation of the microarray experiment. 
As already mentioned the alteration of the expression of 6 genes altered between PEO1 sublines was 
examined in the A2780 line following WWOX siRNA knock-down, and not shown to be reproduced. 
To further address the question of whether the expression changes observed are due to WWOX 
status or are a result of clonal heterogeneity I used two additional systems to test the impact of 
WWOX status on their expression. I transiently over-expressed WWOX in SKOV3 ovarian cancer cell 
line and tested the expression of IGFBP3 and TFPI2 that are highly differentially expressed in PEO1 
clones, suggestive of WWOX–related up-regulation. Their expression was not altered between 
WWOX- and Vector-transfected cells 48 and 72 hrs post transfection, Figure 5.14. 
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Figure 5.14 
The impact of WWOX transient transfection on IGFBP3 and TFPI2 expression in SKOV3 cells 
48 and 72 hrs after seeding (before cells exceeded 80% confluence) RNA was extracted from SKOV3 
cells transfected with WWOX, WWOX-V5 or empty vector. IGFBP3 and TFPI2 expression levels were 
measured by qRT PCR and normalized with the geometric mean of two housekeeping genes 
(TUBA1B, PPIA), relative to empty vector [%]. Quantitation was performed in triplicate for each of 3 
biological replicates, +/-SEM. 
 
Finally, I attempted reversing the changes observed between WWOX–transfected PEO1 clones and 
Vector-p1 and –p2 lines by knocking-down WWOX expression in the WWOX-6 and WWOX-8 lines. 
No relationship between WWOX–status and the expression of PLCε1, TFPI2, VAV3, IGFBP3, TGFBI, 
ESR1 and ARHGAP26 was documented, Figure 5.15 and 5.16. 
This suggests that the changes in the expression of the genes examined in qRT PCR experiments 
are unrelated to WWOX status and arised during clonal selection. Further there are very few gene 
expression changes in A2780 cell line following WWOX knock-down and these are of low fold-change 
level. The lack of clear relationship between WWOX transfection and gene expression is consistent 
with my previously demonstrated lack of impact of WWOX status on the subcellular localization of 
putative WWOX binding transcription factors and no evidence of their physical interaction. 
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Figure 5.15 
The impact of WWOX siRNA knock-down in WWOX-6 cells on TFPI2, PLCε1 and VAV3 
expression 
A.48 hrs after seeding (before cells exceeded 80% confluence) RNA was extracted from PEO1 
WWOX-6 cells following siRNA knock-down of WWOX expression (NT2 –non-targeting 2 siRNA 
oligo). Expression levels were measured by qRT PCR and normalized with the geometric mean of two 
housekeeping genes (TUBA1B, PPIA), Vector-p2 (untreated) used as a control, Quantitation was 
performed in duplicate for each of 2 biological replicates, +/-SEM; B. Western blotting knock-down 
confirmation 72 hrs post transfection. 
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Figure 5.16 
The impact of WWOX siRNA knock-down in WWOX-8 cells on IGFBP3, TGFBI, ARHGAP26 and 
ESR1 expression 
A.48 hrs after seeding (before cells exceeded 80% confluence) RNA was extracted from PEO1 
WWOX-8 cells following siRNA knock-down of WWOX expression (NT2 –non-targeting 2 siRNA 
oligo). Expression levels were measured by qRT PCR and normalized with the geometric mean of two 
housekeeping genes (TUBA1B, PPIA), Vector-p1 and –p2 (untreated) used as a control where 
available. Quantitation was performed in triplicate for each of 2 biological replicates, +/-SEM; 
B.Western blotting knock-down confirmation 72 hrs post transfection (WWOX siRNA oligo 4 
ineffective). 
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5.2.4.4. The impact of WWOX transfection on the expression of genes regulated by putative 
WWOX–binding transcription factors and β-catenin 
WWOX was demonstrated to interact with several PPxY motif containing transcription factors (p73, c-
Jun, AP2γ) and inhibit β-catenin signalling through interaction with DVL2 [37-38, 41, 100, 108]. 
The microarray experiment I conducted in PEO1 cell line has been technically successfully validated 
by qRT PCR. Although my data suggests that most of the differentially expressed genes identified in 
our microarray experiment relate to clonal heterogeneity in the PEO1 stable transfectants, if WWOX is 
truly regulating the activity of these transcription factors then we would expect that our differential 
gene lists would be enriched for their target genes. 
I created an initial list of p73, c-Jun, AP2 and β-catenin transcriptional targets based on the genes 
proposed to be regulated by these proteins in the reports that established their interactions with 
WWOX. These include: p21 and Bax (p73), ERBB2 (AP2γ), p21 and p53 (c-Jun), and CCND1 (β-
catenin). p21, ERBB2 and CCND1 were demonstrated to be altered directly as a consequence of the 
interaction between WWOX and the given binding partners [37, 41, 100, 108]. None of these genes is 
altered in PEO1 cells as a result of WWOX transfection at >1.5-fold change level (Table 5.1). 
I then further extended the list of targets based on published data for each candidate WWOX binding 
partner. For each of them I extracted the target genes from a single study based on an unbiased 
screen - p73 (non-small cell lung cancer model [274]), AP2γ (breast cancer model [275]) or β-catenin 
(colon cancer model [276]). Target genes were confirmed in these studies by demonstrating a change 
in expression following modulation of the relevant transcription factor, the presence of appropriate 
recognition sites in the promoters, and physical interaction of the transcription factor with the promoter 
(chromatin immunoprecipitation or electromobility shift assay). For p73 I narrowed the gene list to 
those that were targeted by p73 but not p53. No such study was available for c-Jun so the target 
genes of this transcription factor are based on a review paper [102]. This is presented in Table 5.1. 
The only gene on this list of 26 putative targets of WWOX modulated transcriptional signalling 
(represented by 57 probes) that was differentially expressed in our PEO1 clone microarray 
experiment was SERPIN1A (Table 5.3). 
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In conclusion, several well validated target genes documented to be controlled by p73, c-Jun, AP2γ or 
β-catenin are not altered as a result of WWOX transfection. These include p21, ERBB2 and CCND1 
that were demonstrated to be altered directly as a consequence of the interaction between WWOX 
and the given binding partners. This argues against the model of WWOX function whereby WWOX 
interacts with potentially oncogenic PPxY motif containing transcription factors, sequesters them in 
the cytoplasm and thus inhibits their activity to block the expression of target genes. 
WWOX-
modulated 
transcriptional 
regulator 
Target gene Affymetrix 
HG-U133A 
probe 
The level of expression 
following WWOX 
transfection normalized to 
vector controls 
Reference 
AP2γ ErbB2 216836_s_at 0.803 [108] 
AP2γ ErbB2 210930_s_at 0.922 [108] 
AP2γ CDH2 203440_at 1.376 [275] 
AP2γ CDH2 203441_s_at 0.836 [275] 
AP2γ IGSF11 Not found Not found [275] 
AP2γ HPSE 219403_s_at 1.415 [275] 
p73 p21/CDKN1A 202284_s_at 1.249 [37, 274] 
p73 Bax 217029_at 1.000 [37] 
p73 Bax 211833_s_at 1.247 [37] 
p73 Bax 208478_s_at 1.417 [37] 
p73 CAN19 204268_at 1.036 [274] 
p73 14-3-3σ/SFN 209260_at 1.064 [274] 
p73 14-3-3σ/SFN 33322_i_at 1.092 [274] 
p73 14-3-3σ/SFN 33323_r_at 1.114 [274] 
p73 SERPINA1 202833_s_at 0.112 [274] 
p73 SERPINA1 211429_s_at 0.272 [274] 
p73 SERPINA1 211428_at 0.943 [274] 
p73 PTGF-beta 221576_at 0.986 [274] 
p73 PTGF-beta 221577_x_at 1.038 [274] 
p73 PIG3 210609_s_at 0.929 [274] 
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p73 JAG2 32137_at 1.183 [274] 
p73 JAG2 209784_s_at 1.298 [274] 
c-Jun p21/CDKN1A 202284_s_at 1.249 [100, 102] 
c-Jun p53 201746_at 1.418 [100, 102] 
c-Jun p53 211300_s_at 1.152 [100, 102] 
c-Jun CCND1 208712_at 1.294 [102] 
c-Jun CCND1 208711_s_at 1.394 [102] 
c-Jun p16/CDKN2A 209644_x_at 1.667 [102] 
c-Jun p16/ CDKN2A 207039_at 0.933 [102] 
c-Jun p16/ CDKN2A 211156_at 0.955 [102] 
c-Jun GM-CSF 210228_at 1.000 [102] 
c-Jun GM-CSF 210229_s_at 0.926 [102] 
c-Jun KGF 205782_at 0.903 [102] 
c-Jun HB-EGF 222076_at 0.984 [102] 
c-Jun HB-EGF 38037_at 1.288 [102] 
c-Jun HB-EGF 203821_at 1.391 [102] 
c-Jun FL1 Not found Not found [102] 
c-Jun FasL 210865_at 1.140 [102] 
c-Jun FasL 211333_s_at 0.755 [102] 
c-Jun Fas 204780_s_at 0.946 [102] 
c-Jun Fas 204781_s_at 0.971 [102] 
c-Jun Fas 216252_x_at 1.054 [102] 
c-Jun Fas 215719_x_at 1.160 [102] 
c-Jun Bcl3 204907_s_at 1.007 [102] 
c-Jun Bcl3 204908_s_at 1.011 [102] 
β-catenin CCND1 208712_at 1.294 [41] 
β-catenin CCND1 208711_s_at 1.394 [41] 
β-catenin c-Jun 201465_s_at 1.472 [276] 
β-catenin c-Jun 201464_x_at 0.734 [276] 
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β-catenin c-Jun 201466_s_at 0.860 [276] 
β-catenin Fra-1 204420_at 1.686 [276] 
β-catenin uPAR 211924_s_at 1.023 [276] 
β-catenin uPAR 210845_s_at 1.028 [276] 
β-catenin uPAR 214866_at 1.150 [276] 
β-catenin ZO-1 202011_at 1.145 [276] 
β-catenin ZO-1 214168_s_at 1.169 [276] 
β-catenin ZO-1 215428_at 0.874 [276] 
 
Table 5.1 
The expression of target genes of putative WWOX binding transcription factors and β-catenin 
in PEO1 microarray experiment 
 
5.2.5. Is WWOX a modulator of ERα signalling in ovarian cancer? 
WWOX is highly expressed in hormonally active or responsive tissues [39], structurally predicted to 
be involved in steroid metabolism [20] and indispensible for steroidogenesis in mice [214]. WWOX 
expression correlated with ERα levels and tamoxifen response in breast cancer [40, 47-48, 52]. These 
data suggest that WWOX might be implicated in ERα signalling and regulate the expression of ERα 
target genes as well as anti-hormonal therapy response in ovarian cancer.  
A series of studies examined the prognostic significance of putative markers of anti-hormonal therapy 
response in ovarian cancer. Candidate markers of patient response to the aromatase inhibitor 
letrozole, as reported in three studies using the same phase II clinical trial patient population [277-
279], were based on the list of genes regulated by estradiol in ovarian cancer cells in vitro (IGFBP3, -
4, -5, TGFBI, VIM, TRAP1, NGAL, HSP27, TFF1, TFF3, MYC) [278-281], other genes belonging to 
IGFBP family (IGFBP-1, -2,  -6) and genes for steroid receptors (ESR1, PR). These were 
supplemented with oncogenes from the EGF receptor family. 60 patients unselected for ERα levels 
were recruited into the trial and 32% achieved disease response or stabilization. The protein 
expression of putative letrozole response markers was measured by immunohistochemistry and 
correlated with response measures [277-279]. I proposed that this dataset would be a very relevant 
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resource enabling us to test the potential role of WWOX as a transcriptional regulator of ERα target 
genes and WWOX impact on anti-hormonal therapy response in ovarian cancer.  
We obtained the samples (35 out of original number of 60 due to availability) and the dataset 
containing expression and response data from Dr Simon Langdon (University of Edinburgh). 
Expression data were available for 18 proteins: ERα, PR, HSP27 (heat shock 27kDa protein 2), 
IGFBP-1, -2, -3, -4, -5, -6 (insulin like growth factor binding protein), TRAP1 (TNF receptor -
associated protein 1), NGAL/LCN2 (lipocalcin 2), VIM (vimentin), TGFBI (transforming growth factor, 
beta–induced, 68 kDa), TFF-1, -3 (trefoil factor), ERBB2, EGFR (epidermal growth factor receptor), 
MYC (v-myc myelocytomatosis viral oncogene homolog <avian>). The WWOX immunohistochemical 
staining was conducted and scored in Dr Mona El-Bahrawy’s laboratory (Imperial College London) 
with an antibody, whose WWOX–specificity I previously demonstrated by immunoprecipitation. 
WWOX was evaluable in 31 samples. Figure 5.17 demonstrates examples of WWOX staining in 
ovarian cancer samples included in this study. 
Out of 18 markers (11 of which were documented to be regulated in response to estradiol in ovarian 
cancer cells as listed above [278-281]), there was only a correlation between WWOX histoscore and 
TFF3 histoscore, which was of moderate significance (p=0.016, r
2
=0.468), Table 5.2. Four of these 
markers were previously reported to correlate with WWOX (ERBB2, ERα, PR and EGFR). In prostate 
cancer WWOX was shown to regulate ERBB2 expression due to an interplay with AP2γ. WWOX 
expression did not correlate with ERBB2 expression in this dataset and this is consistent with the lack 
of functional interaction between WWOX and AP2γ I observed in vitro in ovarian cancer cell line. 
Further WWOX expression was not related to the levels of ERα, PR or EGFR, which were previously 
reported to correlate with WWOX in breast (ERα, EGFR) [40, 47-49], and breast and ovarian (PR) 
[48, 53] cancer. 
Splitting the patient population into cases in which estrogen receptor signalling might be considered 
functional (arbitrarily defined as patients with ERα histoscore higher than median) and those with low 
levels of ERα, yields similar correlation results for WWOX, that is none of the genes apart from TFF3 
is related to WWOX levels in either subgroup (at the significance level of <0.05). The correlation with 
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TFF3 expression is only present in the high ERα population (p=0.002, r
2
=0.765), and not in the low 
ERα samples (p=0.688, r
2
=-0.123). 
In summary there is no compelling evidence for a link between WWOX levels and the expression of 
genes regulated by estrogen signalling in ovarian cancer. 
 
Figure 5.17 
Examples of WWOX immunohistochemical staining of ovarian cancer specimens  
WWOX immunohistochemical staining with N-19 antibody. A. WWOX negative (histoscore=0) serous 
tumour, magnification 10X; B. Strong cytoplasmic staining for WWOX (histoscore=285) in a serous 
tumour, magnification 20X. Images provided by Dr Mona El-Bahrawy. 
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ERα PR EGFR ERBB2 MYC IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFB5 IGFBP6 HSP27 TRAP1 NGAL TFF1 TFF3 TGFBI VIM  
0.001 0.203 0.227 -0.078 -0.083 0.317 0.348 0.171 0.018 -0.017 0.020 0.206 -0.034 0.069 0.047 0.468 
(0.016) 
-0.202 -0.086 WWOX 
 0.073 0.283 
(0.035) 
-0.330 
(0.21) 
-0.035 -0.193 -0.092 -0.391 
(0.010) 
0.200 -0.010 0.046 0.164 0.295 0.397 
(0.011) 
0.157 0.180 -0.231 -0.154 ERα 
  0.106 -0.106 -0.219 0.004 0.062 -0.257 -0.047 -0.307 
(0.043) 
-0.067 0.226 0.067 -0.208 -0.067 0.049 0.136 -0.276 PR 
   -0.346 
(0.016) 
0.004 0.261 0.259 -0.200 0.329 
(0.028) 
-0.101 0.052 -0.002 0.436 
(0.003) 
0,.310 0.189 0.270 -0.258 -0.192 EGFR 
    0.216 0.037 0.165 0.448 
(0.003) 
0.098 0.318 
(0.035) 
0.114 0.220 -0.021 0.273 -0.213 -0.138 0.046 0.233 ERBB2 
     0.219 0.163 0.126 0.489 
(0.001) 
0.123 0.396 
(0.018) 
0.159 0.283 0.384 
(0.019) 
-0.133 0.375 
(0.024) 
-0.083 -0.063 MYC 
      0.428 
(0.005) 
0.127 0.249 -0.139 0.288 0.248 0.283 0.373 
(0.025) 
-0.036 0.293 -0.001 0.028 IGFBP1 
       -0.169 0.417 
(0.008) 
-0.169 0.353 
(0.024) 
0.268 0.202 0.386 
(0.020) 
0.113 0.488 
(0.001) 
-0.206 -0.096 IGFBP2 
        -0.307 0.644 
(0.000) 
0.160 0.165 -0.126 -0.080 -0.463 
(0.003) 
-0.171 0.415 
(0.013) 
0.408 
(0.008) 
IGFBP3 
         -0.117 0.073 0.074 0.505 
(0.000) 
0.600 
(0.000) 
0.299 0.435 
(0.006) 
-0.539 
(0.001) 
-0.331 
(0.035) 
IGFBP4 
          0.025 -0.034 -0.273 0.076 -0.224 -0.215 0.190 0.359 
(0.018) 
IGFB5 
           0.332 
(0.042) 
-0.070 0.268 0.093 0.319 
(0.042) 
0.261 0.208 IGFBP6 
            0.157 0.211 0.110 0.103 0.173 0.024 HSP27 
 
             0.435 
(0.005) 
0.102 0.316 -0.275 -0.123 TRAP1 
              0.146 0.273 -0.259 -0.063 NGAL 
 
               0.056 -0.225 -0.118 TFF1 
 
                -0.194 -0.157 TFF3 
 
                 0.297 TGFBI 
 
 Table 5.2 
Bivariate correlations (r
2
, Spearman) between the histoscores of genes assessed in the population of ovarian cancer patients who entered a 
clinical trial of Letrozole (Cells with significant p values of <0.05 are shadowed and significant p values are provided in brackets) 
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5.2.5.1. High WWOX expression predicts letrozole response in ovarian cancer patients 
Although WWOX expression was not well correlated with a panel of putative ERα response markers 
as described in the preceding paragraph, there is a correlation between WWOX histoscore and 
CA125 response measures in the population of 35 patients treated with letrozole. 
Relative CA125 levels were defined as the ratio of CA125 after 3 months of letrozole therapy to the 
CA125 value measured when the treatment started. WWOX expression was significantly negatively 
correlated with relative CA125 following 3 months of letrozole therapy and high WWOX predicted 
favourable response i.e. low CA125 values (p=0.025, r
2
=-0.448). Subsequently patients were split into 
those above or equal and below median ERα histoscore. ERα-high group represents the cases where 
ERα signalling is considered to be preserved and, based on clinical studies, a population most likely 
to respond to anti-hormonal therapy [282]. WWOX is strongly associated with CA125 letrozole 
therapy response in the ‘high ERα’ cases (p=0.001, r
2
=-0.833) but not in the subgroup of patients with 
lower ERα histoscore. Consequently, WWOX is a predictive marker of anti-oestrogenic therapy 
outcomes, especially in patients selected for high ERα, despite the fact that there is no correlation 
between WWOX expression and the expression of ERα or other candidate markers of letrozole 
therapy response. This demonstrates that WWOX might play a role in cancer cell behaviour or in 
clinical response to therapy that is not dependent on gene expression regulation, Table 5.3 ABC, 
Figure 5.18. Our group is aiming at a validation of the predictive value of WWOX in an extended 
population of ovarian cancer patients treated with anti-hormonal therapy as the information on WWOX 
status may potentially facilitate the selection of patients likely to respond and thus be used clinically.  
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Figure 5.18 
WWOX levels predict response to letrozole 
WWOX levels (immunohistochemical histoscore) correlate with CA125 levels (%, relative to the levels 
before treatment) following 3 months of letrozole therapy. A. all patients; B. Patients with ERα 
histoscore above median (>150). 
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A. All samples (n=59, CA125 available for n=47) 
 WWOX ERα PR EGFR ErbB2 MYC IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFB5 IGFBP6 HSP27 TRAP1 NGAL TFF1 TFF3 TGFBI VIM 
CA125* -0.448 
(0.025) 
-0.287 -0.180 -0.319 
(0.031) 
0.094 -0.102 0.029 -0.220 0.438 
(0.006) 
-0.401 
(0.009) 
0.371 
(0.018) 
0.160 0.090 -0.429 
(005) 
-0.202 -0.449 
(0.004) 
-0.383 
(0.016) 
0.580 
(0.000) 
0.296 
 
B. Samples with ERα histoscore ≤150 (n=33, CA125 available for n=27), 
 WWOX ERα PR EGFR ErbB2 MYC IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFB5 IGFBP6 HSP27 TRAP1 NGAL TFF1 TFF3 TGFBI VIM 
CA125* -0.234 -0.293 -0.132 -0.270 0.117 -0.193 0.192 -0.086 0.348 -0.271 0.292 0.051 0.395 
(0.042) 
-0.049 0.083 -0.158 -0.155 0.745 
(0.000) 
0.153 
 
C. Samples with ERα histoscore >150 (n=26, CA125 available for n=20),   
 WWOX ERα PR EGFR ErbB2 MYC IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFB5 IGFBP6 HSP27 TRAP1 NGAL TFF1 TFF3 TGFBI VIM 
CA125* -0.833 
(0.001) 
-0.020 -0.284 -0.380 -0.107 -0.164 -0.315 -0.458 0.370 -0.509 
(0.031) 
0.408 0.103 -0.232 -0.697 
(0.002) 
-0.462 -0.703 
(0.002) 
-0.507 
(0.038) 
0.492 0.366 
 
Table 5.3 
Bivariate correlations (r
2
, Spearman) between the histoscores of genes assessed in the population of ovarian cancer patients who entered a 
clinical trial of Letrozole and relative CA125 values 
 *CA125 value (%) following 3 months of Letrozole treatment relative to the measurement on the beginning of treatment; cells with significant p values (<0.05) 
are shadowed and significant p values are provided in brackets 
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5.3. WWOX as a transcriptional regulator: discussion 
As discussed in Chapter 1 WWOX contains two predicted WW domains. WW domains mediate 
protein–protein interactions through recognition of proline–rich and phosphorylated serine/threonine–
proline sites. The first WW domain of WWOX was shown to recognize proline-rich PPxY motifs [34]. 
The group led by Carlo Croce followed up a screen for WWOX binding partners conducted by AxCell 
Biosciences. They reported that WWOX binds via its first WW domain to several transcription factors 
containing the PPxY motif such as p73 [37], AP2γ, AP2α [38], c-Jun [100] and ErbB4, a receptor 
tyrosine kinase whose C-terminal cleavage fragment functions in the nucleus [101]. The authors 
proposed a model of WWOX function where WWOX interacts with proline-rich PPxY motif containing 
transcription factors, sequesters them in the cytoplasm and inhibits their activity to block the 
expression of target genes [99]. WWOX was also shown to bind to p53 that does not contain a PPxY 
motif, further supporting its possible effects on gene transcription [25]. Subsequently, WWOX was 
shown to interact with other transcriptional regulators, i.e. RUNX2/AML1 and DVL2, a component of 
β-catenin signalling pathway [41, 114]. 
Our group demonstrated that WWOX transfection inhibits ovarian cancer cells adhesion to fibronectin 
and this is due to reduced integrin α3 expression and function [91]. One of the major hypotheses 
behind my project was that WWOX regulates the trans-activity of PPxY motif-containing transcription 
factors in ovarian cancer, and this modulates the levels or function of integrins or other proteins 
involved in cell adhesion. I studied the physical and functional interactions between WWOX and its 
putative binding partners as well as attempted identification of possible down-stream transcriptional 
effectors of WWOX function in cell adhesion and tumorigenesis so as to subsequently target those 
molecules or pathways and observe the postulated alteration in cancer cell behaviour. 
I focussed on AP2γ protein, the most extensively validated candidate WWOX binding transcription 
factor, and highly expressed in our PEO1 cell line model, as a proof-of-principle experimental target 
for testing the model of WWOX as a transcriptional regulator in the setting of ovarian cancer. I find no 
evidence of interaction between WWOX and AP2γ, no impact of WWOX transfection on AP2γ 
subcellular localization, no alteration of several validated AP2γ target genes including ERBB2, shown 
to be regulated by WWOX/AP2γ complex in prostate cancer, following WWOX transfection in an 
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ovarian cancer cell line, and no correlation between WWOX and ERBB2 in a panel of ovarian cancer 
clinical samples. This is consistent with the lack of interaction and co-localization between WWOX 
and AP2γ observed by the group led by Professor Helen Hurst, Barts and the London School of 
Medicine and Dentistry [personal communication]. Similarly, I found no evidence of physical 
interaction between WWOX and p53. I demonstrated no impact of WWOX transfection on p53 and c-
Jun subcellular localization, nor on the expression of AP2γ, c-Jun, p73 or β-catenin target genes.  
In their more recent work on WWOX role in bone metabolism the group led by Carlo Croce reports 
that WWOX and RUNX2 form a complex associating with osteocalcin promoter, and this nuclear 
localization is in disagreement with the model of WWOX–dependent transcription factor sequestration 
in the cytoplasm [114]. 
AP2, c-Jun, p53, 73 and RUNX2 transcription factors have pleiotropic effects and regulate a plethora 
of processes in various tissues and cellular compartments. Conceivably, the regulation of their activity 
must be a much more fine-tunable and intricate system rather than a model of cytoplasmic 
sequestration disabling the interaction with target promoters. The fact that I did not observe the 
physical interaction between WWOX and the candidate transcription factors might be due to the fact 
that some of the reports are false–positive findings, or that the cell lines I used lack the expression of 
an important co-factor facilitating the formation of a protein complex, or that the interactions are too 
transient.  
The microarray approach I undertook provides no compelling evidence of global transcriptional 
changes due to WWOX expression manipulation. The reduced adhesion of WWOX–transfected cells 
dependent on the abrogation of integrin α3 expression and function does not appear to be due to 
changes at the transcriptional level. 
Finally, while there is no evidence of correlation between WWOX and a number of cancer-relevant 
genes, including ERBB2, in a subset of ovarian cancer patients treated with aromatase inhibitor 
letrozole, there is a link between WWOX levels and patients response to the treatment. Consequently, 
in this clinical context, there is more evidence for a role for WWOX in either the response of cancer 
cells to hormonal cues or cancer cell proliferation and survival in general rather than gene expression 
regulation. The role for WWOX in the response to anti-hormonal therapy was demonstrated 
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previously in breast cancer [52]. Anti-hormonal therapy has been long attempted in ovarian cancer 
where endocrine factors are strongly implicated in tumorigenesis. Estrogen receptor α is expressed in 
about 40-55% ovarian carcinomas, but unlike in breast cancer where anti-oestrogen therapy plays a 
prominent role in cancer treatment and prevention, the clinical benefits are so far limited. It is believed 
that this can be improved with careful selection of patients likely to respond to such therapy. I propose 
that WWOX levels might be used to facilitate such selection and importantly, unlike several other 
markers of anti-hormonal therapy response, WWOX expression is not linked to ERα levels in ovarian 
cancer and may thus provide non-redundant information independent of ERα levels, and be especially 
informative in cases with high ERα expression. Apart from a need for a validation of the association 
between WWOX levels and letrozole response in another population of ovarian cancer patients, it 
remains to be established what is the mechanism of WWOX impact on anti-hormonal therapy 
response in ovarian cancer. It is not determined whether this is because WWOX has specific effects 
on sex steroid signalling and/or reflects more universal effects on cancer cell proliferation and 
survival. Although WWOX was proposed to be involved in oestrogen signalling, I describe in the 
following chapter WWOX–driven apoptosis in ovarian cancer cells revealed in the context of an 
appropriate cellular stress, such as exposure to taxanes. Further studies should assess potential 
WWOX–dependent transcriptional changes under cellular stress, but this might be unrelated to the 
interaction with already proposed WWOX binding transcription factors but rather due to modulation of 
dynamic stress response pathways. 
The data presented in this chapter do not support the role of WWOX as a potent global transcriptional 
regulator and argue against the transcription factor sequestration model of WWOX function. 
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Chapter 6. The pro-apoptotic role of WWOX is revealed in the context of specific cytotoxic 
stimuli 
6.1. Introduction 
6.1.1. Integrin signalling promotes cell survival and chemotherapy resistance 
Cells secrete and assemble a network of proteins called extracellular matrix (ECM), mainly composed 
of collagens, laminins, hyaluronan, vitronectin, tenascin, thrombospondin and fibronectin. ECM is not 
only a scaffold for the cells in the tissues but exerts effects on the cells via receptors on their surface 
and regulates their proliferation, survival, differentiation and migratory potential. The main cellular 
receptors for ECM proteins are integrins, a family of 18 α and 8 β transmembrane subunits combined 
as functional heterodimers, each specific for a unique, but overlapping set of ligands. Most integrins 
have the capacity to activate focal adhesion kinase (FAK), which also leads to activation of SRC-
family kinases, as well as activating integrin–linked kinase (ILK) or ERK/MAPK1 (mitogen–activated 
protein kinase 1). Integrin signalling converges with, and either enhances or inhibits, receptor 
tyrosine–kinase (RTK)–dependent signals. The pro-survival role for integrins is demonstrated by the 
fact that loss of ECM adhesion induces cells to undergo apoptosis – a process known as anoikis, 
death of cells in suspension. Signalling downstream of FAK or ILK activates pro-survival kinases such 
as PI3K and AKT, promotes anti-apoptotic Bcl2 expression or NF-κB activity, and inactivates pro-
apoptotic RIP (receptor-interacting protein, a component of the death-receptor complex) [200, 283-
286]. FAK, SRC and ILK kinases are frequently up-regulated and/or activated in cancer [283, 285-
286], including ovarian carcinoma [287-290], suggesting that integrin signalling is important in tumour 
progression. 
Importantly, integrin signalling dependent on cancer cell–ECM interaction was demonstrated to 
promote cancer chemoresistance. Notably, Sethi et al. [291] demonstrated that small-cell lung cancer 
(SCLC) cells express several integrin subunits and are surrounded by an extensive stroma of 
extracellular matrix. In vitro adhesion of SCLC cells to ECM proteins (laminin, fibronectin, collagen IV), 
but not to poly-L-lysine which is not specific to integrins, results in β1-integrin–stimulated activation of 
tyrosine kinases, which inhibits chemotherapy (doxorubicin, cyclophosphamide, etoposide, cisplatin)–
induced apoptosis and thus promotes chemoresistance. SCLC patients with extensive matrix around 
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their tumours displayed significantly shorter survival than patients with focal or no matrix [291]. In the 
setting of ovarian cancer, several in vivo models demonstrated that disrupting integrins or their 
downstream effectors such as FAK or SRC with targeted antibodies, inhibitors or RNA interference 
enhances efficacy of chemotherapeutic drugs with most evidence for taxanes [201-204]. Interestingly, 
extracellular matrix integrin ligands are strongly implicated in paclitaxel response in ovarian cancer 
[292]. 
It is also important to note that apart from promoting cell survival and chemoresponse, integrins 
modulate a number of other processes important for malignant transformation such as epithelial-
mesenchymal transition (EMT), migration, invasion, matrix remodelling and angiogenesis, and 
integrins are thus promising therapeutic targets in neoplasia [200, 283-286]. As mentioned in the 
Introduction (Chapter 1) a number of integrin antagonists, especially targeting αν-integrins, entered 
clinical trials in several cancers, mainly on the basis of their anti-angiogenic properties [200, 293]. 
Further, pathways down-stream of integrins are also druggable targets and for example desatinib, a 
dual BCR/ABL and SRC family kinase inhibitor, approved for use in Philadelphia-chromosome 
positive acute lymphoblastic leukemia and in chronic myelogenous leukemia after imatinib treatment, 
also entered clinical trials in solid tumours [294-296]. 
6.1.2. Taxane response and resistance 
Microtubules are dynamic protein polymers of α- and β-tubulin subunits in continuous 
assembly/disassembly, and are essential for development, maintenance of cell shape, transport of 
vesicles, cell signalling and, in particular, cell division and mitosis in all eukaryotic cells. Microtubules 
are the targets of a diverse group of anti-mitotic drugs (including primarily Vinca alkaloids, taxanes 
and colchicines), most of which have been identified in screens of natural products, and play an 
important role in the therapy of multiple cancers. Microtubule–targeting drugs are usually classified as 
microtubule–destabilizing (Vinca alkaloids, colchicine) and microtubule–stabilizing agents (taxanes). 
Taxanes (paclitaxel, which was isolated from the bark of the Pacific yew tree, and its semisynthetic 
analogue docetaxel) bind to β-tubulin subunits with high affinity on the inside surface of the 
microtubule, which stabilizes the microtubule and increases its polymerization by largely unknown 
mechanisms (however recent studies suggest that paclitaxel concentrations too low to increase 
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tubulin polymer mass can already affect microtubule dynamics). This leads to damage to the mitotic 
spindle and a mitotic block of the cell cycle, which is considered to be the cause of taxane cytotoxicity 
[297-299]. The downstream events leading to cell death are not clearly understood, but several 
observations have been made. It is believed that, following the cell cycle block at M phase, the 
spindle assembly checkpoint is activated and the prolonged failure to proceed through the cell division 
initiates apoptosis. The mitotic spindle assembly checkpoint monitors that all chromosomes have 
achieved bivalent attachment to microtubules, and unattached kinetochores generate signals that 
delay cell cycle progression by producing inhibitors of the anaphase–promoting complex [298, 300]. 
Paclitaxel–induced apoptosis may occur directly after a mitotic arrest or following an aberrant mitotic 
exit into multinucleated state. The apoptotic programme is mainly modulated by signals that regulate 
the levels or activity of anti-apoptotic (such as Bcl-2 and Bcl-xL) and pro-apoptotic (for example Bax) 
members of the Bcl-2 family, and IAPs (inhibitors of apoptosis such as survivin and XIAP), and 
taxanes have been shown to impact both classes of apoptosis regulators to release the apoptotic 
trigger [298, 300-301]. Paclitaxel–driven cell death seems to be largely independent of p53 status and 
some reports suggest p53 deficient cells are more sensitive to taxanes [298, 301-302]. 
It has been also postulated that a proportion of the cytotoxic activity of taxanes is not due to its anti-
mitotic function, and other anti-mitotic agents (microtubule–destabilizing nocodazole and kinesin Eg5 
inhibitor EMD534085) at a dose titrated to the same level of mitotic arrest caused less cell death than 
taxanes in the same cell lines [303]. 
Taxanes are used in the treatment of ovarian, breast, prostate, head and neck, oesophageal, lung 
and bladder cancers, Kaposi’s sarcoma and melanoma but a development of drug resistance is 
common [297-298]. Several mechanisms of taxane resistance have been suggested including: 
multidrug resistance as a result of up-regulation of a drug efflux pump, such as P-glycoprotein 
encoded by the MDR1 gene; differential expression, mutations and posttranslational modifications of 
tubulin isotypes reducing drug binding; differential expression of microtubule-regulatory proteins; 
defective mitotic checkpoint mechanisms; up-regulation of anti-apoptotic survivin, Bcl-2 or Bcl-xL, or 
mutation of caspase-3; and alteration in protein kinase signalling pathways, such as AURORA-A 
kinase or PI3K/AKT [292, 297-299, 301, 304-305].  
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6.2. Results 
6.2.1. WWOX status does not alter basal rates of apoptosis 
As discussed in detail in Chapter 1 (Introduction) our group previously demonstrated that WWOX 
expression reconstitution by stable transfection into the WWOX-null PEO1 ovarian cancer cell line 
does not alter baseline or cisplatin-induced apoptosis or proliferation rates. This was shown with 
growth curves, clonogenic assays, Annexin V staining and assessment of the sub G1 cell fraction 
[91]. In addition, I measured the levels of apoptosis following WWOX transient transfection in SKOV3 
cells with an Annexin V assay, so as to exclude the possibility that the lack of an increase in the 
apoptotic response in the PEO1 system is due to an acquisition of anti-apoptotic properties during 
clonal selection of the stable transfectants. Consistent with previous data WWOX transfection did not 
increase the levels of cell death in SKOV3 cells, Figure 6.1. 
At the same time, WWOX transfection has phenotypic effects in SKOV3 cells as previously 
demonstrated by decreased fibronectin attachment of WWOX–transfected compared to vector–
transfected SKOV3 cells [91]. I confirmed the functional role of WWOX over-expression in SKOV3 
cells by examining the levels of two fibronectin binding integrins, α3 and α5β1, following WWOX 
transfection. WWOX transfection resulted in a modest but significant reduction of membranous 
fibronectin-binding integrins, Figure 6.2. 
These data demonstrate that WWOX expression modulation has no role in cell survival, in conditions 
in which an impact on cell adhesion and integrin expression is seen, and argues against a pro-
apoptotic role for WWOX. 
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Figure 6.1 
WWOX transfection does not impact basal apoptosis rates in SKOV3 cells 
400 000 SKOV3 cells were plated into a 25 cm
2
 flasks, allowed to attach, and transfected with WWOX 
or empty vector. The proportion of apoptotic cells (defined as Annexin V-positive, PI-negative) was 
measured with Annexin V/PI assay 24, 48 and 72 hrs post transfection. 3 biological replicates, +/-
SEM. 
 
 
Figure 6.2 
WWOX transfection alters the levels of membranous integrins α3 and α5β1 in SKOV3 cells 
150 000 SKOV3 cells were plated into 6-well plates, allowed to attach, and transfected with WWOX or 
empty vector. The levels of membranous integrins α3 and α5β1 were measured 48 hrs post 
transfection by FACS. 6 biological replicates, +/-SEM. 
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6.2.2. WWOX transfection reduces survival of ovarian cancer cells exposed to paclitaxel 
As discussed above WWOX expression reconstitution by stable transfection into WWOX-null PEO1 
ovarian cancer cell line does not alter baseline or cisplatin-induced apoptosis or proliferation rates. I 
hypothetised WWOX may still promote apoptosis in response to specific stimuli different from cisplatin 
as was for example previously shown to be the case for TNFα-related cell death [25]. I proposed 
paclitaxel as a particularly relevant cytotoxic insult because: the mechanism of action is different from 
the genotoxic cisplatin, the combination of platinums and taxanes is the standard chemotherapy 
treatment in ovarian cancer, and integrin signalling is an important regulator of taxane response. 
WWOX- or Vector- transfected PEO1 cells were exposed to 8 and 16 nM paclitaxel and assayed for 
72 hours. The survival of WWOX-transfected cells was significantly lower as compared to Vector-
transfected clones when cells were exposed to 8 nM paclitaxel (similar result was also obtained with 
16 nM paclitaxel although the difference in survival is smaller due to low number of surviving cells in 
the controls at this dose), Figure 6.3. 
 
Figure 6.3 
WWOX sensitizes PEO1 cells to paclitaxel 
6 000 cells per well were plated into 96-well plates. After 24 hrs the medium was removed and 
replaced with medium containing 0, 8 or 16 nM paclitaxel. Cell number was determined with SRB 
assay following 72 hrs of drug exposure. The absorbance relative to untreated cells was designated 
as surviving cell proportion. 4 biological replicates, +/-SEM, p<0.01 (**). 
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6.2.3. Reduced survival of WWOX–transfected cells on paclitaxel exposure is due to increased 
rates of apoptosis and independent of the extent of mitotic arrest 
I utilized commercially available caspase 3/7 activation assays, western blotting for cleaved caspase 
3, and measurement of the proportion of Annexin V positive cells to test whether the decreased rates 
of growth of WWOX–transfected cells on paclitaxel exposure were due to increased apoptosis. 
Following 24 hours of paclitaxel exposure at 8 and 16 nM paclitaxel concentrations the levels of 
caspase 3/7 activation (relative to the reading in untreated cells for each cell line) were significantly 
higher in three separate WWOX–transfected PEO1 clones versus three Vector–transfected lines, 
Figure 6.4A. The caspase activation result is truly an indication of apoptosis and not a difference in 
cell numbers, because the result is similarly significant when normalised with cell number determined 
with the SRB method, Figure 6.4B. This was confirmed by western blotting for cleaved caspase 3, 
Figure 6.4C. 
The fraction of apoptotic cells (Annexin V–positive, PI–negative cells) was also significantly higher in 
WWOX–transfected cells versus Vector–transfected cells following 24 hours exposure to 8 nM 
paclitaxel, Figure 6.4D. Consistent with previous data from our lab, the levels of apoptosis as 
measured with Annexin V assay were not different between the cells in basal conditions, Figure 6.4D. 
I determined the mitotic index of WWOX- or Vector- transfected cells, by measuring the fraction of 
cells positive for MPM2–reactive phosphoproteins, following exposure to 8 nM paclitaxel as described 
previously [224]. The mitotic index was not different between WWOX- and Vector- transfected cells 
following 8 or 24 hours of paclitaxel exposure, demonstrating that WWOX does not synergize with the 
anti-mitotic function of taxanes, Figure 6.5. Thus the differential cytotoxic response is not due to 
increased mitotic arrest but can be attributed to increased rates of apoptosis. 
To confim that the differential response to paclitaxel is driven by WWOX, I conducted siRNA knock-
down of WWOX expression in the WWOX-8 line with two separate siRNA oligos. As expected this 
resulted in increased survival of cells after paclitaxel exposure as compared to controls, and was 
accompanied by a reduction in the levels of cleaved caspase 3, Figure 6.6. In parallel I confirmed that 
WWOX status has no impact on cisplatin response with a transient siRNA approach to complement 
the previous data generated by our group with stable transfectants, Figure 6.7. 
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Figure 6.4 
WWOX transfection increases apoptosis in paclitaxel treated cells 
A. Stably transfected PEO1 cells were plated into 96-well plates (15 000/well). After 24 hrs the 
medium was removed and replaced with medium containing 0, 8, 16 nM paclitaxel. Caspase 3/7 
activity was measured with a luminometer after 24 hrs of drug exposure with Caspase Glo 3/7 Assay 
kit (Promega). The values presented are relative to the values for untreated for each of the cell lines. 
6 replicates, +/-SEM. B. Caspase Glo 3/7 data normalized with the cell count determined with the 
SRB method. The values presented are relative to the values for untreated for each of the cell lines. 6 
replicates, +/-SEM. C. Stably transfected PEO1 cells were plated into 6-well plates (250 000/well). 
Following 24 hrs incubation the medium was removed and replaced with medium containing 0 or 8 
nM paclitaxel. Cells were lysed following 24 hrs of drug exposure and analyzed by western blotting 
with anti-cleaved caspase 3 (Asp 175) antibody. D. Stably transfected PEO1 cells were plated into 6-
well plates (250 000/well). Following 24 hrs incubation the medium was removed and replaced with 
medium containing 0 or 8 nM paclitaxel. Floating and adherent cells were collected following 24 hrs of 
drug exposure and the proportion of apoptotic cells (defined as Annexin V-positive, PI-negative) was 
measured with Annexin V/PI assay. 4 biological replicates, +/-SEM. A-D. p<0.01 (**), p<0.05 (*).
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Figure 6.5 
WWOX transfecton does not affect the extent of paclitaxel-driven mitotic arrest 
Stably transfected PEO1 cells (2.5 x 10
5
 per well) were seeded into 6-well plates. After 24 hrs the 
medium was replaced with medium containing 8 nM paclitaxel. Following 8 or 24 hrs of drug exposure 
floating and adherent cells were collected, fixed and analyzed by FACS as described in Materials and 
Methods. The percentage of cells stained by the MPM2 antibody was designated as mitotic index. 3 
replicates, +/-SEM. 
 
 
Figure 6.6 (next page) 
siRNA depletion in WWOX-8 line confirms that the differential response to paclitaxel is due to 
WWOX status 
A. Following WWOX siRNA knock-down (mock, NT2- non-targeting siRNA oligo 2, WWOX siRNA 
oligos 1 or 15), 6 000 PEO1 WWOX-8 cells per well were plated into 96-well plates. After 24 hrs the 
medium was removed and replaced with medium containing 0, 8 and 16 nM paclitaxel. Cell growth 
was determined with SRB assay following 72 hrs of drug exposure. The absorbance relative to 
untreated cells was designated as surviving cell proportion. 4 replicates, +/-SEM. p<0.05 (*), p<0.01 
(**), p<0.001 (***). B. Following WWOX siRNA knock-down (mock, non-targeting siRNA oligo 2, 
WWOX siRNA oligos 1), 250 000 WWOX-8 cells per well were plated into 6-well plates. After 24 hrs 
the medium was removed and replaced with medium containing 0 and 8 nM paclitaxel. Cells were 
lysed following 24 hrs of drug exposure and analyzed by western blotting with anti-cleaved caspase 3 
(Asp 175) antibody. C. Western blotting comparison of WWOX knock-down efficiency with siRNA 
oligos 1 and 15 (72 hrs post transfection). 
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Figure 6.7 
WWOX depletion does not alter the cytotoxic response to cisplatin 
Following WWOX siRNA knock-down (mock, NT2- non-targeting siRNA oligo 2, WWOX siRNA oligo 
1), 6 000 PEO1 WWOX-8 cells per well were plated into 96-well plates. After 24 hrs the medium was 
removed and replaced with medium containing 0 or 6 µM cisplatin. Cell growth was determined with 
SRB assay following 72 hrs of drug exposure. The absorbance relative to untreated cells was 
designated as surviving cell proportion. 3 replicates, +/-SEM. 
 
6.2.4. The differential response of WWOX–transfected cells to paclitaxel is not related to the 
anti-mitotic action of taxanes 
As presented above WWOX status has no impact on the mitotic index following paclitaxel exposure in 
PEO1 cell line derivatives and thus the role WWOX plays in paclitaxel response is not directly related 
to the extent of mitotic arrest, as is the case for several factors antagonizing paclitaxel action 
identified before such as a number of spindle assembly checkpoint regulators [306]. I further asked 
the question of whether the WWOX–related enhanced response to paclitaxel, although not caused by 
increased mitotic arrest, is dependent on the anti-mitotic function of taxanes (which could explain 
WWOX effects on anti-mitotic paclitaxel response but lack of impact on DNA-damaging platinum 
sensitivity). To this end I utlised transient siRNA approach and a set-up identical to the experiment 
that demonstrated an impact on paclitaxel response and lack of effects on cisplatin cytotoxicity, and 
challenged the cells with differential WWOX status with monastrol — an inhibitor of the kinesin Eg5 
motor protein required for spindle bipolarity, that is more selectively anti-mitotic than taxanes and 
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leads to cell cycle arrest in mitosis due the failure of bipolar spindle formation [307]. There was no 
relationship between cell survival on monastrol exposure and WWOX levels, Figure 6.8. 
 
Figure 6.8 
WWOX depletion does not alter the cytotoxic response to monastrol 
Following WWOX siRNA knock-down (mock, NT2- non-targeting siRNA oligo 2, WWOX siRNA oligo 
1), 6 000 PEO1 WWOX-8 cells per well were plated into 96-well plates. After 24 hrs the medium was 
removed and replaced with medium containing 0 or 100 µM monastrol. Cell growth was determined 
with SRB assay following 72 hrs of drug exposure. The absorbance relative to untreated cells was 
designated as surviving cell proportion. 3 replicates, +/-SEM. 
 
6.2.5. The determination of the levels of apoptosis–related proteins in WWOX- and Vector- 
transfected cells in basal conditions and following paclitaxel exposure 
A commercially available array spotted in duplicate with capture antibodies against 35 apoptosis–
related proteins was used to determine their relative levels in untreated cells or cells treated for 24 hrs 
with 8 nM paclitaxel. The optical densities for all 35 proteins are presented in Appendix 10. 
There were no consistent differences between WWOX- and Vector-transfected cells in baseline 
conditions (Appendix 10). Following paclitaxel exposure there was a lower Bcl-xL/Bax ratio (Figure 
6.9) and an increase in the levels of cleaved caspase 3, consistent with previous assays, as well as 
slightly reduced levels of survivin and TNF RI in WWOX–transfected cells as compared to Vector–
transfected controls (Appendix 10). These changes are indicative of increased cell death and 
consistent with apoptotic response to paclitaxel but no other changes that could explain WWOX–
 201 
 
driven sensitization of ovarian cancer cells to paclitaxel were observed. The lack of alterations 
between WWOX- and Vector-transfected untreated cells is consistent with the lack of previously 
observed difference in survival due to WWOX in baseline culture conditions. 
 
Figure 6.9 
WWOX transfection into PEO1 cells affects the Bcl-Xl/Bax ratio in paclitaxel treated cells 
Stably transfected PEO1 cells were plated into 6-well plates (250 000/well). Following 24 hrs 
incubation the medium was removed and replaced with medium containing 0 or 8 nM paclitaxel. 
Floating and adherent cells were lysed following 24 hrs of drug exposure and analyzed with proteome 
array (R&D). The arrays were developed with a chemiluminescent reagent, films scanned with a 
transmission-mode scanner and pixel densities obtained with ImageQuant. Pixel densities of all 
markers are provided in Appendix.  A. Autoradiography film images of the Bcl-xL and Bax spots from 
the proteome arrays. B. Bcl-xL/Bax ratio (pixel densities). Average of 2 spots, +/-SD. 
 
6.2.6. The differential response of WWOX–transfected cells to paclitaxel is not due to integrin 
α3 regulation and is independent of TGFBI levels 
Our group have previously demonstrated that WWOX expression reconstitution diminishes the 
binding of ovarian cancer cells to an ECM component fibronectin. The fibronectin binding of the PEO1 
cells was demonstrated to be dependent on integrin α3 subunit and WWOX transfection results in the 
attenuation of integrin α3 function and reduction in the membranous levels of this integrin [91]. As 
already discussed integrin signalling and cancer cell interactions with ECM are linked with 
chemoresistance and taxane response.  
I tested the impact of ITGA3 siRNA knock-down on paclitaxel response in PEO1 cells so as to 
establish whether the differential response to paclitaxel following WWOX transfection might be due to 
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integrin α3 regulation. As demonstrated by FACS the siRNA transfection resulted in 62% reduction of 
membranous integrin α3 compared to non-targeting siRNA transfected cells. This reduction had no 
impact of paclitaxel response at either 8 or 16 nM paclitaxel concentration, and thus WWOX–
mediated sensitization to paclitaxel is not due to the regulation of integrin α3 levels, Figure 6.10. 
The ECM protein TGFBI was previously shown to be one of critical mediators of paclitaxel response 
in ovarian cancer in-vitro and in a prospective clinical trial, and is lost in a third of ovarian cancer 
patients [292]. As described in Chapter 5, I examined the expression of TGFBI in PEO1 stable 
transfectants. Quantitative RT-PCR revealed that TGFBI levels vary across the WWOX- and vector-
transfected PEO1 cell lines, but TGFBI expression was not obviously related to WWOX expression or 
paclitaxel response in our cell lines, Figure 5.12. 
 
Figure 6.10 
The differential response of WWOX-transfected cells to paclitaxel is not driven by integrin α3 
regulation 
A. Following ITGA3 siRNA knock-down (mock, NT2- non-targeting siRNA oligo 2, ITGA3 siRNA pool), 
6 000 PEO1 cells per well were plated into 96-well plates. After 24 hrs the medium was removed and 
replaced with medium containing 0, 8 and 16 nM paclitaxel. Cell growth was determined with SRB 
assay following 72 hrs of drug exposure. The absorbance relative to untreated cells was designated 
as surviving cell proportion. 6 replicates, +/-SEM. B. ITGA3 knock-down was confirmed by measuring 
the levels of membranous integrin α3 on PEO1 cells 72 hrs post transfection by FACS. 4 replicates, 
+/-SEM. 
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6.2.7. Paclitaxel exposure has no impact on WWOX protein expression 
Previously I did not observed noticeable impact of 24 hrs paclitaxel exposure on WWOX expression in 
WWOX-7 and WWOX-8 lines (Figure 6.4C and 6.6B), but WWOX protein in those lines is expressed 
following WWOX cDNA transfection and is thus not driven by a natural WWOX promoter, nor subject 
to other locus-specific regulatory effects. A2780 ovarian cancer cells express high levels of 
endogenous WWOX. Approximate IC50 and IC75 values for 48 hours paclitaxel exposure were 
established and cells treated at these concentrations to test whether paclitaxel exposure has an 
impact on endogenous WWOX expression. As demonstrated with Western blotting paclitaxel had no 
effects on WWOX expression apart from a slight reduction following prolonged exposure at very toxic 
concentration (IC75), Figure 6.11. 
 
Figure 6.11 
WWOX protein expression is not affected by paclitaxel exposure 
A.A2780 cells (175 000/well) were plated into 6-well plates, cultured for 48 hrs and treated with a 
range of paclitaxel concentrations (4-64 nM). SRB assay was used to determine cell growth after 24, 
48 and 72 hrs of paclitaxel exposure. B. A2780 cells (175 000/well) were plated into 6-well plates, 
cultured for 48 hrs and treated with 0, 16 and 32 nM paclitaxel, corresponding to approximately IC50 
and IC75 at 48 hrs (as determined in experiment presented in Figure 6.11A), respectively. Cells were 
lysed following 24, 48, 72 hrs of paclitaxel and analyzed by western blotting. Representative 
experiment of 3 replicates presented. 
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6.2.8. Paclitaxel exposure evokes endoplasmic reticulum stress in PEO1 ovarian cancer cells 
Several studies demonstrated that, apart from its anti-mitotic action, cell death due to paclitaxel 
exposure is mediated by endoplasmic reticulum (ER) stress / unfolded protein response (UPR) [306, 
308-310]. Various disturbances lead to accumulation of unfolded proteins in the ER, initiating an 
evolutionary conserved programme termed ER stress response or UPR. Such stimuli include redox 
status dysregulation (e.g. caused by hypoxia), nutrient deprivation, intracellular calcium aberrations 
and viral infections. The UPR is an adaptive mechanism, and its intent is to re-establish homeostasis 
by activating chaperones enhancing protein folding capacity and to inhibit translation. The overview of 
ER stress response pathway is presented in Figure 6.12. Transcriptional and post-translational 
changes in genes/proteins involved in these phenomena are markers of ER stress (Table 6.1). 
Prolonged or excessive ER stress leads to failure of the compensatory mechanisms and cell death 
[311-316]. It was shown in various models that taxanes induce early up-regulation of ER stress 
markers and cause cytosolic calcium disturbances, and that disruption of adaptive ER stress 
signalling by for example GRP78 chaperone knock-down promotes taxane response [306, 308-310, 
317-318]. Further, an increase in the level of pro-apoptotic ER stress component CHOP/GADD153 
following taxane treatment correlated with response in breast cancer patients [319]. 
Target gene ER stress response marker event 
GRP78 (glucose-regulated protein, 78 kDa) transcriptional up-regulation 
GRP94 (glucose-regulated protein, 94 kDa) transcriptional up-regulation 
Calreticulin transcriptional up-regulation 
CHOP(CCAAT/enhancer-binding protein homologous protein) transcriptional up-regulation 
XBP1 (X-box binding protein 1) specific splicing 
PERK/EIF2AK3 (eukaryotic translation initiation factor 2-alpha 
kinase 3) 
phosphorylation 
IRE1/ERN1 (endoplasmic reticulum to nucleus signaling 1) phosphorylation 
eIF2α (eukaryotic translation initiation factor 2, subunit 1 
alpha) 
phosphorylation 
p38/MAPK14 (mitogen-activated protein kinase 14) phosphorylation 
JNK (c-Jun N-terminal kinase) phosphorylation 
 
Table 6.1 
Examples of transcriptional and post-translational changes regarded as ER stress markers 
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Figure 6.12 
Schematic representation of main events during endoplasmic reticulum stress response [311, 
313-314] 
1. ER stress sensors (PERK, IRE1, ATF6) are inhibited in physiological conditions due to GRP78 
chaperone binding. Accumulation of misfolded proteins in the ER leads to the dissociation of GRP78 
from ER stress sensors, due to binding competition, and their activation. 
2. PERK dimerizes, autophosphorylates and subsequently phosphorylates eIF2α translation 
elongation factor leading to general translation inhibition and initiation of a selective translation 
programme; following oligomerization IRE1 autophosphorylates and catalyzes XBP1 splicing to its 
active form as well as well as activates mitogen-association protein kinases (MAPK) via TRAF2 
adapter recruitment; ATF6 is cleaved to its active form in Golgi and translocates to the nucleus. 
3. ATF4, XBP1 and ATF6 initiate the expression of ER stress responsive genes (e.g. GRP78 and -94, 
CHOP, XBP1, PDIA4, calreticulin) that contain in their promoters ERSE (ER stress response element) 
or UPRE (unfolded protein response element). This programme leads to re-establishment of cellular 
homeostasis or, if inefficient, apoptosis thought to be mainly due to CHOP and MAPK related 
regulation of Bcl-2 family proteins as well as ER Ca
2+
 modulation.  
PERK –PRKR-like endoplasmic reticulum kinase, IRE1 –inositol requiring kinase 1, ATF6 and -4 –
activating transcription factor 6 and -4, GRP78 –glucose-regulated protein 78, XBP1 –X-box-binding 
protein 1, TRAF2 –TNF-receptor associated factor 2 
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I showed that 8 nM paclitaxel initiates ER stress response and this precedes apoptosis. JNK1 was 
already activated after 1 hour of paclitaxel exposure (JNK2 phosphorylation was less pronounced), 
and similarly eIF2α elongation factor was phosphorylated after around 4 hrs, whereas GRP78 was up-
regulated after 4-8 hrs. These events preceded caspase 3 cleavage that was evident from around 18 
hours. The changes were very similar in WWOX-8 and Vector-9 cell lines, which demonstrates that 
the initiation of ER stress response is not dependent on WWOX status. In parallel I treated the cells 
with 200 ng/ul tunicamycin, a classic potent experimental ER stress inducer due to protein 
glycosylation inhibition, which resulted in very similar stress response related changes at these 
timepoints, Figure 6.13. 
 
 
Figure 6.13 
Paclitaxel evokes endoplasmic reticulum stress in PEO1 cells 
PEO1 WWOX-8 and Vector-9 cells were plated into 6-well plates (250 000 cells /well). Following 24 
hrs incubation the medium was removed and replaced with medium containing 8 nM paclitaxel (A) or 
200 ng/ul tunicamycin (B). Floating and adherent cells were lysed at 0, 1, 2, 4, 8, 12, 18, 24 and 32 
hrs timepoints and analysed by western blotting. 
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6.2.9. WWOX determines cell fate under prolonged endoplasmic reticulum stress 
I hypothetised that WWOX may regulate cell survival under prolonged endoplasmic reticulum stress, 
and this role may explain the effect of WWOX on paclitaxel response. To test this I induced ER stress 
response in the cells with tunicamycin (200 ng/ul) and observed whether WWOX status affects cell 
survival. Consistent with the hypothesis, WWOX-8 cells had significantly lower survival rates than 
control Vector-9 cells and WWOX depletion with two separate siRNA oligos significantly increased the 
survival of WWOX-8 cells treated with 200 ng/ul tunicamycin, Figure 6.14. 
 
Figure 6.14 
WWOX sensitizes PEO1 cells to the ER stress inducer tunicamycin 
A. 6 000 PEO1 WWOX-8 or Vector-9 cells per well were plated into 96-well plates. After 24 hrs the 
medium was removed and replaced with medium containing 0 or 200 ng/µl tunicamycin. Cell growth 
was determined with SRB assay following 48 hrs of drug exposure. The absorbance relative to 
untreated cells was designated as surviving cell proportion. 3 replicates, +/- SEM. B. Following 
WWOX siRNA knock-down (mock, NT2- non-targeting siRNA oligo 2, WWOX siRNA oligos 1 or 15), 6 
000 PEO1 WWOX-8 cells per well were plated into 96-well plates. After 24 hrs the medium was 
removed and replaced with medium containing 0 or 200 ng/µl tunicamycin. Cell growth was 
determined with SRB assay following 48 hrs of drug exposure. The absorbance relative to untreated 
cells was designated as surviving cell proportion. 4 replicates, +/-SEM. B. A-B. p<0.05 (*), p<0.01 (**), 
p<0.001 (***). 
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In summary, I demonstrated that WWOX increases apoptosis rates in cells exposed to paclitaxel but 
does not influence platinum cytotoxicity. This is independent of the anti-mitotic action of taxanes. 
Paclitaxel initiates ER stress response in PEO1 ovarian cancer cells and the marker changes are very 
similar to those caused by tunicamycin, a potent inducer of ER stress. Furthermore, WWOX depletion 
similarly enhances the survival of cells exposed to either tunicamycin or paclitaxel and thus I conclude 
that the WWOX-dependent differential response to paclitaxel is due to the regulation of cell fate 
during prolonged ER stress. 
WWOX was previously shown to interact with JNK1 under conditions of cellular stress that activate 
JNK such as UV exposure or anisomycin treatment (anisomycin is used in cell biology as a translation 
inhibitor and activator of JNK and p38 MAPKs) [94]. Such stress bears several similarities with the 
response induced by paclitaxel and tunicamycin in PEO1 cells (JNK activation and translation 
inhibition). JNK activation was previously strongly linked to paclitaxel response [320-323]. I tested the 
effects of JNK inhibition with SP600125, a selective competitive inhibitor [225], on paclitaxel response 
in WWOX-8 line. The treatment with SP600125 alone results in slower cell growth at approximately 
two-thirds the
 
level of the untreated cells, consistently at 24, 48 and 72-hour timepoints, which likely 
reflects slower proliferation due to JNK inhibition [324], Figure 6.15A and 6.16. Consistent with the 
hypothesis that the WWOX effect on taxane–induced cell death is JNK dependent, JNK inhibition 
partly rescued WWOX-8 cells from paclitaxel cytotoxicity as shown by increased surviving cell fraction 
and lower levels of cleaved caspase, even despite the fact that SP600125 treatment alone reduces 
WWOX-8 cells growth, Figure. 6.15A-B.  
On the other hand JNK inhibition did not rescue WWOX-8 cells from cell death due to tunicamycin 
exposure, arguing against a role of JNK as a mediator of WWOX pro-apoptotic effects during 
endoplasmic reticulum stress, Figure 6.16. Subsequently, I demonstrated that JNK inhibition, unlike 
WWOX action, antagonizes the anti-mitotic action of taxanes as demonstrated by reduced mitotic 
index (MPM2 positivity) and this likely accounts for the reduced apoptosis, Figure 6.17. Further, I 
found no evidence of WWOX/JNK1 interaction in untreated or paclitaxel stimulated cells, Figure 6.18. 
Consequently, WWOX effects on paclitaxel and tunicamycin response are unlikely related to JNK 
activity. 
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Figure 6.15 
JNK inhibition rescues PEO1 WWOX-8 cells from paclitaxel dependent apoptosis 
A.6 000 WWOX-8 cells per well were plated into 96-well plates. After 24 hrs the medium was 
removed and replaced with medium containing 0 or 8 nM paclitaxel with or without 10 mM SP600125. 
Cell growth was determined with SRB assay following 72 hrs of drug exposure. The absorbance 
relative to untreated cells was designated as surviving cell proportion. 5 replicates, +/-SEM. p<0.01 
(**), p<0.05 (*). B. WWOX-8 cells were plated into 6-well plates (250 000/well). Following 24 hrs 
incubation the medium was removed and replaced with medium containing 8 nM paclitaxel with or 
without 10 mM SP600125. Cells were lysed following 24 hrs of drug exposure and analyzed by 
western blotting with anti-cleaved caspase 3 (Asp 175) antibody.  
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Figure 6.16 
JNK inhibition does not rescue PEO1 WWOX-8 cells from tunicamycin cytotoxicity 
6 000 WWOX-8 cells per well were plated into 96-well plates. After 24 hrs the medium was removed 
and replaced with medium containing 0 or 200 ng/µl tunicamycin with or without 10 mM SP600125. 
Cell growth was determined with SRB assay following 72 hrs of drug exposure. The absorbance 
relative to untreated cells was designated as surviving cell proportion. 5 replicates, +/-SEM. p<0.001 
(***), p<0.05 (*). 
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Figure 6.17 
JNK inhibition in PEO1 WWOX-8 cells  antagonizes  the anti-mitotic action of paclitaxel 
 WWOX-8 cells were plated into 6-well plates (250 000/well). Following 24 hrs incubation the 
medium was removed and replaced with medium containing 8 nM paclitaxel with or without 10 mM 
SP600125. After 16 hrs of drug exposure floating and adherent cells were collected, fixed and 
analyzed by FACS. The percentage of cells stained by the MPM2 antibody was designated as mitotic 
index. 3 replicates, +/-SEM. p<0.001 (***). 
 
Figure 6.18 
There is no evidence of WWOX/JNK interaction in WWOX-7 cells following paclitaxel exposure 
WWOX-7 cells were grown in large dishes and treated with 8 nM paclitaxel for 6 or 16 hrs. 
Immunoprecipitation was conducted with goat anti-WWOX antibodies (N19, P20) and control goat 
antibody as described in Materials and methods and the precipitates analyzed with western blotting.
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6.2.10. WWOX and GRP78 expression predicts progression free survival in taxane treated 
ovarian cancer patients 
I used a publically available HGU133 microarray gene expression dataset (GEO GSE9899) derived 
from a population of ovarian cancer patients [226] to examine the impact of the expression of WWOX, 
and ER stress markers on clinical outcomes of taxane treated patients. Survival analysis was 
conducted with univariate log rank test, and this, including dichotomization of the samples for high- 
and low- expression groups for each gene, is described in Materials and methods. 
Survival data was available for 260 patients diagnosed with ovarian carcinoma. Of these 244 received 
chemotherapy. 243 patients were treated with a platinum-containing drug and 195 patients received a 
taxane (194 patients were treated with platinum and taxane). Clinicopathological characteristics of the 
patients are presented in Table 6.2. 
Total number of subjects 260 
Median age at diagnosis, years (range) 59.3 (22.9 – 80.0) 
Median OS, months (range) 29 (0-214) 
Median PFS, months (range) 15 (0-166) 
  
FIGO stage  
I 16 (6%) 
II 13 (5%) 
III 209 (80%) 
IV 21 (8%) 
unknown 1 (0%) 
  
Tumour grade  
1 11 (4%) 
2 95 (37%) 
3 152 (58%) 
Unknown 2 (1%) 
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Histology 
Endometrioid 18 (7%) 
Serous 242 (93%) 
Adenocarcinoma 1 (0%) 
  
Primary site  
Ovary 218 (84%) 
Peritoneum 34 (13%) 
Fallopian tube 8 (3%) 
  
Residual disease  
Nil 68 (26%) 
< 1 cm 77 (30%) 
< 2 cm 77 (30%) 
Unknown 38 (15%) 
  
Arrayed site  
Ovary 181 (70%) 
Peritoneum 69 (30%) 
Other 10 (4%) 
  
Chemotherapy  
Platinum 243 (93%) 
Taxane 195 (75%) 
Platinum only 49 (19%) 
Taxane only 1 (0%) 
  
Platinum and taxane 194 (75%) 
No chemotherapy 16 (6%) 
 
Table 6.2. 
Clinicopathological characteristics of 260 ovarian cancer patients from the publically available 
GSE9899 dataset 
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High WWOX expression predicted longer PFS (progression free survival) in the group of all patients 
(n=260, p=0.031) and patients who received taxanes (n=195, p=0.019), but not in the group of 
patients who did not receive taxanes (n=65, p=0.666), Figure 6.19 A-C. This is consistent with the role 
for WWOX in taxane response. It must be noted that most patients were treated with a taxane and a 
platinum drug, which is a standard therapy in ovarian cancer, and consequently it is not possible 
using this dataset to distinguish between an effect of WWOX on taxane or on platinum response. 
However, given our in vitro data demonstrating that WWOX has no effect on platinum response but 
produces a strong increase in paclitaxel-related apoptosis, it is most likely that the observed 
correlation of WWOX with longer PFS relates to taxane response.  
GRP78 is the best described marker of ER stress, regarded as a regulator of multiple arms of the 
unfolded proteins response, and transcriptionally up-regulated via a conserved ER stress response 
element (ERSE) in the promoter [311-316]. High GRP78 levels were associated with longer PFS in 
the group of all patients (n=260, p=0.001) and patients who received taxanes (n=195, p=0.003), and 
there was a trend for significance in the group of patients who did not receive taxanes (n=65, 
p=0.072), Figure 6.18 D-F. 
Both WWOX (p=0.032) and GRP78 (p=0.019) expression remain to be significantly associated with 
PFS in taxane treated patients (n=195) when controlled for debulking status (with optimal debulking 
defined as largest focus of residual disease <1 cm, information available for 222 patients), Table 6.3. 
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 All patients (n=260) Patients who received taxanes 
(n=195) 
WWOX 0.08 0.032 
GRP78 0.009 0.019 
 
Table 6.3 
WWOX and GRP78 association with PFS controlled for debulking status (p values, log rank 
test, significant p values in bold) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.19 (next page) 
WWOX and GRP78 levels predict PFS in taxane treated ovarian cancer patients.  
Kaplan–Meier survival curves (PFS= progression free survival) A-C. WWOX, D-F. GRP78. A,D. All 
patients (n=260), B,E. Patients who received taxanes (n=195), C,F. Patients who did not receive 
taxanes (n=65). 
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Although there was a trend for better overall survival (OS) for patients with high WWOX or GRP78 
levels, neither marker reached significance in OS analysis in all patients (WWOX, p=0.122 and 
GRP78, p=0.114), and only GRP78, but not WWOX status, was significantly linked with OS in 
patients who received taxanes (WWOX, p=0.198 and GRP78, p=0.027).  
As GRP78 is regarded as an anti-apoptotic protein, and well documented in vitro to support normal 
and cancer cell survival during the unfolded protein response, it is likely that its high expression does 
not cause longer PFS but rather is a marker of activated, pro-survival ER stress response pathways in 
tumours. Since prolonged activation of ER-stress results in induction of apoptosis, GRP78 might 
indeed correlate with apoptosis and longer PFS whilst itself being anti-apoptotic. If this is the case, 
and GRP78 associates with PFS because it marks tumours with high levels of uncompensated ER 
stress, then it would be expected that other transcriptional markers of ER stress are co-ordinately 
regulated with GRP78. To address this possibility, I examined the associations between the 
expression levels of nine ERSE/UPRE containing, ER stress markers (including GRP78) frequently 
described in the literature [311-316]. The names of the genes and primary references documenting 
the ERSE/UPRE elements in the promoters are gathered in Table 6.4. 
Gene Symbol Gene name Reference 
GRP78 glucose-regulated protein, 78 kDa [325-326] 
GRP94 glucose-regulated protein, 94 kDa [325] 
PDIA4 protein disulfide isomerase family A, member 4 [326] 
XBP1 X-box binding protein 1 [327] 
HERPUD1 homocysteine-inducible, endoplasmic reticulum stress-inducible, 
ubiquitin-like domain member 1 
[328] 
CALR calreticulin [325] 
CHOP/DDIT3 DNA-damage-inducible transcript 3 [327] 
EDEM1 ER degradation enhancer, mannosidase alpha-like 1 [329] 
P58IPK/DNAJC3 DnaJ (Hsp40) homolog, subfamily C, member 3 [330] 
 
Table 6.4 
Nine genes containing ERSE/UPRE elements in the promoter 
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There was a significant overlap (Fisher’s exact test) between samples with high GRP78 and samples 
with high levels of PDIA4 (p=0.001), P58INK (p=0.003), XBP1 (0.004), HERPUD1 (p=0.004) and 
calreticulin (p=0.002) but not CHOP, GRP94 or EDM1. Further, there is evidence of not only GRP78 
co-expression with a number of ER stress markers, but frequent co-expression of several of the other 
examined ER stress responsive genes in this dataset, Table 6.5. WWOX expression was not 
associated with GRP78 levels (p=0.294), neither with other tested ER stress markers apart from 
calreticulin (p=0.018), Table 6.4. This demonstrates that ‘GRP78 high’ tumours display up-regulation 
of a panel of transcriptional ER stress markers, and thus GRP78 signature likely marks the samples 
with high levels of uncompensated ER stress. 
Consistent with the link between WWOX and ER stress response, WWOX effects on PFS are more 
pronounced when controlled for GRP78 status: in all patients (n=260, log rank controlled for GRP78 
strata, p=0.005) and patients who received taxanes (n=195, log rank controlled for GRP78 strata, 
p=0.004). Unexpectedly, WWOX only affects PFS in the subgroup of ‘GRP78 low’ tumours: all 
patients (n=173, p=0.001) and patients who received taxanes (n=137, p=0.003), but not in the 
‘GRP78 high’ subgroup: all patients (n=87, p=0.925) and patients who received taxanes (n=58, 
p=0.469) (Table 6.6, Figure 6.20). WWOX status remains to be linked with PFS in the ‘GRP78 low’ 
group even when controlled for debulking status: all patients (n=146, p=0.01) and patients who 
received taxanes (n=120, p=0.015). 
The samples with high GRP78 expression related to good prognosis likely represent tumours with 
high levels of intrinsic ER stress leading to increased apoptosis, irrespective of chemotherapy, and it 
might be speculated that WWOX status has no impact on these tumours that are already 
characterized by activation of pro-apoptotic pathways. Conversely, WWOX appears to strongly affect 
PFS in the ‘low GRP78’ tumours, and this may correspond to tumours with intrinsically low, but 
chemotherapy-inducible, ER stress. 
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PDIA4 P58IPK XBP1 HERPUD1 CALR CHOP EDM1 GRP94 WWOX  
0.001 0.003 0.004 0.004 0.002 1.0 0.89 0.146 0.294 GRP78 
 0.001 0.005 0.124 0.000 0.04 0.419 0.002 0.125 PDIA4 
  0.004 0.524 0.895 0.097 0.000 0.054 0.202 P58IPK 
   0.001 0.005 0.71 0.018 0.455 0.456 XBP1 
    0.124 0.901 0.036 0.319 1.0 HERPUD1 
     0.082 0.239 0.081 0.018 CALR 
      0.117 0.212 0.32 CHOP 
       0.237 1.0 EDM1 
        0.318 GRP94 
 
 
Table 6.5 
Associations between the expression of ER stress markers and WWOX (p values, Fisher’s exact test, significant p values in bold).  
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Figure 6.20 
WWOX effects on PFS ovarian cancer patients are related to GRP78 levels. 
Kaplan–Meier survival curves (PFS= progression free survival) A. samples with low GRP78 levels 
(n=187), B. samples with high GRP78 levels (n=73).  
 
 
 All patients (n=260) Patients who received taxanes 
(n=195) 
All samples (n=260) 
 
0.031 0.019 
Samples classified as high 
GRP78 expression subgroup 
(n=87) 
0.925 0.469 
Samples classified as low 
GRP78 expression subgroup 
(n=173) 
0.001 0.003 
 
Table 6.6 
The association between WWOX and PFS, stratified by GRP78 levels (p values, log rank test, 
significant p values in bold) 
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6.3. WWOX as a pro-apoptotic tumour suppressor: discussion 
WWOX is a potent bona fide tumour suppressor gene as demonstrated by increased tumorigenicity 
rates in WWOX knock-out and hypomorph animals [86-87]. Xenograft models of several cancers 
showed that WWOX expression reconstitution abolished in vivo tumorigenicity of breast, prostate, 
ovarian, lung and pancreatic cancer cell lines and this was largely attributed to apoptotic cell death 
following WWOX transfection [42, 56, 62, 75, 91-92]. 
The reported down-stream effects of WWOX pro-apoptotic function vary between studies and include 
increase in sub–G1 cell cycle fraction (without otherwise modifying cell cycle profile), decreased 
growth rates, reduced clonogenic capacity, reduction in full–length PARP1 and pro–caspase 3 levels, 
increase in cleaved caspase 3 and 9 signal, decrease in the levels of anti-apoptotic Bcl2 and Bcl-xL or 
higher levels of pro-apoptotic Bax [25, 56, 62, 75, 92]. These changes however have the character of 
endpoint apoptotic read-outs that do not explain the mechanisms of WWOX induced cell death apart 
from pointing to caspase dependence and apoptosis, arguably with the exception of altered Bcl family 
proteins levels (but these are also likely effects of upstream apoptotic events).  
Attempts at elucidating the mechanisms were reported by the group led by Chang, but their relevance 
to the role of WWOX in tumorigenicity, demonstrated by other researchers, is not clear. Several of the 
experiments were conducted with a murine homologue. Unlike other laboratories Chang postulated 
that the WWOX apoptotic phenotype was independent of caspases. Surprisingly, transient expression 
of both the WW (amino acids 1-95) and SDR/ADH (amino acids 180-392) domain regions promoted 
cell death. The authors also reported an interaction between WWOX and p53 and suggest that 
WWOX loss abolishes pro-apoptotic function of p53 (whereas p53 loss did not abolish WWOX 
function) [25]. The interaction with p53 was not confirmed by Croce’s group [37]. The potential pro-
apoptotic interplay between WWOX and p53 does not appear to be important for the increased 
responsiveness of WWOX reconstituted PEO1 cells to paclitaxel and tunicamycin, as TP53 is 
mutated in PEO1 cells [Dr Simon Langdon, Edinburgh, unpublished data]. In conclusion, the data 
generated by Chang’s lab cannot be easily utilized to explain the pro-apoptotic effects of WWOX 
reconstitution in our experiments. 
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Much effort was invested in elucidating WWOX binding partners that interact with WWOX WW 
domains and these interactions were linked to gene expression regulation as discussed in 
Introduction and Chapter 5, but little attention has been paid to other regions of WWOX proteins 
despite the fact that the only two reported cancer-specific WWOX mutations altering amino acid 
sequence target the C-terminal SDR domain region (codons 291 and 329) rather than WW domains 
[23-24]. The bias for WW-domain dependent binding partners is the consequence of the fact that 
most studies aimed at elucidating the interaction of WWOX WW domains only. These reports provide 
no link to the pro-apoptotic phenotype driven by WWOX apart from some role ascribed to WWOX/p73 
interaction but the results are difficult to interpret as enhancement of apoptosis was not only seen 
when wild type WWOX and full length p73 were co-transfected, but was similar or even more 
pronounced when tyrosine 33 mutated WWOX or ΔNp73 isoform (both having no pro-apoptotic effect 
in single transfection) were co-transfected with the WT form of the other protein [37]. Also Croce’s 
group did not relate in their reports the WWOX binding transcription factors to the anti-survival effects 
of WWOX reconstitution in xenograft and cell line models. 
Our group have previously demonstrated that WWOX transfection had no effects on baseline or 
cisplatin-induced apoptosis, but more recently, during the course of my project, our collaborators 
demonstrated that WWOX may play a role in the death of cells in suspension (anoikis) [91]. This lack 
of WWOX-related baseline apoptosis is in disagreement with the studies from Croce’s lab discussed 
above but similar to the findings of Bednarek et al. where reduced tumorigenicity in vivo was not 
coupled with increased rates of in vitro apoptosis due to WWOX transfection but associated with 
reduced anchorage-independent growth in soft agar [42]. The data from our group pointing to WWOX 
role in apoptosis due to attachment loss underlie the possibility that WWOX apoptotic functions might 
be revealed in the conditions of specific cellular stress [91]. This is consistent with several studies by 
Chang that demonstrate WWOX pro-apoptotic function in response to TNF (tumour necrosis factor), 
UV irradiation, neurotoxic 1-methyl-4-phenyl-pyridinium or complement activation [25, 74, 331-332]. 
I propose that WWOX promotes apoptosis in cells undergoing ER stress / UPR as shown by 
increased sensitivity to ER stress inducing tunicamycin and paclitaxel. This is supported by the fact 
that WWOX and GRP78, ER stress response marker, levels are related to the progression free 
survival in taxane treated ovarian cancer patients and WWOX effects are related to GRP78 levels. A 
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programme termed ER stress response / UPR is an adaptive mechanism to re-establish homeostasis 
by up-regulation of ER chaperones and inhibition of translation, while persistent ER stress leads to 
cell death (Figure 6.12). 
Tumours reaching a macroscopic size that is in disproportion with their vascular supply are frequently 
subject to hypoxia, nutrient deprivation and pH alterations and yet they retain the capacity to grow, 
invade or metastasize. UPR mechanisms are activated in cancer as demonstrated by increased 
expression of ER chaperones in hypoxic tumours. A valid example is multiple myeloma whose cells 
are constantly subject to protein overload due to constant synthesis of monoclonal immnunoglobulin 
[311-312, 316] and, interestingly, there are recurrent translocations affecting the 16q23-24 region in 
multiple myeloma [18-19, 70] and WWOX is frequently lost in this neoplasia [19, 76, 83, 333-334]. 
Tumours resembling human multiple myeloma were also noted in Wwox–deficient mice [87]. 
XBP1 (X-box binding protein 1) binds to promoters and induces expression of several genes involved 
in UPR [311-312, 315]. Xbp1–deficient, spontaneously transformed, mouse fibroblasts were unable to 
form tumours in nude mice, unlike Xbp1 wild-type cells. In wild-type tumours XBP1 co-localized with 
areas of hypoxia. This difference in tumorigenic capacity was not reflected by altered in vitro growth 
rates, nor differences in the secretion of pro-angiogenic factors, and thus the authors conclude Xbp1 
supports tumour in vivo growth during hypoxia via activation of adaptive UPR response [335]. This 
resembles the consequences of WWOX reconstitution in ovarian cancer cells where dramatic 
abrogation of tumorigenicity is not accompanied by altered in vitro growth or apoptosis rates as 
reported by our group [91]. These observations could be explained by the potential role of WWOX in 
regulating the survival of tumour cells responding to hypoxia and nutrient deprivation by activation ER 
stress response. 
ER stress / unfolded protein response is believed to constitute an ancient evolutionary conserved 
mechanism preventing replication and spread of viruses by committing infected, viral protein 
overloaded cells, to suicide [311]. Consequently, experiments where viral delivery was used to 
reconstitute WWOX expression in cancer cells should be interpreted with caution as concurrent viral 
transduction may elicit ER stress and co-operate with WWOX over-expression to induce cell death. 
This may partly account for the discrepancies between those findings and the data from our lab where 
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the transfection of WWOX-expression plasmids, a gene delivery method that is not expected to 
induce ER stress, did not enhance apoptosis in baseline conditions [56, 62, 75, 92]. 
Interestingly, endoplasmic reticulum stress / unfolded protein response is strongly implicated in 
neurodegenerative disorders including Alzheimer’s, Parkinson’s and Huntington’s diseases and in 
transmissible spongiform encephalopathies [311]. WWOX was implicated in Alzheimer’s disease 
pathobiology [120] as well as in a Parkinson’s disease model [331] and a Wwox–mutated rat strain 
displays severe neurological deficiencies [220], and this could be related to WWOX function of 
modulating UPR toxicity to the cells of the nervous system. 
Further studies are needed to provide a mechanistic explanation for WWOX impact on cells subjected 
to prolonged ER stress / UPR. My data suggest WWOX is either down-stream of ER stress response 
modulating the apoptotic output, as UPR seems to be similarly activated in both WWOX–positive and 
–negative cells arguing against up-stream regulation, or may itself have a role in UPR. WWOX was 
shown to be a cytoplasmic protein with strong perinuclear signal, co-localizing with Golgi 58K protein 
marker [34, 42], although some studies described WWOX localization to other subcellular structures 
(discussed in detail in Introduction, Table 1.1). WWOX could be a chaperone, regulate protein 
trafficking or exert its role due to the postulated enzymatic activity of its oxidoreductase domain, and 
eventually modulate one of the main arms of UPR (PERK, IRE1 or ATF6-related as depicted in Figure 
6.12), or WWOX could alter the apoptotic pathways down-stream of UPR. Although WWOX was 
demonstrated to physically associate with JNK1 in the conditions of cellular stress [94] and JNK1/2 is 
activated in PEO1 cells following paclitaxel and tunicamycin exposure, I demonstrated that JNK1 is an 
unlikely mediator of WWOX pro-apoptotic effects. Interestingly, WWOX was proposed to interact with 
SCOTIN/SHISA5 [34] that was recently demonstrated to be a pro-apoptotic protein, whose subcellular 
localization in ER is suggestive of its involvement in ER stress response [97, 336]. 
Our group have recently obtained, from a commercial partner (Hybrygenics, France), results of a 
yeast-2-hybrid (Y-2-H) screen of candidate WWOX binding partners, but none of these putative 
interactions has been so far studied and thus validated in our laboratory. None of the targets is a 
transcription factor or a protein with a PPxY motif, but interestingly 5 out of 8 hits are implicated in 
protein folding, transport or localization as indicated by GO terms (process category), and this is 
consistent with the role for WWOX in ER stress response. The results of the Y-2-H screen are 
presented in Table 6.7. 
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My study provides novel insights into the function of the WWOX tumour suppressor and suggests that 
defective pro-apoptotic signalling during endoplasmic reticulum stress response may confer 
chemoresistance in a proportion of ovarian cancer patients. Adaptive UPR mechanisms could be 
targeted to increase chemotherapy efficacy. 
 
Gene Symbol Gene name Interaction 
confidence 
GO (process) 
YIPF5 Yip1 domain family, member 5 very high vesicle-mediated transport, 
protein transport, transport 
APOO apolipoprotein O very high transport, lipid transport 
OAT ornithine aminotransferase high visual perception 
TTC1 tetratricopeptide repeat 
domain 1 
good protein folding 
NSF N-ethylmaleimide-sensitive 
factor 
moderate protein transport, regulation 
of exocytosis, potassium 
ion transport, proteolysis 
VPS13D vacuolar protein sorting 13 
homolog D (S. cerevisiae) 
moderate protein localization 
GOLT1B golgi transport 1 homolog B (S. 
cerevisiae) 
moderate transport, protein transport, 
positive regulation of I-
kappaB kinase/NF-kappaB 
cascade 
SMPD4/NSMASE3 sphingomyelin 
phosphodiesterase 4 
moderate sphingomyelin catabolic 
process 
 
Table 6.7     
WWOX binding partners predicted in a yest-2-hybrid screen and their associated GO terms 
(www.ncbi.nlm.nih.gov/gene) 
 226 
 
Chapter 7. Discussion 
7.1. Synopsis of major findings 
The hypotheses behind this work were that WWOX exerts its tumour suppressive function via 
regulation of cancer cell gene expression or direct pro-apoptotic effects, and that natural variants of 
WWOX could act as genetic modifiers of normal bone physiology or ovarian tumorigenesis.  
WWOX was previously proposed to sequester a number of transcription factors in the cytoplasm due 
to physical interaction, and thus abrogate their function in the nucleus. I found no evidence for WWOX 
as an important regulator of transcription factor activity in the setting of ovarian cancer. WWOX 
transfection into WWOX-null PEO1 ovarian cancer cells did not alter the subcellular localization of a 
number of candidate WWOX-binding transcription factors, and neither was there evidence of their 
direct interaction with WWOX. Further, the WWOX-driven reduction in integrin α3 levels, previously 
documented by our group, is not due to transcriptional regulation, and there is no compelling evidence 
for WWOX regulated changes in gene expression in ovarian cancer cell lines. Finally, as WWOX was 
implicated in ERα signalling in breast cancer, a correlation between WWOX levels and the expression 
of a number of putative markers of anti-hormonal therapy response was evaluated in a panel of 
samples from a trial of letrozole in ovarian cancer. Again, there was no compelling link between 
WWOX and gene expression, but WWOX was positively correlated with therapy response. 
Consistent with previous findings from our group, I demonstrated that WWOX status has no impact on 
baseline or cisplatin-induced apoptosis rates in ovarian cancer cell lines. On the other hand I show 
that WWOX sensitizes ovarian cancer cells to paclitaxel, a major non-genotoxic chemotherapy drug in 
ovarian cancer. This is due to increased rates of apoptosis, independent of the anti-mitotic function of 
taxanes, and is not driven by integrin regulation. I demonstrate that paclitaxel elicits endoplasmic 
reticulum (ER) stress in ovarian cancer cells, and that WWOX decreases survival of cells exposed to 
tunicamycin, a classic potent inducer of ER stress response. I propose that WWOX sensitizes ovarian 
cancer cells to paclitaxel due to a pro-apoptotic role during taxane-driven endoplasmic reticulum 
stress. Further, by re-analysis of a publically available microarray dataset, I demonstrate that high 
WWOX levels predict longer progression free survival (PFS) in ovarian cancer. WWOX impact on 
PFS appears to be related to the levels of GRP78, the best established marker of ER stress, and this 
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demonstrates that the interplay between WWOX and endoplasmic reticulum stress is a clinically 
relevant phenomenon. 
I find no compelling evidence for a tumorigenesis or bone metabolism modifier role for the common 
natural polymorphic variants of the WWOX gene.  
7.2. The contribution to the field 
7.2.1. WWOX loss is linked to the major biological determinants of poor survival in ovarian 
cancer 
Ovarian cancer accounted for 205 000 cases and 125 000 deaths worldwide in 2002 and was the 
seventh cause of death from cancer in women, with the highest incidence in western, industrialized 
countries [337]. The cure rates in ovarian cancer are low and estimated at around one-third. This is 
mainly due to the facts that ovarian cancer typically presents as late stage disease because of high 
frequency of locoregional peritoneal dissemination, and displays very frequent occurrence of acquired 
chemoresistance. 
Transcoelomic dissemination and chemoresistance, two major causes of poor prognosis in ovarian 
cancer, are complex and multifaceted processes and little progress has been made towards their 
inhibition or reversal, or indeed towards their understanding at the molecular level. My study and 
previous data from our group suggest that WWOX may modulate both of these phenomena. The 
elucidation of the WWOX pathway should help to describe and eventually target these major 
determinants of poor prognosis in ovarian cancer. Our group has demonstrated that WWOX regulates 
ovarian cancer cell adhesion to extracellular matrix and promotes anoikis, and thus WWOX loss could 
be causally linked to transcoelomic spread due to promotion of peritoneal implants [91]. Consistently, 
low WWOX expression has been previously linked with late stage disease and poor survival in 
ovarian cancer [53]. The effects of WWOX loss on ECM adhesion could be potentially reverted with 
anti-integrin therapies. Although anti-integrin agents entered clinical trials mainly on the basis of 
postulated anti-angiogenic activity [200], the prevention of the reseeding of ovarian cancer cells within 
the peritoneal cavity could be attempted via intravenous or intraperitoneal administration of such 
agents. This strategy would probably be ineffective against already established peritoneal implants 
however. 
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On the other hand, I demonstrated that WWOX has a pro-apoptotic function during endoplasmic 
reticulum (ER) stress response. Apart from taxane or other anti-neoplastic therapy, ER stress 
response might be elicited in tumours by various microenvironmental cues including hypoxia and 
nutrient deprivation. It might be predicted that poorly vascularised tumours, such as peritoneal 
implants reaching a macroscopic size, are subject to endoplasmic reticulum stress and therefore 
WWOX loss could confer a selective survival advantage. Consequently, WWOX loss may contribute 
to various steps of locoregional peritoneal dissemination, including both the initial colonization and 
subsequent survival. The extent of the overlap of the up-stream regulation of the cell adhesion and 
ER stress response phenotypes within the WWOX pathway remains to be established. Potentially, 
WWOX loss may uninhibit an event common to both phenotypes and this could be targeted for 
pleiotropic effects on ovarian cancer cell ECM adhesion and peritoneal implant survival (as well as 
taxane response). For example, it could be speculated that the potential involvement of WWOX in 
protein transport or maturation could relate to both the effects on membranous integrin levels and ER 
stress outcomes. Such a role is suggested by the predominance of ER/Golgi- and protein transport-
associated WWOX binding partners identified in our Y-2-H experiment, although these interactions 
have yet to be confirmed. An intracellular pool of both α3- and α5β1- integrins is observed in the 
ER/Golgi compartment in some cells and increased maturation, mainly related to glycosylation, was 
shown to increase cell surface levels of those integrins [338-339]. Although WWOX link with the 
outcomes of ER stress response may be related to down-stream apoptotic pathways it is also 
possible that in baseline-conditions WWOX could have a chaperoning or enzymatic function in the ER 
and thus regulate integrin pools. 
The combination of platinums and taxanes is a standard therapeutic regimen in ovarian cancer. 
WWOX effects on taxane cytotoxicity might be a double-edged sword in the clinical setting. 
Conceivably, once defined, WWOX apoptotic pathway could be enhanced or restored to boost taxane 
response. Further, the components of the protective unfolded protein response (UPR) could be 
inhibited or ER stress provoked with other agents, concomitant to chemotherapy and this could 
increase cytotoxic effects on cancer cells. On the other hand, ER stress response is likely protective 
against taxane toxicity in non-neoplastic cells such as neurones and such approaches could 
exacerbate, for example, peripheral neuropathy. To my knowledge there are no reports on the role of 
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UPR in taxane neurotoxicity. Several studies demonstrated that other endoplasmic reticulum 
stressors promote neuronal or myelinating Schwann cell death however [340-342]. 
7.2.2. The link between WWOX, ER stress pathway and paclitaxel response poses questions 
on taxane biology 
My results, pointing to the significance of ER stress response pathways in paclitaxel-induced 
apoptosis, pose important questions on taxane biology. What is the relative impact of anti-mitotic 
actions on cancer cell death versus effects that are independent of mitosis? What proportion of the 
clinical benefit of taxanes is due to targeting dormant non-dividing cells? Would it be clinically 
advantageous to replace taxanes with more selective anti-mitotic or ER-stress inducing agents? 
These questions warrant further investigation into the significance or ER stress response in taxane 
response. It is probably not plausible to design a clinical trial that could answer any of those questions 
currently, but important lessons could be learnt in vitro to improve taxane efficacy, reduce toxicities 
and target resistance. Note should be also taken of that fact that microtubule-binding drugs display 
anti-vascular effects further emphasizing the significance of non-mitotic anti-neoplastic effects [343]. 
7.2.3. WWOX is implicated in anti-hormonal therapy response 
The other clinically relevant finding of my PhD is that WWOX levels predict anti-hormonal therapy 
response in ovarian cancer and this is especially pronounced in ERα-positive disease. Anti-hormonal 
strategies play a prominent role in breast cancer prevention and therapy but proved, so far, largely 
disappointing in ovarian cancer despite strong links between ovarian tumorigenesis and sex hormone 
signalling [193, 196]. Ultimately, WWOX levels could help to identify patients likely to benefit from this 
therapeutic approach, especially by measuring WWOX status in patients with ERα-positive tumours. 
Apart from the need for successful validation in an independent patient population, it remains to be 
established whether this is a sex hormone signalling-specific effect or due to more universal effects 
on cancer cell survival. Interestingly, in breast cancer cells in vitro the over-expression of the spliced 
isoform of XBP1 (typically induced during ER stress) conferred tamoxifen resistance on ERα-positive  
cell lines [344] and oestrogen stimulation induced ER stress response markers [345]. It would be thus 
important to establish whether WWOX effects on anti-hormonal treatment are dependent on ER 
stress response pathway.  
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7.2.4. The impact on apoptotic outcomes of ER stress response may explain the tumour-
suppressive function of WWOX in vivo 
Tumour suppressor genes are targets for therapeutic intervention in cancer through the restoration of 
their function or manipulation of their associated pathways. Animal models provided evidence for 
WWOX as a bona fide tumour suppressor [86-87] and WWOX has been implicated in most common 
malignancies in humans, perhaps with the exception of leukemias, colorectal and kidney cancers 
(Table 1.2).  
Unlike several studies [99], neither my results nor the previous data from our laboratory demonstrate 
apoptotic effects directly following WWOX transfection. This discrepancy might be due to true 
biological differences between different neoplasia and their cell line models or because different 
experimental systems were used. In particular, experiments where viral delivery was used to 
reconstitute WWOX expression in cancer cells should be interpreted with caution as concurrent viral 
transduction may elicit ER stress and co-operate with WWOX over-expression to induce cell death. 
On the other hand, more similar to my results, WWOX was also reported to promote cell death in 
response to specific stimuli such as TNFα stimulation or loss of ECM attachment [25, 91]. 
As reported by our group the abrogation of in vivo tumorigenicity due to WWOX expression 
restoration in ovarian cancer cell line was not accompanied by a change in baseline in vitro 
proliferation or apoptosis rates [91]. Previously proposed to be due to the regulation of cancer cell-
ECM interactions, this impeded growth of xenografted tumours might be also due to an anti-survival 
role of WWOX during ER stress response in such implants subject to nutrient or oxygen deprivation 
as well as other stresses such as pH alterations. This mechanism could account for WWOX effects in 
various reported xenograft models of cancer, and indeed explain WWOX tumour suppressive function 
in vivo in human neoplasia. WWOX loss might be necessary for a switch enabling tumours to survive 
under microenvironmental stress in tumours reaching a macroscopic size. WWOX might be uniqely 
important in the setting of multiple myeloma whose cells are constantly subject to ER stress as a 
consequence of protein overload due to synthesis of monoclonal immunoglobulin [311-312, 316]. 
Interestingly, there are recurrent translocations affecting the 16q23-24 region in multiple myeloma [18-
19, 70] and WWOX is frequently lost in this neoplasia [19, 76, 83, 333-334]. 
 231 
 
The convergence between a tumour suppressor gene pathway and UPR strengthens the notion that 
UPR should be considered a potential therapeutic target in cancer and such strategies are already in 
pre-clinical development. Widely, they can be divided into those aiming at disruption of UPR 
components (for example versipelostatin that inhibits GRP78 expression) or inducing ER stress that 
cannot be compensated (proteasome inhibitors such as bortezomib, HSP90 chaperone inhibitor 
geldanamycin or brefeldin A that inhibits protein transport) [314]. Recently, Saito et al. demonstrated 
that antidiabetic biguanides induce massive cell death in various cancer cells subject to glucose 
deprivation and this is due to inhibition of pro-survival UPR mechanisms. They propose that targeting 
UPR during glucose deprivation can provide selective cancer cell killing [346].  
7.2.5. WWOX role in metabolism 
Several lines of evidence link WWOX and metabolism in humans and in rodents including severe 
metabolic syndrome in Wwox knock-out animals [89, 114], genetic association with HDL cholesterol 
levels in humans [217], associations with hormonal signalling in cancer [52] and the structural 
predictions of a putative enzymatic function of WWOX [20].  
I found no evidence for a link between the polymorphic variants of WWOX and bone mineral density, 
incidence of osteoporotic fractures and serum markers of bone remodelling in a large population of 
postmenopausal women, despite animal models displaying severe bone defects in Wwox knock-out 
animals. Although unsupportive for WWOX role in metabolism this might be explained for example by 
the fact that the effects of those variants on WWOX expression or function might be too subtle to 
result in significant associations. Alternatively this might be due to differences in WWOX metabolic 
function in rodents and humans. 
Interestingly, ER stress has been implicated in several diseases including neurodegeneration, 
atherosclerosis, stroke, heart disease and in particular diabetes. Pancreatic β-cells secrete large 
amounts of insulin and other glycoproteins. Loss of protective ER stress response mechanisms was 
implicated in β-cells death in mice knock-out models of Perk and Xbp1, and mutations of genes 
coding UPR components were identified in hereditary syndromes, in which diabetes develop. Further, 
obesity that contributes to type 2 diabetes development was shown to induce ER stress. In summary 
there is evidence for ER stress response activation in diabetes and there is a need to understand 
what factors decide on the cytoprotective or apoptotic outcomes of this [311, 347]. WWOX pathway 
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could be implicated in the fate of pancreatic β-cells and possibly other secretory cells under ER stress 
although WWOX was not linked with diabetes so far. On the other hand, defects in secretory cells 
could potentially contribute to the observed link between Wwox loss and endocrine deficiencies in 
animal knock-out models [89, 214, 220]. Consistently, in humans WWOX was shown to be most 
strongly expressed in secretory epithelial cells of the reproductive, exocrine and endocrine systems, 
including pancreatic cells [39]. Further, WWOX involvement in ER stress response pathways should 
be considered when attempting to study the reported links between WWOX and neurodegeneration or 
cholesterol levels [120, 217, 331]. 
7.2.6. WWOX as a common fragile site gene 
Common fragile sites and their associated genes display evolutionary conservation. Because of this 
and despite the propensity towards genomic disruption, CFSs are believed to have functional 
significance [2-5]. There is accumulating evidence for a tumour suppressor role for several CFS-
associated genes and for their involvement in stress response pathways. FHIT (FRA3B) [348], 
PARKIN (FRA6E) [29] and WWOX (FRA16D) [86] were shown to be bona fide tumour suppressor 
genes in animal knock-out models and similar function is postulated for RORA (FRA15A), DAB1 
(FRA1B) and GRID2 (4q22) [2-3, 28]. This argues against the possibility that CFS genes are ‘innocent 
by-standers’ in cancers, preferentially disrupted because of CFS fragility in genetically unstable 
tumours. Common fragile site genes seem to be co-regulated in cancer and the well documented co-
ordinate loss of WWOX and FHIT is a particularly valid example [47, 49-50, 57-58]. Smith et al. 
hypothesised that common fragile site genes may form a stress response system [2] and indeed 
several CFS genes including RORA [349], PARKIN [350] and WWOX [351] have been implicated in 
stress response. At the same time it is to some extent paradoxical that genes postulated to be co-
ordinately involved in response to cellular stress should be located within common fragile sites and 
thus prone to disruption, including such promoted by cellular stressors, the response to which they 
are expected to regulate. Nevertheless, cancer cells could select for co-ordinate loss of CFS tumour 
suppressors to gain a survival advantage in exposure to various stressors. Consistent with the 
hypothesis proposed by Smith, I demonstrated that WWOX is involved in ER stress response and 
hypothesise that WWOX loss may allow cancer cells to survive certain microenvironmental conditions. 
Interestingly, hypoxia that leads to UPR is a potent CFS inducer [352-353]. Consequently, although 
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this is purely speculative, similar conditions could be impacting on WWOX status and be regulated by 
WWOX. While surprising, this could for example represent a developmental mechanism where cues 
such as hypoxia change the expression of CFS genes to regulate the differentiation or allow for 
survival of some developing tissues. Such a mechanism could then potentially be hijacked to the 
selective advantage of cancer cells.    
7.3. Future directions 
The genetic association studies examining a link between WWOX and clinicopathological features in 
ovarian cancer or bone metabolism parameters do not warrant further investigation apart from the 
potential role of the rare coding non-synonymous rs7201683 variation that might be linked to 
unfavourable patient outcomes in ovarian cancer as discussed in Chapter 3. I suggest a replication 
study into the association between this SNP and survival in ovarian cancer. The role of this variation 
could be also tested in vitro by demonstrating its impact on WWOX regulated phenotypes, including 
apoptotic response to ER stressors, as compared to wild-type protein. 
I propose a validation study into the association between WWOX levels and letrozole response in 
ovarian cancer. This should be followed by in vitro verification of the impact of WWOX status on cell 
death or growth inhibition due to hormonal deprivation and ultimately further mechanistic experiments.  
WWOX effects on anti-hormonal treatment could be dependent on ER stress response pathway and 
this could be tested in vitro (e.g. following genetic depletion of major UPR components). I also 
propose to test whether there is evidence of ER stress response activation in the clinical samples 
from patients treated with anti-hormonal therapy by assessing the expression of relevant markers.  
Further studies are needed to find a mechanistic explanation for WWOX pro-apoptotic actions in the 
condition of ER stress/UPR. WWOX effects on cell survival should be examined in vitro using further 
stimuli that may, similarly to paclitaxel or tunicamycin, evoke UPR and which have a potential clinical 
utility or relevance, such as proteasome inhibitors and hypoxia. This will extend the spectrum of stress 
conditions where WWOX is predicted to play a role and which should be investigated to understand 
its effects. Further, I propose to test whether viral transduction preferentially promotes cell death in 
WWOX- versus vector-transfected cells so as to verify whether gene delivery method may account for 
the discrepancies in the published data on WWOX. 
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Most importantly, it needs to be defined, which arms of the ER stress response are altered by WWOX 
or what downstream effectors of UPR driven apoptosis collaborate with WWOX, as well as which 
structural motifs/domains of WWOX are responsible for the phenotype. I propose to compare the 
effects of the knock-down of important components of the ER stress response (in particular IRE1, 
PERK, ATF6, XBP1) on paclitaxel or tunicamycin response on a WWOX-positive and WWOX-
negative background (such as provided by WWOX- or vector-transfected PEO1 cells). This could help 
to understand, which arm of the UPR is influenced by WWOX status. I postulate a time course gene 
expression microarray or protein array study comparing the profile of paclitaxel/tunicamycin treated 
cells dependent on WWOX status to define the UPR components altered by WWOX. In parallel, the 
WW and SDR domains of WWOX should be disrupted and the ability of the mutant proteins to 
promote apoptosis during ER stress should be tested in vitro. The putative WWOX interactions 
identified by our yeast-two-hybrid screen, some of which are linked with ER related processes (Table 
6.7), should be validated in baseline and cellular stress conditions. Validated candidates should be 
tested for their impact on paclitaxel/tunicamycin response.  
The co-operation between WWOX and ER stressors such as paclitaxel, proteasome inhibitors, 
nutrient deprivation or hypoxia, as well as the effect of WWOX on intrinsic ER stress response 
pathways, could be also tested in xenograft models. The extent of ER stress marker events and 
apoptotic outcomes should be documented in tumours with differential WWOX status. Eventually, it 
would be important to assess spontaneous or carcinogen-induced neoplasia formation in Wwox 
knock-out animals crossed with Grp78- or Xbp1- knock-out or wild-type animals (or other models 
where a pro-survival component of UPR is disrupted), which could provide evidence that WWOX 
tumour suppressor function is due to modulation of the outcomes of the endoplasmic reticulum stress 
in vivo. 
7.4. Concluding remarks 
I demonstrate a novel role for WWOX in ER stress and show its impact on ovarian cancer cell 
chemoresponse. This function of WWOX might be also linked to its tumour suppression. This work 
indicates WWOX as a potential predictor of taxane and anti-oestrogen therapy response and 
suggests avenues to enhance taxane response or develop novel therapies for ovarian cancer. 
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Appendix 1 
Quantitative RT PCR primers 
name gene Sequence 
PPIA F 
PPIA R 
peptidyl-prolyl cis-trans isomerase A; ctgcactgccaagactga 
gccattcctggacccaaa 
aTUB F 
aTUB R 
tubulin, alpha 1b gccaagcgtgcctttgttc 
cacaccaacctcctcataatcc 
PLCe F 
PLCe R 
phospholipase C, epsilon 1 tgacacaatggattaccgaca 
gtgccattttgcttctcctc 
Rac2 F 
Rac2 R 
ras-related C3 botulinum toxin substrate 2 gcaagacctgccttctcatc 
ttgctgtccaccatcacatt 
VAV3 F 
VAV3 R 
vav 3 guanine nucleotide exchange factor tttccttttcccagcatgac 
gggcaatgagtcaccttgtt 
IGFBP3 F 
IGFBP3 R 
insulin-like growth factor binding protein 3 agggcactctgggaacctat 
tgatgcctctgaatgtggag 
TFPI2 F 
TFPI2 R 
tissue factor pathway inhibitor 2 cgcaccaaagaaaattccat 
attgtcattccctccacagc 
ITGA3 F 
ITGA3 R 
integrin, alpha 3 tgaaggcacgagtgtggaa 
gatgctggttcggaggaatagg 
ITGB1 F 
ITGB1 R 
Integrin beta 1 atcccagaggctccaaagat 
cccctgatcttaatcgcaaa 
ITGA2 F 
ITGA2 R 
integrin, alpha 2 gatttgcgtgtggacatcag 
tgagcagctggtatttgtcg 
Ecad F 
Ecad R 
cadherin1 (CDH1) ggcttccctctttcatctcc 
tctttggctgcagcacttta 
NEDD9 F 
NEDD9 R 
neural precursor cell expressed, 
developmentally down-regulated 9 
cttcctgtggccagtgtgta 
gcttgtggtgtctgtgctgt 
ESR1 F 
ESR1 R 
estrogen receptor 1 taaatgctgccatgttccaa 
aatgcaaaggggtctgtgtc 
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VEGFA F 
VEGFA R 
vascular endothelial growth factor A tcctcacaccattgaaacca 
gatcctgccctgtctctctg 
FN1 F 
FN1 R 
Fibronectin 1 tccaatccagaggaacaagc 
tgatgcttggagaagctgtg 
TGFBI F 
TGFBI R 
transforming growth factor, beta-induced, 68kDa atggggactgtcatggatgt 
tgtagactccttcccggttg 
GABBR2 F 
GABBR2 R 
gamma-aminobutyric acid (GABA) B receptor, 2 cttccagcacagccctctac 
attcaggcctttcttgagca 
CD90 F 
CD90 R 
Thy-1 cell surface antigen atcatccctccctgcctaag 
gacagcctgagagggtcttg 
ARHGAP26 F 
ARHGAP26 R 
Rho GTPase activating protein 26 tacctggagcagtcctggag 
aggttgattctggcatctgg 
WWOX rt5 F 
WWOX rt5 R 
WW domain containing oxidoreductase aggtccaagctctgcaacat 
gcagtgtgtacacccaccag 
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Appendix 2 
Antibodies used for western blotting and immunoprecipitation 
Antigen Species Clone* Epitope* Supplier Catalogue No WB (dilution) IP‡ 
Ack1 mouse   donated by Prof N. Mahajan  1:2500  
β-actin mouse AC-15  Sigma A5441 1:20000  
AP2γ mouse 6E4/4 C-terminus Upstate 05-909 1:1000  
AP2γ goat V-18  Santa Cruz sc-31935  + 
Bcl-xl rabbit 54H6  Cell Signalling 2764 1:1000  
c-Jun mouse 6A6.2  Chemicon MAB3731 1:1000  
cleaved caspase 3 mouse  Asp175 cleaved R&D MAB835 1:1000  
total-eIF2α rabbit  C-terminus Cell Signalling 9722 1:1000  
phospho(Ser51)-eIF2α rabbit 119A11  Cell Signalling 9721 1:1000  
ErbB2 rabbit   Cell Signalling 2242 1:2000  
Erα mouse 6F11  ABDSerotec P03372 1:1000  
Ezrin mouse 4A5  Chemicon MAB3822 1:1000  
goat IgG (HRP) rabbit   Dako P0449 1:2000  
GRP78 mouse 474421  R&D MAB4846 1:20000  
Hsp60 rabbit   Abcam ab-46798 1:20000  
human IgG goat   Pierce 31121  + 
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human IgG mouse HP6017  Chemicon MAB1302  + 
α2-integrin mouse P1E6  Chemicon MAB1950Z  + 
α3-integrin mouse P1B5  Chemicon MAB1952Z  + 
β1-integrin mouse P4C10  Chemicon MAB1987Z 1:2000  
JNK1/JNK2 mouse 252323  R&D MAB2076 1:10000  
phospho(T183/Y185)-JNK rabbit   R&D AF1205 1:1000  
Lamin A/C mouse 14  Chemicon 05-714 1:2000  
mouse IgG (HRP) goat   Dako P0447 1:5000  
p53 mouse DO-1 amino acids 11-25 Santa Cruz sc-126 1:1000  
rabbit IgG (HRP) goat   Dako P0448 1:2000  
β-tubulin rabbit H-235 amino acids 210-444 Santa Cruz sc-9104 1:1000  
WWOX rabbit   donated by Dr M. Aldaz  1:1000  
WWOX goat N-19 amino acids 50-100 Santa Cruz sc-20528  + 
WWOX goat P-20 amino acids 100-150 Santa Cruz sc-20529  + 
*-where provided, WB –western blotting, IP –immunoprecipitation, ‡-use for immunoprecipitation is indicated with a ‘’+’’ sign 
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Appendix 3 
PCR and Massarray extension primers used for genotyping each SNP 
SNP name Multiplex Forward PCR primer Reverse PCR primer Extension primer 
rs11645081 1 acgttggatgacctactgaatcagcactgg acgttggatgtcaagctagggaacatcagg ttgcaatctgcgctc 
rs2287972 1 acgttggatgggagaagtaaagaccatccc acgttggatgttgatgtgacaactgctggg ccctgggtcaggaag 
rs424074 1 acgttggatgcccttccaaatcatccagag acgttggatgtagactaaccctccctaagc agggagtgtgaggct 
C1442T 
a
 1 acgttggatgaagtggagctcagagcggat acgttggatgctgtgttggagggacatttg gagtgccagggctggg 
rs2288035 1 acgttggatggctaggcataggtctctttg acgttggatggggagatacggaacctacac ctctttgctttctggtg 
rs1813526 1 acgttggatggtagctggctgttttgtgag acgttggatggggcatacgtgtaaatgaac agggaggatttcaggac 
rs398255 1 acgttggatggaaaatcccctgtgctgaag acgttggatgttccagatgaggagactgag aagccagaagtccttaca 
rs8061268 1 acgttggatggtctagctttatgaaagggc acgttggatgtgctattaagctgatgggac cgcctatgcatagagtca 
rs12445829 1 acgttggatgctggatgatttggaagggag acgttggatgtttagccagaccactgagcc gaaatggtgaaaggactg 
rs12325408 1 acgttggatgccatgattgcaactaggaga acgttggatgcatagacagagaaaagtaag tgcaactaggagactgtta 
rs11150144 1 acgttggatggagtcgtatcacttgactgc acgttggatgttagcttcttcagtgtcagg cagttttcagaccaactcca 
rs7192129 1 acgttggatgatttccagcagcagagctcc acgttggatgtgtacaggtgagaggaacag agcagcagagctccagtagc 
rs11150046 1 acgttggatgccattgcaccattcataccc acgttggatgcgaagcctaacagatgtcac ttgcagagaggatgtgaagt 
rs270422 1 acgttggatgggactggtatttttctgccc acgttggatgtttcccacaggacagagttc aaaactgaatgtagactcact 
rs2303190 1 acgttggatgcgcattttagaagaatgggt acgttggatgcacactccactgaaatctcc gggttgtcaaatacacatgcc 
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rs4887937 1 acgttggatgtttctctcccagatagccag acgttggatgtaaagttgaccccgtagctg ggccagatataagaaggaagt 
rs8056446 1 acgttggatgtgcaagctcccttgcatttc acgttggatgtccagtaaagttcttggccc cccttgcatttcacaaatgtca 
rs10492874 1 acgttggatgcctttcccagaaaaaagtgc acgttggatgaagctgtggctaatttagag tatgttagatactccagttcatt 
rs10871347 1 acgttggatgccattccgtccaagatcttc acgttggatgatgcaagcaacacagtgacc ggggtgtgtgaagtcccgggctc 
rs1469117 1 acgttggatgaggaataagcattttggtc acgttggatggtgaacccacagcaatgaac gtggtctatgaaaaatggggttt 
rs17572124 1 acgttggatgctcctgctgagatgttttag acgttggatggtactgtccatgttatcctg ctgagatgttttagatgctccaaa 
rs11644126 1 acgttggatgaaggaacgatgggtaggatg acgttggatggagcctaaaagtaggtggag tatgggtaggatgctgaggagtaa 
rs11150044 1 acgttggatgtctgggatcactggtctatc acgttggatgtaattgggtccctgtgagtc ctataaaacagcaaattctatcatc 
rs400497 1 acgttggatgagccacaacagtctaggaag acgttggatgtcgtttgttaacagagggg tattcagctttaaagagtttgagag 
rs12932880 1 acgttggatgccagagatgcagaaagtaac acgttggatgctcacagatttcactcttacc acataaagggtaacgacatgttaaga 
rs11150047 1 acgttggatgagagatgtgaggtgaggaag acgttggatgctatatcatcccccaactcc gatgtgaggtgaggaaggacctgaag 
rs16947106 1 acgttggatgttggccactgtcacagtttg acgttggatgtgctgaaacagggagagttc ataagttgggttcaaaagataaattac 
rs16947129 1 acgttggatggaaaacggacattcacaggg acgttggatgttaatggtgttggtgttccc cgttaaagatttcacggtttatccaaag 
rs442608 2 acgttggatgacaggcttctgttcagagag acgttggatgggcatcatatttgggatggc tggcctttcctgttt 
rs12446313 2 acgttggatgtcaagtgatacgactctggg acgttggatgcagtatcatcaagcagccag ggtgtggaccgtgag 
rs7206823 2 acgttggatgcattatgtgattgcagcctc acgttggatgtactgagtgctccctatctg ttgcagcctcattgat 
rs2161636 2 acgttggatggaggaacaaatctaatggctg acgttggatggatctgtagctaaacaaaaag ggctgatttaggatgcg 
rs368920 2 acgttggatgctgccaataaaagagaaagc acgttggatgcccaaaaggtggtatgaatg gcactttaatcaccatca 
257 
 
rs16947220 2 acgttggatgcagaggagaaacggtccttg acgttggatgggctgcttcatctacagttg tggtgataaaacttccct 
rs1129030 2 acgttggatgatgcatgctgctattctagg acgttggatggttttttcccctctgttaa tgaaggcatgtacttgaa 
rs11642734 2 acgttggatgcctactgcacacatggtttg acgttggatgataggaaaaggctacgtggg aaaaagaagatggagctac 
rs2303191 2 acgttggatggaaatctccatatggttagc acgttggatgagcagtgtcacgcattttag aacaacaacaacagtcaagc 
rs1553723 2 acgttggatggtaaaacaaacagcttctccc acgttggatgcagccagctacttggttttc gaacagcttctcccttccctt 
rs11545028 2 acgttggatgagttcctgagcgagtggac acgttggatgtgtcgtccagccccgcgta agggccaggtgcctccacagt 
rs12927043 2 acgttggatgattctcctctcttcgagtcc acgttggatggccattctccctgacaaaag cacctcttaaaacttcttagtg 
rs8049744 2 acgttggatgccttattacctggtgacacg acgttggatgttcatttcagaccaccaccc tgtttctagttattgacctatg 
rs7190335 2 acgttggatgagcaggacttaacaggtttg acgttggatggctaccaagaaatctgtggg ggtttgtttgggaaaataaaat 
rs 383362 2 acgttggatgcagatccgcaagagtaaagg acgttggatggaattccctgcttcccattg gaagagtaaaggaaataagagca 
rs4887935 2 acgttggatgttgagattacaggcgtgagc acgttggatgccaggaaatgatagtgaagc cgccactgcgcctagccaggagta 
rs441004 2 acgttggatgtatgcaacaccttagcatag acgttggatggagtagtcagcacatgcata acagttacaaaggtatgtcttttt 
rs2072587 2 acgttggatgttctggaggccagaagatag acgttggatgaaccccatttttcatagacc agaagatagattcagtgggccccag 
rs17649341 2 acgttggatgcaaggcaccgtctcaaaaaa acgttggatggatcttttgcttttacatc catcttccattacaatttttattgtg 
rs11645006 2 acgttggatggcttgttggctctgatttgg acgttggatgtccctttcctaacacttccc ctggaaatgccttcagcacggtgaac 
rs8059793 2 acgttggatggaaatggaaaaggtgcaaag acgttggatggacctctgttctaaagagtg caaagtaatttaaatacctacttatct 
rs12828 2 acgttggatgttcctgcctttcaaggtatc acgttggatgcttgtcatagactcctttgc tttgttataatctctaaagaattttttg 
rs6564537 3 acgttggatgtcgtccaagagtacacacag acgttggatgtaaacagagagtgggcagag acacacaggcctgat 
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rs7201683 3 acgttggatgacttgaaaggtggtctccag acgttggatgtcatgtgcttgtgtgcaacg gtgagactccagggta 
rs6564559 3 acgttggatgccatacctttcagatactctc acgttggatgtccaaggtatgggacatgac aaatccttgtccctgtt 
rs7198580 3 acgttggatgaatcttagcaggagcaggag acgttggatgcgtgatccagtatgcctaag aatagggggaggtgata 
rs8055871 3 acgttggatgacaagctgtgggttactagg acgttggatgtagggcaagagaattgcctg tagtgattcaagtccaca 
rs3897139 3 acgttggatggcccttctctctctttttcc acgttggatgtgatcatgctactgcactcc agacaggttctggctctg 
rs9938424 3 acgttggatgctcatgatgaaaaagggtgc acgttggatgcagctgtggtttactactcc gaaaaagggtgctagtaaa 
rs11646795 3 acgttggatgttacccttgaccactggaac acgttggatgtcggtccttacactaacctg ccatgtcaccagctttctga 
rs4083383 3 acgttggatgaatgcttgaatggttgccgc acgttggatgctagacattcgtcggcaaag ccatagactgtctggctgat 
rs7192626 3 acgttggatgtccctccctctttctcatag acgttggatgtggtcccttaaatctgttgc atcaggattcaaataaggtc 
rs9923888 3 acgttggatggagaccaccaggaatttttc acgttggatggtgtatgtactgatgttctgg ggttcaccatttgcaacttct 
rs9928827 3 acgttggatgccaggtctggcagtgaatc acgttggatgcagtttggccatgttttgtg ggagggcagtgaatctgcaac 
rs11150075 3 acgttggatgttggaccatcagcaacacac acgttggatgctctggagctcagtttaatg catcattgtacatggaatactt 
rs9921967 3 acgttggatgcagagtacttctctctagac acgttggatgtttcctattgccattaggag accgaggaaattttcaaatgtc 
rs13331309 3 acgttggatgaaccacagaaactcaaaccc acgttggatggtcagggtttcaacatttgg acctcaaaccctttttccaagtc 
rs11643643 3 acgttggatgtaggacttggattagagccc acgttggatgaagtgtcctgttcagggatg gatgggcagccaagataaaccag 
rs8046289 3 acgttggatgggtttttggtattttccaac acgttggatgggtagattttatggtatgtgc ccaacttttctacaataagcatta 
rs3764340 3 acgttggatgcctgttataagccagcatcg acgttggatgacgactccttgggaaaactg tcgtccaatagtcgttttttgttg 
rs4130513 3 acgttggatgacacaagcacatgaagaggc acgttggatggcatggattatccttggttg gaagaggcctgaaaaataaaatat 
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rs4129722 3 acgttggatgaggagcttgaagtatagtcg acgttggatgttgttcgcctgtgattgtgg aagtatagtcgtaaaaacaatcttc 
rs421405 3 acgttggatgagatcggaaatggcattcgg acgttggatgtaggttgttgacgacacagg agtcgggcatgattaaaaagattct 
rs7200731 3 acgttggatggcagtttgaatacaaccctc acgttggatgtacgtcattatgtccaaagc ttcaaacttacttacatccattggtc 
rs12918952 3 acgttggatgttcagcaaaatgctgcacgc acgttggatgtctcattgcagcataaagcc ttgaagagcgaggtccagggtcattg 
rs4887940 3 acgttggatgcacactcacattctgttctg acgttggatggaagtagatctatatgcac ctttttttttttttaaacttagtactg 
rs12446823 3 acgttggatgacaacagccttgcattctcc acgttggatggttccagtggagggttatag gctctgataaagatattacaatagcaa 
a
 SNP C1442T had not been previously reported in the HapMap database and does not possess an rs######  identifier. C1442T identifier was utilised to 
indicate that it is a C/T polymorphism at base +1442 from the start codon in the WWOX transcript (GenBank AF211943). 
 
260 
 
Appendix 4 
Genes up-regulated at ≥ 2-fold in pooled WWOX-transfected (WWOX-6, -7, -8) cells versus Vector-
transfected (Vector-9, -p1, -p2) in HG-U133A microarray experiment 
 
Affymetrix probe Fold 
change 
Gene 
209990_s_at 9.44 gamma-aminobutyric acid (GABA) B receptor, 2 
205421_at 7.11 solute carrier family 22 (extraneuronal monoamine 
transporter), member 3 
215729_s_at 6.90 Vestigial like 1 (Drosophila) 
205487_s_at 6.36 vestigial like 1 (Drosophila) 
AFFX-HUMRGE/M10098_5_at 5.09  
201042_at 5.09 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) 
211679_x_at 5.03 gamma-aminobutyric acid (GABA) B receptor, 2 
212143_s_at 4.64 Insulin-like growth factor binding protein 3 
211959_at 4.56 Insulin-like growth factor binding protein 5 
217077_s_at 4.42 G protein-coupled receptor 51 
206421_s_at 4.11 serpin peptidase inhibitor, clade B (ovalbumin), member 7 
204363_at 4.09 coagulation factor III (thromboplastin, tissue factor) 
209277_at 3.98 Tissue factor pathway inhibitor 2 
210095_s_at 3.59 insulin-like growth factor binding protein 3 
205924_at 3.50 RAB3B, member RAS oncogene family 
217280_x_at 3.49 gamma-aminobutyric acid (GABA) A receptor, alpha 5 
209278_s_at 3.47 tissue factor pathway inhibitor 2 
213280_at 3.43 GTPase activating Rap/RanGAP domain-like 4 
207627_s_at 3.26 transcription factor CP2 
205581_s_at 3.24 nitric oxide synthase 3 (endothelial cell) 
206032_at 3.19 Desmocollin 3 
204222_s_at 3.12 GLI pathogenesis-related 1 (glioma) 
218888_s_at 3.12 neuropilin (NRP) and tolloid (TLL)-like 2 
206710_s_at 3.11 erythrocyte membrane protein band 4.1-like 3 
218182_s_at 3.11 claudin 1 
218656_s_at 3.11 lipoma HMGIC fusion partner 
203147_s_at 3.07 Tripartite motif-containing 14 
211003_x_at 3.07 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) 
208394_x_at 3.03 endothelial cell-specific molecule 1 
209991_x_at 3.02 gamma-aminobutyric acid (GABA) B receptor, 2 
212681_at 2.95 Transcribed locus 
211719_x_at 2.90 fibronectin 1 
204040_at 2.89 ring finger protein 144 
221147_x_at 2.85 WW domain containing oxidoreductase 
211573_x_at 2.84 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) 
213940_s_at 2.82 Formin binding protein 1 
201739_at 2.77 serum/glucocorticoid regulated kinase 
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218717_s_at 2.76 leprecan-like 1 
209465_x_at 2.75 Pleiotrophin (heparin binding growth factor 8, neurite growth-
promoting factor 1) 
204014_at 2.72 dual specificity phosphatase 4 
222173_s_at 2.70 TBC1 domain family, member 2 
206510_at 2.69 sine oculis homeobox homolog 2 (Drosophila) 
204971_at 2.67 cystatin A (stefin A) 
202975_s_at 2.65 Rho-related BTB domain containing 3 
202976_s_at 2.56 Rho-related BTB domain containing 3 
222113_s_at 2.55 Epidermal growth factor receptor pathway substrate 15-like 1 
205032_at 2.54 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 
213725_x_at 2.54 Xylosyltransferase I 
214247_s_at 2.51 Dickkopf homolog 3 (Xenopus laevis) 
219836_at 2.51 zinc finger, BED-type containing 2 
214772_at 2.50 Chromosome 11 open reading frame 41 
206504_at 2.48 cytochrome P450, family 24, subfamily A, polypeptide 1 
202295_s_at 2.45 cathepsin H 
219453_at 2.43 chromosome 16 open reading frame 44 
209035_at 2.41 midkine (neurite growth-promoting factor 2) 
206033_s_at 2.40 desmocollin 3 
213568_at 2.39 Odd-skipped related 2 (Drosophila) 
218510_x_at 2.36 Family with sequence similarity 134, member B 
210065_s_at 2.36 uroplakin 1B 
217665_at 2.36 CDNA FLJ25947 fis, clone JTH14708 
211212_s_at 2.35 origin recognition complex, subunit 5-like (yeast) 
202177_at 2.35 growth arrest-specific 6 
202971_s_at 2.34 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 
2 
208835_s_at 2.34 Cisplatin resistance-associated overexpressed protein 
200824_at 2.33 glutathione S-transferase pi 
220324_at 2.30 chromosome 6 open reading frame 155 
201925_s_at 2.29 CD55 molecule, decay accelerating factor for complement 
(Cromer blood group) 
220994_s_at 2.28 syntaxin binding protein 6 (amisyn) 
201615_x_at 2.28 Caldesmon 1 
218352_at 2.27 regulator of chromosome condensation (RCC1) and BTB 
(POZ) domain containing protein 1 
205422_s_at 2.27 integrin, beta-like 1 (with EGF-like repeat domains) 
204036_at 2.27 Endothelial differentiation, lysophosphatidic acid G-protein-
coupled receptor, 2 
214085_x_at 2.27 KRR1, small subunit (SSU) processome component, homolog 
(yeast) 
201656_at 2.25 integrin, alpha 6 
220723_s_at 2.24 hypothetical protein FLJ21511 
219161_s_at 2.23 chemokine-like factor 
205466_s_at 2.23 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 
218322_s_at 2.22 acyl-CoA synthetase long-chain family member 5 
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218824_at 2.22 hypothetical protein FLJ10781 
204135_at 2.21 filamin A interacting protein 1-like 
212473_s_at 2.21 601658812R1 NIH_MGC_69 Homo sapiens cDNA clone 
IMAGE:3886131 3', mRNA sequence. 
206461_x_at 2.20 metallothionein 1H 
206142_at 2.18 zinc finger protein 135 
202843_at 2.18 DnaJ (Hsp40) homolog, subfamily B, member 9 
222351_at 2.17 Protein phosphatase 2 (formerly 2A), regulatory subunit A, 
beta isoform 
209598_at 2.16 paraneoplastic antigen MA2 
218432_at 2.16 F-box protein 3 
206392_s_at 2.15 retinoic acid receptor responder (tazarotene induced) 1 
220180_at 2.15 coiled-coil domain containing 68 
209457_at 2.15 dual specificity phosphatase 5 
211776_s_at 2.15 erythrocyte membrane protein band 4.1-like 3 
219239_s_at 2.13 zinc finger protein 654 
216550_x_at 2.12 Ankyrin repeat domain 12 
212487_at 2.11 G patch domain containing 8 
211681_s_at 2.11 predicted protein of HQ2489; Homo sapiens PRO2489 
mRNA, complete cds. 
210846_x_at 2.11 tripartite motif-containing 14 
218401_s_at 2.11 zinc finger protein 281 
216048_s_at 2.10 Rho-related BTB domain containing 3 
203729_at 2.10 epithelial membrane protein 3 
209604_s_at 2.09 GATA binding protein 3 
221583_s_at 2.09 Potassium large conductance calcium-activated channel, 
subfamily M, alpha member 1 
204920_at 2.09 carbamoyl-phosphate synthetase 1, mitochondrial 
202102_s_at 2.09 Bromodomain containing 4 
212923_s_at 2.09 chromosome 6 open reading frame 145 
203234_at 2.09 uridine phosphorylase 1 
206456_at 2.08 gamma-aminobutyric acid (GABA) A receptor, alpha 5 
213272_s_at 2.08 transmembrane protein 159 
219654_at 2.08 protein tyrosine phosphatase-like (proline instead of catalytic 
arginine), member A 
209122_at 2.08 adipose differentiation-related protein 
208022_s_at 2.07 CDC14 cell division cycle 14 homolog B (S. cerevisiae) 
AFFX-HUMRGE/M10098_M_at 2.07  
214464_at 2.07 CDC42 binding protein kinase alpha (DMPK-like) 
203939_at 2.07 5'-nucleotidase, ecto (CD73) 
213144_at 2.06 Golgi SNAP receptor complex member 2 
211993_at 2.06 WNK lysine deficient protein kinase 1 
201340_s_at 2.06 ectodermal-neural cortex (with BTB-like domain) 
221555_x_at 2.06 CDC14 cell division cycle 14 homolog B (S. cerevisiae) 
210933_s_at 2.04 Homo sapiens cDNA clone IMAGE:3530459 
217624_at 2.04 PDGFA associated protein 1 
206067_s_at 2.04 Wilms tumor 1 
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205097_at 2.04 Solute carrier family 26 (sulfate transporter), member 2 
221088_s_at 2.04 protein phosphatase 1, regulatory (inhibitor) subunit 9A 
202075_s_at 2.03 phospholipid transfer protein 
219298_at 2.02 enoyl Coenzyme A hydratase domain containing 3 
206864_s_at 2.02 harakiri, BCL2 interacting protein (contains only BH3 domain) 
210298_x_at 2.01 four and a half LIM domains 1 
221666_s_at 2.01 PYD and CARD domain containing 
201510_at 2.01 E74-like factor 3 (ets domain transcription factor, epithelial-
specific ) 
218546_at 2.01 chromosome 1 open reading frame 115 
209505_at 2.00 Nuclear receptor subfamily 2, group F, member 1 
201540_at 2.00 four and a half LIM domains 1 
205705_at 2.00 ankyrin repeat domain 26 
59644_at 2.00 BMP2 inducible kinase 
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Appendix 5 
Genes down-regulated at ≥ 2-fold in pooled WWOX-transfected (WWOX-6, -7, -8) cells versus Vector-
transfected (Vector-9, -p1, -p2) in HG-U133A microarray experiment 
 
Affymetrix probe Fold 
change 
Gene 
201631_s_at 0.07 immediate early response 3 
218963_s_at 0.07 keratin 23 (histone deacetylase inducible) 
214022_s_at 0.09 Interferon induced transmembrane protein 1 (9-27) 
221530_s_at 0.09 Basic helix-loop-helix domain containing, class B, 3 
208850_s_at 0.10 Thy-1 cell surface antigen 
218162_at 0.10 olfactomedin-like 3 
205862_at 0.10 GREB1 protein 
201601_x_at 0.11 interferon induced transmembrane protein 1 (9-27) 
205778_at 0.11 kallikrein-related peptidase 7 
218807_at 0.11 vav 3 oncogene 
205258_at 0.12 inhibin, beta B (activin AB beta polypeptide) 
202833_s_at 0.13 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
208851_s_at 0.13 Thy-1 cell surface antigen 
213869_x_at 0.13 zr01g01.s1 Stratagene NT2 neuronal precursor 937230 Homo 
sapiens cDNA clone 
203963_at 0.13 carbonic anhydrase XII 
204304_s_at 0.15 prominin 1 
218806_s_at 0.16 vav 3 oncogene 
214844_s_at 0.18 docking protein 5 
204885_s_at 0.18 Mesothelin 
200766_at 0.18 cathepsin D 
210335_at 0.19 peptidylglycine alpha-amidating monooxygenase COOH-
terminal interactor 
206125_s_at 0.20 kallikrein-related peptidase 8 
214164_x_at 0.21 Carbonic anhydrase XII 
206805_at 0.21 sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3A 
215867_x_at 0.21 Homo sapiens mRNA; cDNA DKFZp564D066 (from clone 
DKFZp564D066). 
219937_at 0.21 thyrotropin-releasing hormone degrading enzyme 
205364_at 0.22 acyl-Coenzyme A oxidase 2, branched chain 
202688_at 0.23 tumor necrosis factor (ligand) superfamily, member 10 
202800_at 0.23 solute carrier family 1 (glial high affinity glutamate 
transporter), member 3 
219956_at 0.24 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6 (GalNAc-T6) 
218858_at 0.25 DEP domain containing 6 
218960_at 0.25 transmembrane protease, serine 4 
207626_s_at 0.25 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 2 
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211429_s_at 0.26 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
205899_at 0.26 cyclin A1 
203021_at 0.26 secretory leukocyte peptidase inhibitor 
212614_at 0.26 AT rich interactive domain 5B (MRF1-like) 
205068_s_at 0.26 Rho GTPase activating protein 26 
209395_at 0.26 chitinase 3-like 1 (cartilage glycoprotein-39) 
204114_at 0.27 nidogen 2 (osteonidogen) 
210842_at 0.28 neuropilin 2 
209897_s_at 0.28 slit homolog 2 (Drosophila) 
205413_at 0.28 metallophosphoesterase domain containing 2 
205505_at 0.29 glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-
acetylglucosaminyltransferase) 
213478_at 0.29 Kazrin 
212985_at 0.30 Full-length cDNA clone CS0DC015YK09 of Neuroblastoma 
Cot 25-normalized of Homo sapiens (human) 
210051_at 0.30 Rap guanine nucleotide exchange factor (GEF) 3 
218706_s_at 0.30 GRAM domain containing 3 
40148_at 0.30 Human FE65-like protein (hFE65L) mRNA, partial cds. 
210735_s_at 0.30 carbonic anhydrase XII 
213419_at 0.31 Human FE65-like protein (hFE65L) mRNA, partial cds. 
205112_at 0.31 phospholipase C, epsilon 1 
209875_s_at 0.31 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, 
early T-lymphocyte activation 1) 
207761_s_at 0.32 methyltransferase like 7A 
212328_at 0.32 hypothetical protein 
209396_s_at 0.33 chitinase 3-like 1 (cartilage glycoprotein-39) 
213873_at 0.33 discoidin, CUB and LCCL domain containing 2 
220585_at 0.33 hexokinase domain containing 1 
220149_at 0.33 chromosome 2 open reading frame 54 
202510_s_at 0.34 tumor necrosis factor, alpha-induced protein 2 
219327_s_at 0.34 G protein-coupled receptor, family C, group 5, member C 
209782_s_at 0.34 D site of albumin promoter (albumin D-box) binding protein 
203708_at 0.34 phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 
dunce homolog, Drosophila) 
212324_s_at 0.34 Vacuolar protein sorting 13 homolog D (S. cerevisiae) 
212327_at 0.35 DKFZP686A01247 hypothetical protein 
219127_at 0.35 ATPase family, AAA domain containing 4 
221045_s_at 0.35 period homolog 3 (Drosophila) 
204538_x_at 0.35 nuclear pore complex interacting protein 
212325_at 0.35 hypothetical protein 
205590_at 0.36 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 
214079_at 0.36 Dehydrogenase/reductase (SDR family) member 2 
207119_at 0.36 protein kinase, cGMP-dependent, type I 
202766_s_at 0.36 fibrillin 1 
205640_at 0.37 aldehyde dehydrogenase 3 family, member B1 
212970_at 0.37 Full-length cDNA clone CS0DC015YK09 of Neuroblastoma 
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Cot 25-normalized of Homo sapiens (human) 
221589_s_at 0.37 Transcribed locus 
211564_s_at 0.38 PDZ and LIM domain 4 
214091_s_at 0.38 xf42h12.x1 NCI_CGAP_Brn50 Homo sapiens cDNA clone 
IMAGE:2620775 3' similar to gb:X58295_rna1 
201348_at 0.38 glutathione peroxidase 3 (plasma) 
214564_s_at 0.38 protocadherin gamma subfamily C, 3 
221223_x_at 0.39 cytokine inducible SH2-containing protein 
212736_at 0.39 Chromosome 16 open reading frame 45 
215955_x_at 0.39 Rho GTPase activating protein 26 
207076_s_at 0.39 argininosuccinate synthetase 1 
203277_at 0.39 DNA fragmentation factor, 45kDa, alpha polypeptide 
210542_s_at 0.39 solute carrier organic anion transporter family, member 3A1 
213603_s_at 0.39 Ras-related C3 botulinum toxin substrate 2 (rho family, small 
GTP binding protein Rac2) 
214040_s_at 0.40 Gelsolin (amyloidosis, Finnish type) 
211708_s_at 0.40 stearoyl-CoA desaturase (delta-9-desaturase) 
219049_at 0.40 chondroitin beta1,4 N-acetylgalactosaminyltransferase 
203827_at 0.40 WD repeat domain, phosphoinositide interacting 1 
35148_at 0.40 tight junction protein 3 (zona occludens 3) 
201841_s_at 0.40 heat shock 27kDa protein 1 
210683_at 0.40 neurturin 
214870_x_at 0.41 nuclear pore complex interacting protein ; hypothetical protein 
LOC339047 
213572_s_at 0.41 Serpin peptidase inhibitor, clade B (ovalbumin), member 1 
205111_s_at 0.41 phospholipase C, epsilon 1 
212323_s_at 0.41 Vacuolar protein sorting 13 homolog D (S. cerevisiae) 
221447_s_at 0.41 glycosyltransferase 8 domain containing 2 
219369_s_at 0.41 OTU domain, ubiquitin aldehyde binding 2 
204298_s_at 0.42 lysyl oxidase 
211844_s_at 0.42 neuropilin 2 
201195_s_at 0.42 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 5 
205990_s_at 0.42 wingless-type MMTV integration site family, member 5A 
221588_x_at 0.42 Aldehyde dehydrogenase 6 family, member A1 
204290_s_at 0.42 aldehyde dehydrogenase 6 family, member A1 
203071_at 0.42 sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3B 
207419_s_at 0.42 ras-related C3 botulinum toxin substrate 2 (rho family, small 
GTP binding protein Rac2) 
212326_at 0.43 vacuolar protein sorting 13 homolog D (S. cerevisiae) 
215552_s_at 0.43 Estrogen receptor 1 
203344_s_at 0.43 retinoblastoma binding protein 8 
204513_s_at 0.43 engulfment and cell motility 1 
202855_s_at 0.43 Solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4) 
206373_at 0.44 Zic family member 1 (odd-paired homolog, Drosophila) 
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215138_s_at 0.44 Kazrin 
41660_at 0.44 cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo 
homolog, Drosophila) 
222281_s_at 0.44 Transcribed locus, moderately similar to XP_849056.1  
hypothetical protein XP_843963 [Canis familiaris] 
213355_at 0.44 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 
206508_at 0.44 CD70 molecule 
214016_s_at 0.44 Splicing factor proline/glutamine-rich (polypyrimidine tract 
binding protein associated) 
207147_at 0.44 distal-less homeobox 2 
214240_at 0.44 Galanin 
205660_at 0.45 2'-5'-oligoadenylate synthetase-like 
205428_s_at 0.45 calbindin 2, 29kDa (calretinin) 
208978_at 0.45 cysteine-rich protein 2 
212651_at 0.45 Rho-related BTB domain containing 1 
212093_s_at 0.45 Mitochondrial tumor suppressor 1 
213710_s_at 0.45 Transcribed locus 
211066_x_at 0.45 protocadherin gamma subfamily C, 3 
204542_at 0.45 ST6GALNAC2 
219722_s_at 0.46 glycerophosphodiester phosphodiesterase domain containing 
3 
205226_at 0.46 platelet-derived growth factor receptor-like 
202342_s_at 0.46 tripartite motif-containing 2 
219426_at 0.46 eukaryotic translation initiation factor 2C, 3 
204508_s_at 0.46 carbonic anhydrase XII 
214035_x_at 0.46 Full-length cDNA clone CS0DF038YM01 of Fetal brain of 
Homo sapiens (human) 
205659_at 0.46 histone deacetylase 9 
216052_x_at 0.46 Artemin 
203954_x_at 0.46 claudin 3 
201425_at 0.46 aldehyde dehydrogenase 2 family (mitochondrial) 
222078_at 0.47 Transcribed locus 
214453_s_at 0.47 interferon-induced protein 44 
221501_x_at 0.47 hypothetical protein LOC339047 
206262_at 0.47 alcohol dehydrogenase 1C (class I), gamma polypeptide 
206752_s_at 0.47 DNA fragmentation factor, 40kDa, beta polypeptide (caspase-
activated DNase) 
205255_x_at 0.47 transcription factor 7 (T-cell specific, HMG-box) 
219344_at 0.47 solute carrier family 29 (nucleoside transporters), member 3 
205532_s_at 0.47 Cadherin 6, type 2, K-cadherin (fetal kidney) 
219895_at 0.47 family with sequence similarity 70, member A 
209500_x_at 0.47 tumor necrosis factor (ligand) superfamily, member 13 
205199_at 0.47 carbonic anhydrase IX 
210239_at 0.47 iroquois homeobox protein 5 
202856_s_at 0.47 solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4) 
207675_x_at 0.47 Artemin 
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202599_s_at 0.47 nuclear receptor interacting protein 1 
219691_at 0.48 sterile alpha motif domain containing 9 
205254_x_at 0.48 Transcribed locus, moderately similar to XP_517932.1 
210942_s_at 0.48 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 
210602_s_at 0.48 cadherin 6, type 2, K-cadherin (fetal kidney) 
205022_s_at 0.48 forkhead box N3 
205293_x_at 0.48 BAI1-associated protein 2 
200831_s_at 0.48 Stearoyl-CoA desaturase (delta-9-desaturase) 
213296_at 0.48 RER1 retention in endoplasmic reticulum 1 homolog (S. 
cerevisiae) 
203186_s_at 0.48 S100 calcium binding protein A4 
201945_at 0.48 furin (paired basic amino acid cleaving enzyme) 
211922_s_at 0.49 Catalase 
221768_at 0.49 Splicing factor proline/glutamine-rich (polypyrimidine tract 
binding protein associated) 
210473_s_at 0.49 Homo sapiens p58/GTA protein kinase mRNA, complete cds. 
213238_at 0.49 ATPase, Class V, type 10D 
220230_s_at 0.49 cytochrome b5 reductase 2 
202180_s_at 0.49 major vault protein 
204747_at 0.49 interferon-induced protein with tetratricopeptide repeats 3 
200676_s_at 0.49 ubiquitin-conjugating enzyme E2L 3 
203586_s_at 0.49 ADP-ribosylation factor-like 4D 
204191_at 0.49 interferon (alpha, beta and omega) receptor 1 
211495_x_at 0.49 tumor necrosis factor (ligand) superfamily, member 13 
219179_at 0.50 dapper, antagonist of beta-catenin, homolog 1 (Xenopus 
laevis) 
213589_s_at 0.50 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase-like 1 
204963_at 0.50 sarcospan (Kras oncogene-associated gene) 
206463_s_at 0.50 dehydrogenase/reductase (SDR family) member 2 
209824_s_at 0.50 aryl hydrocarbon receptor nuclear translocator-like 
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Appendix 6 
Genes up-regulated at ≥ 1.5-fold following WWOX siRNA knock-down in A2780 cells versus mock 
transfection in HG-U133A microarray experiment 
 
Affymetrix probe Fold 
change 
Gene 
AFFX-HUMRGE/M10098_5_at 2.08  
211840_s_at 2.05 phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 
dunce homolog, Drosophila) 
204399_s_at 1.99 Echinoderm microtubule associated protein like 2 
207626_s_at 1.98 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 2 
217310_s_at 1.85 forkhead box J3 
214216_s_at 1.84 La ribonucleoprotein domain family, member 5 
207938_at 1.83 peptidase inhibitor 15 
205547_s_at 1.83 transgelin 
208342_x_at 1.82 chorionic somatomammotropin hormone 2 
76897_s_at 1.80 FK506 binding protein 15, 133kDa 
210930_s_at 1.79 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 
AFFX-BioB-M_at 1.75 Biotin synthase ; biotin synthesis, sulfur insertion? 
210310_s_at 1.73 fibroblast growth factor 5 
211453_s_at 1.72 v-akt murine thymoma viral oncogene homolog 2 
AFFX-BioDn-5_at 1.71 dethiobiotin synthetase 
AFFX-BioB-5_at 1.71 Biotin synthase ; biotin synthesis, sulfur insertion? 
221430_s_at 1.69 ring finger protein 146 
205868_s_at 1.69 protein tyrosine phosphatase, non-receptor type 11 (Noonan 
syndrome 1) 
202821_s_at 1.69 LIM domain containing preferred translocation partner in 
lipoma 
202458_at 1.68 protease, serine, 23 
219199_at 1.68 AF4/FMR2 family, member 4 
AFFX-BioB-3_at 1.67 biotin synthesis, sulfur insertion? 
201615_x_at 1.66 Caldesmon 1 
208294_x_at 1.66 chorionic somatomammotropin hormone-like 1, transcript 
variant 3, mRNA. 
219955_at 1.66 LINE-1 type transposase domain containing 1 
208293_x_at 1.66 chorionic somatomammotropin hormone-like 1 
201616_s_at 1.66 Caldesmon 1 
211739_x_at 1.65 chorionic somatomammotropin hormone 1 (placental 
lactogen) 
208790_s_at 1.64 polymerase I and transcript release factor 
212113_at 1.64 Hypothetical LOC552889 
AFFX-BioC-5_at 1.64 Biotin synthesis protein bioC ; biotin biosynthesis; reaction 
prior to pimeloyl CoA 
210158_at 1.64 excision repair cross-complementing rodent repair deficiency, 
complementation group 4 
216733_s_at 1.62 H.sapiens mRNA for  L-arginine:glycine amidinotransferase. 
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208403_x_at 1.62 MYC associated factor X 
211767_at 1.62 GINS complex subunit 4 (Sld5 homolog) 
211990_at 1.61 major histocompatibility complex, class II, DP alpha 1 
203562_at 1.60 fasciculation and elongation protein zeta 1 (zygin I) 
AFFX-r2-Ec-bioC-5_at 1.60 biotin biosynthesis; reaction prior to pimeloyl CoA 
219927_at 1.60 FCF1 small subunit (SSU) processome component homolog 
(S. cerevisiae) 
200930_s_at 1.60 Vinculin 
216997_x_at 1.59 transducin-like enhancer of split 4 (E(sp1) homolog, 
Drosophila) 
220549_at 1.58 fibrinogen silencer binding protein ; RAD54 homolog B (S. 
cerevisiae) 
203807_x_at 1.58 chorionic somatomammotropin hormone 2 
212471_at 1.57 KIAA0241 
218599_at 1.57 REC8 homolog (yeast) 
202290_at 1.57 PDGFA associated protein 1 
205655_at 1.56 Mdm4, transformed 3T3 cell double minute 4, p53 binding 
protein (mouse) 
219717_at 1.55 chromosome 4 open reading frame 30 
210585_s_at 1.55 transportin 2 (importin 3, karyopherin beta 2b) 
219730_at 1.55 mediator of RNA polymerase II transcription, subunit 18 
homolog (S. cerevisiae) 
209997_x_at 1.55 pericentriolar material 1 
213548_s_at 1.55 CDV3 homolog (mouse) 
205699_at 1.55 mitogen-activated protein kinase kinase 6 
201005_at 1.55 CD9 molecule 
220800_s_at 1.54 tropomodulin 3 (ubiquitous) 
217208_s_at 1.54 discs, large homolog 1 (Drosophila) 
216695_s_at 1.54 tankyrase, TRF1-interacting ankyrin-related ADP-ribose 
polymerase 
202493_x_at 1.54 chorionic somatomammotropin hormone 1 (placental 
lactogen) 
201043_s_at 1.54 acidic (leucine-rich) nuclear phosphoprotein 32 family, 
member A 
204340_at 1.53 transmembrane protein 187 
215253_s_at 1.53 Down syndrome critical region gene 1 
219817_at 1.53 apoptosis-related protein PNAS-1 
204264_at 1.53 carnitine palmitoyltransferase II 
207786_at 1.53 cytochrome P450, family 2, subfamily R, polypeptide 1 
205835_s_at 1.53 YTH domain containing 2 
202627_s_at 1.53 Serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1 
200878_at 1.52 endothelial PAS domain protein 1 
203799_at 1.52 CD302 molecule 
205411_at 1.52 serine/threonine kinase 4 
216627_s_at 1.52 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 1 
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207099_s_at 1.52 choroideremia (Rab escort protein 1) 
220885_s_at 1.52 centromere protein J 
222309_at 1.52 Chromosome 6 open reading frame 62 
222161_at 1.51 N-acetylated alpha-linked acidic dipeptidase 2 
216855_s_at 1.51 tumor-associated 120 kDa nuclear protein; Homo sapiens 
mRNA for p120, partial cds. 
202134_s_at 1.50 WW domain containing transcription regulator 1 
207327_at 1.50 eyes absent homolog 4 (Drosophila) 
208478_s_at 1.50 BCL2-associated X protein 
220459_at 1.50 MCM3 minichromosome maintenance deficient 3 (S. 
cerevisiae) associated protein antisense 
205184_at 1.50 guanine nucleotide binding protein (G protein), gamma 4 
215570_s_at 1.50 hypothetical BC331191_1 ; hypothetical protein LOC284323 
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Appendix 7 
Genes down-regulated at ≥ 1.5-fold following WWOX siRNA knock-down in A2780 cells versus mock 
transfection in HG-U133A microarray experiment 
Affymetrix probe Fold 
change 
Gene 
219077_s_at 0.35 WW domain containing oxidoreductase 
217388_s_at 0.41 Kynureninase (L-kynurenine hydrolase) 
200799_at 0.50 heat shock 70kDa protein 1A 
210827_s_at 0.50 E74-like factor 3 (ets domain transcription factor, epithelial-
specific ) 
201739_at 0.51 serum/glucocorticoid regulated kinase 
204920_at 0.51 carbamoyl-phosphate synthetase 1, mitochondrial 
201785_at 0.51 ribonuclease, RNase A family, 1 (pancreatic) 
206157_at 0.53 pentraxin-related gene, rapidly induced by IL-1 beta 
204156_at 0.53 KIAA0999 protein 
205577_at 0.54 phosphorylase, glycogen; muscle (McArdle syndrome, 
glycogen storage disease type V) 
201926_s_at 0.56 CD55 molecule, decay accelerating factor for complement 
(Cromer blood group) 
209366_x_at 0.57 cytochrome b5 type A (microsomal) 
40837_at 0.57 transducin-like enhancer of split 2 (E(sp1) homolog, 
Drosophila) 
202834_at 0.57 angiotensinogen (serpin peptidase inhibitor, clade A, member 
8) 
208127_s_at 0.57 suppressor of cytokine signaling 5 
209648_x_at 0.58 suppressor of cytokine signaling 5 
209834_at 0.58 carbohydrate (chondroitin 6) sulfotransferase 3 
205433_at 0.58 butyrylcholinesterase 
220156_at 0.60 EF-hand calcium binding domain 1 
213256_at 0.60 Membrane-associated ring finger (C3HC4) 3 
208779_x_at 0.60 discoidin domain receptor family, member 1 
204736_s_at 0.60 chondroitin sulfate proteoglycan 4 
209195_s_at 0.60 adenylate cyclase 6 
200606_at 0.61 desmoplakin 
202206_at 0.61 ADP-ribosylation factor-like 4C 
204437_s_at 0.61 folate receptor 1 (adult) 
202855_s_at 0.61 Solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4) 
207144_s_at 0.62 Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 1 
208949_s_at 0.62 lectin, galactoside-binding, soluble, 3 
216860_s_at 0.62 growth differentiation factor 11 
208078_s_at 0.62 zinc finger E-box binding homeobox 1 
204663_at 0.62 malic enzyme 3, NADP(+)-dependent, mitochondrial 
205694_at 0.62 tyrosinase-related protein 1 
207199_at 0.63 telomerase reverse transcriptase; synonyms: TP2, TRT, 
EST2, hEST2; transcript variant 1, mRNA. 
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212151_at 0.63 602269506F1 NIH_MGC_84 Homo sapiens cDNA clone 
IMAGE:4357777 5', mRNA sequence. 
219562_at 0.63 RAB26, member RAS oncogene family 
209267_s_at 0.63 solute carrier family 39 (zinc transporter), member 8 
210695_s_at 0.63 WW domain containing oxidoreductase 
209260_at 0.64 stratifin 
218834_s_at 0.64 transmembrane protein 132A 
206028_s_at 0.64 c-mer proto-oncogene tyrosine kinase 
205622_at 0.64 sphingomyelin phosphodiesterase 2, neutral membrane 
(neutral sphingomyelinase) 
213844_at 0.64 homeobox A5 
204229_at 0.64 Solute carrier family 17 (sodium-dependent inorganic 
phosphate cotransporter), member 7 
200940_s_at 0.64 arginine-glutamic acid dipeptide (RE) repeats 
202391_at 0.65 brain abundant, membrane attached signal protein 1 
212135_s_at 0.65 ATPase, Ca++ transporting, plasma membrane 4 
204966_at 0.65 brain-specific angiogenesis inhibitor 2 
203793_x_at 0.65 polycomb group ring finger 2 
208657_s_at 0.65 septin 9 
215058_at 0.65 Hypothetical protein MGC24039 
204431_at 0.65 transducin-like enhancer of split 2 (E(sp1) homolog, 
Drosophila) 
202455_at 0.65 histone deacetylase 5 
218162_at 0.65 olfactomedin-like 3 
50965_at 0.65 RAB26, member RAS oncogene family 
204588_s_at 0.65 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 7 
211704_s_at 0.66 spindlin family, member 2B 
201820_at 0.66 keratin 5 (epidermolysis bullosa simplex, Dowling-
Meara/Kobner/Weber-Cockayne types) 
91816_f_at 0.66 Ring finger and KH domain containing 1 
210628_x_at 0.66 latent transforming growth factor beta binding protein 4 
211282_x_at 0.66 tumor necrosis factor receptor superfamily, member 25 
208957_at 0.66 Thioredoxin domain containing 4 (endoplasmic reticulum) 
209234_at 0.66 Kinesin family member 1B 
210392_x_at 0.66 nuclear receptor subfamily 6, group A, member 1 
217495_x_at 0.66 calcitonin/calcitonin-related polypeptide, alpha 
59705_at 0.66 Selenocysteine lyase 
211210_x_at 0.66 SH2 domain protein 1A, Duncan's disease 
(lymphoproliferative syndrome) 
203778_at 0.66 mannosidase, beta A, lysosomal 
205705_at 0.67 ankyrin repeat domain 26 
207847_s_at 0.67 mucin 1, cell surface associated 
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Appendix 8 
Genes up-regulated at ≥ 1.5-fold following WWOX siRNA knock-down in A2780 cells versus non-
targeting oligo 1 siRNA transfection in HG-U133A microarray experiment 
 
Affymetrix probe Fold 
change 
Gene 
212023_s_at 2.70 Antigen identified by monoclonal antibody Ki-67 
209651_at 2.38 transforming growth factor beta 1 induced transcript 1 
212337_at 2.35 Taurine upregulated gene 1 
212725_s_at 2.35 Taurine upregulated gene 1 
203501_at 2.29 plasma glutamate carboxypeptidase; aminopeptidase 
209468_at 2.28 low density lipoprotein receptor-related protein 5 
AFFX-HUMRGE/M10098_5_at 2.28  
205407_at 2.27 reversion-inducing-cysteine-rich protein with kazal motifs 
205373_at 2.26 catenin (cadherin-associated protein), alpha 2 
205226_at 2.26 platelet-derived growth factor receptor-like 
203640_at 2.21 hs98f09.x1 NCI_CGAP_Kid13 Homo sapiens cDNA clone 
IMAGE:3145289 3', mRNA sequence. 
213117_at 2.16 Kelch-like 9 (Drosophila) 
222244_s_at 2.13 taurine upregulated gene 1 
207174_at 2.13 glypican 5 
218858_at 2.12 DEP domain containing 6 
202766_s_at 2.05 fibrillin 1 
220770_s_at 2.04 transposon-derived Buster3 transposase-like 
213029_at 2.04 Nuclear factor I/B 
219563_at 2.02 chromosome 14 open reading frame 139 
209240_at 2.02 O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminyl 
transferase) 
204749_at 1.99 nucleosome assembly protein 1-like 3 
201302_at 1.98 annexin A4 
212113_at 1.98 Hypothetical LOC552889 
207786_at 1.98 cytochrome P450, family 2, subfamily R, polypeptide 1 
207327_at 1.96 eyes absent homolog 4 (Drosophila) 
202820_at 1.94 aryl hydrocarbon receptor 
202838_at 1.92 fucosidase, alpha-L- 1, tissue 
221589_s_at 1.92 Transcribed locus 
219717_at 1.92 chromosome 4 open reading frame 30 
209289_at 1.91 Transcribed locus 
219120_at 1.91 chromosome 2 open reading frame 44 
204493_at 1.90 BH3 interacting domain death agonist 
200930_s_at 1.89 Vinculin 
218263_s_at 1.88 transposon-derived Buster1 transposase-like protein gene 
38241_at 1.88 butyrophilin, subfamily 3, member A3 
219703_at 1.86 meiosis-specific nuclear structural 1 
208454_s_at 1.85 plasma glutamate carboxypeptidase 
203633_at 1.84 Carnitine palmitoyltransferase 1A (liver) 
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208940_at 1.84 Selenophosphate synthetase 1 
44669_at 1.83 Hypothetical protein LOC644096 
214647_s_at 1.83 Hemochromatosis 
202619_s_at 1.83 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 
219352_at 1.83 hect domain and RLD 6 
202493_x_at 1.82 chorionic somatomammotropin hormone 1 (placental 
lactogen) 
219828_at 1.81 chromosome 9 open reading frame 86 
205569_at 1.81 lysosomal-associated membrane protein 3 
212884_x_at 1.81 Apolipoprotein E 
207966_s_at 1.81 golgi apparatus protein 1 
215729_s_at 1.80 Vestigial like 1 (Drosophila) 
221564_at 1.80 Protein arginine methyltransferase 2 
212045_at 1.79 Golgi apparatus protein 1 
200878_at 1.79 endothelial PAS domain protein 1 
218800_at 1.79 steroid 5 alpha-reductase 2-like 
218705_s_at 1.79 sorting nexing 24 
207564_x_at 1.79 O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminyl 
transferase) 
208378_x_at 1.78 fibroblast growth factor 5 
204214_s_at 1.78 RAB32, member RAS oncogene family 
204602_at 1.78 dickkopf homolog 1 (Xenopus laevis) 
206082_at 1.78 HLA complex P5 
204290_s_at 1.78 aldehyde dehydrogenase 6 family, member A1 
205347_s_at 1.78 thymosin-like 8 
202948_at 1.77 interleukin 1 receptor, type I 
212114_at 1.76 601661094R1 NIH_MGC_72 Homo sapiens cDNA clone 
IMAGE:3916174 3', mRNA sequence. 
215313_x_at 1.76 Major histocompatibility complex, class I, A 
218685_s_at 1.75 single-strand-selective monofunctional uracil-DNA 
glycosylase 1 
218397_at 1.74 Fanconi anemia, complementation group L 
219395_at 1.74 RNA binding motif protein 35B 
213069_at 1.74 HEG homolog 1 (zebrafish) 
40560_at 1.74 T-box 2 
202920_at 1.73 Ankyrin 2, neuronal 
205017_s_at 1.73 Muscleblind-like 2 (Drosophila) 
212307_s_at 1.73 O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminyl 
transferase) 
201438_at 1.73 collagen, type VI, alpha 3 
218424_s_at 1.73 STEAP family member 3 
208050_s_at 1.73 caspase 2, apoptosis-related cysteine  
204518_s_at 1.72 peptidylprolyl isomerase C (cyclophilin C) 
205372_at 1.72 pleiomorphic adenoma gene 1 
212559_at 1.72 Protein kinase, cAMP-dependent, regulatory, type I, beta 
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213362_at 1.71 za74a07.s1 Soares_fetal_lung_NbHL19W Homo sapiens 
cDNA clone, mRNA sequence. 
209469_at 1.71 Glycoprotein M6A 
219655_at 1.71 chromosome 7 open reading frame 10 
206079_at 1.71 choroideremia-like (Rab escort protein 2) 
210139_s_at 1.70 peripheral myelin protein 22 
203555_at 1.70 protein tyrosine phosphatase, non-receptor type 18 (brain-
derived) 
209318_x_at 1.70 Pleiomorphic adenoma gene-like 1 
206483_at 1.70 leucine rich repeat containing 6 
221295_at 1.70 cell death-inducing DFFA-like effector a 
212020_s_at 1.70 Antigen identified by monoclonal antibody Ki-67 
209970_x_at 1.70 caspase 1, apoptosis-related cysteine peptidase (interleukin 
1, beta, convertase) 
205830_at 1.69 calmegin 
215910_s_at 1.69 fibronectin type III domain containing 3A 
219165_at 1.68 PDZ and LIM domain 2 (mystique) 
216399_s_at 1.68 zinc finger protein 291 
204712_at 1.68 WNT inhibitory factor 1 
215022_x_at 1.68 602498083F1 NIH_MGC_75 Homo sapiens cDNA clone 
IMAGE:4611836 5', mRNA sequence. 
203655_at 1.68 X-ray repair complementing defective repair in Chinese 
hamster cells 1 
203827_at 1.68 WD repeat domain, phosphoinositide interacting 1 
222041_at 1.68 DPH1 homolog (S. cerevisiae) 
202742_s_at 1.67 protein kinase, cAMP-dependent, catalytic, beta 
203799_at 1.67 CD302 molecule 
208124_s_at 1.67 semaphorin 4F 
201746_at 1.67 tumor protein p53 (Li-Fraumeni syndrome) 
206498_at 1.67 oculocutaneous albinism II (pink-eye dilution homolog, 
mouse) 
221740_x_at 1.66 Transcribed locus 
207554_x_at 1.66 thromboxane A2 receptor 
206546_at 1.66 synaptonemal complex protein 2 
219202_at 1.66 rhomboid 5 homolog 2 (Drosophila) 
219571_s_at 1.66 zinc finger protein 12 
218831_s_at 1.66 Fc fragment of IgG, receptor, transporter, alpha 
216678_at 1.66 intraflagellar transport 122 homolog (Chlamydomonas) 
218259_at 1.66 MKL/myocardin-like 2 
210786_s_at 1.65 Friend leukemia virus integration 1 
207002_s_at 1.65 pleiomorphic adenoma gene-like 1 
213456_at 1.65 sclerostin domain containing 1 
211200_s_at 1.65 Homo sapiens cDNA clone IMAGE:3634465 
214804_at 1.64 Transcribed locus 
218844_at 1.64 hypothetical protein FLJ20920 
218325_s_at 1.64 death inducer-obliterator 1 
217979_at 1.64 tetraspanin 13 
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211767_at 1.64 GINS complex subunit 4 (Sld5 homolog) 
211467_s_at 1.64 nuclear factor I/B 
211453_s_at 1.64 v-akt murine thymoma viral oncogene homolog 2 
221916_at 1.63 Neurofilament, light polypeptide 68kDa 
212148_at 1.63 Pre-B-cell leukemia homeobox 1 
216177_at 1.63 Similar to 60S ribosomal protein L29 (P23) 
204920_at 1.63 carbamoyl-phosphate synthetase 1, mitochondrial 
203801_at 1.62 Transcribed locus 
221123_x_at 1.62 zinc finger protein 395 
212613_at 1.62 Butyrophilin, subfamily 3, member A2 
209290_s_at 1.62 nuclear factor I/B 
203634_s_at 1.62 carnitine palmitoyltransferase 1A (liver) 
212314_at 1.62 KIAA0746 protein 
219929_s_at 1.62 zinc finger, FYVE domain containing 21 
222361_at 1.62 Similar to tubulin, beta 8 
210338_s_at 1.62 heat shock 70kDa protein 8 
219368_at 1.61 nucleosome assembly protein 1-like 2 
201340_s_at 1.61 ectodermal-neural cortex (with BTB-like domain) 
207267_s_at 1.61 Down syndrome critical region gene 6 
217650_x_at 1.61 oz96b09.x1 Soares_parathyroid_tumor_NbHPA Homo 
sapiens cDNA clone IMAGE:1683161 
221855_at 1.61 Hypothetical protein LOC644096 
204114_at 1.61 nidogen 2 (osteonidogen) 
212681_at 1.61 Transcribed locus 
218907_s_at 1.60 leucine rich repeat containing 61 
221299_at 1.60 G protein-coupled receptor 173 
220993_s_at 1.60 G protein-coupled receptor 63 
218510_x_at 1.60 Family with sequence similarity 134, member B 
202552_s_at 1.60 cysteine rich transmembrane BMP regulator 1 (chordin-like) 
204143_s_at 1.60 enolase superfamily member 1 
205041_s_at 1.60 orosomucoid 1 
218952_at 1.60 proprotein convertase subtilisin/kexin type 1 inhibitor 
206888_s_at 1.60 Rho GDP dissociation inhibitor (GDI) gamma 
212413_at 1.60 septin 6 
214790_at 1.60 SUMO1/sentrin specific peptidase 6 
205958_x_at 1.60 chorionic somatomammotropin hormone-like 1 
200810_s_at 1.59 cold inducible RNA binding protein 
219852_s_at 1.59 MORN repeat containing 1 
212775_at 1.59 Obscurin-like 1 
219800_s_at 1.59 threonine synthase-like 1 (bacterial) 
213547_at 1.59 cullin-associated and neddylation-dissociated 2 (putative) 
221838_at 1.59 Kelch-like 22 (Drosophila) 
202304_at 1.59 fibronectin type III domain containing 3A 
217889_s_at 1.59 cytochrome b reductase 1 
218204_s_at 1.59 FYVE and coiled-coil domain containing 1 
220392_at 1.59 early B-cell factor 2 
209561_at 1.58 thrombospondin 3 
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36545_s_at 1.58 Sfi1 homolog, spindle assembly associated (yeast) 
221891_x_at 1.58 Heat shock 70kDa protein 8 
206081_at 1.58 solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 1 
204142_at 1.58 enolase superfamily member 1 
204820_s_at 1.57 butyrophilin, subfamily 3, member A3 
220346_at 1.57 methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2-like, mRNA. 
208687_x_at 1.57 heat shock 70kDa protein 8 
204964_s_at 1.57 sarcospan (Kras oncogene-associated gene) 
212909_at 1.57 LY6/PLAUR domain containing 1 
206712_at 1.57 growth hormone regulated TBC protein 1 
219325_s_at 1.57 elaC homolog 1 (E. coli) 
210628_x_at 1.57 latent transforming growth factor beta binding protein 4 
216253_s_at 1.57 Parvin, beta 
209285_s_at 1.56 Chromosome 3 open reading frame 63 
206492_at 1.56 fragile histidine triad gene 
217564_s_at 1.56 Carbamoyl-phosphate synthetase 1, mitochondrial 
202783_at 1.56 nicotinamide nucleotide transhydrogenase 
210224_at 1.56 major histocompatibility complex, class I-related 
208342_x_at 1.56 chorionic somatomammotropin hormone 2 
203688_at 1.56 polycystic kidney disease 2 (autosomal dominant) 
211330_s_at 1.56 hemochromatosis 
201983_s_at 1.56 Epidermal growth factor receptor (erythroblastic leukemia viral 
(v-erb-b) oncogene homolog, avian) 
200020_at 1.56 TAR DNA binding protein 
211203_s_at 1.56 contactin 1 
213321_at 1.56 Branched chain keto acid dehydrogenase E1, beta 
polypeptide (maple syrup urine disease) 
214765_s_at 1.55 N-acylsphingosine amidohydrolase (acid ceramidase)-like 
212801_at 1.55 Citron (rho-interacting, serine/threonine kinase 21) 
218285_s_at 1.55 3-hydroxybutyrate dehydrogenase, type 2 
210495_x_at 1.55 fibronectin 1 
210347_s_at 1.55 B-cell CLL/lymphoma 11A (zinc finger protein) 
206229_x_at 1.55 paired box gene 2 
219908_at 1.55 dickkopf homolog 2 (Xenopus laevis) 
214120_at 1.55 Ret finger protein-like 1 antisense 
201968_s_at 1.55 phosphoglucomutase 1 
201009_s_at 1.55 Thioredoxin interacting protein 
207563_s_at 1.55 O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminyl 
transferase) 
206852_at 1.54 EPH receptor A7 
221440_s_at 1.54 retinoblastoma binding protein 9 
206710_s_at 1.54 erythrocyte membrane protein band 4.1-like 3 
212516_at 1.54 centaurin, delta 2 
202847_at 1.54 phosphoenolpyruvate carboxykinase 2 (mitochondrial) 
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204821_at 1.54 butyrophilin, subfamily 3, member A3 
218796_at 1.54 chromosome 20 open reading frame 42 
201301_s_at 1.53 annexin A4 
200762_at 1.53 dihydropyrimidinase-like 2 
210292_s_at 1.53 protocadherin 11 X-linked 
202974_at 1.53 membrane protein, palmitoylated 1, 55kDa 
213587_s_at 1.53 ATPase, H+ transporting V0 subunit e2 
202291_s_at 1.53 matrix Gla protein 
212254_s_at 1.53 Dystonin 
201828_x_at 1.53 CAAX box 1 
220732_at 1.53 DEP domain containing 2 
220352_x_at 1.52 hypothetical protein MGC4278 
204831_at 1.52 yh11b03.s1 Soares infant brain 1NIB Homo sapiens cDNA 
clone IMAGE:42880 3', mRNA sequence. 
208232_x_at 1.52 neuregulin 1 
208782_at 1.52 follistatin-like 1 
208294_x_at 1.52 chorionic somatomammotropin hormone-like 1, transcript 
variant 3, mRNA. 
204398_s_at 1.52 echinoderm microtubule associated protein like 2 
213463_s_at 1.52 KIAA0974 
218976_at 1.52 DnaJ (Hsp40) homolog, subfamily C, member 12 
212037_at 1.52 Pinin, desmosome associated protein 
214877_at 1.52 601590459F1 NIH_MGC_7 Homo sapiens cDNA clone 
IMAGE:3944463 5', mRNA sequence. 
218785_s_at 1.52 RAB, member RAS oncogene family-like 5 
205695_at 1.51 serine dehydratase 
212839_s_at 1.51 Homo sapiens cDNA FLJ13982 fis, clone Y79AA1001711 
212731_at 1.51 ankyrin repeat domain 46 
203410_at 1.51 adaptor-related protein complex 3, mu 2 subunit 
209515_s_at 1.51 RAB27A, member RAS oncogene family 
210653_s_at 1.51 branched chain keto acid dehydrogenase E1, beta 
polypeptide (maple syrup urine disease) 
220765_s_at 1.51 LIM and senescent cell antigen-like domains 2 
216733_s_at 1.51 H.sapiens mRNA for  L-arginine:glycine amidinotransferase. 
221822_at 1.51 Coiled-coil domain containing 101 
221836_s_at 1.51 NIK and IKK{beta} binding protein 
208747_s_at 1.51 complement component 1, s subcomponent 
203954_x_at 1.51 claudin 3 
221280_s_at 1.51 par-3 partitioning defective 3 homolog (C. elegans) 
214761_at 1.51 Zinc finger protein 423 
205898_at 1.51 chemokine (C-X3-C motif) receptor 1 
209598_at 1.50 paraneoplastic antigen MA2 
216416_at 1.50 CDNA: FLJ23601 fis, clone LNG15501 
216858_x_at 1.50 Homo sapiens genomic DNA; cDNA DKFZp586H0722 (from 
clone DKFZp586H0722). 
202581_at 1.50 heat shock 70kDa protein 1B 
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Affymetrix probe Fold 
change 
Gene 
209803_s_at 0.19 pleckstrin homology-like domain, family A, member 2 
220513_at 0.22 chromosome 6 open reading frame 148 
208523_x_at 0.25 histone cluster 1, H2bi 
207046_at 0.28 histone cluster 2, H4a 
202627_s_at 0.30 Serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1 
215779_s_at 0.32 601140646F1 NIH_MGC_9 Homo sapiens cDNA clone 
IMAGE:3049883 5', mRNA sequence. 
201693_s_at 0.33 Early growth response 1 
218280_x_at 0.34 histone cluster 2, H2aa3 
214502_at 0.34 histone cluster 1, H2bj 
201107_s_at 0.36 Thrombospondin 1 
202310_s_at 0.36 collagen, type I, alpha 1 
204268_at 0.37 S100 calcium binding protein A2 
214290_s_at 0.38 Histone cluster 2, H2aa3 
210827_s_at 0.38 E74-like factor 3 (ets domain transcription factor, epithelial-
specific ) 
214472_at 0.39 histone cluster 1, H3d 
201631_s_at 0.40 immediate early response 3 
206552_s_at 0.41 tachykinin, precursor 1 (substance K, substance P, neurokinin 
1, neuromedin L, neuropeptide K) 
204580_at 0.41 matrix metallopeptidase 12 (macrophage elastase) 
214455_at 0.42 histone cluster 1, H2bc 
205586_x_at 0.42 VGF nerve growth factor inducible 
209398_at 0.42 histone cluster 1, H1c 
222088_s_at 0.42 Solute carrier family 2 (facilitated glucose transporter), 
member 3 
201235_s_at 0.42 BTG family, member 2 
206343_s_at 0.43 neuregulin 1 
209457_at 0.43 dual specificity phosphatase 5 
206115_at 0.43 early growth response 3 
202672_s_at 0.43 activating transcription factor 3 
202628_s_at 0.44 serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1 
208180_s_at 0.44 histone cluster 1, H4h 
207980_s_at 0.44 Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2 
209365_s_at 0.45 extracellular matrix protein 1 
208546_x_at 0.45 histone cluster 1, H2bh 
210090_at 0.46 activity-regulated cytoskeleton-associated protein 
209875_s_at 0.46 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, 
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early T-lymphocyte activation 1) 
216985_s_at 0.46 syntaxin 3 
209357_at 0.47 Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2 
36711_at 0.47 v-maf musculoaponeurotic fibrosarcoma oncogene homolog F 
(avian) 
201531_at 0.48 zinc finger protein 36, C3H type, homolog (mouse) 
219257_s_at 0.48 sphingosine kinase 1 
206212_at 0.48 carboxypeptidase A2 (pancreatic) 
209723_at 0.49 serpin peptidase inhibitor, clade B (ovalbumin), member 9 
219634_at 0.49 carbohydrate (chondroitin 4) sulfotransferase 11 
205534_at 0.49 protocadherin 7 
219730_at 0.49 mediator of RNA polymerase II transcription, subunit 18 
homolog (S. cerevisiae) 
214469_at 0.49 histone cluster 1, H2ae 
217373_x_at 0.49 Mdm2, transformed 3T3 cell double minute 2, p53 binding 
protein (mouse) 
201087_at 0.49 paxillin 
215071_s_at 0.50 histone 1, H2ac 
205860_x_at 0.50 folate hydrolase (prostate-specific membrane antigen) 1 
214397_at 0.50 Methyl-CpG binding domain protein 2 
200637_s_at 0.50 Protein tyrosine phosphatase, receptor type, F 
209305_s_at 0.50 growth arrest and DNA-damage-inducible, beta 
204782_at 0.50 myeloid leukemia factor 1 
214542_x_at 0.51 histone cluster 1, H2ai 
207329_at 0.51 matrix metallopeptidase 8 (neutrophil collagenase) 
205193_at 0.52 v-maf musculoaponeurotic fibrosarcoma oncogene homolog F 
(avian) 
203665_at 0.52 heme oxygenase (decycling) 1 
201596_x_at 0.53 keratin 18 
220987_s_at 0.53 NUAK family, SNF1-like kinase, 2 
204475_at 0.53 matrix metallopeptidase 1 (interstitial collagenase) 
211778_s_at 0.53 ovo-like 2 (Drosophila) 
209189_at 0.53 v-fos FBJ murine osteosarcoma viral oncogene homolog 
204794_at 0.53 dual specificity phosphatase 2 
203413_at 0.53 NEL-like 2 (chicken) 
201694_s_at 0.53 early growth response 1 
205612_at 0.53 multimerin 1 
217996_at 0.54 Pleckstrin homology-like domain, family A, member 1 
217365_at 0.54 PRAME family member 11 
220195_at 0.54 methyl-CpG binding domain protein 5 
221658_s_at 0.54 interleukin 21 receptor 
205828_at 0.54 matrix metallopeptidase 3 (stromelysin 1, progelatinase) 
214827_at 0.54 par-6 partitioning defective 6 homolog beta (C. elegans) 
207103_at 0.54 potassium voltage-gated channel, Shal-related subfamily, 
member 2 
209969_s_at 0.54 signal transducer and activator of transcription 1, 91kDa 
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203394_s_at 0.54 Hairy and enhancer of split 1, (Drosophila) 
215825_at 0.54 Clone 24487 mRNA sequence 
210654_at 0.54 tumor necrosis factor receptor superfamily, member 10d, 
decoy with truncated death domain 
219755_at 0.54 chromobox homolog 8 (Pc class homolog, Drosophila) 
220254_at 0.54 low density lipoprotein-related protein 12 
208078_s_at 0.54 zinc finger E-box binding homeobox 1 
200799_at 0.54 heat shock 70kDa protein 1A 
216017_s_at 0.55 NGFI-A binding protein 2 (EGR1 binding protein 2) 
209304_x_at 0.55 growth arrest and DNA-damage-inducible, beta 
222067_x_at 0.55 histone 1, H2bd 
213182_x_at 0.55 Cyclin-dependent kinase inhibitor 1C (p57, Kip2) 
220167_s_at 0.55 TP53TG3 protein 
209755_at 0.55 nicotinamide nucleotide adenylyltransferase 2 
216034_at 0.55 Suppressor of hairy wing homolog 1 (Drosophila) 
221577_x_at 0.55 growth differentiation factor 15 
216001_at 0.55 Similar to Hypothetical protein DJ1198H6.2 
219358_s_at 0.55 centaurin, alpha 2 
201715_s_at 0.55 apoptotic chromatin condensation inducer 1 
217487_x_at 0.55 folate hydrolase (prostate-specific membrane antigen) 1 
207574_s_at 0.56 growth arrest and DNA-damage-inducible, beta 
201242_s_at 0.56 ATPase, Na+/K+ transporting, beta 1 polypeptide 
210354_at 0.56 Human mRNA for HuIFN-gamma interferon. 
214540_at 0.56 histone cluster 1, H2bo 
212948_at 0.56 calmodulin binding transcription activator 2 
201110_s_at 0.56 thrombospondin 1 
202071_at 0.56 syndecan 4 
207986_x_at 0.56 cytochrome b-561 
219865_at 0.56 HSPC157 protein 
219884_at 0.56 LIM homeobox 6 
205386_s_at 0.56 Mdm2, transformed 3T3 cell double minute 2, p53 binding 
protein (mouse) 
213931_at 0.56 Inhibitor of DNA binding 2, dominant negative helix-loop-helix 
protein 
221188_s_at 0.57 cell death-inducing DFFA-like effector b 
213807_x_at 0.57 Met proto-oncogene (hepatocyte growth factor receptor) 
AFFX-
HUMISGF3A/M97935_5_at 
0.57 signal transducer and activator of transcription 1, 91kDa 
212741_at 0.57 Monoamine oxidase A 
210592_s_at 0.57 spermidine/spermine N1-acetyltransferase 1 
213849_s_at 0.57 Protein phosphatase 2 (formerly 2A), regulatory subunit B, 
beta isoform 
220238_s_at 0.57 kelch-like 7 (Drosophila) 
209710_at 0.57 GATA binding protein 2 
210538_s_at 0.57 baculoviral IAP repeat-containing 3 
207050_at 0.57 calcium channel, voltage-dependent, alpha 2/delta subunit 1 
220941_s_at 0.57 chromosome 21 open reading frame 91 
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221143_at 0.57 replication protein A4, 34kDa 
202498_s_at 0.57 Solute carrier family 2 (facilitated glucose transporter), 
member 3 
204382_at 0.57 N-acetyltransferase 9 
207120_at 0.57 zinc finger protein 667 
202393_s_at 0.57 Kruppel-like factor 10 
220265_at 0.57 G protein-coupled receptor 107 
212086_x_at 0.58 lamin A/C 
214138_at 0.58 Zinc finger protein 79 
205433_at 0.58 butyrylcholinesterase 
210269_s_at 0.58 splicing factor, arginine/serine-rich 17A 
203094_at 0.58 MAD2L1 binding protein 
36554_at 0.58 acetylserotonin O-methyltransferase-like 
205453_at 0.58 homeobox B2 
219901_at 0.58 FYVE, RhoGEF and PH domain containing 6 
218793_s_at 0.58 sex comb on midleg-like 1 (Drosophila) 
214157_at 0.59 GNAS complex locus 
210818_s_at 0.59 BTB and CNC homology 1, basic leucine zipper transcription 
factor 1 
213484_at 0.59 Clone 23700 mRNA sequence 
58308_at 0.59 yi53g05.r1 Soares placenta Nb2HP Homo sapiens cDNA 
clone IMAGE:143000 5', mRNA sequence. 
208490_x_at 0.59 histone cluster 1, H2bf 
206182_at 0.59 zinc finger protein 134 
203879_at 0.59 phosphoinositide-3-kinase, catalytic, delta polypeptide 
202081_at 0.59 immediate early response 2 
33304_at 0.59 interferon stimulated exonuclease gene 20kDa 
206663_at 0.59 Sp4 transcription factor 
204679_at 0.59 potassium channel, subfamily K, member 1 
205282_at 0.59 low density lipoprotein receptor-related protein 8, 
apolipoprotein e receptor 
214414_x_at 0.59 Hemoglobin, alpha 1 
203567_s_at 0.59 Tripartite motif-containing 38 
220264_s_at 0.60 G protein-coupled receptor 107 
215363_x_at 0.60 Folate hydrolase (prostate-specific membrane antigen) 1 
206850_at 0.60 RAS-like, family 10, member A 
221665_s_at 0.60 EPS8-like 1 
208553_at 0.60 histone cluster 1, H1e 
204592_at 0.60 discs, large homolog 4 (Drosophila) 
211165_x_at 0.60 EPH receptor B2 
219531_at 0.60 centrosomal protein 72kDa 
218196_at 0.60 osteopetrosis associated transmembrane protein 1 
210448_s_at 0.60 purinergic receptor P2X, ligand-gated ion channel, 5 
202510_s_at 0.60 tumor necrosis factor, alpha-induced protein 2 
214933_at 0.60 Calcium channel, voltage-dependent, P/Q type, alpha 1A 
subunit 
203234_at 0.60 uridine phosphorylase 1 
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AFFX-
HUMISGF3A/M97935_MA_at 
0.60 signal transducer and activator of transcription 1, 91kDa 
210664_s_at 0.60 tissue factor pathway inhibitor (lipoprotein-associated 
coagulation inhibitor) 
216236_s_at 0.60 solute carrier family 2 (facilitated glucose transporter), 
member 3 
202497_x_at 0.60 solute carrier family 2 (facilitated glucose transporter), 
member 3 
209722_s_at 0.60 serpin peptidase inhibitor, clade B (ovalbumin), member 9 
220394_at 0.61 fibroblast growth factor 20 
212686_at 0.61 protein phosphatase 1H (PP2C domain containing) 
203713_s_at 0.61 lethal giant larvae homolog 2 (Drosophila) 
208583_x_at 0.61 histone cluster 1, H2aj 
213106_at 0.61 ATPase, aminophospholipid transporter (APLT), Class I, type 
8A, member 1 
209992_at 0.61 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 
208104_s_at 0.61 TSC22 domain family, member 4 
221961_at 0.61 Chloride channel 7 
209648_x_at 0.61 suppressor of cytokine signaling 5 
209260_at 0.61 stratifin 
201109_s_at 0.61 Thrombospondin 1 
214911_s_at 0.61 bromodomain containing 2 
217997_at 0.61 Pleckstrin homology-like domain, family A, member 1 
37028_at 0.61 protein phosphatase 1, regulatory (inhibitor) subunit 15A 
219537_x_at 0.61 delta-like 3 (Drosophila) 
211303_x_at 0.61 growth-inhibiting protein 26 
210192_at 0.61 ATPase, aminophospholipid transporter (APLT), Class I, type 
8A, member 1 
217502_at 0.61 Interferon-induced protein with tetratricopeptide repeats 2 
204804_at 0.61 tripartite motif-containing 21 
220292_at 0.61 zinc finger protein 434; synonyms: MGC4179, FLJ20417, 
FLJ31901; Homo sapiens zinc finger protein 434 (ZNF434), 
mRNA. 
36553_at 0.61 Acetylserotonin O-methyltransferase-like 
204698_at 0.61 interferon stimulated exonuclease gene 20kDa 
202254_at 0.62 signal-induced proliferation-associated 1 like 1 
209238_at 0.62 601660942R1 NIH_MGC_72 Homo sapiens cDNA clone 
IMAGE:3915610 3', mRNA sequence. 
219631_at 0.62 low density lipoprotein-related protein 12 
211721_s_at 0.62 zinc finger protein 551 
203453_at 0.62 sodium channel, nonvoltage-gated 1 alpha 
219765_at 0.62 zinc finger protein 329 
209267_s_at 0.62 solute carrier family 39 (zinc transporter), member 8 
220215_at 0.62 zinc finger protein 669 
201108_s_at 0.62 Thrombospondin 1 
91826_at 0.62 EPS8-like 1 
206360_s_at 0.62 suppressor of cytokine signaling 3 
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213429_at 0.62 CDNA FLJ26539 fis, clone KDN09310 
204951_at 0.62 ras homolog gene family, member H 
209394_at 0.62 acetylserotonin O-methyltransferase-like 
211715_s_at 0.62 3-hydroxybutyrate dehydrogenase, type 1 
213112_s_at 0.62 Sequestosome 1 
AFFX-
HUMISGF3A/M97935_MB_at 
0.62 signal transducer and activator of transcription 1, 91kDa 
210605_s_at 0.62 milk fat globule-EGF factor 8 protein 
207029_at 0.62 KIT ligand 
202206_at 0.62 ADP-ribosylation factor-like 4C 
208127_s_at 0.62 suppressor of cytokine signaling 5 
208293_x_at 0.62 chorionic somatomammotropin hormone-like 1 
207144_s_at 0.62 Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 1 
212957_s_at 0.62 Hypothetical protein LOC92249 
201243_s_at 0.63 ATPase, Na+/K+ transporting, beta 1 polypeptide 
206953_s_at 0.63 latrophilin 2 
219569_s_at 0.63 transmembrane protein 22 
214169_at 0.63 Unc-84 homolog A (C. elegans) 
36564_at 0.63 IBR domain containing 3 
206907_at 0.63 tumor necrosis factor (ligand) superfamily, member 9 
206560_s_at 0.63 melanoma inhibitory activity 
215760_s_at 0.63 KIAA0963 
212470_at 0.63 sperm associated antigen 9 
201939_at 0.63 polo-like kinase 2 (Drosophila) 
204141_at 0.63 tubulin, beta 2A 
209619_at 0.63 CD74 molecule, major histocompatibility complex, class II 
invariant chain 
58367_s_at 0.63 Zinc finger protein 419 
204937_s_at 0.63 zinc finger protein 274 
205197_s_at 0.63 ATPase, Cu++ transporting, alpha polypeptide (Menkes 
syndrome) 
201565_s_at 0.63 inhibitor of DNA binding 2, dominant negative helix-loop-helix 
protein 
219823_at 0.63 lin-28 homolog (C. elegans) 
221201_s_at 0.63 zinc finger protein 155 
220409_at 0.63 calmodulin regulated spectrin-associated protein 1 
219239_s_at 0.63 zinc finger protein 654 
218273_s_at 0.63 protein phosphatase 2C, magnesium-dependent, catalytic 
subunit 
204276_at 0.63 Thymidine kinase 2, mitochondrial 
202207_at 0.64 ADP-ribosylation factor-like 4C 
203146_s_at 0.64 gamma-aminobutyric acid (GABA) B receptor, 1 
201695_s_at 0.64 nucleoside phosphorylase 
206648_at 0.64 zinc finger protein 571 
219677_at 0.64 splA/ryanodine receptor domain and SOCS box containing 1 
200887_s_at 0.64 signal transducer and activator of transcription 1, 91kDa 
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202644_s_at 0.64 tumor necrosis factor, alpha-induced protein 3 
218899_s_at 0.64 brain and acute leukemia, cytoplasmic 
210033_s_at 0.64 sperm associated antigen 6 
209324_s_at 0.64 Regulator of G-protein signalling 16 
206110_at 0.64 histone cluster 1, H3h 
219826_at 0.64 zinc finger protein 419 
204689_at 0.64 Homo sapiens hematopoietically expressed homeobox 
(HHEX), mRNA. 
207113_s_at 0.64 tumor necrosis factor (TNF superfamily, member 2) 
219240_s_at 0.64 chromosome 10 open reading frame 88 
209926_at 0.64 myocyte enhancer factor 2B 
207213_s_at 0.64 ubiquitin specific peptidase 2 
210587_at 0.64 inhibin, beta E 
206381_at 0.64 sodium channel, voltage-gated, type II, alpha subunit 
219077_s_at 0.64 WW domain containing oxidoreductase 
208576_s_at 0.64 histone cluster 1, H3b 
207456_at 0.64 hepatocyte nuclear factor 4, gamma 
203455_s_at 0.64 spermidine/spermine N1-acetyltransferase 1 
206748_s_at 0.65 sperm associated antigen 9 
215047_at 0.65 Homo sapiens mRNA; cDNA DKFZp434C091 (from clone 
DKFZp434C091). 
211434_s_at 0.65 chemokine (C-C motif) receptor-like 2 
200636_s_at 0.65 protein tyrosine phosphatase, receptor type, F 
202855_s_at 0.65 Solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4) 
205832_at 0.65 carboxypeptidase A4 
221640_s_at 0.65 leucine-rich repeats and death domain containing 
210258_at 0.65 regulator of G-protein signalling 13 
204523_at 0.65 zinc finger protein 140 
204285_s_at 0.65 Phorbol-12-myristate-13-acetate-induced protein 1 
218639_s_at 0.65 ZXD family zinc finger C 
206027_at 0.65 S100 calcium binding protein A3 
219517_at 0.65 elongation factor RNA polymerase II-like 3 
210850_s_at 0.65 ELK1, member of ETS oncogene family 
220488_s_at 0.65 breast carcinoma amplified sequence 3 
207865_s_at 0.65 bone morphogenetic protein 8b (osteogenic protein 2) 
213072_at 0.65 Cysteine/histidine-rich 1 
202250_s_at 0.65 WD repeat domain 42A 
213368_x_at 0.65 Protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 3 
221207_s_at 0.65 neurobeachin 
206235_at 0.65 ligase IV, DNA, ATP-dependent 
205559_s_at 0.65 proprotein convertase subtilisin/kexin type 5 
218472_s_at 0.65 pelota homolog (Drosophila) 
AFFX-
HUMISGF3A/M97935_3_at 
0.65 signal transducer and activator of transcription 1, 91kDa 
203565_s_at 0.66 menage a trois homolog 1, cyclin H assembly factor (Xenopus 
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laevis) 
212665_at 0.66 TCDD-inducible poly(ADP-ribose) polymerase 
219433_at 0.66 BCL6 co-repressor 
209964_s_at 0.66 ataxin 7 
202014_at 0.66 protein phosphatase 1, regulatory (inhibitor) subunit 15A 
208527_x_at 0.66 histone cluster 1, H2be 
222242_s_at 0.66 kallikrein 5 
204605_at 0.66 cell growth regulator with ring finger domain 1 
208869_s_at 0.66 GABA(A) receptor-associated protein like 1 
201236_s_at 0.66 BTG family, member 2 
211458_s_at 0.66 GABA(A) receptors associated protein like 3 
212468_at 0.66 sperm associated antigen 9 
200787_s_at 0.66 phosphoprotein enriched in astrocytes 15 
220140_s_at 0.66 sorting nexin 11 
219601_s_at 0.66 chromosome 10 open reading frame 12 
204347_at 0.66 Transcribed locus 
217620_s_at 0.66 Phosphoinositide-3-kinase, catalytic, beta polypeptide 
219854_at 0.66 zinc finger protein 14 
207500_at 0.66 caspase 5, apoptosis-related cysteine peptidase 
203597_s_at 0.66 WW domain binding protein 4 (formin binding protein 21) 
221259_s_at 0.66 testis expressed 11 
211348_s_at 0.66 CDC14 cell division cycle 14 homolog B (S. cerevisiae) 
215954_s_at 0.66 Chromosome 19 open reading frame 29 
209959_at 0.66 nuclear receptor subfamily 4, group A, member 3 
205600_x_at 0.66 Homeobox B5 
218368_s_at 0.66 tumor necrosis factor receptor superfamily, member 12A 
216033_s_at 0.66 FYN oncogene related to SRC, FGR, YES 
203730_s_at 0.66 Zinc finger with KRAB and SCAN domains 5 
201869_s_at 0.66 Transducin (beta)-like 1X-linked 
214762_at 0.66 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G2 
220178_at 0.66 chromosome 19 open reading frame 28 
219661_at 0.66 RAN binding protein 17 
203085_s_at 0.66 transforming growth factor, beta 1 
209604_s_at 0.67 GATA binding protein 3 
33323_r_at 0.67 stratifin 
221599_at 0.67 chromosome 11 open reading frame 67 
219568_x_at 0.67 SRY (sex determining region Y)-box 18 
213653_at 0.67 Methyltransferase like 3 
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PIXEL DENSITIES (average, normalized with control spots for each array) 
 
Condition and cell line 
/marker 
UNTREATED 8 nM paclitaxel exposure (24 hrs) 
 
WWOX-7 
 
WWOX-8 Vector-9 Vector-p2 WWOX-7 WWOX-8 Vector-9 Vector-p2 
Bad 0.714 0.551 0.671 0.652 0.564 0.413 0.494 0.400 
Bax 0.522 0.390 0.472 0.419 0.628 0.510 0.471 0.368 
Bcl-2 0.562 0.462 0.492 0.483 0.468 0.447 0.460 0.349 
Bcl-xL 0.686 0.632 0.671 0.755 0.362 0.395 0.544 0.592 
catalase 0.612 0.550 0.650 0.635 0.700 0.688 0.759 0.659 
CDNK1A 0.377 0.314 0.375 0.227 0.258 0.286 0.248 0.098 
cIAP-1 0.644 0.606 0.643 0.583 0.549 0.412 0.662 0.499 
cIAP-2 0.420 0.353 0.375 0.412 0.079 0.021 0.106 0.046 
claspin 0.569 0.444 0.530 0.574 0.188 0.018 0.275 0.289 
cleaved caspase 3 0.143 0.235 0.216 0.156 0.300 0.262 0.089 0.073 
clusterin 0.488 0.365 0.414 0.378 0.078 0.005 0.037 0.025 
cytochrome c 0.924 0.682 0.744 0.815 0.413 0.274 0.308 0.380 
FADD 0.834 0.764 0.760 0.741 0.753 0.691 0.701 0.673 
Fas 0.902 0.821 0.811 0.856 0.973 0.875 0.979 1.003 
HIF-1alpha 0.337 0.451 0.372 0.245 0.372 0.210 0.433 0.362 
HMOX2 0.732 0.720 0.625 0.700 0.738 0.730 0.744 0.620 
HSP27 0.669 0.652 0.698 0.651 0.574 0.511 0.536 0.514 
HSP32 0.571 0.486 0.500 0.547 0.540 0.335 0.488 0.604 
HSP60 0.599 0.547 0.539 0.599 0.258 0.291 0.316 0.316 
289 
 
HSP70 0.784 0.731 0.762 0.725 0.511 0.470 0.521 0.487 
Livin 0.213 0.104 0.046 0.028 -0.008 0.001 0.002 0.004 
Omi 0.904 0.721 0.808 0.822 0.579 0.373 0.692 0.585 
p27/Kip1 0.391 0.416 0.375 0.276 0.214 0.178 0.208 0.119 
phospho-p53 (S15) 0.753 0.660 0.665 0.746 0.680 0.542 0.670 0.650 
phospho-p53 (S392) 0.707 0.664 0.615 0.629 0.494 0.511 0.705 0.647 
phospho-p53 (S46) 0.628 0.603 0.558 0.591 0.523 0.456 0.635 0.567 
phospho-rad17 (S365) 0.273 0.343 0.197 0.230 0.139 0.139 0.286 0.087 
PON2 0.266 0.255 0.219 0.178 0.223 0.212 0.231 0.055 
pro-caspase 3 1.055 1.040 1.090 1.095 1.104 1.043 1.158 1.186 
Smac/Diablo 0.900 0.878 0.894 0.910 0.803 0.891 0.846 0.835 
Survivin 0.703 0.686 0.694 0.747 0.476 0.543 0.697 0.708 
TNF RI 0.474 0.396 0.506 0.506 0.113 0.138 0.266 0.214 
TRAIL R1/DR4 0.949 0.870 0.879 0.921 1.028 0.958 0.943 0.945 
TRIAL R2/DR5 0.764 0.759 0.726 0.704 0.817 0.896 0.832 0.760 
XIAP 0.801 0.643 0.757 0.737 0.469 0.495 0.724 0.572 
 
Appendix 10 
 
Densitometric analysis of the expression of a panel of apoptosis-related proteins in WWOX- and vector- transfected PEO1 cells following 
paclitaxel exposure 
